Isolation and characterization of African marine natural products and repositioning of the natural product antibiotic fusidic acid and privileged benzimidazole scaffold for tuberculosis and malaria by Dziwornu, Godwin Akpeko
Un
ive
rsi
ty 
of 
Ca
pe
 To
wn
Isolation and characterization of African marine natural products 
and repositioning of the natural product antibiotic fusidic acid 
and privileged benzimidazole scaffold for tuberculosis and 
malaria 
 
Thesis submitted for the award of Doctor of Philosophy degree in the department of Chemistry, 
University of Cape Town,  
 
Godwin Akpeko Dziwornu 
 
Supervisor: Prof. Kelly Chibale 
Department of Chemistry, University of Cape Town (UCT) 
 
Co-supervisor: Prof. Denzil R. Beukes 
School of Pharmacy, University of the Western Cape (UWC) 
 
 
December 2018
Un
ive
rsi
ty 
of 
Ca
pe
 To
wn
 
 
 
 
 
 
 
 
 
The copyright of this thesis vests in the author. No 
quotation from it or information derived from it is to be 
published without full acknowledgement of the source. 
The thesis is to be used for private study or non-
commercial research purposes only. 
 
Published by the University of Cape Town (UCT) in terms 
of the non-exclusive license granted to UCT by the author. 
 
i 
Declaration
I hereby declare that this thesis is my original work produced from research undertaken under 
supervision and has not been presented for a degree in this university or another university 
elsewhere for the award of any other degree. 
…………………………………………………. 
Godwin Akpeko Dziwornu 
 
ii 
Dedication 
 
 
 
 
 
To Beatrice Buanya 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
  
 
iii 
Acknowledgements 
This work would not have been successfully completed without the enormous contributions and 
outstanding mentorship of my supervisors, Prof. Kelly Chibale and Prof. Denzil R. Beukes. I 
acknowledge the contributions of Dr. Sunny Sunassee and the constructive criticisms and helpful 
suggestions of Prof. Edith Antunes, Dr. Richard Amewu and Dr. (Mrs.) Dorcas Osei-Safo. 
Special appreciation goes to Elaine Rutherfoord-Jones and Deidre Brooks for their administrative 
support and helpful advice and encouragement.  
Special thanks to Peter Roberts for acquiring some of my NMR data and Daniel Watson for his help 
with acquiring and analyzing some of my HR-ESI-MS data. I appreciate the support received from 
Prof. Adrienne L. Edkins, Prof. Lyn-Marie Birkholtz, Dr. Jo-Anne de la Mare, Ms. Ronnet Seldon, Dr. 
Dale Taylor and Dr. Sergio Wittlin for conducting the biological assays. 
I appreciate the efforts of the Head of Department and both teaching and non-teaching staff of 
the Chemistry Department, University of Cape Town.  
I extend my thanks to the South African Medical Research Council, South African National Research 
Foundation (NRF), the Faculty of Science and Department of Chemistry for their generous financial 
assistance, without which this work would not have been possible. 
I am grateful to my colleagues.  
Finally, I thank God for the lives of Miss Beatrice Buanya and her family, my family, my church, my 
goddaughter, Bernice Nana Yaa Nhyiraba Amoah, Kojo Sekyi Acquah, Henrietta Attram and 
Constance Korkor for every support they provided me, in love, care, encouragement, prayers, etc. 
God richly bless you all. 
  
 
iv 
Abstract 
Many bioactive compounds isolated from nature (microbes, plants and animals) are successfully 
being used as drugs to prevent and/or cure diseases. A greater number of these natural products 
have not progressed to the latter stages of development as drugs largely due to the drawbacks of 
toxicity, limited supply, growing concerns to conserve terrestrial and marine ecosystems and their 
biodiversity, which impedes sample collections in adequate quantities for research, among others. 
However, in spite of these drawbacks, the medicinal chemistry explorations of bioactive natural 
products, which hitherto may have been abandoned in the repositories of research laboratories, 
have afforded an even greater number of drugs in clinical use. The collaboration of natural 
products chemistry and medicinal chemistry to discover, optimize and develop bioactive 
compounds as drugs remains an important endeavor today. 
A chemistry-guided natural products investigation of the newly identified marine red alga 
Laurencia alfredensis, which is an endemic species of South Africa, afforded ten (10) newly 
reported compounds from the genus. Isolation and purification of the compounds from the 
DCM/MeOH 1:1 v/v crude extract was achieved through a combination of normal phase bench-
top column chromatography, preparative TLC, and semi-preparative HPLC. Elucidation of the 
chemical structures was accomplished by 1D- and 2D-NMR, HR-ESI-MS, UV and IR spectroscopic 
techniques, and X-ray diffraction analysis. The isolated compounds belong to the Laurencia 
secondary metabolite classes of labdane diterpenoids, polyether triterpenoids and sterols, and a 
glycolipid, which is reported herein for the first time from the genus. The compounds displayed 
low micromolar to poor in vitro antiproliferative activity towards the human breast (MDA-MB-231) 
and cervical (HeLa) cancer cell lines with IC50 values in the 8.8 – 133.8 µM range.  
A further natural products research effort involving the chemical investigation of two marine 
sponge species, Halichondria sp. and Hymeniacidon sp., is also reported herein. The specimens 
were collected from the Prince Edwards Islands in the Southern Ocean in the vicinity of Antarctica. 
With the aim to investigate the chemical and biological properties of the secondary metabolites 
from the cold continent, the organic crude extracts (DCM/MeOH 1:1 v/v) of the specimens were 
purified by DIOL flash chromatography and reverse phase semi-preparative HPLC. Two previously 
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unreported compounds were isolated from the Halichondria sp., comprising of a bis-zooanemonin 
betaine metabolite and a trimer of proline betaine. The two compounds were inactive (IC50 >10 
µg/mL) towards the drug-sensitive strain of Plasmodium falciparum (NF54), in vitro. Meanwhile, 
the Hymeniacidon sp. afforded the known nucleoside, thymidine, the amino acids, tyrosine, 
leucine, isoleucine and valine, and the small alkaloids, choline and agmatine. 
The natural product antibiotic, fusidic acid, has been in clinical use as, largely, a bacteriostatic 
agent against staphylococcal pathogens since 1962. Having exhibited a similar mode of action via 
inhibition of Mycobacteria tuberculosis and P. falciparum elongation factor G (EF-G), the current 
work expanded the structure-activity relationship (SAR) explorations in the medicinal chemistry 
approach of repositioning for tuberculosis and malaria. Twenty-nine (29) fusidic acid C-21 
ethanamides, anilides and benzyl amides were synthesized and evaluated in vitro against the M. 
tuberculosis strain H37Rv and asexual blood stage and gametocytes parasites of the human malaria 
parasite Plasmodium falciparum. Good antimycobacterial activity (MIC90 <10 µM) was observed in 
the analogues, which possessed bulky and/or polar substituents in close proximity to the amide 
bond. Moreover, hydrophilic electron-withdrawing substituents seem to enhance 
antimycobacterial activity. A fusidic acid anilide formed from the Mannich base, 3-((N,N-
diethylamino)methyl)-4-hydroxy aniline recorded the most potent antimycobacterial activity with 
MIC90 values of 0.40 µM and 10.35 µM in the 7H9/CAS and 7H9/ADC media, respectively. 
Meanwhile, multi-stage antiplasmodium activity was more favored in the fusidic acid 
ethanamides. While the activity was not affected by diastereoisomerism, potency was enhanced 
by para-substituted lipophilic electron-withdrawing/donating groups. The (R)-4-fluoro 
ethanamide analogue of fusidic acid displayed the most potent asexual erythrocytic blood stage 
antiplasmodium activity with IC50 values of 0.57 and 0.47 µM against the NF54 and K1 strains of P. 
falciparum, respectively. The synthesized compounds, however, exhibited moderate to no 
inhibition of gametocyte growth at the highest concentration tested of 5 µM. 
The privileged benzimidazole scaffold has afforded antiviral, antiulcer, antimicrobial, antitumor, 
antihypertensive, anti-inflammatory and antihistaminic clinical chemotherapeutic agents. A 
limited number of studies describing the utility of benzimidazoles as potential antimalarial and 
antimycobacterial agents have been reported. In this context, novel benzimidazole analogues 
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were rationally designed by incorporation of phenolic Mannich bases and synthesized in this thesis 
work. The synthesized compounds exhibited good in vitro potency towards Mtb in the 7H9/CAS 
media and sub-micromolar activity against the asexual blood stage P. falciparum parasites. All the 
compounds were relatively non-cytotoxic (IC50 >10 µM) to the Chinese hamster ovarian (CHO) cell 
line, recording acceptable selectivity indices, S1>10. No correlation was observed between the 
antiplasmodium activity of the synthesized analogues and their likely mode of action as inhibitors 
of hemozoin formation. The 1-((4-trifluoromethyl)benzyl) benzimidazole analogue based on the 
3-((N,N-diethylamino)methyl)-2-hydroxy-5-methyl aniline Mannich base was the most potent 
analogue in both assays. It recorded a MIC90 value of 2.00 µM in the 7H9/CAS media. Moreover, 
IC50 values of 0.19 µM and 0.06 µM were observed against the asexual blood stage NF54 and K1 
strains of P. falciparum, respectively, while it inhibited 91% of growth of early stage gametocytes 
at 1 µM. Although it showed poor aqueous kinetic solubility as a free base at pH 7.4, it conformed 
to Lipinski and Veber rules for oral absorption and bioavailability, while it shared a similar chemical 
space with the clinically used 4-aminoquinoline drug naphthoquine. 
The results presented herein substantiates the fact that the complimentary efforts of natural 
products research and medicinal chemistry exploration of natural products and privileged 
scaffolds continue to remain a viable approach to discovering potent bioactive drug candidates. 
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Chapter One: Introduction 
1.1 Natural Products 
The term ‘natural product’ has been used to describe any substance obtained from nature,1 such 
as the biological part of an organism, extracts, formulations, and isolated chemical compounds, 
including those obtained by total synthesis. In their narrower definition of being chemical 
compounds from nature, natural products are classified as either primary or secondary 
metabolites.2,3  
Primary metabolites refer to those chemical compounds that are essentially encountered in all 
living organisms. In effect, they are necessary for the life, growth and reproduction of the 
organism. These include carbohydrates, fatty acids, amino acids and nucleic acids.2,3 
Carbohydrates are integral components of membranes of cells and cell organelles, the 
polysaccharide forms serve as cell walls of plants, fungi, and microorganisms. Triglycerides and 
phospholipids of cell membranes are formed from fatty acids. The polar and non-polar 
components of fatty acids provide cell membranes with such architecture that ensures 
coordination and regulation of cellular processes. Enzymes, which regulate basic cellular functions, 
are proteins formed from amino acids. Nucleic acids (DNA and RNA), formed from nitrogenous 
bases (adenine, guanine, thymine, uracil and cytosine), monosaccharides and a phosphate group, 
give rise to chromosomes, the genetic ‘storehouse’ of every organism. 
Primary metabolites undergo chemical processes, which may generally comprise synthesis of new 
ones from already existing compounds, degradation of old compounds to small or simpler 
molecules, and interconversion of one compound to another. These chemical processes, called 
primary metabolism, proceed by almost the same pathway per the type of primary metabolite in 
all living organisms. For example, metabolism of carbohydrates occurs by glycolysis and the Krebs 
cycle, fatty acids by β-oxidation, protein syntheses from amino acids, and so on.4 
Secondary metabolites, unlike primary metabolites, are less abundant in nature. They comprise 
chemical compounds that are not directly concerned with the life, growth and reproduction of an 
organism. These compounds play very important evolutionary roles that ensure the continued 
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survival of a given organism. For example, pheromones are responsible for many and diverse social 
communications among specific groups of organisms, toxins are produced for protection from a 
predator, venoms are produced to catch a prey, repellants deter other organisms, which may 
compete for the same nutrients, siderophores facilitate efficient transportation of scarce nutrients 
from the environment, etc. Secondary metabolites are therefore unique to a group of organisms, 
a peculiar trait of a given taxonomic classification.5 
 
Figure 1.1: Examples of secondary metabolites 
The products of the primary metabolic processes photosynthesis, glycolysis and the Krebs cycle 
serve as intermediates/precursors of secondary metabolic pathways leading to secondary 
metabolites. The metabolites obtained from principal primary metabolism, including their 
intermediate/precursor, which serve as building blocks from which secondary metabolites are 
synthesized are summarized in Table 1.1.4 
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Table 1.1: Secondary metabolites from primary metabolism 
Intermediate from primary 
metabolism 
Precursor of secondary 
metabolism 
Secondary metabolite 
Acetyl-CoA Acetate Phenols 
Prostaglandins 
Macrolide antibiotics 
Fatty acids 
Shikimic acid Shikimate Phenols 
Cinnamic acid derivatives 
Lignans 
Alkaloids 
Acetyl-CoA Mevalonate Terpenoids 
Steroids 
Pyruvic acid and glyceraldehyde 
3-phosphate 
Methylerythritol phosphate Terpenoids 
Steroids 
Krebs cycle intermediates 
Shikimate intermediates 
Amino acids Peptides 
Proteins 
Alkaloid antibiotics 
 
Figure 1.2: Major precursors of secondary metabolism 
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A natural product may comprise similar or a mixture of different building blocks. For example, 
papaverine, an opium alkaloid, is used as a drug for relaxation of cardiac and smooth muscles. 
From a biosynthesis perspective, the structure of papaverine is elucidated as arising from two L-
tyrosine amino acids possessing the C6C2 and C6C2N building blocks (Figure 1.2). The C6C2 unit is 
formed from loss of the amino group from one of the molecules to give the C6C3 unit followed by 
a one carbon degradation, while decarboxylation of the other molecule leads to the C6C2N 
scaffold. The four methoxy (C1) groups are the result of four L-methionine amino acids.4 
 
Figure 1.3: Building blocks of papaverine4 
The anticancer drug vinblastine (Figure 1.4) offers another example of elucidating the structure of 
a natural product based on the building blocks from which it was made. In this example, the 
building blocks are not all easily discernible as some have undergone transformations. Vinblastine 
is a terpenoid indole alkaloid produced by Catharanthus roseus. It is biosynthesized from 
precursors from the methylerythritol phosphate (MEP) and shikimate pathways (Figure 1.5). 
Although the indole.C2N scaffold is obvious, the two isoprenyl (C5) units from geraniol are lost 
through molecular transformations leading to secologanin and both vindoline and catharanthine.6 
 
Figure 1.4: Chemical structure of vinblastine 
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Figure 1.5: Biosynthetic pathway of vinblastine6 
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1.2 Pharmaceutical prospects of natural products 
The use of extracts, concoctions, potions, and unrefined substances derived from biological 
sources to address the problem of diseases dates back several thousands of years. Indeed, several 
pharmacopoeia record the use of parts or whole plants for disease remedies, for example. Natural 
sources of ‘drugs’ or agents for treatment of diseases include plant, animals, and microbes. 
Although the use of whole organisms or parts of whole organisms for disease treatment is still 
common in indigenous/traditional medicine all over the world, many pure chemical compounds 
isolated from natural sources have made it as marketable drugs (Figure 1.6). 
 
Figure 1.6: Some unaltered natural products on the market as drugs 
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Many other drug candidates of natural origin or related to natural products are in different stages 
of pharmaceutical development. In their recent review on “Natural products as Sources of New 
Drugs from 1981 to 2014”,7 Newman and Cragg report the continual significance of natural 
products in drug discovery. Natural products and natural product-related compounds contribute 
to about 51% of all new drugs approved in the period under study. However, this has increased to 
65% of all approved small molecule drugs (Figure 1.7 and 1.8). 
 
Figure 1.7: All new approved drugs 1981 – 2014; n = 15627 
(N = Unaltered natural product; NB = Botanical drug (defined mixture); ND = Natural product derivative; S = Synthetic 
drug; S* = Synthetic drug (natural product pharmacophore); NM = Natural product mimic; V = Vaccine; B = Biological 
macromolecule) 
 
Figure 1.8: All small molecule approved drugs 1981 – 2014; n = 12117 
B, 250, 16%
N, 67, 4%
NB, 9, 1%
ND, 320, 
21%
S, 420, 27%
S/NM, 172,
11%
S*, 61, 4%
S*/NM, 162, 10%
V, 101, 6%
N, 67, 6%
NB, 9, 1%
ND, 320, 26%
S, 420, 35%
S/NM, 172, 
14%
S*, 61, 5%
S*/NM, 162, 13%
Chapter One: Introduction 
 
8 
The success of natural products over ‘purely’ synthetic compounds as drugs can be attributed to 
a number of factors8: firstly, natural products are made by proteins (enzymes) in specific 
binding/active site in the structure of the protein and hence have inherent binding scaffold(s) in 
their chemical structure complementary to the enzyme active site. Since all organisms originated 
from a common ancestor and evolved to their current complex forms from less complex ones, 
very different organisms may share very similar genes or gene clusters. Furthermore, because a 
given gene cluster(s) may be involved in the synthesis of several proteins/enzymes, a natural 
product, made by a given enzyme, is able to bind to similar enzyme classes or very diverse ones 
arising from that gene cluster(s). A natural product formed from a peptide substructure in the 
enzyme of one organism may well bind in another organism which bears a similar peptide 
substructure in a similar enzyme or a completely different one. While the binding of a natural 
product to a given enzyme may result in no significant pharmacological effect, a similar binding to 
a different enzyme can cause very significant perturbation in the enzyme’s macromolecular 
structure and lead to ‘good or adverse’ pharmacological effect. Based on the molecular 
complementarity of a natural product to the enzyme that made it, and the similarity in peptide 
substructures amongst similar or different enzymes, natural products can have different medicinal 
effects in different organisms.8 
Secondly, synthesized by enzymes, there is no doubt natural products possess such intriguing 
structural qualities well suited for biological moieties. They are usually three-dimensional in 
conformation while having configurations that are well designed to fit biological targets and 
bypass complex cellular membranes. Natural products have therefore been a good starting point 
in medicinal chemistry and drug discovery explorations. Structural variabilities encountered in 
natural products range from a few daltons in size to very complex and huge peptides (>1000 Da). 
Most have stereocenters and are overall chiral molecules. Sometimes, only one stereoisomer is 
sensitive to the target while the other isomer may be totally inactive or toxic to the organism. With 
many heteroatoms, natural product molecules possess several many hydrogen bond donors and 
acceptors. The molecules could possess scaffolds that ensure non-polar interactions and ionic 
moieties, which encourage interaction with polar scaffolds in biological targets. Natural products, 
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therefore, occupy a wide chemical space that gives them the advantage over synthetic compounds 
to have medicinal properties.8,9 
Thirdly, the physiological/pharmacological significance of a natural product can be understood 
from the standpoint of its importance to the producing organism, both to its continual livelihood 
and ecological importance in ensuring continuous thriving of the organism over its competitors. 
Evolution in organisms has not only been witnessed in their morphological and physiological 
makeup but also in the natural products they produce. In fact, the natural products produced by 
an organism is a consequence of many years of evolving secondary metabolic processes, and 
hence it can be argued to be the reason for the morphological and physiological evolution 
observed in the organism. Evolution therefore provides a basis for observed biomedical 
importance of natural products.8 
The penicillins and other competitive secondary metabolites offer an example of the evolutionary 
and ecological significance of natural products.8 Penicillin, a β-lactam antibiotic, was discovered in 
1928 in a serendipitous event to inhibit bacterial growth. Alexander Fleming writes, “It was noticed 
that around a large colony of a contaminating mould the staphylococcus colonies became 
transparent and were obviously undergoing lysis”.10 It was his hypothesis that a “bacteriolytic 
substance” produced by the mould (Penicillium chrysogenum) inhibited the growth of 
Staphylococci that inspired scientific research leading to the natural product penicillin. In another 
example, capsaicin is a natural product produced by plant species of the genus Capsicum. It is an 
irritant for mammals, producing a burning sensation when it comes into contact with any tissue. 
The ecological importance of capsaicin is well understood as it promotes dispersion of seeds by 
birds rather than humans, for example, thereby ensuring species proliferation, which is an 
evolutionary advantage. Whereas humans crush the seeds as they feed on the fruits thereby 
preventing species propagation, the seeds are unharmed in the digestive tract of birds. Birds 
provide a greater evolutionary advantage to the chili peppers than humans. The vanilloid receptor 
TRPV1 is common to both mammals and birds, although birds have a mutated form. From an 
evolutionary point of view, the chili peppers have adapted to producing capsaicin which is sensitive 
to the TRPV1 in mammals resulting in the burning sensation and discouraging feeding on the fruits, 
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while the mutated form of TRPV1 in birds is not sensitive to capsaicin. Thus, birds are attracted to 
the fleshy and brightly coloured fruits of chilies, becoming efficient dispersers of the seeds.8,11–13 
In view of the foregoing reasons, most drug discovery campaigns have focused on developing 
therapeutic agents inspired by natural products, although this trend has declined in recent times. 
Evidently, this approach has yielded more clinical drugs than purely synthetic/combinatorial 
chemistry drug discovery campaigns (Figures 1.7 and 1.8) as one would note that of the 65% of 
approved small drugs related to natural products, only 6% (67 drugs in 34 years) are unaltered 
natural products (Figure 1.8) while 58% are drugs inspired by natural products.7 This data 
emphasizes the important contribution of organic synthesis in drug discovery despite the approval 
of only three drugs from de novo combinatorial chemistry; specifically, organic syntheses aimed 
at derivatization and mimicking of a natural product [26% (ND) and 27% (NM), respectively] are 
the major contributors of approved drugs on the market. Such an approach requires identifying 
the pharmacophore in the natural product, followed by synthetic derivatization to explore the 
structure-activity relationship (SAR) profiles of analogues to understand the biological target while 
searching for a more potent analogue than the natural product. Many successful drugs developed 
from this approach include the 4-aminoquinolines, penicillins, artemisinins, etc (Figure 1.9).  
Drug discovery from purely natural product sources did experience a down turn in popularity in 
the 1990s and early 2000s due to its drawbacks of re-isolation of already existing compounds, 
paucity of isolated pure and active compounds, ecological and ethical concerns of collection of 
large amounts of the producing organism, structural complexities, which discourage synthesis to 
increase yield, the labour intensive nature of isolation of minute quantities of active compounds 
and accurate characterization of their complex structures thereof, and the ‘incompatibility’ of 
natural product extracts and semi-purified fractions for high throughput screening (HTS) 
technology .14 Indeed, these challenges in natural product-based drug discovery are not cost and 
time efficient for pharmaceutical companies, which resorted to combinatorial chemistry in the 
1990s, hence abandoning their natural products drug discovery campaigns and repositories. 
However, after several years of very low productivity of de novo combinatorial chemistry, in terms 
of approved drugs on the market, novel synthetic strategies/approaches (discussed in Section 1.3 
Chapter One: Introduction 
 
11 
below) based on natural product pharmacophores or their mimetics are proving to be useful. It 
has become evident, therefore, that sustainability of drug discovery campaigns in industries and 
academic research groups would have to integrate these two sectors of research namely, the 
continual search for new chemical entities through ‘classical’ natural products research and the 
medicinal chemistry explorations of synthetic derivatizations of existing natural products, natural 
product pharmacophores and structural mimetics of natural products. This approach promises to 
deliver safe and more efficacious drugs towards meeting the world’s demand for sustainable 
health. 
 
Figure 1.9: Some ND and NM approved drugs from 2010 – 20147 
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1.3 Privileged scaffolds in natural products and medicinal chemistry 
As already indicated in Table 1.1, the products from primary metabolism, acetates, shikimates, 
mevalonates, methylerythritol phosphate and amino acids, are the precursors of secondary 
metabolism leading to secondary metabolites. For example, L-methionine is the source of a single 
carbon atom (C1) in natural products, for example OCH3, NCH3, SCH3, and OCH2O (methylene 
dioxy), etc. A two-carbon unit (C2) is obtained from acetyl-CoA. Mevalonic acid and 
methylerythritol phosphate are the sources of the isoprenyl (C5) unit of terpenoids and steroids. 
Shikimic acid, from which L-phenylalanine, L-tyrosine and L-tryptophan are obtained, is the source 
of aromatic building blocks in natural products. Loss of the alpha amino group from L-
phenylalanine and L-tyrosine will both give the phenylpropyl (C6C3) unit, which can further degrade 
by loss of a carbon or two to give the C6C2 or C6C1 units, respectively. However, the 
phenylethylamine (C6C2N) unit is formed from these amino acids by loss of the carboxyl group. L-
tryptophan is the source of ‘indole.C2N’ scaffold arising from loss of the carboxyl group. Pyrrolidine 
(C4N) and piperidine (C5N) building blocks are obtained from L-ornithine and L-lysine, respectively.4 
Their presence in natural products confers the advantage of effective binding interactions with 
several protein active sites and the ability to possess a wide variety of biological activities. 
Indeed, natural products are ‘privileged’ chemical structures in medicinal chemistry and drug 
discovery explorations. “Privileged scaffolds” are molecular frameworks (or substructures) that 
are seemingly capable of serving as ligands for a diverse array of receptors15 and with judicious 
modification of such structures could provide a viable alternative in the search for new receptor 
agonists and antagonists16 (Figure 1.10 – 1.12). The concept of privileged scaffolds has become 
useful in the advent of all the seemingly unsurmountable challenges encountered in discovering 
novel drugs directly from natural products14 and the ‘limitations’ of de novo combinatorial 
chemistry, which has demonstrated the ease and proficiency in generating large compound 
libraries in a short time but poor success in producing a drug on the market.17-18 Privileged 
scaffolds offer the medicinal chemist the opportunity to explore diverse biological targets with a 
single scaffold; selectivity for a given biological target depends on accessary structural units on the 
scaffold. Once selectivity has been achieved from a small compound library, some researchers 
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have employed combinatorial synthesis to generate large compound libraries to further explore 
the target 19,20 This approach has yielded several active compounds. 
Figure 1.10: Examples of some privileged scaffolds (highlighted in bold bonds) common in natural 
products 21 
Exploration of privileged scaffolds for active leads has provided the medicinal chemist better and 
more efficient opportunities to discovering a drug than natural product-based drug discovery 
alone. Scaffolds identified in natural products have served as inspirations, providing the building 
blocks upon which analogs can be synthesized. This approach, which adopts a pharmacophore of 
a natural product has led to several drugs on the market (Figure 1.11). It has provided a solution 
to the challenges of classical natural products research. Since exploration of the chemical space 
around the core scaffold can afford lead compounds for various targets, the boundaries of 
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medicinal chemistry research seem limitless. Moreover, continued investigations into the 
chemical space can afford second generation drug candidates of already existing drugs, notable 
drug families include the penicillins and 4-aminoquinolines. 
 
Figure 1.11: Examples of some therapeutic drugs with privileged scaffolds (highlighted in bold 
bonds) inspired by natural products – example of natural product pharmacophore based drug 
discovery21 
Privileged scaffold-based drug discovery has served to synergize natural product-based drug 
discovery and de novo combinatorial chemistry and promises a solution to the limitations of its 
predecessors. It drives on the strength of combinatorial chemistry in being able to generate large 
compound libraries with increased confidence of discovering a few active drug-like leads for 
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potential further development into marketable drugs. The drawbacks of de novo combinatorial 
chemistry namely, the lack of diversity in the chemical space of compounds belonging to the same 
library and the prevalence of structural simplicity in terms of the lack of chiral centers, rigidity (less 
sp3 character) of the molecular structure, low numbers of hydrophilic groups, and so on, resulted 
in very small numbers of druggable compounds, which fail in drug development stages. This 
drawback could, however, be potentially resolved by incorporation of privileged scaffolds as 
molecular backbones upon which compound libraries are generated. 
 
Figure 1.12: Examples of novel privileged scaffolds; discovered from medicinal chemistry 
explorations - example of natural product ‘mimic’ based drug discovery 
In search of therapeutic agents, medicinal chemists have not been limited to privileged scaffolds 
clearly discerned from natural products. In fact, they have been inspired to discover and develop 
novel scaffolds from older ones. Moreover, some researchers have explored computational 
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techniques to discover such viable molecular scaffolds, which can be described as privileged.22–28 
These new scaffolds may be described as isosteres or bioisosteres of natural product 
pharmacophores, or molecular mimics of privileged scaffolds in natural products, or bicyclic or 
tricyclic frameworks with close resemblance to general natural product structural characteristics 
(Figure 1.12).21,29 For example, substituted phenyl-based monocycles such as the biphenyls have 
been observed in many drugs with protein binding properties for several biological activities 
including antitumour, antihypertensive and antiatherosclerotic. The diverse biological properties 
observed for this group of privileged scaffolds is not surprising as one takes into account the ability 
of the phenyl ring to provide aromatic and hydrophobic binding interactions with proteins. The 
fused [6-5] ring systems of indoline, indolizine, and hexahydroisoindole and benzothiophene are 
based on the indole scaffold, while benzothiophene is an isostere of benzofuran. Scarcely found 
in natural products, the benzimidazole scaffold has resemblance to benzoxazole and purine 
pharmacophores and hence has such unique structural abilities to serve as mimics with diverse 
biological activities. The fused bicyclic [7-6] ring systems of benzodiazepines have been shown to 
mimic β-turns of peptides and proteins.30,31 They have therefore been explored against diverse 
enzyme targets. Asperlicin, isolated from the fungus Aspergillus alliaceus, is a benzodiazepine 
containing natural product.32–34 It occurs as the 1, 4-benzodiazepin-5-one scaffold. A well-known 
selective cholecystokinin receptor CCKA antagonist, Asperlicin has inspired the development of 
other antagonists of CCKA.35 In fact, the phrase ‘privileged scaffold’ proposed by Evans and co-
workers in 1988 was inspired by their work on benzodiazepines.15 
It is worth mentioning at this point some new synthetic approaches/strategies developed by some 
researchers aimed at discovering biologically and chemically relevant compounds with druggable 
properties for development into marketable drugs. These strategies, namely diversity-oriented 
synthesis (DOS),36–38 biology-oriented synthesis (BIOS),39,40 complexity to diversity (CtD) 
strategy,41,42 and privileged-substructure-based DOS (pDOS),43–46 try to resolve the lack of 
molecular diversity in current compound libraries to achieve more biologically active hits against 
diverse targets for drug discovery. Diversity-oriented synthesis (DOS) is an approach that 
introduces and generates, in an efficient manner, multiple molecular scaffolds within a single 
compound library from simple starting materials (Figure 1.13). Defined as the deliberate, 
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simultaneous and efficient synthesis of more than one target compound in a diversity-driven 
approach, DOS achieves both structural complexity and functional diversity within a library 
thereby increasing the chances of hits against a range of druggable biological targets and 
‘undruggable’ ones. Molecular diversity is achieved by two synthetic pathways, firstly, the reagent-
based approach in which a common starting material is reacted with different reagents to obtain 
distinct molecular scaffolds, and the other, the substrate-based approach where different starting 
materials are put through common reaction conditions to obtain distinct scaffolds.36,47–49 Unlike 
traditional combinatorial synthesis, DOS libraries occupy a much wider chemical space with 
structural diversities observed in moieties around a common molecular framework, functional 
groups present, stereochemistry, and molecular skeletons.47,48,50–52 Consequently, the DOS 
strategy has led to the discovery of bioactive small molecules and therapeutic agents for diverse 
biological targets. 
 
Figure 1.13: An example of reagent-based approach in DOS strategy49,53 
Biology-oriented synthesis (BIOS) was first proposed by Waldmann and coworkers to describe an 
application of DOS strategy based on known biologically relevant small scaffolds derived from 
natural products or known drugs.39,40 The approach focuses on generating a library of natural 
product-like or ‘drug-like’ molecules with complementarity to their protein target, while providing 
the added advantage of enabling bio-and cheminformatic exploration of other possible active sites 
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on the target or identification of new targets. BIOS was developed from the two concepts 
“structural classification of natural products” (SCONP) and “protein structure similarity clustering” 
(PSSC). In the SCONP concept, Waldman and his colleagues generated a hierarchical classification 
of the underlying scaffolds found in natural products that is based on cyclic frameworks and 
linkers.54 Starting from complex natural products scaffolds, and applying a set of defined rules 
derived from organic and medicinal chemistry, the hierarchical classification is a stepwise 
deconstruction from complex scaffolds into smaller parent structures to arrive at a unique scaffold 
tree (Figure 1.14). The scaffolds represented in the hierarchy represents a well-defined chemical 
entity and substructure of the original natural product and provides starting points to construct 
new small molecules through the DOS approach to obtain a compound library of focused and 
biologically meaningful chemical compounds.  
Figure 1.14: A scaffold tree generated in the SCONP53 
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In the PSSC concept, Waldmann and co-workers classified proteins, which are the major biological 
targets of small molecules, into clusters based on structural similarities in the ligand binding sites.55 
They explain that “PSSC relies on bio- and cheminformatic algorithms and analysis of existing data, 
e.g., from the Protein Data Bank (PDB) to identify proteins in which the subfold around the ligand-
binding site, the so-called “ligand-sensing core”, is similar. Structures that show structural similarity 
of the ligand-sensing cores are assigned to one protein structure similarity cluster. If a ligand for 
one member of the cluster is known, the scaffold of this ligand can then be expected to be a 
prevalidated starting point for the synthesis of ligands for the other members of the protein cluster. 
Consequently, members of a library of synthesized derivatives based on the scaffold should target 
several members of the protein cluster”.39 The BIOS approach merges the SCONP and PSSC 
concepts and generates a compound library of structurally diverse small molecules from a 
bioactive scaffold with prevalidated biological relevance to target proteins belonging to the same 
cluster. 
The complexity to diversity (CtD) approach generates a collection of complex and structurally 
diverse small molecules from structurally complex natural products through chemical 
transformations which target the ring system, such as ring cleavage, ring expansion, ring fusion, 
ring rearrangements and combinations. Such a library contains small molecules with core scaffolds 
distinct from each other and from the parent natural product (Figure 1.15). The library contains 
molecules with ‘increased’ chemical space and promises to cover a larger spectrum of biological 
activities comparable to the parent natural product.41,42,56 
Unlike DOS, privileged-substructure-based DOS (pDOS) employs privileged scaffolds as starting 
points to explore new biologically relevant chemical space. The DOS approach leads to compound 
collections, which occupy a wide range of chemical space but the pDOS approach, apart from 
having such wide range of chemical space coverage, produces libraries with high biological 
relevancy. Introduced by Kim and co-workers, the pDOS libraries were generated through two 
approaches namely, design of diverse core skeletons containing common privileged substructures, 
and synthesis of diverse privileged polyheterocycles using a common key intermediate.46 Libraries 
generated based on pDOS have yielded some good active compounds compared to combinatorial 
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synthesis libraries because of the increase in chemical space coverage in the former. The biology-
oriented synthesis (BIOS) libraries have high biological relevance because they are built on natural 
products and known therapeutic agents yet cover a much narrower biological space because it is 
developed with a particular cluster in mind. 
 
Figure 1.15: Some examples of new natural product-like molecules derived from the CtD 
approach41,42,57 
The CtD approach has produced more structurally complex and chemically diverse libraries 
compared to the parent natural products from which they originate. However, the biological 
relevance of the new compounds has to be validated as they may show biological activity toward 
a similar target as reported for the parent natural product or a completely new one. Compared to 
the strategies above, developed from privileged scaffolds, pDOS libraries have both large chemical 
and biological space coverage together with biological relevancy. The application of DOS synthetic 
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methodologies on privileged scaffolds has made pDOS a powerful concept to discovering novel 
therapeutic agents contrary to combinatorial synthesis libraries developed from a privileged 
scaffold. 
In conclusion, natural products and privileged scaffolds are indispensable chemical entities in 
medicinal chemistry and drug discovery. They serve as good starting points for discovering hit 
compounds for potential development into therapeutic agents. Judicious exploration of their 
inherent biological relevance through novel design of small molecules holds the key to discovering 
potent therapeutic agents for the market. For the pharmaceutical industry, it means applying 
novel synthetic methodologies to generate structurally complex and molecularly diverse, yet 
biologically relevant small molecule libraries, which hold the potential to produce more hit 
compounds in high throughput screening (HTS). 
1.4 Scope of the present work 
In view of the discussions presented in the sections above, as part of the continual search for 
bioactive new chemical entities, globally, the present work is a report on a ‘classical’ natural 
products research conducted on two classes of marine organisms, a red alga (belonging to the 
genus Laurencia) and two marine invertebrates (belonging to the genera Halichondria and 
Hymeniacidon), and a medicinal chemistry exploration of the antiplasmodium and 
antimycobacterial (against Mycobacterium tuberculosis) activities of semisynthetic derivatives of 
the natural product fusidic acid and the benzimidazole natural product structural mimetic. 
The marine environment has been a source of novel and bioactive chemical entities. With the seas 
and oceans occupying close to 70% of the earth’s surface, the marine ecosystem is home to rich 
flora and fauna biodiversity not found on land. Barely 50 years ago since their chemical diversity 
gained intense exploration, marine organisms have afforded some very important and useful 
therapeutic agents, currently in different stages of drug development (Figure 1.16). Marine algae 
and marine invertebrates are the most researched marine organisms.58 
Marine algae are a prolific source of new bioactive chemical entities. They have produced such 
novel molecular backbones with intriguing structural characteristics including polyhalogenation. 
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Chapter two of this thesis is a report on the chemical investigation of a newly identified species of 
the red algal genus Laurencia. In the family Rhodomelaceae, Laurencia is the most researched 
because it is a prolific source of halogenated terpenoids, C-15 acetogenins and indoles. Notable 
biological activities reported for Laurencia secondary metabolites include cytotoxicity, 
antibacterial, antiviral, antifouling and anti-insecticidal activities. The results from the chemical 
investigation of the new red algal species Laurencia alfredensis is presented herein as our 
published article in the journal ‘Molecules’ (belonging to Molecular Diversity Preservation 
International (MDPI)) titled, “Isolation, Characterization and Antiproliferative activity of new 
metabolites from the South African endemic red algal species Laurencia alfredensis”.59 
 
Figure 1.16: Some marine secondary metabolites as drugs 
Marine invertebrates of the phylum Porifera (sponges) are sessile water filters, which feed on 
small floating organisms in sea water. Their rich chemical diversity and biologically active 
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secondary metabolites have been attributed to their life forms, being sessile and serving as home 
to numerous microbial symbionts. Chapter three is an account on the chemical investigations 
conducted on two sponges identified as Halichondria and Hymeniacidon species. Although 
members of these two genera have been well researched, our interest in them stems from the 
fact that firstly, they were collected from unexplored (from a natural products perspective) Prince 
Edwards Islands and Marion Islands in the southern oceans of South Africa in the vicinity of the 
ice-cold continent of Antarctica and, secondly, not much literature is reported on the chemical 
diversity of sponges from the continent. It was hypothesized that, as reported for species from the 
genera from other parts of the world, the two sponges collected from the extreme cold 
environment of Antarctica will afford new and intriguing biologically active chemical entities.  
Many discoveries of therapeutic agents, as emphasized already, have come about by medicinal 
chemistry explorations of bioactive natural products and privileged scaffolds. The aim of these 
explorations has been to discover more potent, safe and efficacious agents for use as medicines. 
In the many cases when they are unsuccessful as drugs, due to unsatisfactory pharmacokinetic 
properties, for example, such agents have mostly exhibited better biological activity to serve as 
leads for future explorations against the intended target or a completely different one. The latter 
is exemplified in Chapter four in the natural product fusidic acid which is a commercially available 
natural product used as a topical drug against a number of gram positive bacterial infections. With 
unique structural properties that makes it the most potent of fusidane class of antibiotics, our 
research group has conducted structure-activity relationship (SAR) studies through semisynthetic 
derivatizations to reposition fusidic acid as an antimycobacterial agent against Mycobacterium 
tuberculosis. On the other hand, a three dimensional quantitative structure-activity relationship 
(3D-QSAR) studies on fusidic acid, followed by synthesis of the proposed analogs, led to fusidic 
acid analogs with superior antiplasmodial activity in the sub-micromolar range compared to fusidic 
acid. Chapter four is an account of further SAR investigations conducted on the most active 
analogue. 
The antiplasmodial properties of the benzimidazole privileged scaffold is well reported in the 
literature, having been explored by various groups. Notable therapeutic agents containing the 
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benzimidazole core scaffold include Albendazole, Fenbendazole, Oxfenbendazole, Thiabendazole, 
Mebendazole, Omeprazole, lansoprasole, and Pantoprasoleetc. In Chapter five, the antiplasmodial 
and antimycobacterial properties of benzimidazole derived small molecules by incorporation of 
phenolic Mannich side chain amines, as observed in amodiaquine, was explored. The results 
obtained are intended to be the beginning of future SAR investigations towards antiplasmodial 
leads based on the privileged benzimidazole scaffold. 
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Chapter Two: Chemical investigation of the red algal species Laurencia alfredensis 
2.1 General Introduction 
The family of red algae (Rhodomelaceae) comprises over 1000 recognized species globally. The 
genus Laurencia (Order Ceramiales) in this family has about 285 identified species.1 Species 
distribution is largely in the tropics and temperate regions, although they are widespread in the 
southern hemisphere (Figure 2.1).  
 
Figure 2.1: Global distribution of the genus Laurencia 
Species of Laurencia play very significant ecological roles including serving as a source of food and 
a habitat for microorganisms and some parasitic algae.2–4 Although they deter profound grazing 
from other organisms due to their ‘toxic’ secondary metabolites, some grazing organisms have 
taken advantage, having developed appropriate mechanisms for the detoxification of the toxic 
principles to foster their own survival. For example, the queen conch Strombus gigas makes use 
of Laurencia metabolites to provide chemicals necessary for the development of its larvae, while 
sea hares of the genus Aplysia obtain their chemical defenses from ingested Laurencia species.5–8 
Laurencia species have been a source of both halogenated and non-halogenated secondary 
metabolites. Bromine is the most common halogen in these metabolites, followed by chlorine and 
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then iodine. No fluorinated compounds have yet been isolated. Haloperoxidases have been 
identified as responsible for the biosynthesis of the halogenated metabolites in the chloroplasts.9 
They are mainly stored in cellular organelles called corps en cerise;10 their absence have been 
attributed to the un-detection of halogenated compounds.11–13 In a chemical defence, the 
metabolites are transported in intracellular vesicles from the corps en cerise to the cell surface 
where they are expelled. According to Reis and coworkers, actin microfilaments and microtubules 
play an underlying role in the chemical defence of red algae.14  
2.2 Chemistry and biology of the genus Laurencia 
2.2.1 Chemical constituents of Laurencia 
The secondary metabolites of Laurencia have either carbocylic molecular backbones or aromatic 
backbones (indole and phenols), with or without halogen atom (s). The carbocyclics occur as 
terpenoids (sesquiterpenes, diterpenes and polyether triterpenes) and steroids; monoterpenes 
are yet to be isolated. Apart from the aromatic metabolites, another class of intriguing secondary 
metabolites common to the genus is the non-terpenoid C15 acetogenins.15–17 
The sesquiterpenes comprise about seven different major carbon backbones. The chamigrane and 
related compounds are the most abundant metabolites in this class. Structurally, they are 
characterized by a spiro[5.5]undecane carbon skeleton (Figure 2.2).15 There are four subclasses of 
the chamigranes, α-chamigrenes, β-chamigrenes, C-7-oxy chamigrenes, and the last subclass 
possess either a 5,10-epoxide ring system or another epoxide or a lactone ring connecting the two 
six-membered rings.17 
The sesquiterpenoid class of lauranes and related compounds possess a characteristic substituted 
aromatic/phenyl group attached to a 1,2,3-trisubstituted cyclopentane or a 1,2-
dimethylbicyclo[3.1.0]hexane system (Figure 2.2). Bromine is the most occurring halogen in 
lauranes, while three iodinated compounds have been isolated so far.15,17–19  Eudesmanes, also 
called selinanes, have rarely been encountered in Laurencia species. Halogenated members of this 
group possess a bromine substituent at C-1, while cyclisation between between C-6 and C-8 has 
produced the 6,8-cycloeudesmane subclass of sesquiterpenes. 
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Figure 2.2: Representative sesquiterpenoid metabolites from the genus Laurencia20–28 
To date, only four halogenated brasilanes have been reported.21,29 These sesquiterpenes are 
characterized by a rearranged bicyclo[4.3.0]nonane carbon skeleton with a gem-dimethyl group 
at C-3, an isopropyl moiety at C-5, and another methyl substituent at C-9. A common feature of 
brasilanes is the presence of a tetrasubstituted double bond. Synderanes and bisabolanes, unlike 
brasilanes, are monocyclic compounds believed to arise from farnesane. Synderanes and related 
compounds are formed from C-6 to C-11 cyclisation of farnesane to give the six-membered 
carbocycle. Characteristic features of synderanes include C-10 bromo-substitution and Δ6, Δ7, Δ7,14, 
or Δ9 unsaturated cyclohexane ring. Bisabolanes, like synderanes, possess a cyclohexane ring 
bearing an acyclic side chain. However, the cyclohexane is formed from a C-1 to C-6 cyclisation of 
farnesane. Bisabolanes and related compounds often bear bromine and chlorine atoms in a 2,3-
trans-halide arrangement.15,17 
Cuparanes arise from C-7 to C-11 cyclisation of the bisabolane skeleton to form a five-membered 
ring. The six-membered ring of some members of this class occur as phenyl rings. Cuparanes have 
seldom been encountered in Laurencia, both halogenated and non-halogenated compounds have 
been isolated. The most recent addition to cuparanes is the trihalogenated compound 8-
deoxyalgoane isolated from Laurencia natalensis Kylin collected from the southern coast of South 
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Africa.30 Like cuparanes, aristolanes and perforanes and related compounds represent a small 
group of Laurencia sesquiterpenes. The aristolanes arise from C-6 to C-11 cyclisation of 
eremophilanes, which are derived from eudesmanes. To date, only one halogenated aristolane 
has been isolated.22 The perforanes, on the other hand, are believed to arise from chamigranes.31 
Members of this class are characterized by either a bicyclo[5.4.0]undecane carbon skeleton or a 
4,5,6-fused tricyclic skeleton after further cyclisation of C-1 and C-9 of the seven-membered ring. 
Only a few halogenated compounds of perforanes have so far been isolated. 
Figure 2.3: Representative diterpenoid metabolites from the genus Laurencia32–39 
Diterpenoids are less abundant in Laurencia species compared to sesquiterpenoids. They are 
however a diverse group of compounds with mono- to tricarbocyclic skeletons. The labdanes, for 
example, are a group of bicyclic diterpenes comprising two fused cyclohexane rings with an acyclic 
chain at C-9 (Figure 2.3). The halogenated members of this group possess a C-3 bromine 
substituent. Some common structural features include C-8 or C-9 and C-13 hydroxyl substituents, 
and a vinyl group at C-14.15,17  
Closely related to the labdanes are pimaranes. Only two members of this class have so far been 
isolated.39 The pimaranes are characterized by a C-3-Br, C-7-OH, Δ9,11 and bromohydrin between 
C-14 and C-15. The pimaranes are, structurally, tricyclic compounds obtained after further 
cyclisation of C-13 and C-17 of labdanes. Even further cyclisation of C-3 and C-18 of pimaranes 
Chapter Two: Chemical investigation of the red algal species Laurencia alfredensis 
 
35 
gives the parguerane class of Laurencia diterpenes (Figure 2.3). While an isoparguerane diterpene 
arises from a C-3-C-18-C-19-C-4 cyclobutane moiety, rearrangement of ring A of the pimarane 
skeleton into a seven or eight-membered ring affords the neoparguerane diterpene. 
Irieane diterpenes are another class of tricyclic diterpenes encountered in Laurencia. First isolated 
from L. irieii, irieanes consist of a cyclohexylmethyl unit coupled with an octahydroindene system. 
Members of this class of diterpenes possess bromine substitutions at C-1 and C-14, an α-C-4 oxy 
group and very often a C-11 oxygenation.15,17 
Dactylomelanes are a monocyclic group of diterpenes arising from C-6 to C-11 cyclisation of a 
phytane carbo-skeleton. All but one member of this group bear the same side chain at C-6. 
Bromination in these diterpenes commonly occurs at C-10. Dactylomelanes have not been 
frequently encountered in Laurencia. Other examples of less frequently encountered diterponids 
of the Laurencia genus include the prevazanes, neorogiolanes and the obtusanes and related 
compounds.17 
 
Figure 2.4: Representative triterpenoid metabolites from the genus Laurencia40–42 
Triterpenoids isolated so far from Laurencia species are a group of noncarbocylic polyethers 
biosynthesized from squalene. The members of this class of Laurencia secondary metabolites can 
be divided into three subclasses namely: those possessing a 2,7-dioxabicyclo[4.4.0]decane 
skeleton, those with a 2,8-dioxabicyclo[5.4.0]decane ring system, and those possessing a 
distinctive C2 symmetry element (Figure 2.4). Isolated non-terpenoid C15 acetogenins, which arise 
from fatty acid metabolism,43 are grouped into 12 different classes as either linear molecules or 
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cyclic ethers with varying sizes. Apart from a few members, a characteristic feature of C15 
acetogenins is the presence of conjugated (E) or (Z) enynes or bromoallene terminus. These 
compounds are mostly mono- or polyhalogenated with at least one bromine or chlorine atom or 
both (Figure 2.5).15  
Figure 2.5: Representative C15 acetogenin metabolites from the genus Laurencia44–55 
 
Figure 2.6: Representative indole and steroid metabolites from the genus Laurencia56–59 
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An even smaller group of secondary metabolites of Laurencia origin is the aromatic, largely indole, 
natural products. Brominated indoles have been reported from L. brongniartii, L. 
decumbens and L. similis species only. They have been isolated as mono-, bis-, and until recently, 
spiro-trisindoles58. Like higher plants, some Laurencia species have yielded steroid-type 
compounds such as cholesterol analogs, stigmasterol analogs and the ecdysteroid-type steroid 
pinnasterol from L. pinnata59 (Figure 2.6). 
To conclude, a cursory search through the literature reveals that L. obtusa has produced the most 
abundant of Laurencia natural products comprising the terpenoids and non-terpenoid C15 
acetogenins. With such diversity, however, indole metabolites are yet to be reported. L. viridis 
have yielded more triterpenoids than the other species, while L. brongniartii has afforded most of 
the indoles so far isolated.15–17,60  
2.2.2 Biological activities and ecological significance of Laurencia secondary metabolites 
Laurencia natural products have been evaluated for their cytotoxic, antibacterial, antiviral, 
antiparasitic and anti-inflammatory activities. Moreover, their ecological roles with respect to 
antifeedant, insecticidal, antifouling and allelopathic activities have also been reported15,17. The 
chamigrane sesquiterpene elatol (Figure 2.7) has exhibited good to moderate cytotoxic activities 
(IC50 = 0.3 – 25 µM) against a range of cancer cell lines;61–63 some elatol congeners exhibited 
cytotoxic activity at IC50 = 0.07 – 33 µM.61 Elatol has displayed antibacterial activity against some 
human pathogenic bacteria at inhibitory concentrations comparable to augmentin, latamoxef, 
ceflaclor, ceftriaxone, kanamycin, and netilmicin. It’s mode of action was found to be by 
bacteriostatic rather than bacteriocidal effects.64 Elatol showed nematicidal activity towards 
Caenorrhabditis elegans, exhibited antitrypanosomal activity against Trypanosoma cruzi (IC50 = 
0.92 μg/mL, displayed activity against the promastigote and intracellular amastigote forms of 
Leishmania amazonensis (IC50 = 4.0 μM and 0.45 μM, respectively, after 72 h), but no 
antiplasmodium activity against the human malaria parasite Plasmodium falciparum and no 
inhibition of HIV-1 reverse transcriptase.62,65 The ecological role of elatol and some 
halochamigrane congeners in protecting the algal species from pathogenic marine bacteria has 
also been demonstrated. The biological activity and/or ecological importance of some bioactive 
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Laurencia secondary metabolites against some representative assays are summarized in Table 2.1. 
Indeed, the data presented is not exhaustive as the over 700 halogenated and non-halogenated 
metabolites so far isolated from Laurencia species have been investigated in a wide range of 
assays.15,17 
 
Figure 2.7: Chemical structure of elatol 
Table 2.1: Biological activities of representative metabolites from Laurencia 
Secondary metabolite Activity 
 
Cytotoxicity66 
NCI/60 cancer cell lines: av.GI50 = 0.4 µM 
                                            av.TGI = 0.9 µM 
                                            av.LC50 = 2.8 µM 
 
Cytotoxicity67 
P-388: ED50 = 0.5 nM 
 
Enzyme inhibitory activity68 
Serine/Threonine protein phosphatase 2A (PP2A):  
IC50 = 4 -16 µM 
 
Anti-insecticidal69 
Culex pipiens pallens (mosquito): LC50 = 7.5 – 18.0 
µM 
 
Anti-insecticidal69 
Culex pipiens pallens (mosquito): LC50 = 0.15 – 1.25 
µM 
 
Antiviral70 
Herpes 1 – type (HSV-1): IC50 = 3.6 µM 
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2.3 “Isolation, Characterization and Antiproliferative activity of new metabolites from the South 
African endemic red algal species Laurencia alfredensis”71 
Laurencia alfredensis Francis, Bolton, Mattio & Anderson is a newly described species of the genus 
and is endemic to South Africa. The material investigated here was collected on a rocky intertidal 
seashore at Three Sisters, north of Port Alfred in the Eastern Cape Province of the Republic of 
South Africa in 2011.72  
 
Figure 2.8: Laurencia alfredensis sp. nov.  
[(A) Habit. (B) Outermost cortical and innermost cortical cells (scale bar = 40 lm); Inlet showing pericentral (p) and axial (a) cells 
(scale bar = 100lm). (C) Alternate branching pattern. Note cystocarps on the branchlets (scale bar = 0.6 mm). (D) 4–6 corps en cerise 
per cell (scale bar = 50 lm)].72 
                                                          
 Results have already been published: Dziwornu et al. 2017. Molecules, 22 (4).  
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A sequence of column chromatography, preparative TLC and normal phase HPLC resulted in the 
isolation of 11 compounds, comprising eight newly reported compounds along with the known 
polyether triterpene saiyacenol B (4),73 the synthetic compound (9),74 and the glycolipid, 1,2-di-O-
palmitoyl-3-O-(6-sulfo-α-d-quinovopyranosyl)-glycerol (11) (Figure 2.9).75 Except for compound 4, 
none of the compounds isolated have previously been reported from the genus Laurencia. The 
structural elucidation and the relative configuration assignments of the compounds were 
accomplished by extensive use of 1D- and 2D-NMR, HR-ESI-MS, UV and IR spectroscopic 
techniques, while the absolute configuration of compound 1 was determined by single-crystal X-
ray diffraction analysis. All compounds were evaluated against the MDA-MB-231 breast and HeLa 
cervical cancer cell lines. Compound 2 exhibited low micromolar antiproliferative activity (IC50 = 
9.3 µM) against the triple negative breast carcinoma and compound 7 was similarly active (IC50 = 
8.8 µM) against the cervical cancer cell line. 
 
Figure 2.9: The secondary metabolites (1–11) isolated from Laurencia alfredensis 
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2.3.1 Results and Discussion 
2.3.1.1. Structural Elucidation of Labdane-Type Diterpenes (1–3) 
Table 2.2: 1H (600 MHz, CDCl3) and 13C NMR (151 MHz, CDCl3) data for compounds 1-3 
 1 2 3 
No. δC δH (J, Hz) δC δH (J, Hz) δC δH (J, Hz) 
1a  1.14, dt (3.5, 13.4)  1.15, m  1.42, m 
1b 37.4, CH2 1.62, td (3.9, 12.9, 
13.2) 
37.3, CH2 1.71, m 33.5, CH2 1.71, m 
2a  2.06, dq (3.9, 13.2)  2.09, m  2.12, m 
2b 30.7, CH2 2.30, qd (3.9, 13.2) 30.9, CH2 2.25, qd (3.8, 
13.1) 
30.7, CH2 2.15, m 
3 69.7, CH 3.92, dd (4.1, 12.8) 69.2, CH 3.93, dd (4.1, 
12.7) 
69.6, CH 4.00, dd (4.3, 12.4) 
4 39.5, C  39.4, C  39.6, C  
5 47.6, CH 1.08, dd (2.5, 10.9) 47.1, CH 1.16, m 47.0, CH 1.64, dd (2.7, 12.3) 
6a  1.50, m  1.40, m  1.39, m 
6b 20.2, CH2 1.72, m 22.0, CH2 1.64, m 23.1, CH2 1.60, m 
7a  1.46, m  1.46, m  1.29, m 
7b 36.7, CH2 1.53, m 37.2, CH2 1.58, m 31.3, CH 1.46, m 
8 74.7, C  73.1, C  35.9, CH 1.73, m 
9 59.1, CH 0.84, m 60.9, CH 0.95, m 76.8, C  
10 39.0, C  38.7, C  43.3, C  
11a  1.00, m  1.28, m  1.40, m 
11b 23.0, CH2 1.38, m 20.8, CH2 1.71, m 28.0, CH2 1.55, m 
12a  1.74, m  1.79, m  1.74, m 
12b 43.0, CH2 1.80, m 42.9, CH2 1.82, m 35.8, CH2 1.95, ddd, (5.1, 12.4, 
13.7) 
13 82.9, C  83.2, C  83.3, C  
14 141.6, CH 5.94, dd (11.0, 17.5) 141.8, CH 6.00, dd (11.0, 
17.5) 
141.6, CH 5.90, dd (11.0, 17.5) 
15a  5.13, dd (0.9, 17.5)  5.13, dd (0.9, 
17.5) 
 5.12, dd (0.7, 6.6) 
15b 113.4, CH2 5.15, dd (0.9, 11.0) 113.2, CH2 5.15, dd (0.9, 
11.0) 
113.4, CH2 5.14, dd (0.7, 13.1) 
16 23.5, CH3 1.52, s 23.7, CH3 1.52, s 23.7, CH3 1.52, s 
17 30.9, CH3 1.20, s 31.8, CH3 1.43, s 16.0, CH3 0.82, d (6.6) 
18 17.7, CH3 0.95, s 17.6, CH3 0.91, s 18.4, CH3 0.96, s 
19 30.6, CH3 1.06, s 30.5, CH3 1.07, s 30.9, CH3 1.05, s 
20 24.7, CH3 1.28, s 24.7, CH3 1.09, s 16.2, CH3 0.95, s 
21 169.8, C  169.9, C  169.8, C  
22 22.1, CH3 2.00, s 22.2, CH3 2.00, s 22.1, CH3 2.00, s 
Compound 1 (Figure 2.9) was obtained as a white crystalline solid after recrystallization from 
methanol. HR-ESI-MS (m/z 451.1824, 453.1792 [M + Na]+, calcd. 451.1824 for C22H3779BrO3Na) 
data established a molecular formula of C22H37BrO3, signifying the presence of four degrees of 
unsaturation. The 1H-NMR spectrum (Figure 2.10) exhibited signals of six sharp methyl groups 
(δH 0.95, s; 1.06, s; 1.20, s; 1.26, s; 1.52, s) including a characteristic acetate methyl singlet at 
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δH 2.00 (H3-22), several overlapping multiplets at δH 1.00 – 2.35 characteristic of a terpenoid 
backbone, three methine signals with a coupling pattern indicative of the presence of a vinyl group 
(δH 5.13, dd, J = 0.9, 17.5 Hz, H-15a; 5.15, dd, J = 0.9, 11.0 Hz, H-15b; 5.94, dd, J = 11.0, 17.5 Hz, H-
14) and a methine proton (δH 3.92, dd, J = 4.1, 12.8 Hz, H-3) (Table 2.2). 
 
Figure 2.10: 1H-NMR (600 MHz, CDCl3) spectrum of compound 1  
The 13C-NMR spectrum for compound 1 indicated the presence of 22 non-equivalent carbons 
including characteristic signals, which supported the presence of an ester group (δC 169.8) and 
two olefinic carbons (δC 113.4 and 141.6). The coupling constants recorded for the vicinal coupling 
between H-3 (δH 3.92, dd, J = 4.1, 12.8 Hz) and H2-2, and H-5 (δH 1.08, dd, J = 2.5, 10.9 Hz) and H2-
6 were consistent with the 3J diaxial coupling (J = 9 – 12 Hz) and 3J axial-equatorial coupling (J = 2 
– 4 Hz) observed in substituted cyclohexane rings. The four degrees of unsaturation were 
therefore accounted for by one carbonyl group, one olefinic double bond and two substituted 
cyclohexane rings. Compound 1 was therefore deduced to be a bicyclic diterpenoid molecule. 
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The HSQC-DEPT spectrum showed cross-peaks attributed to six methyl, seven diastereotopic 
methylene, four methine and five quaternary carbons. Four 1H-1H COSY spin systems (Figure 2.11) 
were observed, comprising three similar methine proton→methylene protons→methylene 
protons coupling patterns and the ABX coupling pattern of the vinyl protons. Key HMBC 
correlations included the long range coupling of H-3 to C-4 (δC 39.5), C-18 (δC 17.7) and C-19 
(δC 30.6), and H-14 to C-13 (δC 82.9) and C-16 (δC 23.5) (Figure 2.11). The chemical shifts of the 
methine carbon signals at δC 69.7 and δC 82.9 suggested the presence of the bromine atom and 
the acetate group at C-3 and C-13, respectively. Hence, the backbone structure of 
compound 1 was found to be consistent with that of a brominated labdane-type diterpene, similar 
to the known compounds Isoconncindiol and Pinnatol A that have both been previously isolated 
from the Laurencia genus.76–78 
 
Figure 2.11: Key COSY (blue bold bonds) and HMBC (curved arrows) correlations of compound 1 
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The presence of ROE enhancements between H2-1b, H-3 and H3-18 signified they occupied the 
same face of the cyclohexane ring, as did H3-19 and H3-20 (Figure 2.12). Moreover, a ROESY 
correlation present between H3-20 and H-9 but not H-5 and H3-17 was indicative of the syn-
ent configuration about the cyclohexane ring junction and the equatorial orientation of H3-17 in 
ring B. The structure of 1 was successfully assigned as the 13-acetyl derivative of the known C-3 
brominated labdane diterpene Pinnatol A.78 
 
Figure 2.12: ROESY of compound 1: (a) Relative stereochemistry and (b) relative conformation. 
 
Figure 2.13: Stereoscopic view of 1 (absolute configuration). Non-H atoms are drawn as thermal 
ellipsoids at the 40% probability level and H atoms as spheres of arbitrary size. (Color code: C gray, 
H white, O red, Br yellow.) 
X-ray diffraction analysis of 1 confirmed the relative stereochemistry predicted from the ROESY 
data. Furthermore, the absolute configuration of 1 (Figure 2.13) was unequivocally determined via 
the anomalous X-ray scattering of the bromine atom. Both cyclohexane rings assume the more 
stable chair conformation with a syn-ent configuration at the ring junction. Protons H-1b, H-3, H-
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5 and H3-18 occupy the same face of ring A whilst H3-19 and H3-20 occupy the opposite face. The 
equatorial orientation of H3-17 compared to H3-20 supports the lack of ROESY enhancement 
between the two methyl groups. 
Compounds 2 and 3 gave similar HR-ESI-MS ion peaks (m/z 451.1821, 453.1809 [M + Na]+, calcd. 
451.1824 for C22H3779BrO3Na) to 1, suggesting they were isomeric and this was indeed supported 
by the high degree of similarity in their NMR data. In fact, both 1D- and 2D-NMR data acquired for 
compound 2, except for the ROESY data, were congruent with the NMR spectra for 1. However, 
subtle differences in the proton chemical shifts of H-9 (δH 0.95, m), H-20 (δH 1.09, s), H-17 (δH 1.43, 
s) and H2-11 (δH 1.28, m; 1.71, m) (Table 2.2) were observed in the 1H-NMR spectrum 
of 2 compared to 1. The presence of ROESY cross-peaks from H3-20 to H-9 and H3-17 confirmed a 
similar spatial orientation of these protons and the absence of such a correlation between H3-20 
and H-5, implied a similar configuration about the ring junction as observed in 1 (Figure 2.14a). 
The exact same chemical shift observed for H3-16 (δH 1.52, s) in compounds 1–3 indicated that all 
three labdane diterpenes have the same 13S configuration, consistent with the absolute 
configuration reported for the structurally related marine natural product, isoconncindiol.76,77 The 
structure of 2 was therefore elucidated as the 8S-diastereomer of 1, that is with the only 
difference observed at the stereogenic center C-8, thus confirming the structure of 2 as the 13-
acetyl derivative of isoconcinndiol. 
 
Figure 2.14: (a) Key ROESY (blue curved arrows) of compound 2; and (b) COSY (bold bonds) and 
key HMBC (red curved arrows) of compound 3. 
Compound 3 showed signals for five methyl singlets (δH 0.95; 0.96; 1.05; 1.52; 2.00), a methyl 
doublet (δH 0.86, d, J = 6.6 Hz, H3-17), several overlapping multiplets at δH 1.00 – 2.15, the vinyl 
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protons double doublets (δH 5.12, dd, J = 0.7, 6.6 Hz, H-15a; 5.14, dd, J = 0.7, 13.1 Hz, H-15b; 5.90, 
dd, J = 11.0, 17.5 Hz, H-14) and the “halo-methine” proton H-3 at δH 4.00 (dd, J = 4.3, 12.4 Hz) in 
its 1H-NMR spectrum (Table 2.2). Four different 1H-1H COSY spin systems were observed (Figure 
2.14b), with two of them (H2-1→H-3 and H-14→H2-15) similar to those also observed in 
compounds 1 and 2. However, the presence of the significant H-5→H3-17 (Figure 2.14b), 
concomitant with the absence of the H-9→H2-12 COSY spin system and the splitting of H3-17 into 
a doublet, suggested that 3 was a positional isomer of 1 and 2, with its hydroxyl group present at 
C-9 (δC 76.8) rather than C-8 (δC 35.8). The relative configuration of the groups on the cyclohexane 
ring A was retained whilst no ROE cross-peak was observed between H3-17 and H3-20. The 
structure of 3 was therefore elucidated as the 13-acetyl derivative of concinndiol.79 
2.3.1.2. Structural Elucidation of Polyether Triterpenes (4–7) 
 
Figure 2.15: 1D NMR spectra of compound 4 
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Compound 4 was isolated as a white amorphous solid. The 1H-NMR spectrum (Figure 2.15) 
showed signals of eight methyl groups (δH 1.07, s; 1.10, s; 1.13, s; 1.16, s; 1.18, s; 1.19, s; 1.26, s; 
1.38, s), several overlapping multiplicities at δH 1.3 – 2.3, and six methine proton groups (Figure 
2.15 and Table 2.3). The 13C-NMR spectrum showed 30 carbon signals and a high degree of 
oxygenation was inferred from 10 carbon resonances present in the downfield range δC 70 – 87 
ppm. A signal observed at δC 59.0 suggested the presence of a bromo-methine C-3, characteristic 
in similar polyether triterpenes reported from the genus Laurencia .80,81 This was confirmed by the 
presence of the mono-isotopic bromine peaks at m/z 611/609 [M + Na]+, 571/569 [M − 
OH]+ recorded in the LR-ESI-MS and consistent with the reported values by Cen-Pacheco and 
coworkers.73 Compound 4 was deduced to be a congener of this group of secondary metabolites 
and the structure was found be that of the known compound saiyacenol B, previously isolated 
from L. viridis.73 
After careful examination of the 1D NMR spectra of a fraction obtained from the same HPLC run 
that yielded compound 2, we identified the presence of a mixture of the two very closely related 
compounds 5 and 6. However, due to the paucity of the HPLC fraction obtained (0.5 mg), we were 
unable to separate these two compounds any further. The HR-ESI-MS spectrum obtained for 
compound 5 established a molecular formula of C30H50O6, requiring six degrees of unsaturation. 
Its 1H-NMR spectrum exhibited signals of seven methyls (δH 1.08, s; 1.10, s; 1.13, s; 1.15, s; 1.19, 
s; 1.20, s; 1.68, s), several overlapping multiplicities at δH 1.2 – 2.2, six oxygenated methine protons 
double doublets and two olefinic geminal protons at δH 4.77 (m, H-1a) and 4.98 (m, H-1b) (Table 
2.3).  
The 13C-NMR spectrum showed the presence of 30 non-equivalent carbons and the HSQC-DEPT 
confirmed the presence of seven methyl, 11 diastereotopic methylene, six methine and six 
quaternary carbons. Thorough analysis of the 1D and 2D NMR data identified compound 5 as 
another polyether triterpene, which lacked a C-3 bromine atom and one methyl group (δH 1.26, s, 
H3-1) compared to 4. With evidence of only one double bond (C-1, δH 4.77/4.98, δC 110.2; C-2, 
δC 146.2), compound 5 was deduced to be pentacyclic. 
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Table 2.3: 1H (600 MHz, CDCl3) and 13C NMR (151 MHz, CDCl3) data for compounds 4-7 
 473 5 6 7 
No. δC δH (J, Hz) δC δH (J, Hz) δC δH (J, Hz) δC δH (J, Hz) 
1a    4.77, m  5.23, m  4.76, m 
1b 31.0 1.26, s 110.2 4.98, m 114.7 5.30, m 110.2 4.97, m 
2 74.9  146.2  146.0  145.9  
3 59.0 3.88, dd (4.0, 12.3) 83.4 4.35, dd (6.1, 8.9) 80.7 4.53, dd (5.2, 9.5) 83.3 4.34, dd (6.1, 8.7) 
4a  2.09, dt (4.0, 13.5)  1.71, m  1.83, m  1.71, m 
4b 28.2 2.23, qd (3.7, 13.1) 31.4 2.02, m 32.3 2.15, m 31.3 2.01, m 
5a  1.53, m  1.64, m  1.68, m  1.62, m 
5b 37.4 1.80, m 34.3 2.12, m 34.1 1.81, m 34.2 2.10, m 
6 74.4  84.5  84.5  84.4  
7 86.5 3.03, dd (2.3, 11.4) 83.6 3.32, dd (2.6, 11.6) 83.6 3.31, dd (2.6, 11.6) 83.6 3.34, dd (2.7, 11.6) 
8a  1.40, m  1.44, m  1.44, m  1.45, m 
8b 23.0 1.70, m 25.0 1.64, m 25.0 1.64, m 24.8 1.65, m 
9a  1.52, m  1.57, m  1.57, m  1.56, m 
9b 38.7 1.73, m 38.8 1.76, m 38.7 1.76, m 38.8 1.78, m 
10 71.4  71.3  71.2  72.1  
11 76.7 3.53, dd (7.3, 11.0) 76.6 3.58, dd (7.3, 11.0) 76.6 3.58, dd (7.3, 11.0) 77.8 3.51, dd (6.5, 11.2) 
12a  1.48, m  1.52, m  1.52, m  1.57, m 
12b 21.3 1.86, m 21.4 1.93, m 21.4 1.93, m 21.7 1.88, m 
13a        1.70, m 
13b 21.4 1.77 21.5 1.78, m 21.5 1.78, m 25.8 2.02, m 
14 75.3 3.71, dd (4.3, 11.0) 75.4 3.71, dd (4.8, 11.2) 75.5 3.72, dd (4.8, 11.2) 75.1 4.19, dd (4.0, 9.5) 
15 84.5  84.4  84.4  138.5  
16a  1.61, m  1.64, m  1.64, m   
16b 35.5 1.95, m 35.4 1.96, m 35.4 1.96, m 122.3 5.52, dd (2.7, 13.8) 
17a  1.63, m  1.66, m  1.66, m  2.06, m 
17b 27.6 1.84, m 27.7 1.86, m 27.7 1.86, m 27.6 2.40, ddd (3.1, 7.6, 
15.1) 
18 85.8 3.85, dd (6.1, 8.4) 85.8 3.86, dd (5.8, 8.2) 85.8 3.86, dd (5.8, 8.2) 84.0 3.16, dd (3.2, 6.7) 
19 84.5  84.6  84.6  69.9  
20a  1.59, m      1.56, m 
20b 33.9 1.96, m 34.0 1.96, m 34.0 1.96, m 39.7 1.84, m 
21a        1.49, m 
21b 26.5 1.79, m 26.6 1.80, m 26.6 1.80, m 24.5 1.60, m 
22 86.8 3.76, dd (6.8, 8.6) 86.8 3.77, dd (6.7, 8.7) 86.8 3.77, dd (6.7, 8.7) 84.1 3.14, m 
23 70.6  70.6  70.6  71.6  
24 24.0 1.10, s 24.0 1.10, s 24.0 1.10, s 23.9 1.12, s 
25 23.7 1.38, s 17.7 1.68, s 44.7 4.09, d (0.9) 17.7 1.68, s 
26 20.0 1.19, s 23.2 1.15, s 23.3 1.17, s 23.1 1.16, s 
27 21.2 1.16, s 21.3 1.20, s 21.3 1.20, s 20.1 1.21, s 
28 21.5 1.07, s 21.6 1.08, s 21.6 1.08, s 13.0 1.65, s 
29 23.6 1.13, s 23.6 1.13, s 23.6 1.13, s 20.2 1.18, s 
30 27.5 1.18, s 27.6 1.19, s 27.6 1.19, s 26.1 1.16, s 
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Figure 2.16: (a) COSY (bold bonds) and key HMBC (red curved arrows); and (b) key ROESY (blue 
curved arrows) of compound 5. 
Six 1H-1H COSY spin systems were observed, of which four exhibited the concomitant vicinal AA’BB’ 
coupling pattern involving two methylene groups, with one of the groups further involved in an 
ABX vicinal coupling with a methine proton (Figure 2.16a). The coupling constants recorded, 
especially for the methine protons supported the presence of both substituted oxolane and oxane 
moieties. After careful analysis of the long range 1H–13C correlations, the rest of the molecule was 
found to be similar to 4, apart from the change in chemical shifts observed from C-1 through C-7 
and C-25. An HMBC cross-peak between H-3 and C-1 and the downfield shift of C-3 to δC 83.4 
suggested the absence of a bromine atom to give the exocyclic 2-methyl ethylenyl group on the 
oxolane ring in compound 5, which is consistent with similar isolated compounds.82 ROESY 
enhancements of H-14 and H-18 by H3-28 and H3-29, respectively, led to a similar relative 
configuration for 5 as reported for 473 (Figure 2.16b). Compound 5 is reported for the first time 
here as Alfredensinol A. 
The NMR data obtained for compound 6 were superimposable with that of 5, signifying their 
structures were closely related (Figure 2.17), with the exception of the olefinic geminal protons of 
C-1 resonating downfield at δH 5.23 (m, H-1a) and δH 5.30 (m, H-1b) due to the presence of the 
hydroxyl group on the methylene carbon C-25 (δC 44.7). Moreover, C-1 occurred downfield at 
δC 114.7, while C-3 moved upfield to δC 80.7 (Table 2.3). The HR-ESI-MS ion peak at m/z 545.3457 
[M + Na]+ (calcd. 545.3454) obtained for 6 established a molecular formula of C30H50O7, implying 
an additional O-atom compared to 5. Therefore, compound 6 is reported here as the new C-25 
hydroxyl derivative of compound 5, Alfredensinol B. 
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Figure 2.17: 1H NMR spectrum of alfredensinol A (5) and B (6) 
Compound 7 was isolated as a white amorphous solid. It recorded a HR-ESI-MS ion peak 
of m/z 507.3693 [M + H]+ (calcd. 507.3686) for the molecular formula C30H50O6 and was identified 
as another polyether triterpene from its 1H- and 13C-NMR data. Six oxygenated methine doublet 
of doublets including an olefinic proton (δH 5.52, dd, J = 2.7, 13.8 Hz, H-16) and similar olefinic 
geminal protons (δH 4.77, m, H-1a; 4.98, m, H-1b) to compound 5 (Table 2.3) were evident in 
the 1H-NMR spectrum. With six degrees of unsaturation inferred from the molecular formula, 
compound 7 was deduced to be a tetracyclic molecule with the presence of two double bonds. 
Six 1H-1H COSY spin systems were observed, including the key correlations involving the olefinic 
proton H-16, the diastereotopic methylene protons H2-17 and the oxymethine H-18 (Figure 2.18a). 
Key HMBC cross-peaks observed from H-16 to C-14, C-15, C-18, and C-28 established the 
Δ15,16 olefinic functionality. HMBC correlations from H-22 (3JC, H) and H3-29 (3JC, H) to C-18, along 
H-1b 
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with key COSY correlations between H2-20, H2-21 and H-22, confirmed the presence of an oxane 
ring in the right hand side chain of 7. 
 
Figure 2.18: (a) COSY (bold bonds) and key HMBC (red curved arrows); and (b) some ROESY (blue 
curved arrows) correlations for compound 7 
The absence of ROE enhancement of H-16 by H3-28 was indicative of the trans configuration about 
the double bond between C-15 and C-16, which was further supported by the ROESY correlation 
between H-14 and H-16 (Figure 2.18b). The relative configuration at C-18 was established as a 
result of the observed ROESY cross-peak from H-18 to H-16 and the absence of one to H3-29. The 
absence of an ROE correlation between H-22 and H3-29, implied axial orientations for both these 
groups on the oxane ring. Thus, the structure of 7 was elucidated and identified as a new 
compound which is named here as Alfredensinol C. 
2.3.1.3. Structural Elucidation of Cholestane-Type Ecdysteroids (8–10) 
Compound 8 was isolated as a white amorphous solid and HR-ESI-MS data obtained established 
the molecular formula as C31H48O6. The 1H-NMR spectrum (Figure 2.19) showed the presence of 
seven methyl singlets of which two were acetate methyls at δH 2.03 (s, H3-30) and δH 2.04 (s, H3-
31), and five oxymethine protons. Several overlapping multiplets were observed in the methylene 
envelope between δH 1.11 – 2.15 (Figure 2.19 and Table 2.4). 
The 13C-NMR data showed 31 signals including three carbonyl peaks characteristic of a ketone at 
δC 199.6 (C-6) and two esters (δC 169.3, C-28; 169.5, C-29), two aromatic/olefinic carbons 
(δC 123.3, C-7; 162.5, C-8), and three signals at δC 68.5 (C-2), 68.3 (C-3), and 73.7 (C-22) suggesting 
the presence of C-O chemical environments (Table 2.4). The HSQC-DEPT data indicated the 
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presence of seven methyl, eight diastereotopic methylene, 10 methine, and six quarternary 
carbons. 
 
Figure 2.19: 1H NMR spectrum (600 MHz, CDCl3) of compound 8 
Two 1H-1H COSY spin systems were observed for 8, from H2-1 to H-5 and H-7 to H3-27 (Figure 2.20). 
Some characteristic aspects of a steroidal skeleton became evident from the 1H, 13C and COSY 
NMR data; for example, the 1H chemical shifts for H3-18 and H3-19, and the splitting of H3-21, H3-
26 and H3-27 into doublets (Figure 2.19) were characteristic of the side chain to C-17 for 
cholesterol. The chemical shifts of C-7 and C-8, together with the chemical shift of H-7 (δH 5.75, 
m) and its COSY correlation to H-9 (δH 2.25, ddd, J = 2.5, 6.9, 9.9) and H-14 (δH 2.05, m) suggested 
the ketone carbonyl was adjacent to the C-7-C-8 double bond at C-6 to give the endocyclic α, β-
unsaturated ketone, a structural feature of ecdysteroids. HMBC cross-peaks from H2-1 to C-2, C-
5, C-9, C-10 and C-19; H2-4 to C-2 and C-3; and H-5 to C-4, C-6, C-9, C-10 and C-19 confirmed the 
structure of ring A, and that the ketone was at C-6 (Figure 2.20).  
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Table 2.4: 1H (600 MHz, CDCl3) and 13C NMR (151 MHz, CDCl3) data for compounds 8-10 
 8 9 10 
No. δC δH (J, Hz) δC δH (J, Hz) δC δH (J, Hz) 
1a  1.72, m    1.80, dd (3.4, 15.0) 
1b 36.7, CH2 2.00, m 36.1, CH2 1.88, m 36.6, CH 2.01, m 
2 68.5, CH 4.93, m 71.3, CH 4.88, m 68.5, CH 4.93, m 
3 68.3, CH 5.04, m 66.4, CH 4.01, m 68.3, CH 5.05, m 
4a  1.93, ddd (2.8, 12.6, 15.4)  1.87, m  1.94, m 
4b 21.2, CH2 2.10, m 23.6, CH2 2.03, m 21.1, CH2 2.10, m 
5 48.7, CH 2.58, dd (3.5, 12.5) 47.8, CH 2.74, dd (3.5, 12.4) 49.0, CH 2.63, dd (3.23, 12.2) 
6 199.6, C  200.6, C  199.4, C  
7 123.3, CH 5.75, m 123.3, CH 5.73, m 127.0, CH 5.93, d, (2.2) 
8 162.5, C  162.6, C  157.6, C  
9 50.6, CH 2.25, ddd (2.5, 6.9, 9.9) 50.7, CH 2.25, ddd (2.5, 6.7, 11.7) 46.8, CH 2.68, m 
10 37.7, C  37.9, C  38.0, C  
11a  1.62, m  1.61, m  1.58, m 
11b 21.5, CH2 1.78, m 21.5, CH2 1.79, m 20.3, CH2 1.76, m 
12a  1.40, m  1.41, m  1.69, m 
12b 38.7, CH2 2.14, m 38.7, CH2 2.12, dd (1.9, 13.0) 29.9, CH2 1.94, m 
13 44.8, C  44.8, C  48.2, C  
14 55.2, CH 2.05, m 55.1, CH 2.05, m 96.1, C  
15a  1.53, m  1.53, m  1.72, m 
15b 22.6, CH2 1.64, m 22.6, CH2 1.65, m 24.7, CH2 2.15, m 
16a  1.44, m  1.44, m  1.52, m 
16b 26.9, CH2 1.80, m 26.9, CH2 1.82, m 25.7, CH2 1.89, m 
17 53.3, CH 1.33, m 53.2, CH 1.34, m 47.9, CH 1.89, m 
18 12.3, CH3 0.61, s 12.3, CH3 0.60, s 16.4, CH3 0.76, s 
19 14.9, CH3 0.96, s 14.8, CH3 0.96, s 14.7, CH3 0.97, s 
20 42.4, CH 1.68, m 42.4, CH 1.69, m 41.8, CH 1.74, m 
21 12.6, CH3 0.94, d (6.8) 12.6, CH3 0.94, d (6.4) 12.8, CH3 0.89, d (5.1) 
22 73.7, CH 3.62, dd (1.6, 10.1) 73.8, CH 3.61, m 74.1, CH 3.63, m 
23a  1.24, m  1.25, m  1.23, m 
23b 27.8, CH2 1.36, m 27.7, CH2 1.36, m 27.2, CH2 1.39, m 
24a  1.17, m  1.16, m  1.17, m 
24b 36.0, CH2 1.39, m 36.0, CH2 1.42, m 36.0, CH2 1.39, m 
25 28.1, CH 1.55, m 28.1, CH 1.55, m 28.2, CH 1.56, m 
26 22.4, CH3 0.89, d (6.8) 22.4, CH3 0.89, d (6.9) 22.4, CH3 0.90, d (6.4) 
27 22.9, CH3 0.90, d (6.8) 22.9, CH3 0.90, d (6.9) 23.0, CH3 0.92, d (6.4) 
28 169.3, C  170.0, C  169.6, C  
29 169.5, C  21.2, CH3 2.02, s 169.4, C  
30 21.1, CH3 2.03, s   21.2, CH3 2.04, s 
31 21.2, CH3 2.04, s   21.2, CH3 2.05, s 
Similarly, correlations from H-7 to C-9 and C-14; H-9 to C-7, C-8, C-11 and C-19; and from H-14 to 
C-7, C-8, C-12, C-13, C-15 and C-18 confirmed the structures of rings B, C and D, respectively. The 
single 1H-1H COSY spin system from H-17 to H-27 was supported by the HMBC cross-peaks to arrive 
at the 2-hydroxy-1, 5-dimethylhexyl side chain at C-17, and hence the position of the hydroxyl 
group at C-22. Finally, COSY correlation between H-2 and H-3 and HMBC correlation of H-2 and H-
3 to C-28 and C-29, respectively, signified the acetates were attached to the cholestane 
ecdysteroid backbone at C-2 and C-3. 
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Figure 2.20: Key COSY (bold bonds) and HMBC (red curved arrows) of compound 8 
 
Figure 2.21: Key NOESY (blue curved arrows) of 8 
Key NOESY enhancements together with 13C comparisons enabled the assignment of the relative 
configuration of 8 (Figure 2.21). The chair conformation and trans-fused A/B ring junction were 
established from two 1,3-diaxial NOESY correlations from H3-19β to H3-30β (OAc) and H-4β 
(δH 1.93), respectively, and a further two 1,3-diaxial NOESY correlations from H-5 to H-3 and H-9, 
where the latter three protons are all in the same α-orientation. The trans-ring-fusion between 
rings A and B was further corroborated by the absence of a NOESY cross peak between the 
methine proton H-5 and H3-19. The presence of correlation between H3-18 and H3-19 but not H3-
21 established the β-configuration of H3-18 and H3-19 to the steroid backbone suggesting a chair-
chair-chair conformation of rings A, B and C. The relative configurations at C-17, C-20, C-21 and C-
22 were assigned, by comparison of the 13C-NMR data with that of the structurally related 
22R hydroxyl cholesterol.83 The structure of 8 was determined as a new compound and named 
Alfredensterol. 
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Compound 9 (Figure 2.22) was isolated as a white amorphous solid and its molecular formula was 
found to be C31H48O7 from the HR-ESI-MS ion peak at m/z 533.3488 (calcd. 533.3478). The 1H- 
and 13C-NMR spectroscopic data recorded for compound 9 were virtually identical to 
compound 8 and suggested a closely related cholestane-type ecdysteroid (Table 2.4). The two 
acetate methyl singlets (δH 2.04, s, H3-30; δH 2.05, s, H3-31), together with the signals for H3-19, 
H3-26 and H3-27 for 9 were in close correspondence (±0.02 ppm) with the chemical shifts for 8, 
while a downfield shift to δH 0.76 was observed for H3-18. The HSQC-DEPT spectrum revealed one 
less methine proton and one additional quaternary carbon at δC 96.1, indicating the likely 
presence of a tertiary alcohol functionality at C-14 and therefore accounting for the extra O-atom 
in the molecular formula of 9. Moreover, the 1H-1H COSY spectrum exhibited three spin systems 
from H2-1 to H-5, H-7 to H2-12 and H2-15 to H3-27, thus revealing the absence of H-14. The relative 
configuration of compound 9 was assigned primarily using 13C and ROESY NMR data, and were 
found to be similar to those observed in 8. To the best of our knowledge, there is only one report 
of 9 in the literature as a by-product in the synthesis of ecdysone related compounds, in which no 
extensive NMR assignments could be found, including 13C-NMR data.74 Therefore, this is the first 
report of 9 from a natural source, which we have named 14α-hydroxy Alfredensterol (Figure 2.22). 
 
Figure 2.22: Chemical structures of compounds 9 and 10 
Compound 10 (Figure 2.22) was isolated as a white amorphous solid. It recorded a HR-ESI-MS ion 
peak of m/z 475.3432 [M + H]+ (calcd. 475.3423) for the molecular formula C29H46O5. The 1H- 
and 13C-NMR data for 10 were very similar to both compounds 8 and 9 described above. However, 
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key noticeable differences in the 1H-NMR data of 10 were observed, including the absence of an 
acetate methyl singlet and the upfield chemical shifts of H-2 (δH 4.88, m) and H-3 (δH 4.01, m) 
compared to 8. The 13C-NMR data of 10 showed corresponding changes (δC 71.3, C-2; 66.4, C-3) 
consistent with its 1H-NMR. The 1H-1H COSY spin systems were similarly consistent with those 
observed in compound 8. The position of the single acetate group on ring A was assigned to C-2, 
on the basis of the chemical shifts of C-2 and C-3 (Table 2.4), and HMBC cross-peaks from H-2 to 
C-3, C-4, C-10 and C-28, and from H-3 to C-1, C-2 and C-5. Analysis of the ROESY data revealed the 
same relative configuration of 10 as observed in 8 and 9. Compound 10 has not previously been 
reported and is named here as 3-deacetoxy Alfredensterol (Figure 2.22). 
2.3.1.4. Characterization of Isolated Glycolipid (11) 
Compound 11 (Figure 2.23) was isolated as a white amorphous solid. The HR-ESI-MS data 
of 11 suggested a molecular formula of C41H78O12S for m/z 793.5143 [M − H]−(calcd. 793.5136). 
The structure was elucidated upon analyses of its NMR data as 1, 2-di-O-palmitoyl-3-O-(6-sulfo-α-
d-quinovopyranosyl)-glycerol and confirmed by comparison with published data.75 Compound 11 
was previously reported from the brown alga Lobophora variegata, however, this is the first report 
of 11 from the genus Laurencia. 
 
Figure 2.23: Key HMBC (red curved arrows) of 11 
2.3.1.5. Antiproliferative Activity Results 
Compounds 1–11 were evaluated for their antiproliferative activity against MDA-MB-231 triple 
negative human breast carcinoma and HeLa human cervical carcinoma (Figure 2.24). Generally, all 
the compounds displayed antiproliferative activity in the mid-to-low micromolar range against the 
two cells lines tested. 
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Figure 2.24: In vitro antiproliferative activity of compounds 1–10   
To the best of our knowledge, brominated labdane diterpenes previously isolated from the 
genus Laurencia have not been investigated for their antiproliferative activity. However, non-
halogenated labdanes have been reported to exhibit moderate to weak cytotoxic activity against 
various cancer cell lines.84–86 In this study, the brominated labdane-type diterpenes 1–3 were all 
found to be moderately active against both cancer cell lines tested, with the exception of 
Isoconcinndiol 13-acetate 2, the 8S-diastereomer of 1, which showed the highest antiproliferative 
activity against the HeLa cancer cell line (IC50  = 9.3 ± 1.3 µM), not only in this class of compounds 
but amongst all ten compounds tested in this study (Figure 2.24), indicating that the 
stereochemistry at C-8 in 2 could be playing a role in the observed biological activity. 
Brominated polyether triterpenes of the [4.4.0] class have been reported to have good to 
moderate cytotoxic activity.87 The antiproliferative activity against the HeLa cell line recorded for 
the known compound 4, saiyacenol B, in our study was found to be within the previously reported 
values.73 To the best of our knowledge, this current work is the first report of the antiproliferative 
effects of this class of polyether triterpenes against the MDA-MB-231 breast cancer cell line, with 
the new compound 7, alfredensinol C, exhibiting the highest activity (IC50 = 8.8 ± 5.6 µM) in this 
particular class of compounds and also amongst all compounds tested (Figure 2.24). 
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The antiproliferative activity recorded for the ecdysteroids 8–10 was consistent with biological 
activity data previously reported for both natural and semi-synthetic congeners, which have been 
shown to exhibit moderate antiproliferative or cytotoxic activity.88 In this particular class of 
compounds, the new alfredensterol 8 was found to be the most active against the HeLa cervical 
cancer cell line (IC50 = 25.6 ± 1.2 µM), whilst its 14α-hydroxyl derivative 9 exhibited the best 
antiproliferative effect (IC50 = 15.8 ± 1.1 µM) against the MDA-MB-231 breast cancer cell line 
(Figure 2.24). 
In summary, the new compounds 2 and 7 exhibited the best antiproliferative activity against the 
HeLa and MDA-MB-231 cancer cell lines, respectively, while 11 was found to be non-toxic to both 
cell lines. 
2.3.2. Materials and Methods 
2.3.2.1. General Experimental Procedures 
Melting points (uncorrected) were recorded on a Reichert-Jung Thermovar hot-stage microscope 
(Reichert Optische Werke, Vienna, Austria). Optical rotations were measured on a PerkinElmer141 
polarimeter by using Na lamp (PerkinElmer Ltd., Beaconsfield, Buckinghamshire, UK. UV spectra 
were obtained on a CARY 60 UV-VIS 2.00 with software version 5.0.0.999 by Agilent Technologies 
(Santa Clara, CA, USA). PerkinElmer Spectrum Version 10.03.02 (PerkinElmer Ltd., Llantrisant, 
Wales, UK) was used to record the IR spectra. NMR spectra were obtained on a BRUKER Ascend 
600 ((Bruker, Billeria, MA, USA) cryoprobe prodigy at 600 MHz and 151 MHz for 1H and 13C nuclei, 
respectively. CDCl3 (δH 7.25, δC 77.00) was used for 1–10 while DMSO-d6 (δH 2.50, δC 49.00) was 
used for 11. HR-ESI-MS data were obtained via LC-TOF-MS on a Waters Synapt G2 (Waters Corp, 
Boston, MA, USA), ESI probe injected into a stream of acetonitrile, Cone voltage 15 V. Normal 
phase HPLC was carried out on Agilent 1220LC system/1260 Infinity (Santa Clara, CA, USA) 
equipped with a photodiode array and refractive index detectors. Column chromatography was 
carried out on silica gel 60 (Fluka 70–230 mesh, 63–200 μm, (Sigma-Aldrich, Buchs, Switzerland), 
and preparative TLC on silica gel 60 Analtech GF254 (20 × 20 cm, 2000 μm, Analtech Inc., Newark, 
DE, USA). Analytical TLC were performed on Merck silica gel 60 F254 (Merck KGaA, Darmstadt, 
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Germany) and silica gel 60 RP-18 F254 plates and bands were visualized by heating after staining 
with ceric ammonium sulfate reagent. 
2.3.2.2. Plant Material 
The species studied here has only recently been described.72 It was previously known in South 
Africa as Laurencia elata (C. Agardh) Hooker & Harvey. The latter is an Australian species, which 
has recently been placed in a new genus as Coronaphycus elatus (C. Agardh) Metti.89 The South 
African material has been described as a new endemic species Laurencia alfredensis.72 It is the 
same material previously described as “Laurencia cf. elata”, and used in 1H-NMR profiling of crude 
organic extracts as an identification tool for nine species of South African Laurencia.72 
2.3.2.3. Extraction, Isolation, and Characterization 
The fresh alga (239.2 g) was extracted sequentially with MeOH (15 min) and then CH2Cl2/MeOH 
(2:1 v/v) (24 h) by cold maceration at room temperature. The solvents were evaporated in vacuo 
giving 5.1 g and 1.1 g of dark green MeOH and CH2Cl2/MeOH (2:1 v/v) crude extracts, respectively. 
The two extracts were combined based on close similarity of their 1H-NMR data. The resultant 
extract was triturated with CH2Cl2/MeOH (1:1 v/v) to obtain 1.5 g of organic fraction and 4.7 g of 
aqueous fraction. Fractionation by flash chromatography was carried out on 1 g of the organic 
fraction with n-hexane and EtOAc mixtures of increasing polarity and finally with EtOAc/MeOH 
(1:1 v/v). The fractions obtained with 80%, 70% and 40% n-hexane in EtOAc gave similar TLC 
profiles and were combined and further chromatographed on a silica column with n-
hexane/EtOAc (9:1 v/v) with increasing polarity to n-hexane/EtOAc (4:6 v/v) to afford 12 sub-
fractions A–L. Preparative TLC (n-hexane/EtOAc 8.5:1.5 v/v) of B gave 3 (1.1 mg) while 1 (3.7 mg) 
and 4 (4.8 mg) were obtained with n-hexane/EtOAc (3:1 v/v) from E and D, respectively. 
Compounds 8 (3.1 mg) and 9 (3.5 mg) were obtained from I with n-hexane/EtOAc (1:1 v/v) 
and 10 (1.9 mg) from J with the same mobile phase. Further purification on Phenomenex Luna 10 
μm Prep Silica (2) 250 mm × 10 mm (Phenomenex, Torrance, CA, USA) of F with n-hexane/EtOAc 
(4:1 v/v) at a flow rate of 4 mL/min gave 2 (0.5 mg) and 0.5 mg of a mixture of 5 and 6. 
Compound 7 (2.5 mg) was obtained on a Whatman Partisil column 10 μm, 500 mm × 10 mm 
(Hichrom Ltd., Reading, Berkshire, UK) from K and L with n-hexane/EtOAc (3:2 v/v) eluting at 4 
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mL/min, followed by reversed phase preparative TLC with MeOH/H2O (1:4 v/v). Meanwhile, the 
EtOAc/MeOH (1:1 v/v) fraction precipitated out a solid which on trituration with 
CH2Cl2 afforded 11 (49.6 mg). 
13-Acetyl Pinnatol A (1): Clear crystals; Mp.: 115–117 °C; +26.6 (c 0.15, CHCl3); IR (cm−1): 3450, 
2950, 2850, 1700, 1350, 1250, 1100; 1H- and 13C-NMR data (CDCl3), Table 2.2; HR-ESI-
MS m/z 451.1824 [M + Na]+ (calcd. for C22H37O379BrNa, 451.1824). 
Isoconcinndiol 13-acetate (2): White amorphous solid; +14.4 (c 0.09, CHCl3); IR (cm−1): 3455, 2943, 
1732, 1367, 1251, 1095; 1H- and 13C-NMR data (CDCl3), Table 2.2; HR-ESI-MS m/z 451.1821 [M + 
Na]+ (calcd. for C22H37O379BrNa, 451.1824). 
Concinndiol 13-acetate (3): White amorphous solid; +16.7 (c 0.06, CHCl3); IR (cm−1): 3467, 2923, 
1732, 1462, 1367, 1241; 1H- and 13C-NMR data (CDCl3), Table 2.2; HR-ESI-MS m/z 451.1821 [M + 
Na]+ (calcd. for C22H37O379BrNa, 451.1824). 
Saiyacenol B (4)73: White amorphous solid; 1H- and 13C-NMR data (CDCl3), Table 2.3; ESI-
MS m/z 611, 609, 606, 604, 571, 569 and 507. 
Alfredensinol A (5): Clear oil; 1H- and 13C-NMR data (CDCl3), Table 2.3; HR-ESI-MS m/z 505.3527 [M 
− H]+ (calcd. for C30H49O6, 505.3529). 
Alfredensinol B (6): Clear oil; 1H- and 13C-NMR data (CDCl3), Table 2.3; HR-ESI-MS m/z 545.3457 [M 
+ Na]+ (calcd. for C30H51O7Na, 545.3454). 
Alfredensinol C (7): White amorphous solid; +15.0 (c 0.25, CHCl3); IR (cm−1): 3409, 2940, 1374, 
1092; 1H- and 13C-NMR data (CDCl3), Table 2.3; HR-ESI-MS m/z 507.3693 [M + H]+ (calcd. for 
C30H51O6, 507.3686). 
Alfredensterol (8): White amorphous solid; +22.0 (c 0.13, CHCl3); UV (MeOH) λmax(log ε), nm: 239 
(3.43); IR (cm−1): 3425, 2925, 1737, 1643, 1350, 1234, 1035; 1H- and 13C-NMR data (CDCl3), Table 
2.4; HR-ESI-MS m/z 517.3527 [M + H]+ (calcd. for C31H49O6, 517.3529). 
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14α-Hydroxy Alfredensterol (9): White amorphous solid; +25.8 (c 0.26, CHCl3); UV (MeOH) λmax(log 
ε), nm: 222 (3.76); IR (cm−1): 3240, 2925, 1738, 1645, 1375, 1234, 1036; 1H- and 13C-NMR data 
(CDCl3), Table 2.4; HR-ESI-MS m/z 533.3488 [M + H]+ (calcd. for C31H49O7, 533.3478). 
3-Deacetoxy Alfredensterol (10): White amorphous solid; +24.0 (c 0.30, CHCl3); UV (MeOH) 
λmax(log ε), nm: 231 (3.27); IR (cm−1): 3397, 2948, 1715, 1660, 1325, 1240, 1030; 1H- and 13C-NMR 
data (CDCl3), Table 2.4; HR-ESI-MS m/z 475.3432 [M + H]+ (calcd. for C29H47O5, 475.3423). 
1,2-di-O-Palmitoyl-3-O-(6-sulfo-α-d-quinovopyranosyl)-glycerol (11)75: White amorphous 
solid; 1H-NMR (600 MHz, DMSO-d6): δ 4.13 (dd, J = 7.3, 12.0 Hz, 1H, H-1a), 4.33 (dd, J = 2.8, 11.9 
Hz, 1H, H-1b), 5.12 (m, 1H, H-2), 3.40 (m, 1H, H-3a), 3.88 (dd, J = 5.9, 10.4 Hz, 1H, H-3b), 2.28 (m, 
4H, H-2′ and 2″), 1.45–1.57 (m, 4H, H-3′ and 3″), 1.19–1.31 (m, 48H, H-4′–15′ and 4″–15″), 0.85 
(t, J = 6.8 Hz, 6H, H-16′ and 16″), 4.57 (d, J = 2.4 Hz, 1H, H-1′′′), 3.19 (m, 1H, H-2′′′), 3.35 (m, 1H, H-
3′′′), 2.94 (dt, J = 4.5, 9.1 Hz, 1H, H-4′′′), 3.77 (dt, J = 6.2, 10.3 Hz, 1H, H-5′′′), 2.56 (dd, J = 6.2, 13.9 
Hz, 1H, H-6′′′a), 2.88 (dd, J = 4.8, 13.9 Hz, 1H, H-6′′′b), 4.58 (d, J = 5.1 Hz, 1H, OH-2′′′), 4.65 (d, J = 
4.6 Hz, 1H, OH-3′′′), 5.39 (d, J = 3.6 Hz, 1H, OH-4′′′); 13C-NMR (151 MHz, DMSO-d6): δ 62.5 (C-1), 
69.6 (C-2), 64.6 (C-3), 172.2 (C-1′), 172.4 (C-1″), 33.3 (C-2′), 33.5 (C-2″), 24.3 (C-3′ and 3″), 28.3–
28.9 (C-4′–15′ and 4″–15″), 13.8 (C-16′ and 16″), 98.3 (C-1′′′), 71.5 (C-2′′′), 72.8 (C-3′′′), 74.3 (C-4′′′), 
68.4 (C-5′′′), 54.5 (C-6′′′); HR-ESI-MS m/z 793.5143 [M − H]− (calcd. for C41H77O12S, 793.5136). 
2.3.2.4. X-ray Crystallographic Data 
The crystal for compound 1 was obtained by recrystallization from methanol and its structure was 
solved by direct methods from intensity data collected from the crystal specimen at 173(2) K on a 
Bruker Apex II Duo diffractometer and refined by full-matrix least-squares. The Flack x parameter 
value of −0.013(6), indicating that the correct absolute configuration had been assigned, was 
determined using 1652 quotients [(I+) − (I−)]/[(I+) + (I−)]. Salient crystallographic data for 1 are as 
follows: 
Crystal Data for C22H37O3Br (M = 429.42 g/mol): monoclinic, space group P21 (no. 4), a = 
11.1926(11) Å, b = 7.2138(7) Å, c = 14.8442(13) Å, β = 111.571(2)°, V = 1114.60(18) Å3, Z = 2, T = 
173(2) K, μ(MoKα) = 1.861 mm−1, Dcalc = 1.280 g cm−3, 20,619 reflections measured (2.95° ≤ 2θ ≤ 
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56.02°), 5386 unique (Rint = 0.0549, Rsigma = 0.0537) which were used in all calculations. The final 
R1 was 0.0378 (I > 2σ(I)) and wR2 was 0.0760 (all data). 
2.3.2.5. Cell Culture and Antiproliferative Activity Assay 
MDA-MB-231 breast cancer cells (ATCC HTB-26) were maintained in culture in phenol-red free L-
15 medium supplemented with 10% (v/v) heat-inactivated fetal bovine serum (FBS), 1 mM l-
glutamine, 100 U/mL penicillin, 100 μg/mL streptomycin and 12.5 μg/mL amphotericin (PSA) at 37 
°C in a humidified incubator. HeLa cervical cancer cells (ATCC CCL-2) were cultured in Dulbecco’s 
Modified Eagle Medium (DMEM) supplemented as above at 37 °C and 9% CO2 in a humidified 
incubator. 
The antiproliferative effects of the compounds were assessed using the WST-1 assay (Sigma-
Aldrich, Johannesburg, South Africa) as previously described.90,91 Briefly, cells were seeded at a 
density of 6000 cells per well into 96-well plates and incubated overnight, followed by treatment 
with a range of concentrations (0.32, 1.6, 8, 40, 200 and 1000 μM) of the compounds or dimethyl 
sulfoxide (DMSO) vehicle control (0.02% v/v DMSO) for 96 h. Thereafter 2.5 µL of WST-1 Cell 
Proliferation Reagent was added per well and the absorbance at 450 nm after 8 h recorded using 
a Synergy Mx spectrophotometer (BioTek). The half maximal inhibitory concentration (IC50) for 
each compound was calculated relative to the vehicle-treated control from a dose response curve 
(log concentration vs absorbance at 595 nm) using non-linear regression with GraphPad Prism 4 
(GraphPad Inc., San Diego, CA, USA). 
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Chapter Three: Chemical investigation of Marion Island sponges 
3.1 General Introduction 
Marine organisms belonging to the phylum Porifera, mostly sponges, have been the most 
abundant source of new compounds from the marine environment.1–3 This is due in part to their 
wide distribution in the world and their sedentary life form which makes them easy to collect.4 
Chemical compounds produced by sponges belong to the structural classes of terpenes, alkaloids, 
lipids, peptides, and steroids. Compared to their terrestrial partners, these natural products have 
novel molecular frameworks as well as intriguing stereochemistry and numbers of heteroatoms. 
Secondary metabolites of sponge origin are not only structurally intriguing but biologically active 
too.5 In fact, sponges have yielded drug candidates in clinical development, while some developed 
compounds based on sponge metabolites, for example cytabarine (Ara-C) and vidarabine (Ara-A), 
are approved drugs.6 The rich chemical diversity of these sedentary and soft-bodied organisms is 
as a result of the need for effective chemical defense against the environmental threats of 
predation, fouling and microbial infections.7 It is believed that some of the natural products 
isolated from sponges are biosynthesized by either microbial symbionts or microbes inhaled by 
filter feeding.3 
3.2 Background to current work 
The sponge specimens studied herein were obtained in 2015 as part of a collaboration between 
researchers from the University of Cape Town, Rhodes University, the Council for Scientific and 
Industrial Research, the South African Environmental Observation Network and the Department 
of Environmental Affairs who participated in the annual relief expedition to the Prince Edward 
Islands on board the research vessel SA Agulhas II. The specimens were collected as part of the 
inter-island biodiversity survey between Prince Edward and Marion Islands. The collection strategy 
involved benthic trawling using a steel dredge towed behind the vessel (for 15-20 min.) at varying 
depths (60-254 m) along four pre-determined stations (Figure 3.1). Nine sponge specimens were 
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collected in all. They were processed, frozen for storage, and later transported to the laboratory 
for analysis.8 
 
Figure 3.1: Survey area around the Prince Edward Islands, indicating the position of the four 
benthic dredge stations: (1) Prince Edward Island (PEI); (2 and 3) between the islands; and (4) 
south of Marion Island. Station depths are: 130 m (1), 65 m (2), 230 m (3) and 254 m (4).8 
The animals were identified by Dr. Toufiek Samaai (Department of Environmental Affairs, South 
Africa). The sponge specimens were lyophilized, followed by preparation of aqueous (100% 
deionized water) and organic extracts (DCM:MeOH 1:1 v/v) using standard procedures.9 The 
cytotoxic activities of the crude extracts against the HeLa, MCF7 and A549 cancer cell lines have 
already been published. In general, the extracts displayed poor to no activity.8 However, based on 
reported work on the new and/or bioactive secondary metabolites isolated from sponges of the 
genera Halichondria and Hymeniacidon (Figure 3.2), we undertook a chemical investigation of the 
organic extracts, which is reported herein. 
 
Figure 3.2: (A) Halichondria sp. and (B) Hymeniacidon sp. investigated in the current work 
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3.3 Chemistry and biology of the genus Halichondria 
Secondary metabolites reported from Halichondria species include lipids, alkaloids, peptides, 
terpenes and steroid-based compounds. The rich chemical diversity and biological activities 
reported for Halichondria are discussed below. The information was retrieved from MarinLit 
database “compound” search of genus Halichondria and considers secondary metabolites from 
Halichondria species,10 but the following discussion excludes those metabolites isolated from 
microorganisms (bacteria and fungi) associated with Halichondria species. 
The ‘lipid’ class of Halichondria metabolites comprise long chain hydrocarbons,11–15 cerebrosides, 
and polyketides, including macrolides and macrocycles (Figure 3.3). The long chain hydrocarbon 
compounds reported so far include fatty acids,11 glycerides,15 and polyacetylenic alcohol.13,14 Apart 
from the new straight chain fatty acid metabolites isolated from the Caribbean H. magniconulosa 
and H. lutea,11 halicholactone16 and neohalicholactone17, are unusual fatty acids having both 
cyclopropane and nine-membered lactone rings. Isopetrosynol, a new polyacetylenic alcohol 
isolated from H. cf. panicea and related congeners have been reported to inhibit protein tyrosine 
phosphate 1B (PTP1B) (IC50 = 7.8 – 21.6 µM).13 However, in another study, the pellynols 
demonstrated submicromolar anti-inflammatory activity towards HeLa and K562 cancer cell lines. 
Isopellynol A was the least active of the compounds tested with IC50 values of 4.13 µM and 1.95 
µM against HeLa and K562 cell lines, respectively. According to Miyamoto and coworkers, the 
“hexa-2,4-diyn-1,6-diol” and “pent-1-en-4-yn-3-ol” on the termini of the pellynols are essential for 
activity.14 Hardardottir and coworkers found the lipophilic fractions from H. sitiens to decrease 
secretion of the proinflammatory cytokines IL-12p40 and IL-6 by dendritic cells at 10 µg/mL with 
maximum inhibition at 64% and 25%, respectively. However, after isolation, the new glyceride 2,3-
dihydroxypropyl 2-methylhexacanoate and its known congeners showed no immunomodulatory 
activity.15 
Halicylindrosides are a class of cerebrosides first isolated from the Japanese marine sponge H. 
cylindrata. The first ten members of the halicylindrosides (A1-A4 and B1-B6) were discovered 
based on the high antifungal activity of the ethanol crude extract against Mortierella remanniana. 
These N-acetylglucosaminyl ceramides were also found to be cytotoxic to P-388 cancer cell lines.18 
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The Oregon sponge H. panacea has also afforded two new galactosyl-ceramides.19 This report is 
the second regarding the presence of galactosyl-ceramides from Halichondria.20 
Figure 3.3: Examples of ‘lipid’ metabolites from Halichondria species 
The halichondrins, halichondramides and halishigamides are macrolide-based natural products 
from Halichondria. The halichondrins were first reported from the Japanese H. okadai. These 
compounds are characterized by a long acyclic chain, a polyether macrolide and a novel 2,6,9-
trioxatricyclo[3.3.2.03,7]decane system. Halichondrin B exhibited the most potent in vitro 
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cytotoxic activity against B-16 melanoma with an IC50 value of 0.083 nM. It also demonstrated 
good in vivo activity in mice against B-16 melanoma, P-388 and L-1210 leukemia.21 Eribulin 
(Halaven®) is a synthetic analog of halichondrin B and is an anticancer drug marketed by Eisai Co. 
The halichondramides and halishigamides both share similar structural features, for example the 
presence of oxazole rings and a straight carbon chain (Figure 3.3). Faulkner and coworkers have 
reported the antifungal activity and inhibition of cell division in fertilized sea urchin egg assay by 
the halichondramides.22,23 Moreover, in a recent study, the parent compound halichondramide 
has been suggested as a potential inhibitor of tumor cell metastasis with modulation of 
phosphatase of regenerating liver-3 (PRL-3) in metastatic PC3 human prostate cancer cells having 
exhibited inhibitory activity with an IC50 value of 0.81 µM.24 Lee and coworkers have also 
demonstrated that (19Z)-halichondramide, isolated from Chondrosia corticata causes cell cycle 
arrest and modulates mTOR/AMPK signaling pathways in human lung cancer cells.25 Halishigamide 
A, on the other hand, has exhibited potent cytotoxic activity against murine lymphoma L-1210 and 
human KB cancer cells with IC50 values of 4 and 14 nM, respectively. It displayed antifungal activity 
against Trichophyton mentagrophytes with a MIC of 0.1 µM. Halishigamides B-D, however, 
displayed weak cytotoxic activity and moderate antifungal activity.26 
Cylindramide is a macrocylic lactam bearing an acyltetramic acid and a trisubstituted 
bicyclo[3.3.0]octane (Figure 3.3). It exhibited cytotoxic activity against B-16 melanoma with an IC50 
value of 1.7 µM. The franklinolides are polyketide phosphodiesters isolated from a Geodia sp. and 
a Halichondria sp. sponge association.27 Franklinolide A exhibited GI50 values of 0.1 and 0.3 µM 
against HT-29 and AGS cancer cell lines, respectively, and an IC50 range of 1.1 - 1.8 µM against the 
cancer cell lines tested, including SH-SY5Y neuroblastoma cells.28  
The alkaloid class is a rather small group of Halichondria secondary metabolites. The compounds 
so far isolated can be subclassified into indole and piperidine-based alkaloids (Figure 3.4). 
Halichrome A is a bisindole alkaloid isolated from H. okadai. It was cytotoxic against B-16 
melanoma cells. It is noteworthy that the yellow pigment halichrome A is the first report of the 
isolation of a novel compound from a metagenomics library derived from a marine sponge.29 H. 
melanodocia has also afforded a new indole-lactam metabolite.30 Halichondramine is an example 
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of the piperidine-based alkaloids.31 This compound is a member of a group of tetracyclic 
bipiperidine alkaloids. The other members of Halichondria origin are the three new 3-
alkylpiperidine alkaloids, the tetradehydrohaliclonacyclamines,32 which were reported for the first 
time from Haliclona sp.,33,34 and later from Arenosclera brazilensis35 and Pachychalina 
alcaloidifera36.  
 
Figure 3.4: Examples of alkaloids and peptide from Halichondria species 
Other examples of piperidine alkaloids are pinnarine37 and halichlorine.38 These are macrocylic 
alkaloids isolated from H. okadai in two different studies. These compounds possess an intriguing 
6-aza-spiro[4.5]decane bicyclic ring system. In fact, halichlorine was described to be an 
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azabicyclo[4.4.0] with the nitrogen atom in the piperidine in a [5.6]-spiro ring with the 
cyclopentane. Proposed to be biosynthesized from pinnaic acid, a metabolite of the bivalve Pinna 
muricata, halichlorine has demonstrated significant inhibition of vascular cell adhesion molecule-
1 (VCAM-1) induction in cultured human umbilical vein endothelial (HUVE) cells with an IC50 value 
of 17 µM.38 
Halichondria sulphonic acid is a new sulphur-containing guanidine alkaloid isolated from H. rugose. 
The structure of this compound was elucidated through a combination of NMR and crystal 
structure analysis. Halichondria sulphonic acid exhibited anti-HIV-1 activity with an EC50 value of 
143 µM, and IC50 >1.1 mM.39 
Halicylindramides A-E are depsipeptides isolated from the Japanese sponge H. cylindrata.40,41 The 
first three members comprise fourteen amino acid residues with a formyl group at the N-terminus 
and a lactonized threonine at the C-terminus. Halicylindramide D has similar termini to 
halicylindramides A-C but it is a thirteen-amino acid-membered peptide.41 Halicylindramide E, 
unlike its congeners, is a linear peptide with eleven amino acid residues. Halicylindramides A-C 
exhibited antifungal activity against Mortierella ramanniana at 7.5 µg/disk, while halicylindramides 
D and E were antifungal at 5 and 160 µg/disk, respectively. The five depsipeptides have also 
demonstrated cytotoxicity towards P-388 murine leukemia cells in the IC50 range of 0.1 to 3 
µM.40,41 
Halichondria species have so far been a prolific source of terpenoid secondary metabolites. Only 
a few diterpenes and sesterterpenes have been isolated.42–44 The majority of terpenoids so far 
reported are sesquiterpenes. They occur as aromatic sesquiterpenes (paniceins), halichonines, 
halichonadins, halichondriamines, halichons, and other novel scaffolds such as halipanicine,45 
amorphene isocyanide-formamide compounds,46 and bisabolane-based sesquiterpenoids (Figure 
3.5).47 The paniceins are aromatic sesquiterpenes isolated from H. panicea. A characteristic 
feature of the paniceins is that the sesquiterpene is linked to a quinol or quinone moiety.48 The 
halichonines are sesquiterpene alkaloids isolated from H. okadai. These natural products are 
characterized by a 6,6-bicyclic ring system and two prenylated amine moieties. Three members of 
this group, halichonines A-C, have so far been isolated and shown to be cytotoxic to L1210 mouse 
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leukemia cells with IC50 values of 7.2, 10.5, and 5.2 µM, respectively, and 11.5, 12.6, and 7.7 µM, 
respectively, against PC13 human lung cancer cells. Halichonine B was cytotoxic to HL60 human 
leukemia cells with an IC50 value of 1.4 µM and induced apoptosis in HL60 cells.49 
Figure 3.5: Examples of sesquiterpene and steroid-based compounds from Halichondria species 
The halichonadins are eudesmane sesquiterpenoids (Figure 3.5). Seventeen members have so far 
been isolated. Halichonadin A and I possess two eudesmane scaffolds linked by a urea moiety. 
Halichonadin E, unlike halichonadins A and I, has eudesmane and aromadendrane sesquiterpenes 
linked by the urea moiety. Halichonadin G possesses a much longer linker comprising the urea 
moiety and two N-aminoacyl groups between the eudesmane sesquiterpenes. In halichonadin H, 
the linker is a 2-hydroxymalonamide. Halichonadins M and N have nitrotriacetic acid and 
pyrrolidine linkers, respectively, between the two eudesmane fragments, while halichonadin O 
and P have piperidine units as the linkers. The other members of this group, halichonadins B, C, D, 
F, J and Q, are all mono eudesmane sesquiterpene molecules. Halichonadin K was cytotoxic to 
human epidermoid carcinoma KB cells with an IC50 value of 14.9 µM. Meanwhile, halichonadin O 
Chapter Three: Chemical investigation of Marion Island sponges 
 
81 
was reported to have demonstrated antimicrobial activity against Staphylococcus aureus, 
Micrococcus luteus, and Trichophyton mentagrophytes.50–55 
A Halichondria species collected from Thailand afforded sesquiterpene isocyanides, 
isothiocyanates, thiocyanates and formamides (Figure 3.5). Of the 20 compounds that were 
isolated, 11 had been previously reported, while 9 were new. These were named the halichons. 
Halichons A, B, and H are isothiocyantes, halichon C and 4-epi-halichon C are isocyanides, while 
two thiocyanates (halichon D and E) were isolated along with the formamides, halichons F and G. 
Halichon C and its 4-epi isomer both showed moderate cytotoxicity, IC50 values of 20.9 and 29.0 
µM, respectively, against the MOLT-3 cell line. Moreover, halichon C demonstrated similar activity 
towards HepG2 and MDA-MB-231 cell lines with IC50 values of 24.0 and 19.3 µM, respectively. All 
the compounds were not cytotoxic to HuCCA-1, A549 and HeLa cancer cell lines.56 
3.4 Chemistry and biology of the genus Hymeniacidon 
Hymeniacidon species have predominantly yielded alkaloidal secondary metabolites.10 The furan 
fatty acid, (8Z,11Z,14Z,17Z)-3,6-epoxyeicos-3,5,8,11,14,17-hexenoic acid isolated from H. hauraki 
appears to be the only member of the ‘lipid’ class reported so far, exhibiting cytotoxic activity 
against P-388 with IC50 value of 13.4 µg/mL, whereas the methyl and stearyl esters of the acid 
showed anti-inflammatory activity (Figure 3.6).57 Congeners of this compound, plakorsin A-C, have 
also been reported from Plakortis simplex.58 
Alkaloidal natural products of Hymeniacidon origin are dominated by pyrrole-guanidine containing 
compounds. Apart from the characteristic presence of the pyrrole ring in all reported metabolites, 
which may be brominated, the guanidine functionality could cyclize into a 2-aminoimidazoyl 
group. The pyrrole and guanidine moieties are connected by a linker, usually a 5-unit chain, which 
has an amide group next to the pyrrole. This molecular framework is true for Hymeniacidon 
secondary metabolites such as hymenidin,59 manzacidins A-C,60 and tauroacidin A and B (Figure 
3.6).61 In other reported metabolites, however, C-4 to C-10 cyclization between the pyrrole and 
the linker has resulted in a seven-membered lactam ring. Examples of such compounds include 
hymenialdesine,62 aldisins,63 spongiacidins A-D,64 and hymenin (Figure 3.6).65 It has been 
Chapter Three: Chemical investigation of Marion Island sponges 
 
82 
suggested that these congeners are possibly biosynthesized from oroidin through isomerization, 
oxidation and reduction, dimerization, and/or cyclization reactions.66 
 
Figure 3.6: Some representative fatty acid and alkaloids from Hymeniacidon species. 
Hymenin potently blocked α-adrenoceptor receptors. According to Miyazawa and coworkers, in 
the isolated rabbit aorta, the contractile response to norepinephrine (10-7 M) was abolished by 
hymenin (10-6 M), whereas the responses to potassium chloride (4 x 10-2 M) and serotonin (10-6 
M) were not affected by hymenin (10-6 M).65 Spongiacidins A and B exhibited inhibitory activity 
Chapter Three: Chemical investigation of Marion Island sponges 
 
83 
against c-erbB-2 kinase with IC50 values of 21.2 µM and 18.5 µM, respectively, and cyclin-
dependent kinase 4 (IC50, 80 and 37 µM, respectively). Meanwhile, spongiacidins C and D were 
inactive at 50% inhibitory concentration up to 50 µg/mL.64 Other alkaloidal natural products 
isolated from the genus include 1,9-dimethyl-6-imino-8-oxopurine,67 the structurally intriguing 
konbu’acidin,68and hymeniacidin and four bromoindole ethyl esters (Figure 3.6).69 Konbu’acidin 
was not cytotoxic to L1210 and KB cancer cells but inhibited cyclin dependent kinase 4 with an IC50 
value of 26.7 µM.68 
Hymenidin, isolated from an Okinawan marine sponge Hymeniacidon sp., has a potent 
antiserotonergic activity equal to that of keramadin, a known antagonist of serotonergic 
receptors.59 Manzacidins A-C are characterized by a tetrahydropyrimidine ring in place of the 2-
aminoimidazoyl moiety.60 Like manzacidins, another Okinawan marine sponge Hymeniacidon sp. 
afforded the tauroacidins A and B. These metabolites possess a taurine group at C-15 of the 2-
aminoimidazoyl moiety, hence the name tauroacidin. The two new compounds inhibited EFG 
receptor kinase and c-erbB-2 kinase, each with an IC50 value of 20 µg/mL.61 
The first reported peptide secondary metabolite from the genus Hymeniacidon was hymenistatin 
1 from a Western Pacific Ocean sponge. Hymenistatin 1 is a cyclo-octapeptide comprising valine, 
leucine, tyrosine, two isoleucine and three proline amino acid units (Figure 3.7). It was active 
against the P-388 leukemia cell line with an IC50 of 3.9 µM.70 Moreover, an Okinawan marine 
sponge Hymeniacidon sp. afforded the hymenamides A-K. The first six members, hymenamides A-
F,71–73 are cyclic heptapeptides, while the four hymenamides G-K are cyclic octapeptides (Figure 
3.7).74 Hymenamide B and J were cytotoxic towards L1210 and KB cancer cell lines with IC50 values 
of 3.8 and 7.2 µM, respectively, and 2.4 and 0.7 µM, respectively.71,74 Hymenamide H was only 
cytotoxic towards L1210 cancer cells with an IC50 of 7.0 µM.74 
A cursory glance through the literature suggests that the diterpenoid isocyanides, the 
amphilectenes, are the only terpenoids from Hymeniacidon. Two amphilectene compounds were 
isolated from H. amphilecta by Cardy and his colleagues.75 Meanwhile, a Puerto Rican marine 
sponge Hymeniacidon sp. afforded a new amphilectene-type natural product, monamphilectine, 
which possesses a β-lactam side chain (Figure 3.7). It showed an IC50 value of 0.6 µM against the 
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chloroquine-resistant Plasmodium falciparum W2 strain. When tested against the Mycobacterium 
tuberculosis H37Rv strain, it displayed a MIC value of 36 µM. Furthermore, according to Rodriguéz 
and Avilés, preliminary KB assays against Escherichia coli revealed that at 150 nM, 
monamphilectine possessed bactericidal strength at 43% and 38% that of the β-lactam antibiotics 
carbenicillin and ampicillin, respectively. In fact, 8,15-diisocyano-11(20)-amphilectene, which was 
previously isolated by Cardy and coworkers, demonstrated better antiplasmodium and 
antitubercular activities than monamphilectine with an IC50 of 0.04 µM and a MIC of 9.8 µM, 
respectively.76 
 
Figure 3.7: Examples of peptides, terpenes, and steroids isolated from Hymeniacidon species 
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The steroid class of Hymeniacidon secondary metabolites has been dominated by the metabolites 
isolated from the Okinawan marine sponge H. aldis. Six 3β-hydroxymethyl-A-nor-sterane 
compounds were isolated. These secondary metabolites were obtained as their acetates. The 
acetate group was located on the five-membered ring A for all these steroids. The structural 
difference was in the side chain at C-17 of the tetracyclic steroid backbone.62 Moreover, H. perlevis 
afforded a similar steroid, 3β-hydroxymethyl-24-methylene-A-nor-5α-cholestane. This congener 
lacked the acetate moiety (Figure 3.7).77 
3.5 Results and Discussion 
3.5.1 Secondary metabolites from Halichondria sp. 
A chemical investigation of the MeOH fraction of the organic extract of the Halichondria specimen 
led to the isolation and identification of betaine-type secondary metabolites comprising the 
previously unreported bisimidazoyl betaine (1) and a trimer of the proline betaine stachydrine (2) 
(Figure 3.8). The DCM/MeOH 1/1 v/v crude extract of the sponge material was initially fractionated 
according to the NCI protocol.9 Two rounds of C18 HPLC of the MeOH fraction afforded the two 
compounds 1 and 2. 
 
Figure 3.8: Compounds 1 and 2 isolated from Halichondria sp. 
HR-ESI-MS analysis of compound 1 revealed a pseudomolecular ion mass peak at m/z 155.0813 
(1/2M + H; calcd. for C7H11N2O2, 155.0815,) consistent with a molecular formula of the dimer 
C14H20N4O42+. The 1H NMR spectrum exhibited four singlets resonating at δH (ppm) 3.43 (H2-6, 6’), 
3.56 (H3-9, 9’), 3.66 (H3-8, 8’) and 7.08 (H-5, 5’). Examination of the 13C NMR and the 2D 
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heteronuclear HSQC data suggested the presence of two NMe groups (δC 34.4, δH 3.56 ppm; δC 
36.9, δH 3.66 ppm), a characteristic carboxylic acid or amide carbonyl (δC 176.1), and two sp2 
hybridized quaternary carbons at δC 133.0 and δC 136.0 ppm (Table 3.1). 
Table 3.1: 1H, 13C and HMBC NMR data for compound 1 
No. δC, type δH (J, Hz) HMBC 
2, 2' 136.0, C 
  
4, 4' 133.0, C 
  
5, 5' 122.7, CH 7.08, s C-2, 2', 4, 4' 
6, 6' 33.4, CH2 3.43, s C-4, 4', 5, 5', 7, 7' 
7, 7' 176.1, C 
  
8, 8' 36.9, CH3 3.66, s C-2, 2', 5, 5' 
9, 9' 34.4, CH3 3.56, s C-2, 2', 4, 4' 
Analyses of the HMBC spectrum revealed correlations from the methylene protons H2-6 to the 
carboxylic acid moiety and C-4 and C-5. Moreover, the methine proton H-5 showed HMBC 
correlations to the two quaternary carbons C-2 and C-4. Similar correlations from the N-CH3’s to 
C-2, C-4 and C-5 suggested the presence of the imidazoyl scaffold. This was corroborated by 1H-
15N HMBC correlations between the methine and methyl groups and the two nitrogen atoms of 
the imidazoyl scaffold (Figure 3.9). Finally, the presence of quaternary carbon C-2 and evidence 
from the HR-ESI-MS data suggested compound 1 was symmetrical about the C-2 to C-2’ bond. 
Long range COSY cross peaks between H-5 and H2-6 supported the assignment of the structure of 
1.  
 
Figure 3.9: (a) 1H – 13C HMBC and (b) 1H – 15N HMBC correlations of compound 1 
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Compound 2 was confirmed to be the proline betaine stachydrine by comparison of its HR-ESI-MS 
and NMR data to reported data.78 Examination of the 13C NMR spectrum, however, revealed that 
the signals due to C-2, C-5, C-6 and C-7 were tripled (Figure 3.10). The intensities of the methylene 
carbons (C-3 and C-4) and the carboxyl carbon C-1 were also unusually higher than expected. That 
compound 2 occurred as a trimer was corroborated by the presence of LR-ESI-MS m/z values 
responsible for 2M and 3M mass units. The structure of 2 is therefore as proposed and suggested 
that the betaine monomers served as counter ions of each other. It is also likely that 2 could be 
involved in complexation with a cation (a metal ion perhaps) although no such ion was observed. 
 
Figure 3.10: Expanded sections of the 13C NMR spectrum of compound 2 
 
 
2 1 
7 5 
3 
4 
6 
Chapter Three: Chemical investigation of Marion Island sponges 
 
88 
3.5.2 Secondary metabolites from Hymeniacidon sp. 
A combination of DIOL solid phase extraction flash chromatography and C18 HPLC of the organic 
extract of the Hymeniacidon species led to the isolation and identification of the nucleoside 
thymidine, four amino acid residues tyrosine, leucine, isoleucine and valine, along with the small 
molecular weight ionic metabolites choline, and agmatine (Figure 3.11). The structures of these 
metabolites were confirmed by comparison of their NMR and mass data to authentic and/or 
literature information. 
 
Figure 3.11: Secondary metabolites isolated from Hymeniacidon sp. 
3.5.3 Antiplasmodium activity results 
Compounds 1 and 2 were evaluated for their in vitro antiplasmodium activity against the drug 
sensitive strain of Plasmodium falciparum, NF54 (Table 3.2). Generally, 1 and 2 displayed no 
activity at the highest concentration (10 µg/mL) of test compounds. Chloroquine and artesunate 
were used as positive controls. 
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Table 3.2: In vitro antiplasmodium activity against P. falciparum (NF54) strain 
Compound 
Pf(NF54) 
IC50 (µg/mL) 
1 >10 
2 >10 
Artesunate 15 nM 
Chloroquine 33 nM 
Imidazoyl betaine natural products have been reported from marine organisms. Examples include 
zooanemonin,79–82 norzooanemonin,81,83,84 norzooanemonin methyl ester,81 
aminozooanemonin,82 and echinobetaine B (Figure 3.12).81,85 The (+)-echinobetaine B isomer 
exhibited nematocidal activity against Haemonchus contortus (LD99 = 8.3 µg/mL) comparable to 
the commercial anthelminthics closantel and levamisole (LD99 = 5 - 10 µg/mL). Compared to 
zooanemonin, norzooanemonin and its methyl ester congener, the OMe group in (+)-
echinobetaine B was suggested to be necessary for the anthelminthic activity. Meanwhile, 
zooanemonin has exhibited antifouling activity towards the barnacle Balanus amphitrite 
comparable to that of CuSO4 (4.0 – 5.2 ppm).80 Aminozooanemonin displayed antibacterial activity 
against the Gram positive bacteria Bacillus subtilis and Staphylococcus aureus with MIC values of 
14 µM and 50 µM, respectively.82  
 
Figure 3.12: Zooanemonin-type compounds and examples of betaines from marine organisms 
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Glycine and proline betaine are two major organic osmolytes reported to play osmoregulatory 
roles in various plant species in response to environmental stress such as drought, salinity, 
extreme temperature, UV radiation and heavy metals.86 Proline betaine, also known as 
stachydrine or cadabine, has not only been described in many plant species but in the bacteria 
Klebsiella pneumoniae, Escherichia coli, Rhizobium meliloti and Staphylococcus aureus, it has also 
been reported to play similar osmoprotective roles.87 Moreover, Chambers and Kunin 
demonstrated that glycine and proline betaines are present in human urine playing 
osmoprotective roles against hypertonic NaCl for E. coli.78 Stachydrine has been reported in 
marine organisms, for example the red algae Griffithsia flosculosa and the extremely euryhaline 
mollusk Elysia chlorotica. According to Warren and coworkers, E. chlorotica does not utilize 
intracellular free amino acids for cell volume regulation during osmotic stress but rather proline 
betaine.88 
It is evident, therefore, that the metabolites isolated from the two sponge specimens investigated 
in the current work are necessary for the organisms’ survival in the harsh environmental 
conditions of Antarctica. The data presented herein therefore complements reports from other 
researchers in the field. 
3.5.4 Materials and Methods 
3.5.4.1 General Experimental Procedures 
UV spectra were obtained on a CARY 60 UV-VIS 2.00 with software version 5.0.0.999 by Agilent 
Technologies (Santa Clara, CA, USA). PerkinElmer Spectrum Version 10.03.02 (PerkinElmer Ltd., 
Llantrisant, Wales, UK) was used to acquire the IR data. NMR spectra were obtained on a BRUKER 
Ascend 600 (Bruker, Billeria, MA, USA) cryoprobe prodigy at 600 MHz and 151 MHz for 1H and 13C 
nuclei, respectively. D2O-DMSO-d6 (used as internal standard for calibration at δH 2.50 and 
δC 49.00) was used as solvent for acquiring all NMR data throughout the investigation. HR-ESI-MS 
data were obtained via an HRMS LC-MS/MS on a SCIEX X500R QTOF instrument. Reverse phase 
(C18) HPLC was carried out on Agilent 1200LC system (Santa Clara, CA, USA) equipped with a 
G1322A degasser, G1311A quaternary pump, G1329A autosampler (maximum injection 100 µL), 
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and a G1316A DAD and multiple wavelength detector. Low Resolution-ESI-MS was acquired on an 
Agilent 1260 Infinity HPLC coupled to Agilent 6120 Quardrupole MS systems. Normal phase DIOL 
solid phase extraction flash column chromatography was carried out with Spe-ed Catridge DIO 
2gr/6ml prepacked (Applied Separations, Allentown, PA, USA). Solvents used were of HPLC grade. 
3.5.4.2 Collection and Extraction, Isolation, and Characterization 
The sponge specimens were processed and extracted as previously reported.8  
Sequential fractionation by flash chromatography on DIOL SPE was carried out on 567.2 mg of 
CH2Cl2/MeOH (1:1 v/v) organic extract of the Halichondria sp. with n-hexane/ CH2Cl2 (1:1 v/v), 
CH2Cl2/EtOAc (20:1 v/v), EtOAc, EtOAC/MeOH (5:1 v/v) and MeOH to obtain five fractions A - E. 
After preliminary analysis of the fractions by 1H NMR, the MeOH fraction (150 mg) was proceeded 
on further purification by semi-preparative C18 HPLC on a Phenomenex Luna 10 µm C18 (2) 100Å 
250 mm x 10 mm (Phenomenex, Torrance, CA, USA) with H2O and acetonitrile as mobile phase (2 
– 100% acetonitrile, total run time 30 min) at a flow rate of 3 mL/min and wavelength detection 
at 254 and 330 nm. Twenty fractions (A – U) were collected. All fractions were analyzed by 1H NMR 
spectroscopy. Fractions F and G were further chromatographed on semi-preparative C18 HPLC on 
a Phenomenex Onyx monolithic C18 100 mm x 10 mm (Phenomenex, Torrance, CA, USA) isocratic 
at 1% acetonitrile in H2O for 5 mins at flow rate 2 mL/min and wavelengths 254 and 330 nm to 
afford compounds 1 (1.3 mg) and 2 (1.8 mg), respectively. 
The Hymeniacidon sp. was investigated in a similar manner as described above. The organic extract 
(7.01 g) was fractionated on DIOL SPE and the fractions analyzed by 1H NMR. Fraction C (29 mg) 
was further purified by semi-preparative C18 HPLC on a Phenomenex Luna 10 µm C18 (2) 100Å 
250 mm x 10 mm (Phenomenex, Torrance, CA, USA) with H2O and acetonitrile as mobile phase (5 
– 100% acetonitrile, total run time 26 min) at a flow rate of 3 mL/min and wavelength detection 
at 254 and 330 nm. Twenty-one fractions were collected, fraction J (1.5 mg) was analyzed by 
spectroscopic methods (NMR and MS) and identified to be the nucleoside thymidine. Meanwhile, 
the MeOH fraction (500 mg) was purified by semi-preparative C18 HPLC to obtain 15 fractions 
(HPLC conditions were same as described for the first round HPLC purification described for 
Halichondria sp. above). Four fractions, C, E, G2, and G4, were further purified by semi-preparative 
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C18 HPLC on a Phenomenex Onyx monolithic C18 100 mm x 10 mm (Phenomenex, Torrance, CA, 
USA) isocratic at 1% acetonitrile in H2O for 5 mins at flow rate 2 mL/min and wavelengths 254 and 
330 nm. A mixture of choline and agmatine (1.9 mg) was obtained from fraction C, fraction E and 
G2 afforded 1.4 mg of isoleucine and 3.5 mg of valine, respectively, while tyrosine and leucine (0.8 
mg) were obtained as a mixture from fraction G4. 
Compound 1: Clear oil; 1H- and 13C-NMR data (600 MHz, D2O, DMSO-d6), Table 3.1; HR-ESI-MS m/z 
155.0813 [1/2M + H] (calcd. for C7H11N2O2, 155.0815, molecular formula C14H20N4O42+). 
Compound 2:78 Clear oil; 1H-NMR (600 MHz, DMSO-d6): δ 1.92 – 2.04 (m, 2H, H-4), 2.04 – 2.14 (m, 
1H, H-3a), 2.31 (m, 1H, H-3b), 2.92 (s, 3H, H-6), 3.11 (s, H-7), 3.30 – 3.38 (m, 1H, H-5a), 3.52 (m, 
1H, H-5b), 3.84 (td, J = 2.1, 8.7, 9.5 Hz, 1H, H-2); 13C-NMR (151 MHz, D2O, DMSO-d6): δ 169.7 (C-
1), 75.7 (C-2), 66.4 (C-5), 51.4 (C-7), 45.2 (C-6), 24.6 (C-3), 18.0 (C-4); HR-ESI-MS m/z 144.1018 [M 
+ H] (calcd. for C7H14NO2, 144.1019), 287.1964 [2M + H] (calcd. for C14H27N2O4, 287.1965). 
Thymidine:89 Clear oil; 1H NMR (600 MHz, MeOH-d4): δ 1.87 (d, J = 1.2 Hz, 3H, H-10), 2.17 – 2.27 
(m, 2H, H-6), 3.72 (dd, J = 3.7, 12.0 Hz, 1H, H-9a), 3.79 (dd, J = 3.2, 12.0 Hz, 1H, H-9b), 3.90 (m, 1H, 
H-8), 4.31 – 4.44 (m, 1H, H-7), 6.22 – 6.30 (m, 1H, H-5), 7.80 (q, J = 1.2 Hz, 1H, H-3); 13C NMR (151 
MHz, MeOH-d4): δ 166.4 (C-1), 152.4 (C-2), 138.1 (C-3), 111.5 (C-4), 88.8 (C-8), 86.3 (C-5), 72.2 (C-
7), 62.8 (C-9), 41.2 (C-6), 12.4 (C-10); HR-ESI-MS m/z 243.0980 [M + H]+ (calcd. for C10H15N2O5, 
243.0903). 
Tyrosine:90 Clear oil; 1H NMR (600 MHz, D2O, DMSO-d6): δ 3.18 (dd, J = 7.8, 14.6 Hz, 1H, H-3a), 3.34 
(dd, J = 5.2, 14.6 Hz, 1H, H-3b), 4.04 (dd, J = 5.2, 7.8 Hz, 1H, H-2), 7.01 – 7.13 (m, 2H, H-6), 7.32 – 
7.41 (m, 2H, H-5); 13C-NMR (151 MHz, D2O, DMSO-d6): 175.3 (C-1), 155.0 (C-7), 130.6 (C-5), 127 
(C-4), 116.1 (C-6), 56.5 (C-2), 36.4 (C-3); ESI-MS  m/z 182.1 [M + H]+. 
Leucine:91 Clear oil; 1H NMR (600 MHz, D2O, DMSO-d6): δ 1.12 (d, J = 4.4 Hz, 3H, H-5), 1.14 (d, J = 
6.5 Hz, 3H, H-6), 1.80 – 1.86 (m, 1H, H-3a), 1.86 – 1.94 (m, 2H, H-3b, 4), 3.87 (dd, J = 5.2, 8.4 Hz, 
1H, H-2); 13C NMR (151 MHz, D2O, DMSO-d6): δ 176.1 (C-1), 53.9 (C-2), 40.5 (C-3), 24.6 (C-4), 22.5 
(C-6), 21.5 (C-5); ESI-MS m/z 132.2 [M + H]+. 
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Isoleucine:92 Clear oil; 1H NMR (600 MHz, D2O, DMSO-d6): δ 0.77 (t, J = 7.4 Hz, 3H, H-5), 0.83 (d, J 
= 7.0 Hz, 3H, H-6), 1.03 – 1.12 (m, 1H, H-4a), 1.31 (dqd, J = 4.6, 7.4, 14.8 Hz, 1H, H-4b), 1.78 (m, 
1H, H-3), 3.40 (d, J = 4.1 Hz, 1H, H-2); 13C NMR (151 MHz, D2O, DMSO-d6): δ 174.9 (C-1), 60.1 (C-
2), 36.6 (C-3), 24.7 (C-4), 15.4 (C-6), 11.7 (C-5); ESI-MS m/z 132.2 [M + H]+. 
Valine:93 Clear oil; 1H NMR (600 MHz, D2O, DMSO-d6): δ 0.82 (d, J = 7.0 Hz, 3H, H-4), 0.87 (d, J = 
7.0 Hz, 3H, H-5), 2.09 (m, 1H, H-3), 3.37 (d, J = 4.3 Hz, 1H, H-2); 13C NMR (151 MHz, D2O, DMSO-
d6): δ 175.3 (C-1), 60.7 (C-2), 29.3 (C-3), 18.5 (C-5), 17.2 (C-4); ESI-MS m/z 118.1 [M + H]+. 
Choline:94 Clear oil; 1H NMR (600 MHz, D2O, DMSO-d6) δ 3.01 (s, 9H, H-3), 3.30 – 3.35 (m, 2H, H-
1), 3.86 (m, 2H, H-2); 13C NMR (151 MHz, D2O, DMSO-d6): δ 68.8 (C-1), 56.8 (C-2), 55.2 (C-3); HR-
ESI-MS m/z 104.1069 [M]+ (calcd. for C5H14NO, 104.1070). 
Agmatine:95 Clear oil; 1H NMR (600 MHz, D2O, DMSO-d6) δ 1.37 (quin., J = 6.4Hz, 2H, H-3), 1.41 – 
1.49 (quin., J = 7.4 Hz, 2H, H-4), 2.74 (t, J = 7.4 Hz, 2H, H-5), 2.94 (t, J = 6.9 Hz, 2H, H-2); 13C NMR 
(151 MHz, D2O, DMSO-d6): δ 162.5 (C-1), 40.7 (C-2, 5), 27.6 (C-3), 25.7 (C-4); HR-ESI-MS m/z 
131.1294 [M + H]+ (calcd. for C5H15N4, 131.1291). 
3.5.4.3 Antiplasmodium assay 
The malaria strain used for testing was the drug sensitive strain of Plasmodium falciparum, NF54 
obtained from the Malaria Research and Reference Reagent Resource Center (MR4). The 
plasmodium parasites were cultured continuously in vitro according to a modified method 
described by Trager and Jensen.96,97 The samples were tested against the NF54 strain using the 
parasite lactate dehydrogenase (pLDH) assay to determine in vitro efficacy.98 The samples were 
tested at a starting concentration of 10 000 ng/ml. Chloroquine and artesunate were used as 
positive controls. 
Plasmodium falciparum were maintained in human erythrocytes (2% hematocrit) incubated at 
37°C in RPMI 1640 medium containing 25 mM HEPES buffer, 20 µg/mL of gentamicin, 27 mM 
bicarbonate, and 10% normal type A human serum maintained below 2% parasitemia for 48 hr 
under an atmosphere of a gas mixture containing in 3% 02, 6% CO2, and 91% N2.98  
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Fifteen microliters from each well of re-suspended culture was transferred into another 96-well, 
flat-bottomed microtiter plate that contained 100 µL of the proprietary Malstav@ reagent (Flow 
Inc., Portland, OR). The sample was left to lyse for thirty minutes to ensure an accurate reading. 
At the end of this period, each well received 25 µL of a 20:1 mixture of nitro blue tetrazolium and 
phenazine ethosulfate (1 mg and 0.05 mg/ml, respectively). The reduction of the tetrazolium to 
the blue formazan salt is followed for 10 min at 650 nm (K650 nm) 98 
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Chapter Four: Semi-synthetic derivatization, antimycobacterial and antiplasmodium evaluations 
of analogues of the natural product fusidic acid 
4.1 General Introduction 
4.1.1 Fusidic acid and fusidane triterpenes: Chemistry 
Fusidane triterpenes are a small group of fungal 29-nor protostane triterpenes. Only 20 congeners 
have so far been reported.1,2 They are tetracyclic compounds with a similar side chain at C-17 as 
observed in dammarane triterpenoids (Figure 4.1).  
 
Figure 4.1: Carbon backbone of dammarane, protostane and fusidane triterpenoids 
Fusidane triterpenes share similar structural conformations of the tetracycles to protostanes. A 
common protostane precursor, 3β-hydroxy-protosta-17(20)Z, 24-diene, has been proposed to be 
involved in the biosynthesis of the fusidanes. Further demethylation of C-29 produces the fusidane 
triterpenoid skeleton (Figure 4.2).1 
Structural characteristics of the fusidanes include the presence of a C-O functionality at position 
C-3, Δ17,20, Δ24,25, a carboxylic acid group at C-21, and an acetoxy group at C-16 (except 16-
deacetoxy-7-β-hydroxy fusidic acid)3. Oxygen substituents can be present at positions C-6, C-7, C-
11 and C-12. Fusilactidic acid is the only fusidane with a seven-membered lactone functionalized 
ring C.4 
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Figure 4.2: Biosynthesis of fusidane triterpenoid skeleton1 
Naturally occurring fusidanes can be classified into four general subclasses: helvolic acid, 
viridominic acids A-C, cephalosporin P1 and its congeners, as well as fusidic acid and related 
compounds. Helvolic acid was the first reported fusidane and was isolated from the soil fungus 
Aspergillus fumigatus in 1942. It is a C-3 and C-7 di-oxo compound and possesses a Δ1,2 double 
bond and an extra acetoxy group at C-6.5,6 Helvolic acid demonstrated bacteriostatic activity 
against gram-positive bacteria but not gram-negatives. It exhibited comparable activity to that of 
penicillin and exerted superior activity over the sulfonamides.6 Its anti-tubercular activity has also 
been reported.7 Helvolic acid demonstrated higher antibacterial (IC50 values between 0.98 - 33.19 
µg/mL) and antifungal (IC50 value of 7.20 µg/mL) activities than all other steroids isolated from the 
plant endophyte fungus Pichia guilliermondii Ppf98 and similar activity against phytopathogenic 
fungi with a MIC value of >6.25 µg/mL, which is comparable to those of commercial fungicides 
such as carbendazim and hymexazol.9,10  
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Figure 4.3: Chemical structures of helvolic acid, viridominic acids and cephalosporin P1 metabolites 
The viridominic acids A-C were isolated from the culture filtrate of Cladosporium sp. These 
fusidanes are characterized by the presence of an acetoxy group at C-6 and a C-7 hydroxyl group. 
Viridominic acids A and B possess a C-11-oxo- functionality while this is reduced to the hydroxyl 
group in viridominic acid C. Moreover, viridominic acid B bears an extra hydroxyl group at C-12 
(Figure 4.3). Viridominic acids A-C have exhibited chlorosis-inducing activity against higher 
plants.11,12 Cephalosporin P1, isocephalosporin P1, and monodesacetyl cephalosporin P1 were 
isolated from Cephalosporium acremonium.13,14 The cephalosporin P1 congeners are not related 
to the beta lactam cephalosporins. Cephalosporin P1 possesses an acetoxy and a hydroxyl 
substituent at positions 6 and 7, respectively. Isocephalosporin P1 possesses a hydroxyl and an 
acetoxy group at positions 6 and 7, respectively, and hence a positional isomer of cephalosporin 
P1. Meanwhile, C-6 deacetylation of cephalosporin P1 produces monodesacetyl cephalosporin P1 
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(Figure 4.3). Cephalosporin P1 has demonstrated potent antibacterial activity against methicillin-
sensitive, methicillin-resistant and vancomycin-intermediate Staphylococcus aureus.15,16  
Fusidane triterpenes represent a class of antibiotics and fusidic acid is the most potent congener. 
It was first reported from the fungus Fusidium coccineum by Godtfredsen and coworkers.4,17 Since 
then, it has been reported from other fungal species including Epidermophyton floccosum,18 
Acremonium fusidioides, Calcarisporium arbuscula, C. lamellaecula, C. acremonium, Gabarnaudia 
tholispora, Mucor ramannianus, and Paecilomyces fusidioides.19 Industrial fermentation of F. 
coccineum yielded fusidic acid and eight metabolites including 3-epifusidic acid, 11-epifusidic acid, 
3-ketofusidic acid, 11-ketofusidic acid, 9,11-anhydrofusidic acid, 9,11-anhydro-9α-11α-
epoxyfusidic acid, 9,11-anhydro-12-hydroxyfusidic acid, and fusilactidic acid (Figure 4.4).4  
 
Figure 4.4: Representative structures of fusidic acid and related compounds 
The dermatophyte E. floccosum also afforded the new 3,11-diketofusidic acid, together with 
fusidic acid and 3-epifusidic acid. According to Noble and coworkers, the antibacterial activity of 
E. floccosum was attributable to these three metabolites.18 Acremonium crotocinigenum has 
yielded 16-deacetoxy-7-β-hydroxy fusidic acid,3 while recently, two new members have been 
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identified after Cunninghamella elagans NRRL 1392 mediated hydroxylation of ring B to produce 
6-β-hydroxy fusidic acid and 7-β-hydroxy fusidic acid.2 
4.1.2 Antibacterial activity of fusidic acid 
Fusidic acid has been clinically used as an antibiotic since 1962. It has displayed consistent activity 
against staphylococcal pathogens including methicillin-resistant Staphylococcus aureus (MRSA). Its 
major clinical indications include systemic treatment for severe staphylococcal infections, systemic 
treatment for colonization and infection with MRSA, topical treatment of skin infections and 
topical treatment of atopic dermatitis.20 It is reported that “at a proposed susceptible breakpoint 
(≤ 1 µg/mL), fusidic acid inhibited 99.7% of MRSA strains and 99.3% to 99.9% of multi-drug 
phenotypes of S. aureus”, and that “S. aureus strains unsusceptible to fusidic acid (0.35%) generally 
had detectable resistance mechanisms (fusA, B, C, and E)”.21 
Fusidic acid is largely bacteriostatic but exhibits bactericidal activity at high concentrations. It acts 
by inhibiting protein synthesis in the bacteria. It interferes with the function of the protein 
elongation factor G (EF-G). EF-G is necessary for the hydrolysis of guanosine triphosphate (GTP) to 
guanosine diphosphate (GDP) to provide energy for the translocation of the peptidyl-tRNA from 
the A site to the P site on the 50S unit of the ribosome. Fusidic acid binds to EF-G and the ribosome 
after hydrolysis of GTP, thereby sterically blocking the next stage of protein synthesis. Unlike 
eukaryotes, prokaryotes possess only one type of elongation factor, which when inhibited affects 
the process of protein synthesis.20 
Although almost exclusively used as an anti-staphylococcol agent, fusidic acid has displayed 
antibacterial activity against a wide range of pathogens (Table 4.1). Gram-negative bacilli are 
resistant to fusidic acid with MIC values of ≥32 µg/mL.21 Extensive studies on the antibacterial 
structure-activity relationship (SAR) of fusidic acid has been reported. The findings made so far on 
the structural features necessary for activity are depicted in Figure 4.5. Essentially, the trans-syn-
trans conformation of the tetracylic triterpene backbone and the carboxylic acid and acetoxy 
groups are required for activity.22–25 
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Table 4.1: Antimicrobial spectrum of fusidic acid26 
Microorganisms In vitro MIC90 (µg/mL) 
Gram-positive  
Staphylococcus aureus 
(methicillin-susceptible) 
0.06 
Staphylococcus aureus 
(methicillin-resistant) 
0.12 
Staphylococcus epidermidis 
(methicillin-susceptible) 
0.25 
Staphylococcus epidermidis 
(methicillin-resistant) 
0.50 
Corynebacterium diptheriae 0.0044 
Clostridium tetani 0.05 
Clostridium perfringens 0.5 
Propionibacterium acnes 1.0 
Other Corynebacterium spp. 2.0 
Clostridium difficile 2.0 
Other Clostridium spp. ≤1.0 
Staphylococcus saprophyticus 3.12 
Streptococcus faecalis 6.25 
Streptococcus pyogenes 12.5 
Streptococcus pneumoniae 25.0 
Gram-negative  
Neisseria meningitidis 0.12 
Legionella pneumophila ≤0.25 
Neisseria gonorrhoeae 1.0 
Bacteroides fragilis 2.0 
Other Bacteroides spp. ≤2.0 
A recent study has demonstrated the importance of the orientation of the side chain of fusidic 
acid to activity. Amongst the four stereoisomers synthesized based on saturation of the 17(20) 
double bond, only one analogue, 17S,20S-dihydrofusidic acid, exhibited activity comparable to 
fusidic acid while the other three showed less or no activity. The findings of this work highlighted 
the importance of the spatial arrangement of substituents around the Δ17(20) bond which 
contradicted earlier assumptions that the ∆17(20) bond was an essential feature in the molecule.24 
Further exploration via cyclopropanation of the Δ17(20) bond led to the analogue 17S,20S-
methanofusidic acid which possessed a 17(20) spiro-cyclopropane system. The spiro-cyclopropane 
system orients the side chain into a bioactive conformational space. The new 17S,20S-
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methanofusidic acid was found to exert antibacterial activity against several Gram-positive species 
with potency essentially equal to natural fusidic acid.25 
 
Figure 4.5: Antimicrobial structure-activity relationship of fusidic acid22–25 
4.1.3 Repositioning of fusidic acid for tuberculosis and malaria 
Drug repositioning is the medicinal chemistry approach of finding new therapeutic uses of old and 
existing drugs through appropriate synthetic modifications. In contrast, drug repurposing refers to 
using an old or existing drug in its original form for a new disease indication with modification in 
the dosage amounts. Examples of successful repositioned/repurposed drugs include Viagra® 
(repurposed from a treatment of hypertension to its current use for treatment of erectile 
dysfunction),27 Thalidomide® (repositioned from a sedative, analgesic and antiemetic but 
currently used for erythema nodosum leprosum and multiple myeloma),28 and Minoxidil® 
(repurposed from a treatment of hypertension but currently used for the treatment of hair loss).29 
Drug repositioning/repurposing is a time and cost effective approach to drug development.30 
Examples of drugs repositioned for the treatment of tuberculosis and malaria are shown in Figure 
4.6 and 4.7, respectively. Most of these drugs have been previously used for the treatment of 
microbial infections, including bacterial and protozoan diseases.31  
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Figure 4.6: Examples of repositioned drugs for the treatment of TB31 
 
Figure 4.7: Examples of repositioned drugs for the treatment of malaria31 
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4.1.3.1 Antimycobacterial activity of fusidic acid 
Fusidic acid has exhibited activity against some Mycobacterium species including M. tuberculosis 
(Mtb), M. avium, M. chelonei, M. fortuitum and M. kansasii. It exhibited in vitro activity against 
Mtb with MIC90 value of 31 µM32–34 and displayed antimycobacterial activity against the H37Rv 
strain of Mtb with an IC90 value of 1.2 µM.35 An in vitro susceptibility study of 170 clinical isolates 
of Mtb to fusidic acid was conducted. Of the 170 isolates, 19 were resistant to one or more first-
line anti-tuberculosis drugs (INH, RIF, STR and ETB) while the rest were susceptible. It was found 
that only 3 of the 151 susceptible clinical isolates were resistant to fusidic acid with an MIC90 value 
>128 mg/L. All the 19 resistant isolates were susceptible to fusidic acid with MIC90 value of ≤16 
mg/L. Meanwhile, no cross resistance was observed between fusidic acid and the first-line drugs.32 
Inspired by the good antibacterial and antimycobacterial activities of fusidic acid, coupled with the 
need for new drugs to curb the global burden of the disease tuberculosis in terms of high mortality 
and increased emergence of resistance to current chemotherapy, our laboratory has adopted a 
multi-disciplinary approach to the repurposing and repositioning of fusidic acid as an anti-
tubercular drug. This approach has involved collaborative efforts of medicinal chemists, 
pharmacologists and biologists. 
With the goal to identify the mechanism of action (MoA) and plausible mechanisms of resistance 
(MoR) of fusidic acid in M. smegmatis and Mtb, resistant mutant selection and whole genome 
sequencing studies were conducted. The studies revealed EF-G as the target of fusidic acid in Mtb. 
This was further confirmed through target-based whole cell screening conducted using an 
anhydrotetracycline responsive knockdown strain of fusidic acid underexpressing EF-G, in which 
hypersensitivity was observed for fusidic acid and three analogues.36  
The in vitro metabolism of fusidic acid has been demonstrated to be species specific. A key 
metabolite of fusidic acid in mouse and rat liver microsomes was found to be its inactive 3-epimer. 
It was observed in all analogues possessing a free hydroxyl group at C-3 and in 3-ketofusidic acid. 
The formation of this metabolite is hypothesized to result from C-3 oxidation, followed by non-
stereoselective reduction to give fusidic acid and 3-epifusidic acid. Apart from metabolism at the 
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C-3 position, metabolites arising from hydroxylation reactions have also been observed.37 Some 
C-3 esters were found to act as prodrugs of fusidic acid in rodent liver microsomes and plasma, 
following hydrolysis of the acyl group.38 However, this was not observed in C-21 esters and 
amides.36 In the cell lysate of M. smegmatis, a metabolite arising from first, hydrolysis of the C-16 
acetyl group, followed by lactonization with C-21 was observed. However, the fusidic acid lactone 
was absent in either Mtb supernatant or in the buffer control.37 Meanwhile, the main metabolites 
of fusidic acid in humans include 3-ketofusidic acid, C-21 glucoronide, C-27 carboxylic acid, and 
hydroxylates (Figure 4.8).39 These compounds are less active than the parent drug. 3-epifusidic 
acid is not a metabolite in humans. The metabolism of fusidic acid to its inactive 3-epimer in mice 
has made the mouse model inappropriate for in vivo studies of fusidic acid and its analogues. 
 
Figure 4.8: Key metabolites of fusidic acid in rodents and man 
Seven current Mtb drugs have been shown to synergize with fusidic acid in inhibiting the growth 
of Mtb. These include rifampicin (RIF), erythromycin (ERY), clarithromycin (CLR), roxythromycin 
(ROX), linezolid (LZD), streptomycin (STR), and spectinomycin (SPC). The strongest synergies were 
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observed for the two drugs, ERY and SPC, with a fractional inhibitory concentration index (FICI) 
value of 0.25 observed for each drug. It is noteworthy that “synergy with fusidic acid was achieved 
in vitro at concentrations lower than the reported peak plasma concentrations achievable for all 
the drugs, with the exception of ERY”.40 
The biological findings presented above were possible due, in part, to the judicious efforts of 
medicinal chemists who synthesized fusidic acid analogues leading to fusidic acid prodrugs, 
bioisosteres and hybrid analogues. Some of these analogues are shown in Figure 4.9.  
 
Figure 4.9: Representative fusidic acid analogues synthesized from antimycobacterial structure-
activity relationship explorations.36,38,41 
GKFA37 
MIC
99
 (H37Rv): 1.25 µM 
n = 1: GKFA16; n =2: GKFA17 
MIC
99
 (H37Rv): 1.25 µM; 2.5 µM  Ethers 
18.7 µM 
0.8 µM 
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In this context, the SAR explorations have focused on synthesizing C-3, C-16, and C-21 fusidic acid 
analogues as antimycobacterial agents.36,38,41 The in vitro antimycobacterial activity of the 
analogues was evaluated against the H37Rv strain of Mtb, determined at the minimum 
concentration required to inhibit the growth of 99% of the bacterial population (MIC99). 
In general, the C-3 analogues of fusidic acid have exhibited the most potent (<5 µM) 
antimycobacterial activity so far.38,41 These analogues explored so far include esters, amides, 
silicates, oximes, and amines (Figure 4.9). 3-ketofusidic acid (GKFA37) exhibited good activity with 
a MIC99 value of 1.25 µM, while 3-epifusidic acid lost significant activity with a MIC99 value of 11.4 
µM as compared to fusidic acid (MIC99, 0.6 µM). The C-3 butyrate derivative (GKFA16, MIC99, 1.25 
µM) of fusidic acid was found to be the optimum chain length for the C-3 long chain ester 
analogues. The acetate derivative exhibited moderate activity (MIC99, 20 µM) while chain lengths 
exceeding seven carbons resulted in poor activity. The unsubsitituted C-3 oxime (MIC99 = 2.5 µM) 
was the most active of that class of C-3 analogues of fusidic acid. The C-3 trialkoxysilicate 
analogues demonstrated good antimycobacterial activity (MIC99 0.2 – 2.5 µM). Generally, the n-
alkyl silicates were more active than branched ones.38  
Hydrolysis of the C-16 acetyl group, followed by alkylation has afforded two C-16 ether analogues 
of fusidic acid (Figure 4.9). The C-16 ethyl ether analogue exhibited comparable activity (MIC99 0.8 
µM) to fusidic acid while the methyl ether analogue showed moderate activity (MIC99 = 18.7 µM).38  
C-21 fusidic acid analogues were synthesized largely based on a bioisostere approach. The 
synthesized analogues included esters, amides, hydrazides, sulfonamides and oxadiazoles (Figure 
4.9).38,41 Moreover, fusidic acid amide and ester aminoquinoline hybrid compounds have also 
been explored.36 The available antimycobacterial activity data have provided evidence for the 
importance of the COOH group to antimycobacterial activity. Briefly, conversion of fusidic acid to 
the C-21 methyl ester and amide derivatives led to loss of activity (MIC99 >160 µM). However, 
cyclic amides regained activity (MIC99 = 40 µM). The hydrazide analogues of fusidic acid 
demonstrated moderate activity (MIC99 10 - 40 µM), with the exception of long chain n-alkyl or 
aromatic sulfonylhydrazides (MIC99 >160 µM). The methyl sulfonylhydrazide analogue and a 
hydrazide synthesized from fusidic acid and isoniazid both exhibited MIC99 value of 10 µM. 
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Meanwhile, substituted aryl sulfonamides displayed moderate activity (MIC99 20 µM). Five 1,2,4-
oxadiazole derivatives, together with 5-oxo-1,3,4-oxadiazole and 5-thioxo-1,3,4-oxadiazole 
derivatives, have been synthesized as C-21 bioisosteres. However, all of these derivatives were 
found to be either poorly active or inactive (MIC99 80 - 160 µM).38,41 
The C-3 triisopropoxy silicate analogue was found to be stable in vivo. It displayed a better 
pharmacokinetic profile than that of fusidic acid in mice. It achieved higher concentrations in 
blood, a longer half-life (5 h versus 1 h after oral administration), with a lower clearance rate. In 
contrast to the other congeners (GKFA16 and GKFA17), this analogue did not act as a prodrug of 
fusidic acid.38 This could perhaps explain its in vivo stability in mice since it was not hydrolyzed to 
fusidic acid, which has been found to be rapidly converted to its inactive 3-epimer in mice. In fact, 
pharmacokinetic studies conducted on GKFA16 and GKFA17 revealed that the latter was rapidly 
cleared compared to the former. The concentrations of fusidic acid were sustained longer in 
GKFA16. GKFA16 and GKFA17 were evaluated for their organ distribution in the lungs and spleen, 
liver and kidneys, and heart and brain. The compounds showed improved organ distribution 
compared to fusidic acid. Thus, tissue concentrations of fusidic acid were higher than in the 
blood.42  
4.1.3.2 Antiplasmodium activity of fusidic acid 
Fusidic acid has displayed antiplasmodium activity against the D10, NF54, and K1 strains of 
Plasmodium falciparum with IC50 values of 52.8 µM, 59.0 µM, and 19.0 µM, respectively.43,44 It has 
been suggested that fusidic acid exhibits antiplasmodium activity by inhibiting plasmodial EF-Gs in 
the apicoplast and mitochondria.43  
A series of antiplasmodium fusidic acid derivatives were synthesized by replacing the carboxylic 
acid group with various bioisosteres. A 2 - 35 fold increase in antiplasmodium activity was reported 
for most of the derivatives. Moreover, docking studies on the most active analogue revealed 
similar binding orientation to fusidic acid within the active site of plasmodial EF-G.44 Subsequent 
explorations around the carboxylic acid group by its replacement with amide and ester groups led 
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to more potent derivatives with 4 - 49 and 5 - 17 fold increase in activity against P. falciparum 
NF54 and K1 strains, respectively.45 
In a ligand-based 3D-QSAR (Three-Dimensional Quantitative Structure−Activity Relationship) 
modeling approach to design fusidic acid derivatives toward the identification of derivatives with 
improved antiplasmodium activity, compounds I-III were shown to possess significant activity 
against P. falciparum NF54 and K1 strains (Figure 4.10).46  
Kaur and coworkers developed the 3D-QSAR models based on the antiplasmodium activities of 61 
previously synthesized fusidic acid derivatives in our laboratory. After validation of the selected 
model Hypo 2, a 3D query for virtual screening was conducted to search for potential hits from a 
fusidic acid-based combinatorial library. Eight virtual hit compounds were synthesized and 
evaluated for their antiplasmodium activity against P. falciparum. All synthesized compounds 
displayed superior activity than the parent compound fusidic acid (Figures 4.11 and 4.12).46  
 
Figure 4.10: Chemical structures of lead compounds I-III 
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Figure 4.11: Flow chart summarizing 3D-QSAR studies38 
61 Fusidic acid derivatives 
(C-3 and C-21 derivatives) 
  Training set 
(29 molecules) 
     Test set 
(32 molecules) 
3D-QSAR Pharmacophore model generation 
Discovery Studio 4.0 
Fischer’s randomization test  
Inactive set validation 
Test Set Validation 
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Figure 4.12: Pharmacophore models based on fusidic acid derivatives generated by HypoGen  
A. The best HypoGen model, Hypo 2; B. Mapping of Hypo 2 with one of the most active compounds 
(IC50 = 390 nM) from the training set; C. Mapping of Hypo 2 with one of the least active compounds 
(IC50 = 91000 nM) from the training set; Pharmacophore features are color-coded: orange for ring 
aromatic (RA) and cyan for hydrophobic (HY).38 
 
 
A       B 
 
C 
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4.2 Research Program 
4.2.1 Hypothesis 
It is possible to identify new C-21 analogues of fusidic acid with superior antimycobacterial and 
multi-stage antiplasmodium activities through semi-synthesis towards expanding the structure-
activity relationship (SAR) profile. 
4.2.2 Main objective 
To conduct SAR studies of fusidic acid amide derivatives I–III identified from 3-dimensional 
quantitative SAR (3D-QSAR) modeling studies. 
4.2.3 Specific aims 
 To synthesize anilide, N-benzyl amide, and 1-aryl and 1-alkyl ethanamide derivatives of 
fusidic acid as potential antimycobacterial and antiplasmodium agents. 
 To evaluate the synthesized target compounds for in vitro antimycobacterial, 
antiplasmodium and cytotoxic activities 
4.3 Design, Synthesis and characterization of fusidic acid derivatives 
4.3.1 Design and Synthesis of C-21 derivatives 
SAR studies based on the most active compound I were explored. Enantiomerically pure (R or S) 
and racemic N-aryl/alkyl ethanamines were employed. The aryl groups comprised phenyl, pyridyl, 
and pyrazinyl groups. The alkyl amines included both (R)- and (S)-N-cyclohexyl ethanamines. 
Anilide analogues of fusidic acid based on compound II were also explored.   This included a 4-
aminophenol analogue incorporating a Mannich base side chain. Lastly, derivatives based on the 
least active compound III were synthesized, the choice of benzyl amines used enabled exploration 
of which quadrant (in terms of substituents on the phenyl ring) of the Craig plot contributed the 
most to antiplasmodium activity. 
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Scheme 4.1: Summary of fusidic acid derivatives. Reagents and conditions: (a) RNH2, T3P (50% w/v 
solution in EtOAc), NEt3, DCM, 35 oC, 5-24 h; (b) HATU, DCM, 30 oC, 2 h (for 1.23 and 1.24); (c) 
RNH2, KH2PO4, n-BuOH, 100 oC, 16-24 h (for 1.23 and 1.24) 
The synthetic route to arrive at the 1-aryl/alkyl ethanamides (1.1-1.17), anilides (1.18-1.24) and N-
benzyl amides (1.25-1.29) of fusidic acid is outlined in Scheme 4.1. Synthesis of the 4-
hydroxyaniline Mannich base is described in Scheme 4.2. 
In Scheme 4.1 (a), the C-21 amide derivatives were obtained by heating commercially sourced 
fusidic acid (1.0) and the respective amines in DCM in the presence of triethylamine (NEt3) as base 
and propylphosphonic anhydride (T3P®) as a coupling reagent. The amide coupling reactions 
proceeded to completion in a time range of 5-24 hours depending on the amine used. Aqueous 
work-up to get rid of the reaction by-products afforded the crude organic residue, which upon 
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further purification by normal phase silica preparative TLC gave the compounds in low to high yield 
(10-70%). Pure (R)- and (S)-fusidic acid ethanamide derivatives were obtained from the 
corresponding amines. The racemic ethanamines afforded fusidic acid diastereomers (1.9-1.14) in 
a 1:1 to 3:2 ratio, except 1.5 and 1.6 which were well separated and hence were isolated in their 
pure forms. 
The fusidic acid derivative incorporating a phenolic Mannich base moiety (1.24) was obtained in 
two steps (Scheme 4.1 (b and c) and 4.2). The first step was the reaction between fusidic acid and 
the coupling agent HATU to obtain intermediate 6.0 (Scheme 4.2). After purification, 6.0 was then 
subjected to a nucleophilic substitution reaction by heating with 5.0 in the presence of KH2PO4 as 
base and n-BuOH as solvent. The derivative 1.23 was also obtained in a similar manner. It is 
noteworthy that all attempts to obtain 1.23 and 1.24 in a one-pot reaction involving fusidic acid, 
the amine and the coupling reagent (EDCI, T3P or HATU), exploring different reaction conditions, 
neither afforded the desired product nor any product at all. 
Synthesis of the 4-aminophenolic Mannich base was accomplished in three steps (Section 4.2). 
The first step involved protection of the amine group as the acetamide (3.0) in the presence of 
acetic anhydride in THF at 60 oC. The 4-hydroxy acetamide intermediate then underwent a 
Mannich condensation reaction by heating in EtOH in the presence of formaldehyde and 
diethylamine to afford compound 4.0. The last step was the deacetylation of 4.0 under acidic 
conditions to obtain the desired phenolic Mannich base amine (5.0). 
Progress of the reactions was monitored by normal phase silica TLC and reversed phase C18 LCMS. 
The synthesized compounds were fully characterized by their TLC retardation factor (Rf) values in 
appropriate solvents, reversed phase C18 LC retention time (tR), mass spectrometry and 1D NMR 
spectroscopic data. Where necessary, 2D NMR spectroscopic data was acquired to enable correct 
assignment of NMR signals. 
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Scheme 4.2: Synthesis of 1.23 and 1.24. Reagents and conditions: (d) (CH3CO)2O, THF, 60 oC, 1 h; 
(e) HCHO, NHEt2, EtOH, 85 oC, 2 h; (f) 6N HCl, 100 oC, 2 h 
4.3.1.1 Mechanism of T3P-mediated amide coupling 
Propylphosphonic anhydride (T3P®) is a highly reactive n-propyl phosphonic acid cyclic anhydride. 
It is generally employed as a coupling agent and also for scavenging water in reactions. With low 
toxicity and low allergenic effects, T3P tolerates a broad range of functional groups and reduces 
the possibility of epimerization in reactions such as peptide synthesis. The by-products of T3P are 
water-soluble, thus offering an easy means of reaction work-up. T3P reactions proceed under mild 
reaction conditions. Apart from its common use in amide coupling, other T3P-mediated reactions 
have been reported including formation of nitriles from carboxylic acids and amides, formation of 
Weinreb amides, synthesis of esters, dehydration reactions, oxidation of alcohols, synthesis of 
isonitriles, conversion of alcohols to alkenes, C-C coupling reactions, and so on.47 
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The T3P-mediated amide coupling reaction proceeds in the presence of a base. The base abstracts 
a proton from the carboxylic acid group to form the carboxylate ion (Figure 4.13). The anion 
attacks T3P at one of the phosphorus atoms leading to ring opening and conjugation to the 
carboxylic acid scaffold. The amine attacks the now activated carboxylic acid-derived intermediate. 
Subsequent deprotonation of the amide cation by a second equivalence of the base affords the 
neutral amide desired compound. 
 
Figure 4.13: Mechanism of T3P-mediated amide coupling48 
4.3.1.2 Mechanism of HATU-mediated amide coupling 
Hexafluorophosphate Azabenzotriazole Tetramethyl Uronium (HATU) is a reagent used to 
generate an active ester form of a carboxylic acid. The reagent has been employed in peptide 
coupling reactions. HATU can exist as either the uranium salt (O form) or the less reactive iminium 
salt (N form) (Figure 4.14a).49 Typical HATU reactions proceed in two steps: firstly, formation of 
the carboxylic acid-HATU intermediate, and secondly, addition of the hydroxyl or amino 
nucleophile to afford the desired acylated product.  
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Figure 4.14: HATU-assisted formation of amide49,50 
The mechanism of HATU assisted coupling reactions begins with deprotonation of the carboxylic 
acid by a base (usually diisopropyl ethylamine, DIPEA). The carboxylate ion then attacks HATU to 
form the O-acyl(tetramethyl)isouronium salt (Figure 4.14b).50 The isouronium salt is rapidly 
attacked by the 1-hydroxy-7-azabenzotriazole anion (-OAt) to form a more stable intermediate. 
The activated acyl-OAt ester is finally converted to the desired ester or amide product in the 
presence of the alcohol or amine, thereby releasing HOAt as a by-product. 
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4.3.1.3 Mechanism of phenolic Mannich reaction 
The Mannich reaction is a multi-component condensation of a nonenolizable aldehyde, a primary 
or secondary amine and an enolizalible carbonyl compound to afford an aminomethylated/β-
amino carbonyl compound known as a Mannich base.51 Nucleophilic addition of the amine to the 
nonenolizable carbonyl group is followed by dehydration to form a Schiff base (Figure 4.15). 
Electrophilic addition of the Schiff base to the enol affords the desired condensation product. 
 
Figure 4.15: Mechanism of Mannich reaction52 
4.3.2 Characterization of C-21 derivatives 
Twenty-nine C-21 fusidic acid derivatives were synthesized in total comprising 17 1-aryl and alkyl 
ethanamides, 7 anilides and 5 N-benzyl amides (Scheme 4.1). The synthesized fusidic acid 
derivatives were characterized using their 1D NMR spectroscopic and mass spectrometric data. 
The 1D NMR signals were assigned by comparison with those of fusidic acid. The target compounds 
were confirmed by assignment of the new signals due to the amine moiety incorporated.  
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The 1H and 13C NMR data acquired for fusidic acid was in agreement with previously reported 
data.53 Evidence of the tetracyclic triterpenoid backbone was observed by the presence of several 
overlapping multiplets in the methylene envelope (δH 1.0 - 2.6 ppm) of the 1H NMR spectrum. The 
methyl groups resonated at δH 0.91 – 0.93 (m, H3-18 and H3-28), 0.98 (s, H3-19), 1.38 (s, H3-30), 
1.60 (s, H3-26), 1.67 (s, H3-27) and 1.97 (s, OAc). The oxymethine protons, H-3, H-11 and H-16, 
occurred at δH 3.76, 4.35 and 5.89 ppm, respectively, while the signals at δH 3.06 and 5.10 ppm 
were assigned to H-13 and H-24 methine protons, respectively (Figure 4.16).  
 
Figure 4.16:  1H NMR (CDCl3, 400 MHz) spectrum of fusidic acid 
The 13C NMR spectrum showed 31 signals including two carbonyl peaks for the acetate group (δC 
170.5) and the carboxylic acid carbonyl carbon (δC 173.2). The four olefinic carbons, C-17, C-20, C-
24 and C-25, resonated at δC 150.9, 129.4, 123.0 and 132.6 ppm, respectively. Signals due to the 
three C-O chemical environments of C-3, C-11 and C-16 occurred at δC 71.4, 68.2 and 74.4, 
respectively. Moreover, all other signals due to the un-functionalized carbon atoms were observed 
upfield between δC 10.0 – 50.0 ppm (Figure 4.17). 
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Figure 4.17: 13C NMR (CDCl3, 101 MHz) spectrum of fusidic acid 
4.3.2.1 Characterization of 1-aryl and 1-alkyl ethanamides 
Apart from 1.16 and 1.17, all the ethanamide derivatives showed new olefinic proton and carbon 
signals in their NMR spectra due to the aromatic amine moiety incorporated. The structures of the 
synthesized compounds were also confirmed by the presence of a new methine proton (δH ≈5.0 
for the aryl derivatives and δH ≈3.7 for the alkyl derivatives). Furthermore, a new methyl doublet 
was observed at δH ≈1.4 ppm for the aryl derivatives and δH ≈1.0 ppm for the alkyl derivatives 1.16 
and 1.17. Characterization of the 1D NMR data of 1.1 is described below (Figure 4.18 and 4.19).  
C-21 
OAc 
C-17 
C-24 
C-20 C-25 
C-16 
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Figure 4.18: 1H NMR (CDCl3, 400 MHz) spectrum of 1.1 
The 1D NMR data of 1.1 were in congruence with fusidic acid (Figure 4.18 and 4.19). Its formation 
was confirmed by the presence of the doublet at δH 1.41 (d, J = 6.9 Hz, H3-36), 5.00 - 4.93 (m, H-
31), 5.72 (d, J = 7.5 Hz, NH), and overlapping multiplets in the chemical shift range δH 7.16 – 7.30 
ppm for the five aromatic protons (H-33 – H-35). Formation of the amide bond was corroborated 
by the shift of C-21 more upfield to δC 170.9 (Figure 4.19). Similarly, C-17 shifted to δC 143.3 and 
C-20 occurred more downfield at δC 135.9 ppm. Four additional olefinic signals attributable to the 
phenyl ring at δC 126.2 (X2), 127.4, 128.70 (X2) and 141.2 ppm were observed. An extra signal at 
δC 77.3 due to the aminomethine carbon C-31 was also observed. All 39 carbon signals for 1.1 
were therefore fully accounted for. 
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CH3-19 
CH3-26 
CH3-30 
CH3-36 
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H-33, 34, 
35 
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Figure 4.19: 13C NMR (CDCl3, 101 MHz) spectrum of 1.1 
It is noteworthy that all fluorinated analogues exhibited characteristic coupling patterns in their 
1H NMR and 13C NMR spectra, specifically within the aromatic moiety, due to the fluorine atom. 
This is exemplified in the 1D NMR spectra of the fusidic acid ethanamide 1.3 (Figure 4.20 and 4.21). 
Contrary to the 1H NMR spectrum of the other para substituted congeners, wherein the aromatic 
protons were split into doublets as a result of ortho coupling, the aromatic protons of compound 
1.3 exhibited splitting patterns as a result of firstly, ortho coupling between H-33 and H-34 and, 
secondly, further meta and ortho couplings between the fluorine atom and H-33 and H-34, 
respectively (Figure 4.20). Consequently, H-34 (δH = 7.01) was observed as a triplet due to the two 
equal ortho coupling constant values (J = 8 - 10 Hz). Meanwhile, the aromatic carbons of the benzyl 
moiety were each split into a doublet (Figure 4.21). As a result, the C-33 (X2) and C-34 (X2) signals 
were not twice as intense as the other carbon signals, as observed in the 13C NMR spectra of the 
analogues bearing symmetrical phenyl or benzyl moieties. 
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Figure 4.20: 1H NMR (CDCl3, 400 MHz) spectrum of 1.3 
 
Figure 4.21: The olefinic region of the 13C NMR (CDCl3, 101 MHz) spectrum of 1.3 
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4.3.2.2 Characterization of anilides 
The 1H and 13C NMR spectroscopic data obtained for 1.23 were in agreement with 1.0. The 
aromatic protons H-32 and H-33 occurred as doublets at δH 7.37 (d, J = 8.6 Hz, H-32) and δH 6.74 
(d, J = 8.6 Hz, H-33), integrating for two protons each. The acetoxy methyl singlet resonated at δH 
1.73 ppm (Figure 4.22). The amide carbonyl carbon was observed at δC 172.6 while the acetoxy 
carbonyl occurred at δC 172.3 in the 13C NMR spectrum. Furthermore, 1.23 exhibited extra carbon 
signals in the olefinic region due to the presence of the symmetrical 4-hydroxyphenyl amide 
moiety (Figure 4.23). The signals of C-3, C-11 and C-16 were discernible at δC 72.4, 68.6 and 75.5, 
respectively. All other carbon signals occurred upfield in the range of δC 10.0 – 50.0 ppm, just like 
fusidic acid. 
 
Figure 4.22: 1H NMR (MeOH-d4, 400 MHz) spectrum of 1.23 
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Figure 4.23: 13C NMR (MeOH-d4, 101 MHz) spectrum of 1.23 
Compound 1.24 exhibited three aromatic proton signals with the coupling pattern characteristic 
of a 1,3,4-trisubstituted phenyl ring in its 1H NMR spectrum. The methine proton H-36 resonated 
at δH 7.29 (dd, J = 2.7, 8.6 Hz), the coupling constants supported a meta coupling to H-32 (δH 7.33, 
d, J = 2.6 Hz) and an ortho coupling to H-35 (δH 6.69, d, J = 8.5 Hz). Signals confirming the presence 
of the Mannich base side chain occurred at δH 3.86 (s, H2-37), 2.75 (q, J = 7.1 Hz, 4H, 2×H2-38), and 
1.16 (t, J = 7.1 Hz, 6H, 2×H3-39) which integrated for two, four, and six protons, respectively. All 
other proton signals were in agreement with fusidic acid (Figure 4.24). Figure 4.25 is the stacked 
1H NMR spectrum comparing 1.23 and 1.24. Differences in the two spectra are observed in the 
aromatic protons signifying the change in splitting pattern of 1.24 compared to 1.23 as a result of 
substitution of the diethylaminomethyl side chain. Moreover, signals arising from the protons of 
the Mannich base side chain of 1.24 are discernible compared to 1.23. 
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Figure 4.24: 1H NMR (MeOH-d4, 400 MHz) spectrum of 1.24 
 
Figure 4.25: Stacked 1H NMR (MeOH-d4, 400 MHz) spectrum of 1.23 and 1.24 
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Figure 4.26: 13C NMR (MeOH-d4, 101 MHz) spectrum of 1.24 
The 13C NMR spectrum of 1.24 exhibited 40 signals including 6 extra olefinic signals corresponding 
to the phenyl group. Signals due to the Mannich base side chain were observed at δC 56.6 (C-37), 
47.8 (C-38) and 11.1 (C-39). The two carbonyl carbons occurred at δC 172.5 and 172.3, similar to 
1.23 for the presence of the anilide moiety (Figure 4.26). 
4.3.2.3 Characterization of N-benzyl amides 
The N-benzyl amides exhibited comparable 1D NMR spectra. The presence of the benzylic protons 
was observed as two separate doublet signals, integrating for one proton each in the 1H NMR 
spectrum, signifying that the methylene protons resonated as diastereotopic protons (H-31a and 
H-31b). The 1H NMR spectrum of 1.28 is shown in Figure 4.26. All proton signals were congruent 
with fusidic acid (1.0). The benzylic methylene protons were observed at δH 4.15 (d, J = 14.3 Hz, 
H2-31a) and δH 4.37 (d, J = 14.3 Hz, H2-31b). The strong geminal (2J) coupling between these 
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protons is accounted for by the large coupling constant (J = 14.3 Hz). The aromatic protons were 
observed at δH 7.11 (d, J = 8.5 Hz, 2H, 2×H-33) and 6.70 (d, J = 8.5, 2H, 2×H-34) (Figure 4.27).  
The 13C NMR spectrum (Figure 4.28) of 1.28 exhibited 36 signals, the signals at δC 116.4 (C-34) and 
130.4 (C-33) integrating for two carbons each as a result of the symmetrical disubstituted benzyl 
moiety. The amide carbonyl carbon resonated at δC 174.0 while the acetoxy carbonyl was 
observed at δC 172.5 ppm. The four additional olefinic signals of the phenyl ring, assigned to C-32, 
C-33, C-34 and C-35, were observed at δC 135.7, 130.4 (X2), 116.4 (X2), and 158.0, respectively. 
 
Figure 4.27: 1H NMR (MeOH-d4, 400 MHz) spectrum of 1.28 
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Figure 4.28: 13C NMR (MeOH-d4, 101 MHz) spectrum of 1.28 
4.4 Biological results and discussion 
4.4.1 Antimycobacterial activity 
In vitro antimycobacterial activity evaluation of all the synthesized analogues were carried out on 
the H37Rv strain of Mtb by the TB Biology group of the UCT Drug Discovery and Development 
Centre, H3D, based at the Institute of Infectious Diseases and Molecular Medicine (IDM), 
University of Cape Town, South Africa. Two media were employed, namely 7H9 GLU ADC TW 
(Middlebrook 7H9 media enriched with albumin-dextrose-catalase (ADC) and supplemented with 
0.4% Glucose and 0.05% Tween 80) and 7H9 GLU CAS TX (Middlebrook 7H9 media supplemented 
with 0.03% Casitone, 0.4% Glucose and 0.05% Tyloxpol). The former is a protein-based media 
containing the serum protein albumin, which is known to bind to drugs in the blood. However, the 
7H9 GLU CAS TX is a non-protein-based media. The activity was evaluated at MIC90 (minimum 
concentration required to inhibit the growth of 90% of the bacterial population), using rifampicin 
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as the reference drug. The synthesized compounds were tested at a maximum concentration limit 
set at 125 μM. 
Table 4.2: In vitro antimycobacterial (H37Rv strain) and cytotoxic (CHO cell line) activities of 
the fusidic acid amide analogues 
 
Compound R 
Antimycobacterial activity, 
H37Rv, MIC90 (µM) 
Cytotoxicity, 
IC50 (µM) 
7H9 GLU ADC 
TW 
7H9 GLU CAS 
TX 
CHO 
1.1 
 
>125 8.90 45.95 
1.2 
 
>125 11.00 47.61 
1.3 
 
>125 7.59 47.40 
1.4 
 
>125 >125 8.24 
1.5 
 
41.52 9.80 45.15 
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1.6 
 
>125 10.10 18.16 
1.7/ 
 
38.83 7.10 42.88 
1.8 
 
15.73 9.10 >50 
1.9 
 
>125 2.91 47.90 
1.10 
 
>125 19.82 45.30 
1.11 
 
32.26 7.20 >50 
1.12 
 
>125 17.87 >50 
1.13 
 
125 13.03 >50 
1.14 
 
62.5 17.49 >50 
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1.15 
 
>125 13.90 36.84 
1.16 
 
>125 4.50 44.69 
1.17 
 
>125 7.45 >50 
1.18 
 
43.21 6.20 46.13 
1.19 
 
>125 >125 42.68 
1.20 
 
>125 >125 47.12 
1.21 
 
125 >125 >50 
1.22 
 
125 125 39.90 
1.23 
 
>125 6.90 45.39 
1.24 
 
10.35 0.40 8.69 
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1.25 
 
125 >125 44.10 
1.26 
 
125 >125 40.20 
1.27 
 
62.27 2.71 30.20 
1.28 
 
125 125 >50 
1.29 
 
125 >125 >50 
Rifampicin  0.009 0.02  
Emetine    0.02 
To enable analysis of their SAR, all compounds with MIC90 ≤10 μM were regarded as active; those 
with MIC90 ranging from 10 – 20 μM had moderate activity; MIC90 = 20 – 125 μM denoted as poorly 
active; whereas compounds exhibiting MIC90 >125 μM were considered inactive. The SAR of the 
compounds are discussed within their chemical classes as ethanamides, anilides and benzyl 
amides. 
In this regard, the fusidic acid ethanamide analogues were either poorly active or inactive in the 
protein-based 7H9/ADC media, except compound 1.8 which showed moderate activity (MIC90 = 
15.73 µM). The poor activity could be attributed to binding to albumin since all the analogues 
(except 1.4) showed improved potency in the non-protein-based media. In general, analogues with 
polar groups and/or substituents in close proximity to the amide bond showed inhibitory activity 
in the 7H9/ADC media, suggesting they were less bound to albumin. This is particularly exemplified 
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in the activities of 1.7, 1.8, 1.11 and 1.14, which displayed MIC90 values of 38.83, 15.73, 32.26, and 
62.5 µM, respectively (Table 4.2).  
The enantiomerically pure fusidic acid ethanamide analogues exhibited comparable activity (MIC90 
= 7 - 12 µM) in the 7H9/CAS media, except compound 1.4 which was inactive. Generally, the S-
enantiomers were more potent than the R-enantiomers. The cyclohexyl congener 1.16 was the 
most potent analogue amongst the chiral fusidic acid ethanamides in the 7H9/CAS media, 
exhibiting about 2-fold better activity (MIC90 = 4.50 µM). Meanwhile, all diastereomeric 
ethanamide analogues exhibited moderate activity ((MIC90 = 13 - 20 µM), except compounds 1.9 
(MIC90 = 2.91 µM) and 1.11 (MIC90 = 7.20 µM). The 4-pyridinyl analogue 1.13 was the most active 
(MIC90 = 13.03 µM) analogue amongst the nitrogen heterocyclic benzyl ethanamide fusidic acid 
analogues. The 3-pyridinyl and the 2,5-pyrazinyl congeners exhibited comparable activity (MIC90 
~17 µM). 
Amongst the fusidic acid anilide analogues, it was observed that substitution at the ortho position 
favored activity in both the 7H9/ADC and 7H9/CAS media. This is exemplified by comparison of 
the activities of the three methoxy-substituted anilide regioisomers 1.18, 1.19 and 1.20 (Table 4.2). 
Compound 1.18 with the methoxy group ortho to the amide bond displayed good activity (MIC90 
= 6.20 µM) in the non-protein-based media but poor activity (MIC90 = 43.21 µM) in the protein-
based media. However, the meta- and para-substituted congeners were not potent in both media. 
Similarly, compounds 1.21 and 1.22, which bear lipophilic electron-releasing and electron-
withdrawing groups, respectively, were equally inactive in both media. Meanwhile, it was 
observed that activity in the 7H9/CAS media was restored if the para position bears a hydrophilic 
electron-donating group capable of forming hydrogen bonds, as exemplified by 1.23 (MIC90 = 6.90 
µM). Compound 1.24, which bear the Mannich base side chain, was the most active of all the 
synthesized fusidic acid analogues. It exhibited good activity in both media (7H9/ADC: MIC90 = 
10.35 µM; 7H9/CAS: MIC90 = 0.40 µM). Therefore, it can be hypothesized that the presence of the 
bulky diethylaminomethyl moiety, coupled with the basicity of the nitrogen atom, which is capable 
of forming intramolecular hydrogen bond to the para-hydroxyl group, enhances the 
antimycobacterial activity of 1.24. 
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The fusidic acid benzyl amide analogues offered an opportunity to analyze the contribution of 
different Craig plot substituents to activity. It was observed that all analogues, including the 
unsubstituted benzyl amide 1.25, were inactive in both 7H9/ADC and 7H9/CAS media, except 
compound 1.27 (7H9/ADC: MIC90 = 62.27 µM; 7H9/CAS: MIC90 = 2.71 µM), which bear a 
sulfonamide group at the para position. It can therefore be deduced that hydrophilic electron-
withdrawing groups favor antimycobacterial activity. The data supports the hypothesis that bulky 
polar groups contribute to activity. Moreover, the good activity displayed by 1.27 is congruent with 
previously reported data on the importance of the sulfonamide group to the antimycobacterial 
activity of fusidic acid, as already mentioned in Section 4.1.3.1. 
In summary, the ethanamide analogues of fusidic acid, generally, exhibited better activity than 
their anilide and benzyl amide congeners; however, the anilide analogue 1.24 exhibited the most 
potent antimycobacterial activity amongst the synthesized compounds. The enantiomerically pure 
ethanamide analogues showed better activity than the diastereomeric analogues, except 1.9.  
Safety profiling of the synthesized compounds to mammalian cells was evaluated as their cytotoxic 
activity against the Chinese Hamster Ovarian (CHO) cell line at H3D, Division of Clinical 
Pharmacology, University of Cape Town. The compounds were assayed using the 3-(4,5-
dimethylthiazol-2-yl)-2,5-diphenyltetrazolium bromide (MTT) assay, which is a colorimetric assay 
that measures cell viability as a function of metabolism/reduction of MTT (yellow colour) to 
formazan (purple colour) by cytosolic NAD(P)H-dependent oxidoreductase enzymes. With an 
acceptable level of cytotoxicity cut-off set to IC50 >10 µM, all the synthesized compounds displayed 
low to no cytotoxicity, except compounds 1.3 (IC50 = 8.24 µM) and 1.24 (IC50 = 8.69 µM). 
Measurement of antimycobacterial activity as a MIC90 and cytotoxicity as IC50 could not allow for 
an assessment of the selectivity indices of the compounds.  
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4.4.2 Antiplasmodium and cytotoxic activities 
The synthesized fusidic acid analogues were evaluated in vitro against asexual blood stage and 
gametocyte P. falciparum parasites. In vitro antiplasmodium activity was investigated against the 
asexual chloroquine-sensitive (NF54) and multi-drug resistant (K1) strains of P. falciparum and the 
early and late gametocyte marker cell line NF54-PfS16-GFP-Luc. The activity of the compounds 
against the asexual parasites was assessed using the modified [3H]-hypoxanthine incorporation 
assay, except for the analogues, 1.6, 1.7, 1.14, 1.21, 1.22 and the benzyl amide derivatives, which 
were evaluated using the modified lactate dehydrogenase assay.54 The former assay is based on 
the incorporation of radioactive [3H]-hypoxanthine into parasite nucleic acids. The malaria parasite 
depends on hypoxanthine for nucleic acid synthesis and energy metabolism. Incorporation of 
radiolabeled hypoxanthine into parasite cultures ensures incorporation of the radiolabeled purine 
into the parasite’s nucleic acids and, thus, enables the quantification of cell proliferation using a 
scintillation counter.55 The [3H]-hypoxanthine incorporation assay was conducted at the Swiss 
Tropical and Public Health Institute, University of Basel. 
Lactate dehydrogenase (LDH) is an intracellular enzyme necessary for the interconversion of 
pyruvate and lactate with associated interconversion of NADH and NAD+. Plasmodium lactate 
dehydrogenase (pLDH) can be distinguished from human LDH by its ability to use the NAD analog 
3-acetyl pyridine adenine dinucleotide (APAD), in the conversion of lactate to pyruvate. Since pLDH 
can utilize APAD at ~200-fold more rapidly and effectively than human LDH isoforms, pLDH activity 
can easily be distinguished in blood samples of 0.2 – 10% parasitemia. Parasite proliferation was 
therefore measured by monitoring the conversion of APAD to APADH by pLDH.54,56–58 For the 
purpose of discussion, test compounds are classified to have potent activity if they displayed low 
micromolar antiplasmodium activity (IC50 ≤1 µM). Compounds exhibiting IC50 values in the range 
of 1 - 5 µM were deemed moderately active while they are inactive if they exhibited IC50 value >5 
µM. 
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Table 4.3: In vitro activity against blood stage (NF54 and K1 strains) and gametocyte (NF54 strain) P. 
falciparum parasites and cytotoxicity (CHO cell line) of the fusidic acid amide analogues 
 
Compound R 
Asexual parasites, 
IC50 (µM) 
Gametocyte 
parasites,  
% inhibition, 5 µM 
Cytotoxicity 
IC50 (µM) 
Pf(NF54) Pf(K1) 
Early 
stage 
Late 
stage 
CHO SI 
1.1 
 
3.45 2.33 13 50 45.95 13.31 
1.2 
 
2.22 1.25 32 55 47.61 21.44 
1.3 
 
3.80 3.18 3 0 47.40 12.47 
1.4 
 
0.57 0.47 48 30 8.24 14.45 
1.5 
 
2.91 - - - 45.15 15.51 
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1.6 
 
4.26 - 15 12 18.16 4.26 
1.7 
 
5.47 - - - 42.88 7.83 
1.8 
 
>10 >10 24 22 >50 - 
1.9 
 
0.96 0.67 21 32 47.90 49.89 
1.10 
 
0.80 0.65 40 49 45.30 56.62 
1.11 
 
1.00 0.85 27 27 >50 >50 
1.12 
 
>10 >10 44 43 >50 - 
1.13 
 
2.98 2.59 36 41 >50 >16.77 
1.14 
 
6.00 - 14 37 >50 >8.33 
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1.15 
 
6.74 5.20 - - 36.84 5.46 
1.16 
 
1.37 1.04 60 56 44.69 32.62 
1.17 
 
1.72 1.04 39 59 >50 >29.06 
1.18 
 
1.00 0.71 52 55 46.13 46.13 
1.19 
 
2.42 1.41 30 30 42.68 17.63 
1.20 
 
0.86 0.63 36 34 47.12 54.79 
1.21 
 
1.27 - 54 43 >50 >39.37 
1.22 
 
1.93 - 17 37 39.90 20.67 
1.23 
 
3.82 2.67 0 14 45.39 11.88 
1.24 
 
5.11 3.21 66 39 8.69 1.70 
1.25 
 
3.92 - 6 17 44.10 11.25 
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1.26 
 
2.76 - 15 28 40.20 14.56 
1.27 
 
6.00 - 0 14 30.20 5.03 
1.28 
 
6.00 - 0 13 >50 8.33 
1.29 
 
4.87 - 8 37 >50 10.26 
Chloroquine  0.01 0.42     
Artesunate  4.42 nM 3.12 nM     
MMV390048    77 92   
Emetine      0.02  
In general, the synthesized fusidic acid analogues displayed better in vitro antiplasmodium 
potency against the multidrug-resistant K1 strain than the drug-sensitive NF54 strain, suggesting 
the absence of cross-resistance. The ethanamide analogues 1.4 (IC50 PfNF54/K1 = 0.57/0.47 µM), 
1.9 (IC50 PfNF54/K1 = 0.96/0.67 µM), 1.10 (IC50 PfNF54/K1 = 0.80/0.65 µM) and 1.11 (IC50 
PfNF54/K1 = 1.00/0.85 µM) displayed low micromolar activities against both asexual strains (Table 
4.3). The comparable potencies of the 4-fluoro ethanamides, single diastereomer 1.4 and 
diastereomeric mixture 1.10, coupled with the weak activity displayed by 1.3, the opposite 
diastereomer of 1.4, suggests that there is no antagonism from the opposite diastereomer. 
Analysis of the relative potencies of the enantiomerically pure ethanamides seem to suggest that 
the R-enantiomers are better inhibitors of parasite proliferation than their S-congeners, 
exemplified by compounds 1.2, 1.4, and 1.6; however, 1.16 and 1.17 demonstrated comparable 
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activity (Table 4.3). Meanwhile, among the analogues with nitrogen-containing heterocyclic 
aromatic ring, the 3-pyridinyl and 2-pyrazinyl analogues, 1.12 and 1.14, respectively, both lost 
activity while the 4-pyridinyl analogue, 1.13, was moderately active (IC50 PfNF54 = 2.98 µM). 
Similarly, the C-31-acetoxy and C-31 acetamido fusidic acid analogues, 1.7 (IC50 PfNF54 = 5.47 µM) 
and 1.8 (IC50 PfNF54 >10 µM), were both inactive, contrary to 1.1 or 1.2, which exhibited moderate 
activity, suggesting that a bulky group at the C-31 position of the ethanamides compromises 
activity. The cyclohexyl ethanamides 1.16 (IC50 PfNF54/K1 = 1.37/1.04 µM) and 1.17 (IC50 
PfNF54/K1 = 1.72/1.04 µM) were only slightly more potent than their phenyl counterparts, 1.1 
(IC50 PfNF54/K1 = 3.45/2.33 µM) and 1.2 (IC50 PfNF54/K1 = 2.22/1.25 µM). In summary, among the 
ethanamide derivatives, antiplasmodium activity is not affected by diastereoisomerism, although 
R-enantiomers are more potent than their S-congeners. While nitrogen-containing heterocyclic 
phenyl rings led to loss of activity, saturation of the phenyl ring, as exemplified by 1.16 and 1.17, 
is tolerated for activity. Finally, functionalization of the methyl group at C-31 (exemplified by 1.7 
and 1.8) or the presence of a bulky group, such as the cyclopropyl group in 1.15 (IC50 PfNF54/K1 = 
6.74/5.20 µM) at the C-31 position led to complete loss of activity. 
The ortho and para-methoxy anilide analogues, 1.18 (IC50 PfNF54/K1 = 1.00/0.71 µM) and 1.20 
(IC50 PfNF54/K1 = 0.86/0.63 µM), respectively, exhibited low micromolar potency against both 
asexual strains of P. falciparum. The meta-methoxy derivative, 1.19, however, displayed moderate 
activity (IC50 PfNF54/K1 = 2.42/1.41 µM), suggesting that meta-substitution leads to reduction in 
activity. Similarly, the 4-methyl (1.21), 4-fluoro (1.22) and 4-hydroxy (1.23) fusidic acid anilides 
were moderately active, the latter displaying about two-fold less potency (IC50 PfNF54 = 3.82 µM) 
than 1.21 (IC50 PfNF54 = 1.27 µM) and 1.22 (IC50 PfNF54 = 1.93 µM). Compound 1.24, which 
possessed the Mannich base side chain, was the least active (IC50 PfNF54/K1 = 5.11/3.21 µM) 
analogue of the anilide derivatives. Compared to 1.23, the reduction in antiplasmodium activity of 
1.24 seems to suggest that the Mannich base side chain is not tolerated for antiplasmodium 
activity.  
Meanwhile, the fusidic acid benzyl amides, 1.25, 1.26 and 1.29, displayed moderate activities with 
IC50 values of 3.92 µM, 2.76 µM, and 4.87 µM, respectively, against the NF54 strain. However, 
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compounds 1.27 and 1.28 were both inactive, suggesting that, on the basis of the contribution of 
Craig plot substituents to activity, hydrophilic groups, either electron-withdrawing or electron-
donating, are not tolerated for in vitro asexual blood stage antiplasmodium activity. This is in 
marked contrast to the antimycobacterial activity. 
Initial screening at 1 µM and 5 µM of the synthesized compounds against both early (EG) and late 
(LG) stage gametocytes was conducted using the luciferase reporter assay. Compounds 1.16 (% 
inhibition: EG = 60%, LG = 56%) and 1.18 (% inhibition: EG = 52%, LG = 55%) exhibited moderate 
activity against both gametocyte stages at 5 µM. The fusidic acid Mannich base anilide (1.24) 
displayed 66% inhibition at 5 µM against the early stage gametocyte but lost activity to the late 
gametocyte parasites. Similarly, compounds 1.1 and 1.2 were active only against the late 
gametocytes. They displayed moderate activity (% inhibition >50%). All other analogues were 
inactive at the test concentrations. (Table 4.3). 
The safety profiles of the compounds were analyzed in terms of their selectivity indices with 
respect to the NF54 strain of P. falciparum (Table 4.3). The selectivity indices were calculated as a 
ratio of the IC50 (CHO) to IC50 (NF54). With SI ≥10 considered safe, most of the synthesized fusidic 
acid amides were generally non-cytotoxic, except compounds 1.3 (SI = 2.16), 1.6 (SI = 4.26), 1.7 (SI 
= 7.83), 1.14 (SI = 8.33), 1.15 (SI = 5.46), 1.24 (SI = 1.70), 1.27 (SI = 5.03), and 1.28 (SI = 8.33). 
4.5 Conclusion and recommendations for future work 
C-21 fusidic acid ethanamides, anilides and benzyl amides were synthesized as potential 
antimycobacterial and multi-stage antiplasmodium agents. Antimycobacterial activity was favored 
by the presence of bulky and/or polar substituents, notably, in close proximity to the amide bond. 
The most potent antimycobacterial analogue was found to be the fusidic acid Mannich base 
anilide, 1.24. Future SAR aimed at exploring fusidic acid phenolic amides incorporating a Mannich 
base side chain and hydrophilic electron-withdrawing substituents is encouraged. 
The fusidic acid ethanamides were, generally, the most potent of the analogues evaluated for 
multi-stage antiplasmodium activity with sub-micromolar IC50 values (0.5 – 0.9 µM) recorded for 
some analogues against the asexual parasites. Meanwhile, the compounds exhibited moderate to 
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no activity against P. falciparum gametocytes. It was observed that antiplasmodium activity was 
more favored by the ethanamide moiety and the presence of para substituted lipophilic groups. 
Thus, future SAR involving C-3 and C-16 fusidic acid ethanamides is highly encouraged. 
The data generated and results reported confirms the initial hypothesis to identify new C-21 
analogues of fusidic acid with superior antimycobacterial and multi-stage antiplasmodium 
activities through semi-synthesis. 
4.6 Experimental 
4.6.1 General Experimental Procedures 
All chemicals and reagents were sourced from commercial vendors. Fusidic acid was purchased 
from AvaChem Scientific. All other reagents (starting materials) were purchased from Sigma-
Aldrich, Combi-Blocks or Fluorochem. Solvents and reagents used to prepare the mobile phase for 
LCMS analyses were of HPLC-grade and were obtained Sigma-Aldrich (NH4OAc as an additive), 
Merck (glacial acetic acid) and Microsep (acetonitrile and methanol). Bulk solvents used for 
extraction and purification purposes were obtained from Scienceworld Chemicals and were of CP 
or AR grade. 
Reactions were monitored using aluminum silica pre-coated thin layer chromatography (TLC) 
plates (60 F254 from Merck or Al foils 60 Å medium pore diameter from Merck). Visualization of 
TLC spots were accomplished with the aid of either ultraviolent light (UV) at 245 nm or by using 
Ce(SO4)2 stain (15% aqueous sulfuric acid saturated with ceric sulfate).  
Purification of synthesized compounds was achieved by preparative TLC (Silica gel GF254, 2000 
μm on glass from Analtech). Melting points (uncorrected) were determined using a Stuart 
Automatic Melting Point Apparatus, SMP40 (Bibby Scientific).  
Low Resolution-ESI-MS was acquired on an Agilent 1260 Infinity HPLC system (Agilent® 1260 
Infinity Binary Pump, Agilent® 1260 Infinity Diode Array Detector (DAD), Agilent® 1290 Infinity 
Column Compartment, and Agilent® 1260 Infinity Standard Auto sampler) coupled to Agilent 6120 
Quardrupole MS system and Peak Scientific® Genius 1050 Nitrogen Generator. Phenomenex 
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Kinetex® 2.6 µm EVO C18 100 Å (30 x 2.1 mm) reverse phase analytical column was used. The 
chromatographic method included a column temperature of 40 oC, an injection volume of 2 µL, 
flow rate of 0.7 mL/min and maximum column back pressure set at 600 bars. The mobile phase 
was made up of 10 mM NH4OAc in water (A) and 10 mM NH4OAc in methanol (B). The LC run is a 
4.50 min duration beginning with 15% of B from 0 - 0.30 min, followed by a speedy increase in the 
gradient to 100% B over 0.90 min. The mobile phase composition at 100% of B is maintained to 
the 4.50 min. 
Characterization of synthesized compounds was achieved by analyses of their MS and 1D NMR 
data. The NMR data was acquired on either a Bruker UltraShield-Plus (400 MHz and 101 MHz 
for 1H and 13C nuclei, respectively) spectrometer or on a BRUKER Ascend 600 cryoprobe prodigy 
(600 MHz and 151 MHz for 1H and 13C nuclei, respectively). The 1H NMR data was acquired using 
standard proton pulse sequence while all 13C NMR data were acquired using the full proton 
decoupled pulse program. All compounds were dissolved in deuterated solvents for analyses 
(referenced as follows: CDCl3: δH 7.26, δC 77.0 ppm; MeOH-d4: δH 3.30, δC 49.0 ppm; or DMSO-d6: 
δH 2.50, δC 37.5 ppm). Chemical shifts (δ) are reported in part per million (ppm) to two decimal 
place for 1H NMR and one decimal places for 13C NMR relative to TMS at 0 ppm. Coupling constants 
(J) are reported in Hertz (Hz) to one decimal place. Proton (1H) NMR splitting patterns are 
abbreviated as follows: s (singlet), broad singlet (br s), d (doublet), dd (doublet of doublets), t 
(triplet), q (quartet) and m (multiplet).  
4.6.2 General Synthetic Procedure for compounds 1.1 - 1.22 and 1.25 - 1.29 
To a mixture of fusidic acid (1.0) (1 eq.) and the respective amine (1.5 eq.) in DCM (1 mL) was 
added triethylamine (3 eq.) dropwise at 25 oC. T3P solution (3.0 eq., 50% w/v in EtOAc, d=0.534 
g/mL) was added dropwise. The temperature of the reaction mixture was increased to 35 oC and 
left to stir until reaction was complete (5 – 24 h depending on amine). The progress of the reaction 
was followed by TLC and LCMS. On completion, the reaction mixture was diluted with DCM (20 
mL) and the by-products were extracted with water (15 mL x2) in a separating funnel. The organic 
layer was dried with anhydrous sodium sulfate, filtered and concentrated in vacuo to obtain the 
crude product. Further purification was accomplished by normal phase preparative TLC using 
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DCM-EtOAc mixture or DCM-MeOH mixture as eluent depending on the amine. Bands were 
detected under UV-254 nm, scraped and extracted with EtOAc or acetone. After extraction of the 
compounds, the silica was filtered off and the filtrate was concentrated in vacuo to obtain the 
target compounds as amorphous solids.  
N-((S)-1-(phenyl)ethyl)fusidic acid amide (1.1)  
White powder (0.080 g obtained from 0.100 g of 1.0, 
65%); Rf 0.6 (60% EtOAc:DCM); Mp 182-184 oC; 1H 
NMR (400 MHz, CDCl3) δ 7.30-7.16 (m, 5H, 2×H-33, 
2×H-34 and H-35), 5.72 (d, J = 7.5 Hz, 1H, NH), 5.67 
(d, J = 8.2 Hz, 1H, H-16), 5.01 (m, 1H, H-24), 5.00-
4.93 (m, 1H, H-31), 4.28 (m, 1H, H-11), 3.69 (m, 1H, 
H-3), 2.94 (m, 1H, H-13), 2.48-2.37 (m, 1H, H-22), 
2.35-2.29 (m, 1H, H-22), 2.27-2.24 (m, 1H, H-12), 
2.17-1.97 (m, 5H, H-1, H-5, H-15 and 2×H-23), 1.90 (s, 3H, OAc), 1.85-1.61 (m, 4H, 2×H-2, H-7 and 
H-12), 1.58 (s, 3H, CH3-27), 1.56-1.48 (m, 4H, H-1, H-4, H-6 and H-9), 1.47 (s, 3H, CH3-26), 1.41 (d, 
J = 6.9 Hz, 3H, CH3-36), 1.33 (s, 3H, CH3-30), 1.30-1.24 (m, 1H, H-15), 1.13-0.99 (m, 2H, H-6 and H-
7), 0.93 (s, 3H, CH3-19), 0.90 (s, 3H, CH3-18), 0.87 (d, J = 6.9 Hz, 3H, CH3-28); 13C NMR (101 MHz, 
CDCl3) δ 170.9, 170.4, 143.3, 141.2, 135.9, 132.4, 128.7 (2C), 127.4, 126.2 (2C), 123.3, 74.1, 71.4, 
68.3, 49.3, 49.1, 48.6, 43.3, 39.5, 39.4, 37.0, 36.3, 36.1, 35.7, 32.3, 30.2, 30.0, 29.6, 28.0, 25.6, 
24.0, 22.8, 21.4, 21.1, 20.8, 17.8, 17.7 and 15.9; LC-MS (ESI): m/z 642 [M+Na]+, 560 [M-OAc]+; 
purity (LC-MS): 98% (tR = 3.11 min.) 
 
 
 
 
 
 
 
Chapter Four: Semi-synthetic derivatization, antimycobacterial and antiplasmodium evaluation of analogues of the 
natural product fusidic acid 
 
155 
N-((R)-1-(phenyl)ethyl)fusidic acid amide (1.2) 
White powder (0.074 g obtained from 0.100 g of 1.0, 
60%); Rf 0.5 (60% EtOAc:DCM); Mp 181-183 oC; 1H 
NMR (400 MHz, CDCl3) δ 7.38-7.18 (m, 5H, 2×H-33, 
2×H-34 and H-35), 5.79 (d, J = 7.6 Hz, 1H, NH), 5.51 
(d, J = 8.0 Hz, 1H, H-16), 5.09 (m, 1H, H-24), 5.03 (m, 
1H, H-31), 4.31 (m, 1H, H-11), 3.72 (m, 1H, H-3), 2.97 
(m, 1H, H-13), 2.56-2.43 (m, 1H, H-22), 2.38-2.31 (m, 
1H, H-22), 2.30-2.22 (m, 1H, H-12), 2.18-2.00 (m, 5H, 
H-1, H-5, H-15 and 2×H-23), 1.78 (s, 3H, OAc), 1.85-1.61 (m, 4H, 2×H-2, H-7 and H-12), 1.66 (s, 3H, 
CH3-27), 1.58 (s, 3H, CH3-26), 1.56-1.48 (m, 4H, H-1, H-4, H-6 and H-9), 1.48 (d, J = 6.9 Hz, 3H, CH3-
36), 1.34 (s, 3H, CH3-30), 1.30-1.24 (m, 1H, H-15), 1.15-1.00 (m, 2H, H-6 and H-7), 0.96 (s, 3H, CH3-
19), 0.92-0.88 (m, 6H, CH3-18 and CH3-28); 13C NMR (101 MHz, CDCl3) δ 170.4, 170.3, 142.8, 141.4, 
135.8, 132.5, 128.8 (2C), 127.5, 126.4 (2C), 123.4, 74.5, 71.4, 68.3, 49.3, 49.1, 48.5, 43.2, 39.6, 
37.0, 36.3, 36.1, 35.8, 32.3, 30.2, 30.0, 29.8, 28.1, 25.7, 24.0, 22.8, 21.8, 21.0, 20.8, 18.0, 17.8 and 
15.9; LC-MS (ESI): m/z 642 [M+Na]+, 560 [M-OAc]+; purity (LC-MS): 98% (tR = 3.07 min.) 
N-((S)-1-(4-fluorophenyl)ethyl)fusidic acid amide (1.3) 
White powder (0.032 g obtained from 0.100 g of 1.0, 
25%); Rf 0.6 (60% EtOAc:DCM); Mp 171-173 oC; 1H 
NMR (400 MHz, CDCl3) δ 7.30-7.23 (m, 2H, 2×H-33), 
7.01 (t, J = 8.7 Hz, 2H, 2×H-34), 5.71 (d, J = 8.1 Hz, 
1H, H-16), 5.65 (d, J = 7.5 Hz, 1H, NH), 5.02 (m, 1H, 
H-24), 5.00-4.94 (m, 1H, H-31), 4.32 (m, 1H, H-11), 
3.74 (m, 1H, H-3), 2.98 (m, 1H, H-13), 2.53-2.40 (m, 
1H, H-22), 2.36-2.29 (m, 1H, H-22), 2.30-2.23 (m, 1H, 
H-12), 2.21-1.96 (m, 5H, H-1, H-5, H-15 and 2×H-23), 1.96 (s, 3H, OAc), 1.89-1.64 (m, 4H, 2×H-2, 
H-7 and H-12), 1.62 (s, 3H, CH3-27), 1.60-1.52 (m, 4H, H-1, H-4, H-6 and H-9), 1.50 (s, 3H, CH3-26), 
1.43 (d, J = 6.9 Hz, 3H, CH3-36), 1.36 (s, 3H, CH3-30), 1.30-1.24 (m, 1H, H-15), 1.15-1.00 (m, 2H, H-
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6 and H-7), 0.96 (s, 3H, CH3-19), 0.93 (s, 3H, CH3-18), 0.91 (d, J = 6.8 Hz, 3H, CH3-28); 13C NMR (101 
MHz, CDCl3) δ 170.9, 170.3, 162.0 (d, J = 245.6 Hz, C-35), 141.3, 139.2 (d, J = 3.2 Hz, C-32), 135.8, 
132.5, 127.8 (d, J = 8.0 Hz, 2×C-33), 123.2, 115.4 (d, J = 21.4 Hz, 2×C-34), 74.0, 71.4, 68.3, 49.3, 
48.6, 48.4, 43.3, 39.5, 39.4, 37.1, 36.2 (2C), 35.7, 32.4, 30.3, 30.0, 29.6, 27.9, 25.6, 24.1, 22.7, 21.4, 
21.1, 20.8, 17.9, 17.7 and 15.9; LC-MS (ESI): m/z 578 [M-OAc]+; purity (LC-MS): 98% (tR = 3.22 min.) 
N-((R)-1-(4-fluorophenyl)ethyl)fusidic acid amide (1.4) 
White powder (0.026 g obtained from 0.100 g of 1.0, 
20%); Rf 0.5 (60% EtOAc:DCM); Mp 182-184 oC; 1H 
NMR (400 MHz, CDCl3) δ 7.29-7.23 (m, 2H, 2×H-33), 
7.05-6.99 (t, J = 8.7 Hz, 2H, 2×H-34), 5.68 (d, J = 7.5 
Hz, 1H, NH), 5.52 (d, J = 8.0 Hz, 1H, H-16), 5.08 (m, 
1H, H-24), 5.00-4.94 (m, 1H, H-31), 4.31 (m, 1H, H-
11), 3.73 (m, 1H, H-3), 2.97 (m, 1H, H-13), 2.53-2.43 
(m, 1H, H-22), 2.38-2.29 (m, 1H, H-22), 2.30-2.23 (m, 
1H, H-12), 2.21-2.03 (m, 5H, H-1, H-5, H-15 and 2×H-23), 1.80 (s, 3H, OAc), 1.89-1.61 (m, 4H, 2×H-
2, H-7 and H-12), 1.66 (s, 3H, CH3-27), 1.58 (s, 3H, CH3-26), 1.56-1.48 (m, 4H, H-1, H-4, H-6 and H-
9), 1.46 (d, J = 6.9 Hz, 3H, CH3-36), 1.34 (s, 3H, CH3-30), 1.30-1.24 (m, 1H, H-15), 1.15-1.00 (m, 2H, 
H-6 and H-7), 0.96 (s, 3H, CH3-19), 0.93-0.88 (m, 6H, CH3-18 and CH3-28); 13C NMR (101 MHz, 
CDCl3) δ 170.4, 170.3, 162.0 (d, J = 245.6 Hz, C-35), 141.5, 138.6 (d, J = 3.2 Hz, C-32), 135.8, 132.5, 
128.1 (d, J = 8.0 Hz, 2×C-33), 123.3, 115.5 (d, J = 21.3 Hz, 2×C-34), 74.0, 71.4, 68.3, 49.3, 48.6, 48.5, 
43.2, 39.6, 39.3, 37.1, 36.2 (2C), 35.7, 32.5, 30.3, 30.0, 29.8, 28.1, 25.7, 24.1, 22.7, 21.4, 21.1, 20.8, 
17.9, 17.7 and 15.9; LC-MS (ESI): m/z 578 [M-OAc]+; purity (LC-MS): 98% (tR = 3.21 min.) 
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N-((S)-1-(2-chlorophenyl)ethyl)fusidic acid amide (1.5) 
White powder (0.043 g obtained from 0.100 g of 1.0, 
33%); Rf 0.6 (60% EtOAc:DCM); Mp 237-239 oC; 1H 
NMR (400 MHz, CDCl3) δ 7.38-7.13 (m, 4H, H-34, H-
35, H-36 and H-37), 5.81 (d, J = 7.0 Hz, 1H, NH), 5.75 
(d, J = 8.2 Hz, 1H, H-16), 5.31-5.21 (m, 1H, H-31), 
5.04 (m, 1H, H-24), 4.33 (m, 1H, H-11), 3.75 (m, 1H, 
H-3), 3.00 (m, 1H, H-13), 2.50-2.40 (m, 1H, H-22), 
2.36-2.28 (m, 1H, H-22), 2.27-2.23 (m, 1H, H-12), 
2.22-2.00 (m, 5H, H-1, H-5, H-15 and 2×H-23), 1.99 (s, 3H, OAc), 1.91-1.66 (m, 4H, 2×H-2, H-7 and 
H-12), 1.63 (s, 3H, CH3-27), 1.64-1.55 (m, 4H, H-1, H-4, H-6 and H-9), 1.52 (s, 3H, CH3-26), 1.46 (d, 
J = 6.9 Hz, 3H, CH3-38), 1.38 (s, 3H, CH3-30), 1.30-1.24 (m, 1H, H-15), 1.20-1.05 (m, 2H, H-6 and H-
7), 0.97 (s, 3H, CH3-19), 0.91-0.87 (m, 6H, CH3-18 and CH3-28); 13C NMR (101 MHz, CDCl3) δ 170.9, 
170.1, 141.3, 140.6, 135.8, 132.8, 132.4, 130.2, 128.5, 127.3, 127.2, 123.3, 73.9, 71.4, 68.4, 49.3, 
48.6, 47.4, 43.3, 39.5, 39.4, 37.1, 36.3, 36.2, 35.6, 32.6, 30.4, 30.0, 29.7, 27.9, 25.6, 24.2, 22.7, 
21.1, 20.7, 20.5, 17.9, 17.7 and 15.9; LC-MS (ESI): m/z 594 [M-OAc]+; purity (LC-MS): 98% (tR = 
3.25 min.) 
N-((R)-1-(2-chlorophenyl)ethyl)fusidic acid amide (1.6) 
White powder (0.011 g obtained from 0.100 g of 1.0, 
8%); Rf 0.5 (60% EtOAc:DCM); Mp 178-180 oC; 1H 
NMR (400 MHz, CDCl3) δ 7.36 (dd, J = 1.7, 7.3 Hz, 1H, 
H-34), 7.28-7.17 (m, 3H, H-35, H-36 and H-37), 6.10 
(d, J = 8.4 Hz, 1H, NH), 5.51 (d, J = 8.1 Hz, 1H, H-16), 
5.48-5.38 (m, 1H, H-31), 5.10 (m, 1H, H-24), 4.33 (m, 
1H, H-11), 3.74 (m, 1H, H-3), 2.99 (m, 1H, H-13), 
2.55-2.46 (m, 1H, H-22), 2.40-2.32 (m, 1H, H-22), 
2.31-2.24 (m, 1H, H-12), 2.21-2.00 (m, 5H, H-1, H-5, H-15 and 2×H-23), 1.90-1.70 (m, 4H, 2×H-2, 
H-7 and H-12), 1.68 (s, 3H, OAc), 1.67 (s, 3H, CH3-27), 1.60-1.52 (m, 4H, H-1, H-4, H-6 and H-9), 
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1.59 (s, 3H, CH3-26), 1.48 (d, J = 6.9 Hz, 3H, CH3-38), 1.36 (s, 3H, CH3-30), 1.30-1.24 (m, 1H, H-15), 
1.15-1.00 (m, 2H, H-6 and H-7), 0.96 (s, 3H, CH3-19), 0.91-0.87 (m, 6H, CH3-18 and CH3-28); 13C 
NMR (101 MHz, CDCl3) δ 170.2, 170.1, 141.5, 140.1, 135.7, 132.6, 132.4, 130.4, 128.6, 128.1, 
127.3, 123.4, 74.4, 71.4, 68.4, 49.3, 48.5, 47.5, 43.1, 39.5, 39.3, 37.1, 36.2 (2C), 35.8, 32.4, 30.3, 
30.0, 29.8, 28.2, 25.7, 24.1, 22.7, 21.4, 20.8 (2C), 18.0, 17.8 and 15.9; LC-MS (ESI): m/z 594 [M-
OAc]+; purity (LC-MS): 98% (tR = 3.26 min.) 
N-((R)-2-(phenyl)methylacetyl)fusidic acid amide (1.7) 
White powder (0.006 g obtained from 0.050 g of 1.0, 
9%); Rf 0.6 (60% EtOAc:DCM); Mp 238-240 oC; 1H 
NMR (400 MHz, CDCl3) δ 7.40-7.27 (m, 5H, 2×H-33, 
2×H-34 and H-35), 6.59 (d, J = 7.5 Hz, 1H, NH), 5.73 
(d, J = 8.0 Hz, 1H, H-16), 5.50 (d, J =7.3 Hz, 1H, H-31), 
5.06 (m, H-24), 4.33 (m, 1H, H-11), 3.75 (s, 3H, OMe), 
3.71 (m, 1H, H-3), 3.02 (m, 1H, H-13), 2.54-2.44 (m, 
1H, H-22), 2.39-2.30 (m, 1H, H-22), 2.29-2.23 (m, 1H, 
H-12), 2.21-2.00 (m, 5H, H-1, H-5, H-15 and 2×H-23), 1.84 (s, 3H, OAc), 1.85-1.65 (m, 4H, 2×H-2, 
H-7 and H-12), 1.64 (s, 3H, CH3-27), 1.61-1.54 (m, 4H, H-1, H-4, H-6 and H-9), 1.53 (s, 3H, CH3-26), 
1.37 (s, 3H, CH3-30), 1.35-1.24 (m, 1H, H-15), 1.18-0.99 (m, 2H, H-6 and H-7), 0.97 (s, 3H, CH3-19), 
0.93 (s, 3H, CH3-18), 0.92 (d, J = 7.5 Hz, 3H, CH3-28); 13C NMR (101 MHz, CDCl3) δ 171.0, 170.5, 
170.1, 142.8, 136.8, 135.1, 132.5, 128.9 (2C), 128.4, 127.1 (2C), 123.2, 73.9, 71.4, 68.4, 56.2, 52.9, 
49.3, 48.7, 43.4, 39.6, 39.3, 37.1, 36.3, 36.1, 35.7, 32.5, 30.3, 30.0, 29.5, 27.9, 25.6, 24.2, 22.6, 
20.8, 20.7, 18.0, 17.7 and 15.9; LC-MS (ESI): m/z 604 [M-OAc]+; purity (LC-MS): 98% (tR = 3.21 min.) 
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N-((R)-2-(phenyl)acetamido)fusidic acid amide (1.8) 
White powder (0.022 g obtained from 0.100 g of 1.0, 
17%); Rf 0.4 (EtOAc); Mp 181-183 oC; 1H NMR (400 
MHz, CDCl3) δ 7.42-7.28 (m, 5H, 2×H-33, 2×H-34 and 
H-35), 6.95 (d, J = 6.8 Hz, 1H, NH), 5.77 (d, J = 7.9 Hz, 
1H, H-16), 5.39 (d, J =6.8 Hz, 1H, H-31), 5.05 (m, H-
24), 4.32 (m, 1H, H-11), 3.74 (m, 1H, H-3), 3.02 (m, 
1H, H-13), 2.53-2.41 (m, 1H, H-22), 2.39-2.30 (m, 1H, 
H-22), 2.32-2.22 (m, 1H, H-12), 2.20-1.99 (m, 5H, H-
1, H-5, H-15 and 2×H-23), 1.79 (s, 3H, OAc), 1.88-1.63 (m, 4H, 2×H-2, H-7 and H-12), 1.64 (s, 3H, 
CH3-27), 1.62-1.54 (m, 4H, H-1, H-4, H-6 and H-9), 1.51 (s, 3H, CH3-26), 1.37 (s, 3H, CH3-30), 1.35-
1.24 (m, 1H, H-15), 1.16-1.01 (m, 2H, H-6 and H-7), 0.97 (s, 3H, CH3-19), 0.93 (s, 3H, CH3-18), 0.92 
(d, J = 7.5 Hz, 3H, CH3-28); 13C NMR (101 MHz, CDCl3) δ 171.7, 170.5, 170.2, 142.9, 138.1, 135.2, 
132.5, 129.1 (2C), 128.4, 127.4 (2C), 123.2, 74.1, 71.4, 68.4, 56.8, 49.3, 48.7, 43.5, 39.6, 39.3, 37.1, 
36.3, 36.2, 35.7, 32.5, 30.3, 30.0, 29.6, 27.9, 25.6, 24.1, 22.6, 20.9, 20.7, 18.1, 17.7 and 15.9; LC-
MS (ESI): m/z 589 [M-OAc]+; purity (LC-MS): 98% (tR = 3.10 min.) 
N-(1-(4-methylphenyl)ethyl)fusidic acid amide (1.9) 
White powder (0.073 g obtained from 0.100 g of 1.0, 
58%); Rf 0.5, 0.6 (60% EtOAc:DCM); a 2:1 mixture of 
diastereomers; Major product: 1H NMR (400 MHz, 
CDCl3) δ 7.16 (d, J = 8.0 Hz, 2H, 2×H-33), 7.13 (d, J = 
8.0 Hz, 2H, 2×H-34), 5.75 (m, 1H, NH), 5.50 (d, J = 8.0 
Hz, 1H, H-16), 5.08 (m, 1H, H-24), 4.97 (m, 1H, H-31), 
4.30 (m, 1H, H-11), 3.70 (m, 1H, H-3), 2.95 (m, 1H, 
H-13), 2.56-2.46 (m, 1H, H-22), 2.42-2.34 (m, 1H, H-
22), 2.32 (s, 3H, CH3-37), 2.30-2.22 (m, 1H, H-12), 2.20-2.00 (m, 5H, H-1, H-5, H-15 and 2×H-23), 
1.81 (s, 3H, OAc), 1.91-1.67 (m, 4H, 2×H-2, H-7 and H-12), 1.65 (s, 3H, CH3-27), 1.62-1.45 (m, 4H, 
H-1, H-4, H-6 and H-9), 1.57 (s, 3H, CH3-26), 1.45 (d, J = 6.8 Hz, 3H, CH3-36), 1.33 (s, 3H, CH3-30), 
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1.28-1.23 (m, 1H, H-15), 1.16-1.01 (m, 2H, H-6 and H-7), 0.95 (s, 3H, CH3-19), 0.92-0.87 (m, 6H, 
CH3-18 and CH3-28); 13C NMR (101 MHz, CDCl3) δ 170.4, 170.3, 141.3, 139.7, 137.1, 135.9, 132.4, 
129.4 (2C), 126.3 (2C), 123.4, 74.5, 71.4, 68.3, 49.4, 48.9, 48.5, 43.2, 39.6, 39.3, 37.0, 36.4, 36.0, 
35.8, 32.2, 30.2, 30.0, 29.8, 28.1, 25.7, 23.8, 22.9, 21.7, 21.0 (2C), 20.9, 18.0, 17.8 and 15.9; Minor 
product: 1H NMR (400 MHz, CDCl3) δ 7.17 (d, J = 8.0 Hz, 2H, 2×H-33), 7.10 (d, J = 8.0 Hz, 2H, 2×H-
34), 5.68 (m, 1H, NH), 5.50 (d, J = 8.0 Hz, 1H, H-16), 5.08 (m, 1H, H-24), 4.97 (m, 1H, H-31), 4.30 
(m, 1H, H-11), 3.70 (m, 1H, H-3), 2.95 (m, 1H, H-13), 2.56-2.46 (m, 1H, H-22), 2.42-2.34 (m, 1H, H-
22), 2.30 (s, 3H, CH3-37), 2.30-2.22 (m, 1H, H-12), 2.20-2.00 (m, 5H, H-1, H-5, H-15 and 2×H-23), 
1.92 (s, 3H, OAc), 1.91-1.67 (m, 4H, 2×H-2, H-7 and H-12), 1.61 (s, 3H, CH3-27), 1.62-1.45 (m, 4H, 
H-1, H-4, H-6 and H-9), 1.50 (s, 3H, CH3-26), 1.42 (d, J = 6.9 Hz, 3H, CH3-36), 1.35 (s, 3H, CH3-30), 
1.28-1.23 (m, 1H, H-15), 1.16-1.01 (m, 2H, H-6 and H-7), 0.95 (s, 3H, CH3-19), 0.92-0.87 (m, 6H, 
CH3-18 and CH3-28); 13C NMR (101 MHz, CDCl3) δ 170.9, 170.3, 141.1, 140.3, 137.0, 135.9, 132.3, 
129.3 (2C), 126.1 (2C), 123.4, 74.1, 71.4, 68.3, 49.4, 48.8, 48.6, 43.3, 39.5, 39.3, 37.0, 36.4, 36.0, 
35.7, 32.2, 30.2, 30.0, 29.7, 28.0, 25.6, 23.9, 22.9, 21.4, 21.1, 21.0, 20.8, 17.8, 17.7 and 15.9; LC-
MS (ESI): m/z 574 [M-OAc]+; purity (LC-MS): 98% (tR = 3.30 min.) 
N-(1-(4-fluorophenyl)ethyl)fusidic acid amide (1.10) 
White powder (0.051 g obtained from 0.100 g of 1.0, 
40%); Rf 0.5 (60% EtOAc:DCM); a 3:2 mixture of 
diastereomers; Major product: 1H NMR (400 MHz, 
CDCl3) δ 7.31-7.20 (m, 2H, 2×H-33), 7.07-6.94 (m, 
2H, 2×H-34), 5.74 (d, J = 7.6 Hz, 1H, NH), 5.51 (d, J = 
8.0 Hz, 1H, H-16), 5.08 (m, 1H, H-24), 5.05-4.93 (m, 
1H, H-31), 4.31 (m, 1H, H-11), 3.72 (m, 1H, H-3), 2.97 
(m, 1H, H-13), 2.55-2.44 (m, 1H, H-22), 2.40-2.31 (m, 
1H, H-22), 2.29-2.20 (m, 1H, H-12), 2.18-2.00 (m, 5H, H-1, H-5, H-15 and 2×H-23), 1.89-1.67 (m, 
4H, 2×H-2, H-7 and H-12), 1.79 (s, 3H, OAc), 1.66 (s, 3H, CH3-27), 1.62-1.45 (m, 4H, H-1, H-4, H-6 
and H-9), 1.57 (s, 3H, CH3-26), 1.45 (d, J = 6.8 Hz, 3H, CH3-36), 1.33 (s, 3H, CH3-30), 1.28-1.23 (m, 
1H, H-15), 1.16-1.01 (m, 2H, H-6 and H-7), 0.95 (s, 3H, CH3-19), 0.92-0.87 (m, 6H, CH3-18 and CH3-
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28); 13C NMR (101 MHz, CDCl3) δ 170.4, 170.3, 162.1 (d, J = 245.7 Hz, C-35), 141.5, 138.6 (d, J = 
3.1 Hz, C-32), 135.7, 132.5, 128.1 (d, J = 8.1 Hz, 2×C-33), 123.3, 115.5 (d, J = 21.4 Hz, 2×C-34), 74.3, 
71.4, 68.3, 49.3, 48.6, 48.4, 43.2, 39.5, 39.3, 37.0, 36.3 (2C), 35.7, 32.3, 30.2, 30.0, 29.7, 28.1, 25.7, 
24.0, 22.8, 21.9, 21.0, 20.8, 18.0, 17.8 and 15.9; Minor product: 1H NMR (400 MHz, CDCl3) δ 7.31-
7.20 (m, 2H, 2×H-33), 7.07-6.94 (m, 2H, 2×H-34), 5.71 (d, J = 7.6 Hz, 1H, NH), 5.70 (d, J = 8.0 Hz, 
1H, H-16), 5.08 (m, 1H, H-24), 5.05-4.93 (m, 1H, H-31), 4.31 (m, 1H, H-11), 3.72 (m, 1H, H-3), 2.97 
(m, 1H, H-13), 2.52-2.38 (m, 1H, H-22), 2.36-2.31 (m, 1H, H-22), 2.29-2.20 (m, 1H, H-12), 2.18-2.00 
(m, 5H, H-1, H-5, H-15 and 2×H-23), 1.95 (s, 3H, OAc), 1.89-1.67 (m, 4H, 2×H-2, H-7 and H-12), 
1.61 (s, 3H, CH3-27), 1.62-1.45 (m, 4H, H-1, H-4, H-6 and H-9), 1.49 (s, 3H, CH3-26), 1.42 (d, J = 6.8 
Hz, 3H, CH3-36), 1.35 (s, 3H, CH3-30), 1.28-1.23 (m, 1H, H-15), 1.16-1.01 (m, 2H, H-6 and H-7), 0.95 
(s, 3H, CH3-19), 0.92-0.87 (m, 6H, CH3-18 and CH3-28); 13C NMR (101 MHz, CDCl3) δ 170.8, 170.3, 
162.0 (d, J = 245.7 Hz, CF-35), 141.2, 139.2 (d, J = 3.2 Hz, C-32), 135.7, 132.4, 127.8 (d, J = 8.0 Hz, 
2×C-33), 123.2, 115.4 (d, J = 21.4 Hz, 2×C-34), 74.0, 71.4, 68.3, 49.3, 48.6, 48.4, 43.3, 39.5, 39.4, 
37.0, 36.0 (2C), 35.6, 31.9, 30.2, 30.0, 29.7, 27.9, 25.6, 24.0, 22.8, 21.4, 21.1, 20.8, 17.8, 17.7 and 
15.9; LC-MS (ESI): m/z 578 [M-OAc]+; purity (LC-MS): 98% (tR = 3.25 min.) 
N-(1-(3,4-dichlorophenyl)ethyl)fusidic acid amide (1.11) 
White powder (0.034 g obtained from 0.100 g of 
1.0, 25%); Rf 0.6 (60% EtOAc:DCM); a 1:1 mixture of 
diastereomers; 1H NMR (400 MHz, CDCl3) δ 7.41 (d, 
J = 8.5 Hz, 1H, H-36), 7.39 (d, J = 2.2 Hz, 1H, H-33), 
7.37 (d, J = 8.2 Hz, 1H, H-36), 7.37 (d, J = 2.2 Hz, 1H, 
H-33), 7.16-7.11 (m, 2H, 2×H-37), 5.75-5.66 (m, 3H, 
2×NH and H-16), 5.54 (d, J = 8.0 Hz, 1H, H-16), 5.09 
(m, 1H, H-24), 5.03 (m, 1H, H-24), 5.00-4.94 (m, 1H, 
H-31), 4.94-4.87 (m, 1H, H-31), 4.32 (m, 2H, 2×H-11), 3.74 (m, 2H, 2×H-3), 2.98 (m, 2H, 2×H-13), 
2.53-2.40 (m, 2H, 2×H-22), 2.36-2.29 (m, 2H, 2×H-22), 2.30-2.23 (m, 2H, 2×H-12), 2.21-1.96 (m, 
10H, 2×H-1, 2×H-5, 2×H-15 and 4×H-23), 1.98 (s, 3H, OAc), 1.89-1.64 (m, 8H, 4×H-2, 2×H-7 and 
2×H-12), 1.80 (s, 3H, OAc), 1.67 (s, 3H, CH3-27), 1.63 (s, 3H, CH3-27), 1.60-1.52 (m, 8H, 2×H-1, 2×H-
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4, 2×H-6 and 2×H-9), 1.58 (s, 3H, CH3-26), 1.51 (s, 3H, CH3-26), 1.44 (d, J = 6.9 Hz, 3H, CH3-38), 
1.41 (d, J = 7.0 Hz, 3H, CH3-38), 1.37 (s, 3H, CH3-30), 1.34 (s, 3H, CH3-30), 1.30-1.24 (m, 2H, 2×H-
15), 1.15-1.00 (m, 4H, 2×H-6 and 2×H-7), 0.97 (s, 3H, CH3-19), 0.96 (s, 3H, CH3-19), 0.94 (s, 3H, 
CH3-18), 0.95-0.86 (m, 9H, CH3-18 and 2×CH3-28); 13C NMR (101 MHz, CDCl3) δ 170.8, 170.4, 170.3, 
170.2, 143.9, 143.2, 142.0, 141.6, 135.5 (2C), 132.7 (2C) 132.6 (2C), 131.5, 131.2, 130.8, 130.6, 
128.5, 128.1, 126.0, 125.7, 123.2, 123.1, 74.3, 73.8, 71.4 (2C), 68.3 (2C), 49.3 (2C), 48.6 (2C) 48.2, 
48.1, 43.4, 43.3, 39.6, 39.5, 39.4, 39.3, 37.1 (2C), 36.2 (3C), 36.1, 35.7, 35.6, 32.5 (2C), 30.3 (2C), 
30.0 (2C), 29.7 (2C), 28.1, 27.9, 25.7, 25.6, 24.1 (2C), 22.7, 22.6, 21.7, 21.3, 21.1, 21.0, 20.7 (2C), 
18.1, 17.8, 17.8, 17.7 and 15.9 (2C); LC-MS (ESI): m/z 628 [M-OAc]+; purity (LC-MS): 98% (tR = 3.31 
min.) 
N-(1-(3-pyridinyl)ethyl)fusidic acid amide (1.12) 
White powder (0.028 g obtained from 0.050 g of 
1.0, 48%); Rf 0.3 (EtOAc); a 1:1 mixture of 
diastereomers; 1H NMR (400 MHz, CDCl3) δ 8.72-
8.45 (m, 4H, 2×H-33 and 2×H-34), 7.75-7.67 (m, 2H, 
2×H-35), 7.39-7.33 (m, 1H, H-36), 7.32-7.27 (m, 1H, 
H-36), 6.24 (d, J = 7.6 Hz, 1H, NH), 6.14 (d, J = 7.6 
Hz, 1H, NH), 5.74 (d, J = 8.2 Hz, 1H, H-16), 5.53 (d, J 
= 8.2 Hz, 1H, H-16), 5.14-4.97 (m, 4H, 2×H-24 and 
2×H-31), 4.31 (m, 2H, 2×H-11), 3.72 (m, 2H, 2×H-3), 2.95 (m, 2H, 2×H-13), 2.53-2.40 (m, 2H, 2×H-
22), 2.39-2.30 (m, 2H, 2×H-22), 2.33-2.23 (m, 2H, 2×H-12), 2.23-1.96 (m, 10H, 2×H-1, 2×H-5, 2×H-
15 and 4×H-23), 1.97 (s, 3H, OAc), 1.89-1.64 (m, 8H, 4×H-2, 2×H-7 and 2×H-12), 1.74 (s, 3H, OAc), 
1.65 (s, 3H, CH3-27), 1.60 (s, 3H, CH3-27), 1.57 (s, 3H, CH3-26), 1.59-1.53 (m, 8H, 2×H-1, 2×H-4, 
2×H-6 and 2×H-9), 1.48 (s, 3H, CH3-26), 1.53-1.49 (m, 6H, 2×CH3-37), 1.34 (s, 3H, CH3-30), 1.32 (s, 
3H, CH3-30), 1.30-1.24 (m, 2H, 2×H-15), 1.18-1.04 (m, 4H, 2×H-6 and 2×H-7), 0.96 (s, 6H, 2×CH3-
19), 0.95 (s, 3H, CH3-18), 0.94-0.90 (m, 9H, CH3-18 and 2×CH3-28); 13C NMR (101 MHz, CDCl3) δ 
170.9, 170.7, 170.5, 170.3, 147.7, 147.5, 147.2, 147.1, 141.9, 141.7, 135.7, 135.3 (2C), 135.0, 
132.6, 132.5, 124.1, 123.8, 123.3 (2C), 123.2 (2C), 74.3, 73.9, 71.3 (2C), 68.3 (2C), 49.4, 49.3, 48.6, 
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48.5, 47.0, 46.9, 43.4, 43.3, 39.5 (2C), 39.4, 39.3, 37.0 (2C), 36.3 (2C), 36.1, 36.0, 35.7, 35.6, 32.3, 
32.2, 30.2 (2C), 30.0 (2C), 29.7 (2C), 28.1, 28.0, 25.7, 25.6, 24.0, 23.9, 22.9 (2C), 21.7, 21.1 (2C), 
20.9, 20.8 (2C), 17.9, 17.8 (2C), 17.7 and 15.9 (2C); LC-MS (ESI): m/z 644 [M+H+Na]+, 561 [M-OAc]+; 
purity (LC-MS): 98% (tR = 3.06 min.) 
N-(1-(4-pyridinyl)ethyl)fusidic acid amide (1.13) 
White powder (0.028 g obtained from 0.050 g of 
1.0, 48%); Rf 0.5 (EtOAc); a 1:1 mixture of 
diastereomers; 1H NMR (400 MHz, CDCl3) δ 8.61-
8.52 (m, 4H, 4×H-34), 7.37-7.30 (m, 4H, 4×H-33), 
6.29-6.18 (m, 2H, 2×NH), 5.77 (d, J = 8.2 Hz, 1H, H-
16), 5.58 (d, J = 8.0 Hz, 1H, H-16), 5.11-5.00 (m, 3H, 
2×H-24 and H-31), 4.98-4.88 (m, 1H, H-31), 4.32 (m, 
2H, 2×H-11), 3.73 (m, 2H, 2×H-3), 2.98 (m, 2H, 2×H-
13), 2.50-2.38 (m, 2H, 2×H-22), 2.39-2.30 (m, 2H, 2×H-22), 2.33-2.23 (m, 2H, 2×H-12), 2.23-1.96 
(m, 10H, 2×H-1, 2×H-5, 2×H-15 and 4×H-23), 1.98 (s, 3H, OAc), 1.88-1.68 (m, 8H, 4×H-2, 2×H-7 and 
2×H-12), 1.73 (s, 3H, OAc), 1.66 (s, 3H, CH3-27), 1.63 (s, 3H, CH3-27), 1.58 (s, 3H, CH3-26), 1.59-
1.53 (m, 8H, 2×H-1, 2×H-4, 2×H-6 and 2×H-9), 1.51 (s, 3H, CH3-26), 1.46 (d, J = 7.0 Hz, 3H, CH3-35), 
1.44 (d, J = 7.0 Hz, 3H, CH3-35), 1.34 (s, 3H, CH3-30), 1.33 (s, 3H, CH3-30), 1.30-1.24 (m, 2H, 2×H-
15), 1.16-1.02 (m, 4H, 2×H-6 and 2×H-7), 0.98 (s, 6H, 2×CH3-19), 0.95 (s, 3H, CH3-18), 0.94-0.87 
(m, 9H, CH3-18 and 2×CH3-28); 13C NMR (101 MHz, CDCl3) δ 170.8, 170.8, 170.6, 170.5, 154.6, 
154.0, 148.5 (2C), 142.0 (2C), 135.2, 135.1, 132.6 (2C), 132.5, 123.3 (2C), 123.2 (2C), 122.2 (2C), 
121.8., 74.5, 73.8, 71.3 (2C), 68.3, 68.2, 49.4, 49.3, 48.6, 48.5, 47.0, 46.9, 43.4, 43.3, 39.5 (2C), 
39.4, 39.3, 37.0 (2C), 36.3 (2C), 36.1, 36.0, 35.7, 35.6, 32.3, 32.2, 30.2 (2C), 30.0 (2C), 29.7 (2C), 
28.1, 28.0, 25.7, 25.6, 24.0, 23.9, 22.9 (2C), 21.7, 21.1 (2C), 20.9, 20.8 (2C), 17.9, 17.8 (2C), 17.7 
and 15.9 (2C); LC-MS (ESI): m/z 644 [M+H+Na]+, 561 [M-OAc]+; purity (LC-MS): 98% (tR = 3.06 min.) 
 
 
 
Chapter Four: Semi-synthetic derivatization, antimycobacterial and antiplasmodium evaluation of analogues of the 
natural product fusidic acid 
 
164 
N-(1-(pyrazin-2-yl)ethyl)fusidic acid amide (1.14) 
White powder (0.047 g obtained from 0.100 g of 1.0, 
40%); Rf 0.3 (EtOAc); a 3:2 mixture of diastereomers; 
Major product: 1H NMR (400 MHz, CDCl3) δ 8.62-8.43 
(m, 3H, H-33, H-34 and H-35), 6.80 (d, J = 8.2 Hz, 1H, 
NH), 5.47 (d, J = 8.2 Hz, 1H, H-16), 5.23 (m, 1H, H-31), 
5.11 (m, 1H, H-24), 4.32 (m, 1H, H-11), 3.73 (m, 1H, 
H-3), 2.99 (m, 1H, H-13), 2.55-2.40 (m, 1H, H-22), 
2.41-2.32 (m, 1H, H-22), 2.32-2.22 (m, 1H, H-12), 
2.21-1.93 (m, 5H, H-1, H-5, H-15 and 2×H-23), 1.89-1.67 (m, 4H, 2×H-2, H-7 and H-12), 1.77 (s, 3H, 
OAc),1.59 (s, 3H, CH3-27), 1.60-1.48 (m, 4H, H-1, H-4, H-6 and H-9), 1.50-1.42 (m, 6H, CH3-26 and 
CH3-36), 1.35 (s, 3H, CH3-30), 1.21-1.15 (m, 1H, H-15), 1.15-1.00 (m, 2H, H-6 and H-7), 0.95 (s, 3H, 
CH3-19), 0.95-0.87 (m, 6H, CH3-18 and CH3-28); 13C NMR (101 MHz, CDCl3) δ 170.3, 170.0, 156.1, 
143.7, 143.3, 143.1, 141.7, 135.5, 132.4, 123.4, 74.0, 71.3, 68.3, 49.3, 48.5, 47.1, 43.2, 39.5, 39.2, 
37.1, 36.3, 36.1, 35.7, 32.3, 30.3, 30.0, 29.5, 28.0, 25.7, 24.0, 22.8, 20.8 (2C), 20.7, 17.9, 17.8 and 
15.9; Minor product: 1H NMR (400 MHz, CDCl3) δ 8.62-8.43 (m, 3H, H-33, H-34 and H-35), 6.56 (d, 
J = 7.6 Hz, 1H, NH), 5.74 (d, J = 8.2 Hz, 1H, H-16), 5.15 (m, 1H, H-31), 5.02 (m, 1H, H-24), 4.32 (m, 
1H, H-11), 3.73 (m, 1H, H-3), 2.99 (m, 1H, H-13), 2.55-2.40 (m, 1H, H-22), 2.41-2.32 (m, 1H, H-22), 
2.32-2.22 (m, 1H, H-12), 2.21-1.93 (m, 5H, H-1, H-5, H-15 and 2×H-23), 1.96 (s, 3H, OAc), 1.89-1.67 
(m, 4H, 2×H-2, H-7 and H-12), 1.66 (s, 3H, CH3-27), 1.60-1.48 (m, 4H, H-1, H-4, H-6 and H-9), 1.50-
1.42 (m, 6H, CH3-26 and CH3-36), 1.37 (s, 3H, CH3-30), 1.33-1.27 (m, 1H, H-15), 1.15-1.00 (m, 2H, 
H-6 and H-7), 0.96 (s, 3H, CH3-19), 0.95-0.87 (m, 6H, CH3-18 and CH3-28); 13C NMR (101 MHz, 
CDCl3) δ 170.8, 170.7, 157.0, 143.9, 143.7, 143.3, 141.7, 135.5, 132.3, 123.3, 74.1, 71.3, 68.3, 49.3, 
48.6, 47.7, 43.4, 39.5, 39.4, 37.1, 36.3, 36.1, 35.7, 32.4, 30.3, 30.0, 29.5, 27.9, 25.6, 24.0, 22.8, 
21.5, 21.2, 20.8, 17.8, 17.7 and 15.9; LC-MS (ESI): m/z 644 [M+Na]+, 562 [M-OAc]+; purity (LC-MS): 
98% (tR = 3.10 min.) 
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N-(1-(phenyl)cyclopropyl)fusidic acid amide (1.15) 
White powder (0.017 g obtained from 0.050 g of 1.0, 
28%); Rf 0.6 (60% EtOAc:DCM); Mp 199-201 oC; 1H 
NMR (400 MHz, CDCl3) δ 7.36-7.31 (m, 2H, 2×H-33), 
7.29-7.23 (m, 2H, 2×H-32), 7.21-7.15 (m, 1H, H-34), 
6.13 (s, 1H, NH), 5.59 (d, J = 7.8 Hz, 1H, H-16), , 5.07 
(m, 1H, H-24), 5.00-4.94 (m, 1H, H-31), 4.32 (m, 1H, 
H-11), 3.74 (m, 1H, H-3), 2.98 (m, 1H, H-13), 2.53-2.40 
(m, 1H, H-22), 2.36-2.29 (m, 1H, H-22), 2.30-2.23 (m, 
1H, H-12), 2.21-1.96 (m, 5H, H-1, H-5, H-15 and 2×H-23), 1.86-1.69 (m, 4H, 2×H-2, H-7 and H-12), 
1.80 (s, 3H, OAc), 1.66 (s, 3H, CH3-27), 1.62-1.47 (m, 4H, H-1, H-4, H-6 and H-9), 1.55 (s, 3H, CH3-
26), 1.36 (s, 3H, CH3-30), 1.34-1.00 (m, 3H, H-6, H-7 and H-15), 0.97 (s, 3H, CH3-19), 0.94-0.78 (m, 
10H, CH3-18, CH3-28 and 4×H-35); 13C NMR (101 MHz, CDCl3) δ 171.1, 170.7, 142.4, 141.3, 136.3, 
132.5, 128.4 (2C), 126.8 (2C), 126.7, 123.3, 74.3, 71.4, 68.4, 49.2, 48.5, 43.4, 39.5, 39.4, 37.2, 36.3, 
36.1, 35.7, 35.3, 32.6, 30.4, 30.0, 29.9, 28.1, 25.7, 24.2, 22.6, 21.1, 20.7, 18.1, 17.8, 17.0, 16.2 and 
15.9; LC-MS (ESI): m/z 572 [M-OAc]+; purity (LC-MS): 98% (tR = 3.07 min.) 
N-((S)-1-(cyclohexyl)ethyl)fusidic acid amide (1.16) 
White powder (0.043 g obtained from 0.100 g of 1.0, 
35%); Rf 0.6 (60% EtOAc:DCM); Mp 159-161 oC; 1H 
NMR (400 MHz, CDCl3) δ 5.58 (d, J = 8.1 Hz, 1H, H-
16), 5.28 (d, J = 8.8 Hz, 1H, NH), 5.08 (m, 1H, H-24), 
4.31 (m, 1H, H-11), 3.79-3.71 (m, 1H, H-31), 3.74 (m, 
1H, H-3), 2.96 (m, 1H, H-13), 2.50-2.40 (m, 1H, H-22), 
2.36-2.29 (m, 1H, H-22), 2.29-2.25 (m, 1H, H-12), 
2.28-2.00 (m, 5H, H-1, H-5, H-15 and 2×H-23), 1.99 
(s, 3H, OAc), 1.91-1.68 (m, 6H, 2×H-2, H-7, H-12, and 2×H-34), 1.66 (s, 3H, CH3-27), 1.64-1.55 (m, 
4H, H-4, H-6, H-9 and H-35), 1.58 (s, 3H, CH3-26), 1.49 (m, 1H, H-1), 1.36 (s, 3H, CH3-30), 1.35 (m, 
1H, H-32), 1.30-1.24 (m, 1H, H-15), 1.23-1.05 (m, 6H, H-6, H-7, and 4×H-33), 1.05-0.93 (m, 3H, 
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2×H-34 and H-35), 1.00 (d, J = 6.7 Hz, 3H, CH3-36), 0.95 (s, 3H, CH3-19), 0.92 (s, 3H, CH3-18), 0.89 
(d, J = 6.7 Hz, 3H, CH3-28); 13C NMR (101 MHz, CDCl3) δ 170.9, 170.5, 140.4, 136.4, 132.3, 123.3, 
74.0, 71.4, 68.3, 49.5, 49.3, 48.5, 43.2, 42.9, 39.5, 39.4, 37.0, 36.3, 36.1, 35.6, 32.4, 30.3, 30.0, 
29.7, 29.3, 28.6, 28.0, 26.4, 26.2 (2C), 25.7, 24.0, 22.8, 21.3, 20.8, 17.8, 17.8, 16.8 and 15.9; LC-
MS (ESI): m/z 648 [M+Na]+, 566 [M-OAc]+; purity (LC-MS): 98% (tR = 3.21 min.) 
N-((R)-1-(cyclohexyl)ethyl)fusidic acid amide (1.17) 
White powder (0.026 g obtained from 0.050 g of 1.0, 
43%); Rf 0.5 (60% EtOAc:DCM); Mp 182-184 oC; 1H 
NMR (400 MHz, CDCl3) δ 5.58 (d, J = 8.1 Hz, 1H, H-
16), 5.28 (d, J = 8.8 Hz, 1H, NH), 5.08 (m, 1H, H-24), 
4.31 (m, 1H, H-11), 3.79-3.71 (m, 1H, H-31), 3.74 (m, 
1H, H-3), 2.96 (m, 1H, H-13), 2.50-2.40 (m, 1H, H- 
22), 2.36-2.29 (m, 1H, H-22), 2.29-2.25 (m, 1H, H-
12), 2.28-2.00 (m, 5H, H-1, H-5, H-15 and 2×H-23), 
1.99 (s, 3H, OAc), 1.91-1.68 (m, 6H, 2×H-2, H-7, H-12, and 2×H-34), 1.66 (s, 3H, CH3-27), 1.64-1.55 
(m, 4H, H-4, H-6, H-9 and H-35), 1.58 (s, 3H, CH3-26), 1.49 (m, 1H, H-1), 1.36 (s, 3H, CH3-30), 1.35 
(m, 1H, H-32), 1.30-1.24 (m, 1H, H-15), 1.24-1.08 (m, 6H, H-6, H-7, and 4×H-33), 1.05-0.93 (m, 3H, 
2×H-34 and H-35), 1.00 (d, J = 6.7 Hz, 3H, CH3-36), 0.95 (s, 3H, CH3-19), 0.92 (s, 3H, CH3-18), 0.89 
(d, J = 6.7 Hz, 3H, CH3-28); 13C NMR (101 MHz, CDCl3) δ 170.6, 170.5, 141.0, 136.5, 132.4, 123.4, 
74.8, 71.4, 68.4, 49.5, 49.3, 48.6, 43.2, 42.7, 39.6, 39.4, 37.1, 36.2 (2C), 35.8, 32.4, 30.3, 30.1, 30.0, 
29.6, 28.4, 28.1, 26.4, 26.3, 26.1, 25.7, 24.1, 22.7, 21.3, 20.8, 18.2, 17.8, 17.3 and 15.9; LC-MS 
(ESI): m/z 648 [M+Na]+, 566 [M-OAc]+; purity (LC-MS): 98% (tR = 3.22 min.) 
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N-(2-methoxyphenyl)fusidic acid amide (1.18) 
White powder (0.061 g obtained from 0.250 g of 1.0, 
20%); Rf 0.6 (60% EtOAc:DCM); Mp 322-324 oC; 1H NMR 
(400 MHz, CDCl3) δ 8.40 (dd, J = 1.7, 7.9 Hz, 1H, H-36), 
7.75 (s, 1H, NH), 7.01 (td, J = 1.7, 7.7 Hz, 1H, H-34), 6.92 
(td, J = 1.4, 7.7 Hz, 1H, H-35), 6.85 (dd, J = 1.4, 8.0 Hz, 
1H, H-33), 5.74 (d, J = 8.6 Hz, 1H, H-16), 5.11 (m, 1H, H-
24), 4.36 (m, 1H, H-11), 3.88 (s, 3H, OMe), 3.75 (m, 1H, 
H-3), 3.06 (m, 1H, H-13), 2.63-2.51 (m, 1H, H-22), 2.45-
2.39 (m, 1H, H-22), 2.36-2.28 (m, 1H, H-12), 2.26-2.05 (m, 5H, H-1, H-5, H-15 and 2×H-23), 1.93-
1.71 (m, 4H, 2×H-2, H-7 and H-12), 1.68 (s, 3H, OAc), 1.65 (s, 3H, CH3-27), 1.63-1.49 (m, 4H, H-1, 
H-4, H-6 and H-9), 1.59 (s, 3H, CH3-26), 1.41 (s, 3H, CH3-30), 1.28-1.22 (m, 1H, H-15), 1.17-1.06 (m, 
2H, H-6 and H-7), 0.98 (s, 3H, CH3-19), 0.94 (s, 3H, CH3-18), 0.92 (d, J = 6.9 Hz, 3H, CH3-28); 13C 
NMR (101 MHz, CDCl3) δ 170.5, 169.3, 147.8, 142.2, 135.5, 132.5, 127.7, 123.5, 123.3, 121.0, 
119.3, 110.0, 73.8, 71.3, 68.4, 55.8, 49.4, 48.5, 43.1, 39.5, 39.4, 37.1, 36.3, 36.2, 35.7, 32.5, 30.3, 
30.0, 29.4, 28.1, 25.6, 24.2, 22.8, 20.8, 20.5, 17.8, 17.7 and 15.9; LC-MS (ESI): m/z 644 [M+Na]+ 
562 [M-OAc]+; purity (LC-MS): 98% (tR = 3.24 min.) 
N-(3-methoxyphenyl)fusidic acid amide (1.19) 
White powder (0.058 g obtained from 0.250 g of 1.0, 
19%); Rf 0.6 (60% EtOAc:DCM); Mp 322-324 oC; 1H 
NMR (400 MHz, CDCl3) δ 7.27 (dd, J = 1.9, 2.4 Hz, 1H, 
H-32), 7.18 (t, J = 8.1 Hz, 1H, H-35), 7.12 (s, 1H, NH), 
6.96 (dd, J = 1.9, 7.8 Hz, 1H, H-36), 6.64 (dd, J = 2.4, 8.2 
Hz, 1H, H-34), 5.75 (d, J = 8.6 Hz, 1H, H-16), 5.11 (m, 
1H, H-24), 4.36 (m, 1H, H-11), 3.79 (s, 3H, OMe), 3.75 
(m, 1H, H-3), 3.05 (m, 1H, H-13), 2.63-2.51 (m, 1H, H-
22), 2.47-2.37 (m, 1H, H-22), 2.34-2.26 (m, 1H, H-12), 2.26-2.05 (m, 5H, H-1, H-5, H-15 and 2×H-
23), 1.91-1.71 (m, 4H, 2×H-2, H-7 and H-12), 1.76 (s, 3H, OAc), 1.67 (s, 3H, CH3-27), 1.63-1.49 (m, 
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4H, H-1, H-4, H-6 and H-9), 1.60 (s, 3H, CH3-26), 1.39 (s, 3H, CH3-30), 1.28-1.22 (m, 1H, H-15), 1.17-
1.06 (m, 2H, H-6 and H-7), 0.98 (s, 3H, CH3-19), 0.95 (s, 3H, CH3-18), 0.92 (d, J = 6.8 Hz, 3H, CH3-
28); 13C NMR (101 MHz, CDCl3) δ 170.6, 169.4, 160.1, 142.5, 139.1, 135.3, 132.7, 129.6, 123.2, 
111.7, 110.1, 105.2, 73.8, 71.4, 68.3, 55.3, 49.4, 48.7, 43.1, 39.5, 39.3, 37.1, 36.3, 36.2, 35.7, 32.4, 
30.3, 30.0, 29.4, 28.1, 25.7, 24.1, 22.8, 20.9, 20.8, 17.9, 17.8 and 15.9; LC-MS (ESI): m/z 644 
[M+Na]+ 562 [M-OAc]+; purity (LC-MS): 98% (tR = 3.22 min.) 
N-(4-methoxyphenyl)fusidic acid amide (1.20) 
White powder (0.062 g obtained from 0.250 g of 
1.0, 21%); Rf 0.5 (60% EtOAc:DCM); Mp 262-264 
oC; 1H NMR (400 MHz, CDCl3) δ 7.40 (d, J = 8.9 Hz, 
2×H, H-32), 7.08 (s, 1H, NH), 6.83 (d, J = 8.9 Hz, 
2×H, H-33), 5.77 (d, J = 8.5 Hz, 1H, H-16), 5.12 (m, 
1H, H-24), 4.35 (m, 1H, H-11), 3.77 (s, 3H, OMe), 
3.74 (m, 1H, H-3), 3.03 (m, 1H, H-13), 2.62-2.51 (m, 
1H, H-22), 2.50-2.37 (m, 1H, H-22), 2.34-2.26 (m, 
1H, H-12), 2.26-2.07 (m, 5H, H-1, H-5, H-15 and 2×H-23), 1.91-1.71 (m, 4H, 2×H-2, H-7 and H-12), 
1.76 (s, 3H, OAc), 1.67 (s, 3H, CH3-27), 1.64-1.47 (m, 4H, H-1, H-4, H-6 and H-9), 1.60 (s, 3H, CH3-
26), 1.39 (s, 3H, CH3-30), 1.28-1.22 (m, 1H, H-15), 1.17-1.06 (m, 2H, H-6 and H-7), 0.98 (s, 3H, CH3-
19), 0.94 (s, 3H, CH3-18), 0.92 (d, J = 6.8 Hz, 3H, CH3-28); 13C NMR (101 MHz, CDCl3) δ 170.7, 169.2, 
156.3, 142.1, 135.5, 132.6, 131.0, 123.3, 121.3 (2C), 114.1 (2C), 73.8, 71.4, 68.3, 55.4, 49.4, 48.7, 
43.1, 39.5, 39.3, 37.1, 36.3, 36.1, 35.7, 32.4, 30.3, 30.0, 29.4, 28.1, 25.7, 24.0, 22.8, 20.9, 20.8, 
17.9, 17.8 and 15.9; LC-MS (ESI): m/z 644 [M+Na]+ 562 [M-OAc]+; purity (LC-MS): 98% (tR = 3.22 
min.) 
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N-(4-methylphenyl)fusidic acid amide (1.21) 
White powder (0.010 g obtained from 0.050 g of 1.0, 
16%); Rf 0.6 (60% EtOAc:DCM); Mp 322-324 oC; 1H 
NMR (400 MHz, MeOH-d4) δ 7.43 (d, J = 8.4 Hz, 2H, 
2×H-32), 7.09 (d, J = 8.2 Hz, 2H, 2×H-33), 5.80 (d, J = 
8.6 Hz, 1H, H-16), 5.16 (m, 1H, H-24), 4.32 (m, 1H, H-
11), 3.66 (m, 1H, H-3), 3.09 (m, 1H, H-13), 2.72-2.63 
(m, 1H, H-22), 2.38-2.34 (m, 1H, H-22), 2.33-2.19 (m, 
1H, H-12), 2.28 (s, 3H, CH3-35), 2.19-2.09 (m, 5H, H-
1, H-5, H-15 and 2×H-23), 1.91-1.70 (m, 4H, 2×H-2, H-7 and H-12), 1.67 (s, 3H, OAc), 1.64 (s, 3H, 
CH3-27), 1.61-1.44 (m, 4H, H-1, H-4, H-6 and H-9), 1.59 (s, 3H, CH3-26), 1.40 (s, 3H, CH3-30), 1.22-
1.16 (m, 1H, H-15), 1.17-1.07 (m, 2H, H-6 and H-7), 1.00 (s, 3H, CH3-19), 0.95 (s, 3H, CH3-18), 0.89 
(d, J = 6.8 Hz, 3H, CH3-28); 13C NMR (101 MHz, MeOH-d4) δ 172.6, 172.5, 143.7, 137.3, 135.8, 
134.9, 133.3, 130.1 (2C), 124.5, 121.3 (2C), 75.5, 72.4, 68.6, 50.8, 49.9, 44.4, 40.7, 40.3, 38.3, 37.8, 
37.4, 36.8, 32.9, 31.0 (2C), 30.6, 28.8, 25.9, 23.8 (2C), 22.4, 21.0, 20.9, 17.9 (2C) and 16.4; LC-MS 
(ESI): m/z 629 [M+Na]+ 546 [M-OAc]+; purity (LC-MS): 98% (tR = 3.27 min.) 
N-(4-fluorophenyl)fusidic acid amide (1.22) 
White powder (0.021 g obtained from 0.050 g of 1.0, 
35%); Rf 0.5 (60% EtOAc:DCM); Mp 322-324 oC; 1H 
NMR (400 MHz, CDCl3) δ 7.47 (dd, J = 5.4, 8.6 Hz, 2H, 
2×H-32), 7.13 (s, 1H, NH), 6.99 (t, J = 8.7 Hz, 2H, 2×H-
33), 5.78 (d, J = 8.5 Hz, 1H, H-16), 5.12 (m, 1H, H-24), 
4.36 (m, 1H, H-11), 3.76 (m, 1H, H-3), 3.06 (m, 1H, H-
13), 2.64-2.53 (m, 1H, H-22), 2.49-2.38 (m, 1H, H-22), 
2.35-2.27 (m, 1H, H-12), 2.26-2.01 (m, 5H, H-1, H-5, 
H-15 and 2×H-23), 1.91-1.71 (m, 4H, 2×H-2, H-7 and H-12), 1.74 (s, 3H, OAc), 1.67 (s, 3H, CH3-27), 
1.64-1.47 (m, 4H, H-1, H-4, H-6 and H-9), 1.60 (s, 3H, CH3-26), 1.40 (s, 3H, CH3-30), 1.28-1.22 (m, 
1H, H-15), 1.17-1.06 (m, 2H, H-6 and H-7), 0.99 (s, 3H, CH3-19), 0.95 (s, 3H, CH3-18), 0.93 (d, J = 
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6.8 Hz, 3H, CH3-28); 13C NMR (101 MHz, CDCl3) δ 170.6, 169.3, 159.1 (d, J = 244.4 Hz, C-34), 142.6, 
135.2, 133.9, 132.8, 123.2, 121.2 (d, J = 7.7 Hz, 2×C-32), 115.6 (d, J = 22.4 Hz, 2×C-33), 73.8, 71.4, 
68.3, 49.4, 48.7, 43.2, 39.5, 39.3, 37.1, 36.3, 36.2, 35.7, 32.4, 30.3, 30.0, 29.4, 28.1, 25.7, 24.1, 
22.8, 20.8, 20.7, 17.9, 17.8 and 15.9; LC-MS (ESI): m/z 550 [M-OAc]+; purity (LC-MS): 98% (tR = 3.23 
min.) 
N-(benzyl)fusidic acid amide (1.25) 
White powder (0.042 g obtained from 0.050 g of 1.0, 
70%); Rf 0.6 (60% EtOAc:DCM); Mp 182-184 oC; 1H 
NMR (400 MHz, CDCl3) δ 7.35-7.27 (m, 5H, 2×H-33, 
2×H-34 and H-35), 5.73 (d, J = 8.0 Hz, 1H, H-16), 5.39 
(dd, J = 4.7, 5.6 Hz, 1H, NH), 5.07 (m, 1H, H-24), 4.59 
(dd, J = 6.4, 14.4 Hz, 1H, H-31b), 4.32 (m, 1H, H-11), 
4.11 (dd, J = 4.2, 14.4 Hz, 1H, H-31a), 3.73 (m, 1H, H-
3), 2.97 (m, 1H, H-13), 2.56-2.46 (m, 1H, H-22), 2.43-
2.31 (m, 1H, H-22), 2.29-2.21 (m, 1H, H-12), 2.18-1.99 (m, 5H, H-1, H-5, H-15 and 2×H-23), 1.98 (s, 
3H, OAc), 1.89-1.67 (m, 4H, 2×H-2, H-7 and H-12), 1.63 (s, 3H, CH3-27), 1.62-1.45 (m, 4H, H-1, H-
4, H-6 and H-9), 1.55 (s, 3H, CH3-26), 1.36 (s, 3H, CH3-30), 1.30-1.25 (m, 1H, H-15), 1.17-1.03 (m, 
2H, H-6 and H-7), 0.97 (s, 3H, CH3-19), 0.94 (s, 3H, CH3-18), 0.91 (d, J = 6.8 Hz, 3H, CH3-28); 13C 
NMR (101 MHz, CDCl3) δ 171.1, 170.8, 141.8, 137.9, 135.6, 132.4, 128.8 (2C), 128.1 (2C), 127.6, 
123.3, 73.7, 71.4, 68.3, 49.3, 48.7, 43.9, 43.2, 39.5, 39.3, 37.1, 36.2, 36.2, 35.7, 32.4, 30.3, 30.0, 
29.4, 28.0, 25.6, 24.0, 22.7, 21.0, 20.8, 17.8, 17.8 and 15.9; LC-MS (ESI): m/z 628 [M+Na]+, 546 [M-
OAc]+; purity (LC-MS): 98% (tr = 3.23 min.) 
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N-(4-fluorobenzyl)fusidic acid amide (1.26) 
White powder (0.031 g obtained from 0.050 g 
of 1.0, 50%); Rf 0.5 (60% EtOAc:DCM); Mp 182-
184 oC; 1H NMR (400 MHz, CDCl3) δ 7.25 (m, 2H, 
2×H-33), 7.00 (t, J = 8.6 Hz, 2H, 2×H-34), 5.74 (d, 
J = 8.5 Hz, 1H, H-16), 5.39 (m, 1H, NH), 5.06 (m, 
1H, H-24), 4.55 (dd, J = 6.5, 14.3 Hz, 1H, H-31b), 
4.32 (m, 1H, H-11), 4.07 (dd, J = 4.2, 14.4 Hz, 1H, 
H-31a), 3.73 (m, 1H, H-3), 2.97 (m, 1H, H-13), 
2.55-2.44 (m, 1H, H-22), 2.40-2.31 (m, 1H, H-22), 2.29-2.20 (m, 1H, H-12), 2.18-2.00 (m, 5H, H-1, 
H-5, H-15 and 2×H-23), 1.98 (s, 3H, OAc), 1.89-1.67 (m, 4H, 2×H-2, H-7 and H-12), 1.63 (s, 3H, CH3-
27), 1.62-1.45 (m, 4H, H-1, H-4, H-6 and H-9), 1.54 (s, 3H, CH3-26), 1.35 (s, 3H, CH3-30), 1.28-1.23 
(m, 1H, H-15), 1.16-1.01 (m, 2H, H-6 and H-7), 0.97 (s, 3H, CH3-19), 0.94 (s, 3H, CH3-18), 0.91 (d, J 
= 6.8 Hz, 3H, CH3-28); 13C NMR (101 MHz, CDCl3) δ 171.1, 170.7, 162.2 (d, J = 246.1 Hz, C-35), 
141.9, 135.5, 133.8, 132.5, 129.8 (d, J = 8.1 Hz, 2×C-33), 123.3, 115.5 (d, J = 21.5, Hz, 2×C-34), 73.7, 
71.4, 68.3, 49.3, 48.7, 43.3, 43.1, 39.5, 39.3, 37.1, 36.2 (2C), 35.6, 32.5, 30.3, 30.0, 29.4, 28.0, 25.6, 
24.1, 22.7, 21.0, 20.7, 17.8 (2C) and 15.9; LC-MS (ESI): m/z 646 [M+Na]+, 564 [M-OAc]+; purity (LC-
MS): 98% (tR = 3.24 min.) 
N-(4-sulfamoylbenzyl)fusidic acid amide (1.27) 
White powder (0.007 g obtained from 0.050 g 
of 1.0, 10%); Rf 0.5 (EtOAc); Mp 182-184 oC; 1H 
NMR (400 MHz, MeOH-d4) δ 7.83 (d, J = 8.3 Hz, 
2H, 2×H-34), 7.46 (d, J = 8.3, 2H, 2×H-33), 5.79 
(d, J = 8.4 Hz, 1H, H-16), 5.11 (m, 1H, H-24), 4.53 
(d, J = 15.0 Hz, 1H, H-31b), 4.30 (m, 1H, H-11), 
4.15 (d, J = 15.0 Hz, 1H, H-31a), 3.64 (m, 1H, H-
3), 3.04 (m, 1H, H-13), 2.65-2.52 (m, 2H, 2×H-
22), 2.30-2.19 (m, 1H, H-12), 2.19-2.01 (m, 5H, H-1, H-5, H-15 and 2×H-23), 1.91-1.69 (m, 4H, 2×H-
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2, H-7 and H-12), 1.90 (s, 3H, OAc), 1.64 (s, 3H, CH3-27), 1.63-1.43 (m, 4H, H-1, H-4, H-6 and H-9), 
1.55 (s, 3H, CH3-26), 1.38 (s, 3H, CH3-30), 1.24-1.18 (m, 1H, H-15), 1.17-1.07 (m, 2H, H-6 and H-7), 
0.99 (s, 3H, CH3-19), 0.94 (s, 3H, CH3-18), 0.89 (d, J = 6.7 Hz, 3H, CH3-28); 13C NMR (101 MHz, 
MeOH-d4) δ 174.3, 172.5, 144.6, 144.0, 143.7, 135.5, 133.3, 129.4 (2C), 127.4 (2C), 124.4, 75.3, 
72.4, 68.6, 50.8, 49.9, 44.6, 43.9, 40.7, 40.3, 38.2, 37.9, 37.3, 36.9, 32.9, 31.0 (2C), 30.6, 28.8, 25.8, 
23.8, 23.7, 22.3, 21.1, 17.9 (2C) and 16.4; LC-MS (ESI): m/z 625 [M-OAc]+; purity (LC-MS): 98% (tR 
= 3.01 min.) 
N-(4-hydroxybenzyl)fusidic acid amide (1.28) 
Brown powder (0.011 g obtained from 0.050 g of 
1.0, 17%); Rf 0.3 (60% EtOAc:DCM); Mp 182-184 oC; 
1H NMR (400 MHz, MeOH-d4) δ 7.11 (d, J = 8.5 Hz, 
2H, 2×H-33), 6.70 (d, J = 8.5, 2H, 2×H-34), 5.76 (d, J 
= 8.4 Hz, 1H, H-16), 5.09 (m, 1H, H-24), 4.37 (d, J = 
14.3 Hz, 1H, H-31b), 4.30 (m, 1H, H-11), 4.15 (d, J = 
14.3 Hz, 1H, H-31a), 3.65 (m, 1H, H-3), 3.02 (m, 1H, 
H-13), 2.61-2.51 (m, 2H, 2×H-22), 2.28-2.19 (m, 1H, 
H-12), 2.19-2.00 (m, 5H, H-1, H-5, H-15 and 2×H-23), 1.91 (s, 3H, OAc), 1.89-1.70 (m, 4H, 2×H-2, 
H-7 and H-12), 1.64 (s, 3H, CH3-27), 1.61-1.43 (m, 4H, H-1, H-4, H-6 and H-9), 1.54 (s, 3H, CH3-26), 
1.37 (s, 3H, CH3-30), 1.24-1.16 (m, 1H, H-15), 1.17-1.07 (m, 2H, H-6 and H-7), 0.99 (s, 3H, CH3-19), 
0.94 (s, 3H, CH3-18), 0.88 (d, J = 6.7 Hz, 3H, CH3-28); 13C NMR (101 MHz, MeOH-d4) δ 174.0, 172.5, 
158.0, 143.2, 135.7, 133.1, 130.5, 130.4 (2C), 124.5, 116.4 (2C), 75.3, 72.4, 68.6, 50.8, 49.9, 44.4, 
44.0, 40.7, 40.3, 38.2, 37.8, 37.3, 36.9, 32.9, 31.0 (2C), 30.5, 28.7, 25.8, 23.9, 23.8, 22.4, 21.1, 17.9 
(2C) and 16.4; LC-MS (ESI): m/z 644 [M+Na]+, 562 [M-OAc]+; purity (LC-MS): 98% (tR = 3.09 min.) 
 
 
 
 
 
Chapter Four: Semi-synthetic derivatization, antimycobacterial and antiplasmodium evaluation of analogues of the 
natural product fusidic acid 
 
173 
N-(4-methylbenzyl)fusidic acid amide (1.29) 
White powder (0.035 g obtained from 0.050 g of 1.0, 
56%); Rf 0.6 (60% EtOAc:DCM); Mp 182-184 oC; 1H 
NMR (400 MHz, CDCl3) δ 7.16 (d, J = 8.1 Hz, 2H, 2×H-
33), 7.12 (d, J = 8.0 Hz, 2H, 2×H-34), 5.72 (d, J = 8.4 
Hz, 1H, H-16), 5.41 (m, 1H, NH), 5.07 (m, 1H, H-24), 
4.53 (dd, J = 4.1, 14.2 Hz, 1H, H-31b), 4.32 (m, 1H, H-
11), 4.07 (dd, J = 4.2, 14.2 Hz, 1H, H-31a), 3.73 (m, 
1H, H-3), 2.96 (m, 1H, H-13), 2.56-2.46 (m, 1H, H-22), 
2.42-2.34 (m, 1H, H-22), 2.32 (s, 3H, CH3-36), 2.30-2.22 (m, 1H, H-12), 2.20-2.00 (m, 5H, H-1, H-5, 
H-15 and 2×H-23), 1.98 (s, 3H, OAc), 1.91-1.67 (m, 4H, 2×H-2, H-7 and H-12), 1.63 (s, 3H, CH3-27), 
1.62-1.45 (m, 4H, H-1, H-4, H-6 and H-9), 1.55 (s, 3H, CH3-26), 1.35 (s, 3H, CH3-30), 1.28-1.23 (m, 
1H, H-15), 1.16-1.01 (m, 2H, H-6 and H-7), 0.96 (s, 3H, CH3-19), 0.94 (s, 3H, CH3-18), 0.91 (d, J = 
6.8 Hz, 3H, CH3-28); 13C NMR (101 MHz, CDCl3) δ 171.1, 170.7, 141.7, 137.3, 135.6, 134.7, 132.4, 
129.4 (2C), 128.1 (2C), 123.3, 73.7, 71.4, 68.3, 49.3, 48.7, 43.7, 43.2, 39.5, 39.3, 37.1, 36.2 (2C), 
35.7, 32.4, 30.3, 30.0, 29.4, 28.0, 25.6, 24.0, 22.7, 21.0 (2C), 20.8, 17.8 (2C) and 15.9; LC-MS (ESI): 
m/z 642 [M+Na]+, 560 [M-OAc]+; purity (LC-MS): 98% (tR = 3.31 min.) 
4.6.3 General synthetic procedure for the synthesis of compound 3.0 
A mixture of 4-hydroxyaniline (1.0 eq.) and acetic anhydride (1.5 eq.) in THF was heated at 60 οC 
for 1 h. After completion of reaction (TLC and LCMS), solvent was removed under reduced 
pressure and residue was triturated with diethyl ether to obtain N-(4-hydroxyphenyl)acetamide 
(3.0). 
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N-(4-hydroxyphenyl)acetamide (3.0) 
Light pink solid (1.3 g obtained from 1.0 g of 2.0, 94%); Rf 0.3 (7% MeOH-
DCM); Mp 168-170 οC; 1H NMR (600 MHz, MeOH-d4) δ 7.35 (d, J = 8.8 Hz, 2H, 
2×H-2), 6.72 (d, J = 8.8 Hz, 2H, 2×H-3), 2.06 (s, 3H, CH3-6); 13C NMR (151 MHz, 
MeOH-d4) δ 171.2, 155.2, 131.5, 123.2 (2C), 116.0 (2C) and 23.3; LC-MS (ESI): 
m/z 152 [M+H]+; purity (LC-MS): 98% (tR = 0.19 min.) 
 
4.6.4 General synthetic procedure for the synthesis of compound 4.0 
Compound 3.0 (1 eq) was dissolved in EtOH (10 mL) and heated (80 oC) with diethylamine (1.5 eq) 
and formaldehyde (1.5 eq.) until completion (TLC, 2 h). The solvent was removed in vacuo. The 
residue was dissolved in DCM (20 mL) and acidified with 1M HCl (15 mL). The aqueous layer was 
separated through a separating funnel and basified with a saturated solution of NaOH to a pH of 
8-10. This was followed by extraction of the target compound with DCM (2×20 mL). The combined 
organic phase was dried over anhydrous Na2SO4. After filtration, the solvent was removed under 
reduced pressure to obtain compound 4.0. 
N-(3-((N,N-diethylamino)methyl)-4-hydroxyphenyl)acetamide (4.0) 
Yellow oil (0.500 g obtained from 0.500 g of 3.0, 64%); Rf 0.2 (7% MeOH-
DCM); 1H NMR (600 MHz, DMSO-d6) δ 9.66 (br s, 1H, NH), 7.31 (d, J = 2.6 
Hz, 1H, H-2), 7.26 (dd, J = 2.6, 8.6 Hz, 1H, H-6), 6.63 (d, J = 8.6 Hz, 1H, H-
5), 3.70 (s, 2H, 2×H-9), 2.58 (q, J = 7.1 Hz, 4H, 4×H-10), 1.97 (s, 3H, CH3-
8), 1.03 (t, J = 7.1 Hz, 6H, 2×CH3-11); 13C NMR (151 MHz, DMSO-d6) δ 
167.6, 153.1, 130.8, 122.0, 120.4, 119.7, 115.1, 54.8, 45.9 (2C), 23.7 and 
10.9 (2C); LC-MS (ESI): m/z 237 [M+H]+; purity (LC-MS): 98% (tR = 0.12 
min.) 
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4.6.5 General synthetic procedure for the synthesis of compound 5.0 
Compound 4.0 (2 mmol) was refluxed in 6N HCl (2 mL) at 100 οC for 2 h (TLC). Solvent was removed 
under reduced pressure. The residue was dissolved in EtOH (2×15 mL) and solvent was removed 
in vacuo to obtain product 5.0 (as HCl salt) as an oil. 
4-Amino-2-((N,N-diethylamino)methyl)phenol (5.0) 
Brown viscous oil (0.360 g obtained from 0.500 g of 4.0, 88%); Rf 0.2 (20% 
MeOH-DCM); 1H NMR (600 MHz, MeOH-d4) δ 7.56 (d, J = 2.7 Hz, 1H, H-3), 
7.40 (dd, J = 2.7, 8.7 Hz, 1H, H-5), 7.10 (d, J = 8.7 Hz, 1H, H-6), 4.37 (s, 2H, 
H-7), 3.06 (m, 4H, 4×H-8), 1.38 (t, J = 7.2 Hz, 6H, 2×CH3-9); 13C NMR (151 
MHz, MeOH-d4) δ 158.4, 128.5, 127.4, 123.5, 119.2, 117.8, 51.9, 48.9 (2C) 
and 9.2 (2C); LC-MS (ESI): m/z 195 [M+H]+; purity (LC-MS): 98% (tR = 0.12 
min.) 
4.6.6 General synthetic procedure for the synthesis of compound 6.0 
To a mixture of fusidic acid 1.0 (1 eq) in DCM (5 mL) at 30 oC was added the base DIPEA (3 eq) 
dropwise. The reaction was allowed to stir for while (10 min.) after which HATU (2 eq.) was added. 
The reaction was allowed to proceed until completion (TLC, 2 h). The reaction was diluted with 
DCM (20 mL) and extracted with water (2x15 mL). The organic phase was dried over anhydrous 
Na2SO4, filtered and the solvent removed in vacuo. Further purification to obtain 6.0 was 
accomplished by flash chromatography using a mixture of DCM and EtOAc as mobile phase.  
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O-(3H-[1,2,3]triazolo[4,5-b]pyridin-3-yl)fusidic acid ester (6.0) 
Yellow semi-solid (0.240 g obtained from 0.370 g of 
1.0, 53%); Rf 0.6 (60% EtOAc:DCM); 1H NMR (600 
MHz, CDCl3) δ 8.67 (dd, J = 1.4, 4.4 Hz, 1H, H-33), 
8.39 (dd, J = 1.4, 8.3 Hz, 1H, H-35), 7.40 (dd, J = 4.4, 
8.3, 1H, H-34), 5.93 (d, J = 8.4 Hz, 1H, H-16), 5.23 (m, 
1H, H-24), 4.40 (m, 1H, H-11), 3.77 (m, 1H, H-3), 3.19 
(m, 1H, H-13), 2.82-2.75 (m, 1H, H-22), 2.72-2.65 (m, 
1H, H-22), 2.45-2.39 (m, 3H, H-12 and 2×H-23), 2.33-
2.26 (m, 1H, H-15), 2.22-2.13 (m, 2H, H-1 and H-5), 2.12 (s, 3H, OAc), 1.99-1.92 (m, 1H, H-12), 
1.92-1.72 (m, 3H, 2×H-2 and H-7), 1.71 (s, 3H, CH3-27), 1.67 (s, 3H, CH3-26), 1.66-1.52 (m, 4H, H-
1, H-4, H-6 and H-9),1.41 (s, 3H, CH3-30), 1.43-1.37 (m, 1H, H-15), 1.21-1.06 (m, 2H, H-6 and H-7), 
1.01 (s, 3H, CH3-19), 1.00 (s, 3H, CH3-18), 0.91 (d, J = 6.8 Hz, 3H, CH3-28); 13C NMR (151 MHz, CDCl3) 
δ 170.9, 164.9, 157.4, 151.5, 140.8, 135.0, 133.4, 129.2, 124.9, 122.5, 120.7, 74.3, 71.3, 68.2, 49.2, 
49.0, 45.3, 39.5, 39.0, 37.1, 36.2 (2C), 35.6, 32.4, 30.3, 29.9, 29.0, 28.5, 25.7, 24.2, 22.8, 21.1, 20.7, 
18.1, 17.8 and 15.9; LC-MS (ESI): m/z 635 [M+H]+; purity (LC-MS): 98% (tR = 3.23 min.) 
4.6.7 General synthetic procedure for the synthesis of compounds 1.23 and 1.24 
To a mixture of compound 6.0 and the corresponding amine (4-hydroxyaniline for 1.23 and 5.0 for 
1.24) in n-BuOH at 25 oC was added the base KH2PO4 (5 eq). The reaction was then heated gently 
to 100oC until reaction was complete (TLC, LCMS; 16 h for 1.23 and 24 h for 1.24). The solvent was 
removed completely by drying in the Genevac. Further purification to afford the target compounds 
was accomplished by preparative TLC using 10% MeOH:DCM as mobile phase. 
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N-(4-hydroxyphenyl)fusidic acid amide (1.23) 
Brown powder (0.015 g obtained from 0.050 g of 
6.0, 32%); Rf 0.3 (60% EtOAc:DCM); Mp 332-334 oC; 
1H NMR (400 MHz, MeOH-d4) δ 7.37 (d, J = 8.6 Hz, 
2H, 2×H-32), 6.74 (d, J = 8.6, 2H, 2×H-34), 5.84 (d, J 
= 8.5 Hz, 1H, H-16), 5.19 (m, 1H, H-24), 4.35 (m, 1H, 
H-11), 3.68 (m, 1H, H-3), 3.12 (m, 1H, H-13), 2.74-
2.63 (m, 2H, 2×H-22), 2.39-2.29 (m, 1H, H-12), 2.29-
2.15 (m, 5H, H-1, H-5, H-15 and 2×H-23), 1.94-1.65 
(m, 4H, 2×H-2, H-7 and H-12), 1.73 (s, 3H, OAc), 1.68 (s, 3H, CH3-27), 1.63 (s, 3H, CH3-26), 1.60-
1.45 (m, 4H, H-1, H-4, H-6 and H-9), 1.43 (s, 3H, CH3-30), 1.24-1.18 (m, 1H, H-15), 1.20-1.11 (m, 
2H, H-6 and H-7), 1.03 (s, 3H, CH3-19), 0.98 (s, 3H, CH3-18), 0.92 (d, J = 6.7 Hz, 3H, CH3-28); 13C 
NMR (101 MHz, MeOH-d4) δ 172.6, 172.3, 155.3, 143.4, 135.8, 133.3, 131.8, 124.6, 123.1 (2C), 
116.2 (2C), 75.5, 72.4, 68.6, 50.8, 49.9, 44.4, 40.7, 40.3, 38.3, 37.8, 37.4, 36.8, 32.9, 31.1, 31.0, 
30.6, 28.8, 25.9, 23.9, 23.8, 22.4, 21.0, 17.9 (2C) and 16.4; LC-MS (ESI): m/z 631 [M+Na]+, 548 [M-
OAc]+; purity (LC-MS): 98% (tR = 2.92 min.) 
N-(3-((N,N-diethylamino)methyl)-4-hydroxyphenyl)fusidic acid amide (1.24) 
Brown powder (0.015 g obtained from 0.075 g 
of 6.0, 21%); Rf 0.5 (10% MeOH:DCM); Mp 332-
334 oC; 1H NMR (400 MHz, MeOH-d4) δ 7.33 (d, 
J = 2.6 Hz, 1H, H-32), 7.29 (dd, J = 2.6, 8.6 Hz, 
1H, H-36), 6.69 (d, J = 8.5, 1H, H-35), 5.82 (d, J 
= 8.5 Hz, 1H, H-16), 5.16 (m, 1H, H-24), 4.32 (m, 
1H, H-11), 3.86 (s, 2H, 2×H-37), 3.65 (m, 1H, H-
3), 3.09 (m, 1H, H-13), 2.75 (q, J = 7.1, 4H, 4×H-
38), 2.71-2.60 (m, 2H, 2×H-22), 2.37-2.24 (m, 1H, H-12), 2.27-2.11 (m, 5H, H-1, H-5, H-15 and 2×H-
23), 1.92-1.63 (m, 4H, 2×H-2, H-7 and H-12), 1.69 (s, 3H, OAc), 1.65 (s, 3H, CH3-27), 1.60 (s, 3H, 
CH3-26), 1.58-1.42 (m, 4H, H-1, H-4, H-6 and H-9), 1.40 (s, 3H, CH3-30), 1.24-1.18 (m, 1H, H-15), 
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1.20-1.11 (m, 2H, H-6 and H-7), 1.16 (t, J = 7.1 Hz, 6H, 2×CH3-39), 1.00 (s, 3H, CH3-19), 0.95 (s, 3H, 
CH3-18), 0.89 (d, J = 6.8 Hz, 3H, CH3-28); 13C NMR (101 MHz, MeOH-d4) δ 172.5, 172.3, 155.7, 
143.6, 135.8, 133.2, 131.5, 124.5, 123.0, 122.7, 122.4, 116.7, 75.5, 72.4, 68.6, 56.6, 50.8, 49.9, 
47.8 (2C), 44.4, 40.7, 40.3, 38.2, 37.8, 37.4, 36.8, 32.8, 31.1, 31.0, 30.5, 28.8, 25.9, 23.9, 23.8, 22.4, 
21.0, 17.9 (2C), 16.4 and 11.1 (2C); LC-MS (ESI): m/z 633 [M-OAc]+; purity (LC-MS): 98% (tR = 2.80 
min.) 
4.6.8 Antimycobacterial evaluation protocol 
The minimum inhibitory concentration (MIC90) that inhibits 90% of growth of the bacterial 
population was determined using the broth micro dilution method against the Mtb H37Rv strain.59 
A 10 mL culture of the H37Rv strain was grown to an optical density (OD600) of 0.6 – 0.7. Test 
compounds were reconstituted in DMSO to a concentration 10 mM. Duplicate two-fold serial 
dilutions of the test compounds were prepared across 10 wells in a 96-well microtitre plate, in a 
volume of 50 µL, after which, 50 μL of the diluted Mtb culture (1:500) was added to each well in 
the plate (including the control wells). The final volume per well was 100 µL. The plate layout was 
a modification of the method previously described.60 Controls used were a minimum growth 
control (Rifampicin at 2xMIC: 0.150 µM), a maximum growth control (DMSO), and a Rifampicin 
dose response (range 0.15 – 0.0002 µM). The microtitre plate was sealed in a secondary container 
and incubated at 37 oC with 5% CO2 and humidification. Alamar Blue reagent was added to each 
well of the assay plate, 24 hours prior to the assay end data, after which the assay was re-incubated 
for 24 h. The assay was scored visually at day 7: the lowest concentration of material displaying no 
visible growth was scored as the MIC90. Relative fluorescence (excitation 540 nm; emission 590 
nm) was measured using a SpecraMax i3x Plate reader at day 7, while the data analyses was done 
using Softmax® Pro 6 software (Version 6.5.1). 
Media used 
7H9 GLU ADC TW: Middlebrook 7H9 media (DifcoTM) supplemented with 0.4% Glucose, 
Middlebrook albumin-dextrose-catalase (ADC) enrichment (DifcoTM) and 0.05% Tween 80.61 The 
culture was diluted 1:500.  
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7H9 GLU CAS TX: Middlebrook 7H9 media (DifcoTM) supplemented with 0.03% Casitone, 0.4% 
Glucose and 0.05% Tyloxpol.62 The culture was diluted 1:500. 
Media recipe 
Middlebrook 7H9 Broth 1 L – 7H9 GLU ADC TW  
4.7 g powder  
900 mL distilled water  
2 g Glucose  
100 mL Middlebrook ADC  
0.05% Tween 80 
Middlebrook 7H9 Broth 1 L – 7H9 GLU CAS TX 
4.7 g powder  
900 mL distilled water  
4 g Glucose  
0.3 g Casitone  
0.81 g NaCl  
0.05% Tyloxapol 
The above components were dissolved in distilled water. The pH was adjusted to 6.6, if necessary, 
then filter sterilized (0.2 μM filter) and stored at 37 oC. 
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4.6.9 Antiplasmodium evaluation protocol 
4.6.9.1 The modified [3H]-hypoxanthine incorporation assay for asexual blood stage parasites 
Compounds were screened against multidrug-resistant (K1) and chloroquine-sensitive (NF54) 
strains of P. falciparum in vitro using the modified [3H]-hypoxanthine incorporation assay.63 P. 
falciparum was cultivated in a variation of the medium previously described,64,65 consisting of 
RPMI 1640 supplemented with 0.5% ALBUMAX® II, 25 mM Hepes, 25 mM NaHCO3 (pH 7.3), 0.36 
mM hypoxanthine and 100 μg/mL neomycin. Human erythrocytes served as host cells. Cultures 
were maintained at 37 oC in an atmosphere of 3% O2, 4% CO2 and 93% N2 in humidified modular 
chambers. Compounds were dissolved by sonication in DMSO (10 mg/mL) and diluted in 
hypoxanthine-free culture medium. Infected erythrocytes (100 μL per well with 2.5% hematocrit 
and 0.3% parasitemia) were added to each drug titrated in 100 μL duplicates over a 64-fold range. 
After 48 h incubation, 0.5 μCi of [3H]hypoxanthine in 50 μL medium was added and plates were 
incubated for an additional 24 h. Parasites were harvested onto glass-fiber filters and radioactivity 
was counted using a Betaplate liquid scintillation counter (Wallac, Zurich). The results were 
recorded as counts per minute (cpm) per well at each drug concentration and expressed as a 
percentage of the untreated controls. Fifty percent inhibitory concentrations (IC50) were estimated 
by linear interpolation.66 
4.6.9.2 The lactate dehydrogenase assay for asexual blood stage parasites 
The test samples were tested in triplicate on two occasions against chloroquine-sensitive (CQS) 
strain of P. falciparum (NF54). Continuous in vitro cultures of asexual erythrocyte stages of P. 
falciparum were maintained using a modified method of Trager and Jensen.67 Quantitative 
assessment of antiplasmodium activity in vitro was determined via the parasite lactate 
dehydrogenase assay using a modified method described by Makler and coworkers.54  
The test samples were prepared to a 20 mg/mL stock solution in 100% DMSO. Stock solutions were 
stored at -20 oC. Further dilutions were prepared on the day of the experiment. Chloroquine (CQ) 
and artesunate were used as the reference drug in all experiments. A full dose-response was 
performed for all compounds to determine the concentration inhibiting 50% of parasite growth 
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(IC50 value). Test samples were serially diluted 2-fold in complete medium to give 10 
concentrations. The same dilution technique was used for all samples. Control compounds were 
tested at a starting concentration of 1000 ng/ml. The highest concentration of solvent to which 
the parasites were exposed to had no measurable effect on the parasite viability. The IC50 values 
were obtained using a non-linear dose-response curve fitting analysis via Graph Pad Prism v.4.0 
software. 
4.6.9.3 The luciferase reporter assay for early and late gametocyte parasites 
The luciferase reporter assay68 was established to enable accurate, reliable and quantifiable 
investigations of the stage-specific action of gametocytocidal compounds for the early and late 
gametocyte marker cell line NF54-PfS16-GFP-Luc. Drug assays were set up on day 5 and 10 
(representing >90% of either early stage II/III or mature stage IV/V gametocytes, respectively). In 
each instance, assays were set up using a 2 – 3% gametocytemia, 1.5% hematocrit culture and 48 
h drug pressure in a gas chamber (90% N2, 5% O2, and 5% CO2) at 37 oC. Luciferase activity was 
determined in 30 μL parasite lysates by adding 30 μL luciferin substrate (Promega Luciferase Assay 
System) at room temperature and detection of resultant bioluminescence at an integration 
constant of 10 s with the GloMax® Explorer Detection System with Instinct® Software. Methylene 
blue (5 μM) and internal project specific controls (MMV390048, 5 μM) are routinely included as 
controls. Dual point screens are routinely performed as technical triplicates for a single biological 
assay. 
4.6.10 Cytotoxicity evaluation protocol 
The in vitro cytotoxicity of the synthesized compounds was evaluated against the Chinese Hamster 
Ovarian (CHO) cancer cell line using the MTT [3-(4,5-dimethylthiazolyl-2)-2,5-diphenyltetrazolium 
bromide] assay, which is a colorimetric assay based on assessing the cell metabolic activity.69  
The synthesized compounds were assayed in triplicate. Stock solutions of 2 mg/mL of test samples 
in DMSO were prepared with poorly soluble samples being tested as suspensions. The compounds 
were kept at -20 oC until required. In all experiments, emetine was used as a reference drug. 
Starting from an initial concentration of 100 µg/mL, ten-fold serial dilutions were made in 
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complete medium to give 6 concentrations to the lowest concentration of 0.001 µg/mL. The cell 
viability was not affected by the highest concentration of the solvent to which the cells were 
exposed. The full dose-response curves were plotted using a non-linear dose-response curve 
fitting analysis via GraphPad Prism V4 software. By this, the minimum concentration required for 
50% inhibition (IC50) values were determined for each compound. 
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Chapter Five: Synthesis and antiplasmodium and antimycobacterial evaluations of analogues of 
the privileged benzimidazole scaffold 
5.1 General Introduction 
5.1.1 Benzimidazole natural products 
Benzimidazole is an aromatic bicycle containing an imidazole ring fused to a phenyl ring via its two 
adjacent carbon atoms. 
 
Figure 5.1: Chemical structure of benzimidazole 
 
Figure 5.2: Chemical structures of benzimidazole-containing natural products 
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There are only a few reports of natural products containing the benzimidazole scaffold. 
Kealiiquinone is a benzimidazole containing natural product isolated from the Micronesian marine 
sponge Leucetta sp. (Figure 5.2).1 Its congener, 2-deoxy-2-aminokealiiquinone, was isolated from 
another Micronesian sponge Leucetta chagosensis.2 This marine sponge species also afforded 
three more benzimidazole metabolites, the kealiinines A-C.3 The benzimidazole scaffold occurs in 
vitamin B12 (cobalamine) where it serves as a coordination site to the central cobalt cation (Figure 
5.2).4 The imidazole heteroaromatic moiety is however common in natural products. Examples of 
naturally occurring imidazole metabolites include oroidin, hymenidin, sceptrin, stylissazoles, 
dihydrosventrin, etc. 
5.1.2 Properties of benzimidazole as a privileged scaffold 
The benzimidazole scaffold is a substituted derivative of the imidazole heterocyclic compound. It 
therefore possesses some inherent physicochemical properties of the imidazole ring system which 
are modified as a result of the benzene ring. Benzimidazole has a lower basicity but an increased 
acidity compared to imidazole (pKa1: 5.53; pKa2: 12.8). The acid and base properties of 
benzimidazole confers on the scaffold the ability to form salts with strong acids or bases, which 
contributes to improved solubility in polar media.5 
The presence of the benzene ring renders the benzimidazole scaffold more lipophilic (LogP: 1.50) 
compared to imidazole (LogP: -0.08). Further, the benzimidazole ring offers more opportunity to 
either increase lipophilicity by appropriate substitutions on the phenyl ring or decrease 
lipophilicity by incorporation of hydrophilic substituents or exchanging one or more CH of the 
phenyl ring with N. Thus, the benzimidazole molecular framework offers more room for diverse 
structural modifications well-suited to target diverse biological active sites.5 
The benzimidazole scaffold possesses a H-bond donor site, a H-bond acceptor site and a lipophilic 
aromatic ring for hydrophobic and π-stacking interactions. Optimization of the structure for 
binding interactions can therefore be achieved by judicious substitution on the core benzimidazole 
scaffold. Effective binding of the benzimidazole scaffold to biological targets is supported by the 
fact that it is a structural isostere of naturally occurring scaffolds, especially the purine bases 
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adenine and guanine. The antagonistic effect of benzimidazole to the growth of some species of 
yeast and bacteria (e.g. E. coli) has long been reported.6 However, it was also demonstrated that 
the aminopurines (adenine and guanine) are able to reverse the inhibitory effect of benzimidazole 
with guanine exhibiting a more potent antagonism than adenine.6–10 Thus, although benzimidazole 
is not widespread in nature, it efficiently functions as a natural product mimetic to biological 
systems.5 
The importance of benzimidazole as a privileged scaffold can also be viewed from the standpoint 
of its potential as a bioisostere of indole, which is common in natural products, being 
biosynthesized from the amino acid tryptophan. Due to structural similarities, the benzimidazole 
scaffold can also play similar roles in biological systems as do scaffolds like benzoxazole and 
benzofuran. It can also be employed as a substitute for other privileged scaffolds such as indoline, 
benzothiophene and indolozine in medicinal chemistry explorations. 
5.1.3 Benzimidazoles: Chemistry and Biology 
Historically, the first benzimidazole was prepared in 1872 by Hoebrecker, who obtained 2,5(or 
2,6)-dimethylbenzimidazole by reducing 2-nitro-4-methylacetanilide.11 Since then, a number of 
synthetic methods have been developed to obtain benzimidazole derivatives, depending on the 
substituents intended on the benzimidazole scaffold.12  
A common starting reagent to benzimidazole is o-phenylenediamine, which is condensed with 
carbonyl groups present in carboxylic acid, acid anhydrides, esters, amides, acid chlorides, 
lactones, aldehydes and ketones (Figure 5.3). Other functional groups include nitriles, imino-
ethers and imino-thioethers, amidines and guanidines. Moreover, synthetic methods to 
benzimidazole derivatives possessing C2-O or C2-N substitutions such as 2-hydroxybenzimidazole, 
2-aminobenzimidazole, and 2-mercaptobenzimidazole have been reported in the literature. 
Meanwhile, 2-halo benzimidazole is also known.12–14 
Benzimidazole derivatives have also been synthesized from other starting reagents including 
monoacyl- and diacyl-o-phenylenediamines, by reduction of acylated o-nitroanilines, o-aminoazo 
compounds, and Schiff bases. Derivatives with substituents on the phenyl ring have mostly been 
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synthesized from the corresponding substituted o-diaminobenzene or an appropriate precursor 
(Figure 5.3).12 
 
Figure 5.3: Syntheses of benzimidazole derivatives5 
Reactions of benzimidazole derivatives may involve either the benzimidazole core scaffold or 
substituent groups on the scaffold. The nitrogen atoms of benzimidazole have been employed in 
alkylation, acylation and Mannich reactions. Grignard reagents react with the active hydrogen in 
the 1-position of benzimidazole to form benzimidazole-1-magnessium bromide, which readily 
affords 1-acylated benzimidazole derivatives upon reaction with carboxylic acid derivatives. The 
hydrogen in the 1-position of benzimidazoles is sufficiently acidic to be replaced by metals to give 
N-metal benzimidazoles. Other reactions reported for the benzimidazole scaffold include 
reduction, cleavage of the imidazole moiety, halogenation and nitration.12 
The 2-position of benzimidazole is another important site of benzimidazole reactions. Reactions 
involving the 2-methylene group have been extensively documented.12 Other 2-position reactions 
of benzimidazole have been reported for 2-benzimidazole carboxylic acids, 2-(α-haloalkyl) 
benzimidazoles, 2-hydroxybenzimidazoles, 2-mercaptobenzimidazole, 2-aminobenzimidazole, 
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and oxidation.12 The benzimidazole scaffold therefore affords the organic chemist a wide range of 
opportunities for synthetic derivatizations.  
 
Figure 5.4: Chemical structures of some drugs containing the benzimidazole scaffold5 
Complemented by its binding possibilities to a wide range of biological targets, the benzimidazole 
scaffold has been extensively explored in drug discovery (Figure 5.4 and Figure 5.5). Several 
reviews and research articles have been published on the diverse biological properties of 
benzimidazole derivatives. 15–17 These biological activities include antiparasitic, anticonvulsant, 
analgesic, antihistaminic, antiulcer, antihypertensive, antiviral, anticancer, antifungal, anti-
inflammatory, anticoagulant and proton pump inhibition.18–24 The Merck Index Online database 
(licensed to the Royal Society of Chemistry) records about 48 drug molecules based on the 
benzimidazole scaffold.25 The medicinal chemistry explorations of the benzimidazole scaffold is an 
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active area of current research. This is evident in the over 200 publications so far reported in this 
year 2018 according to a PubMed search.26 
 
Figure 5.5: Some bioactive benzimidazole derivatives16,27,28 
5.1.4 Mannich bases in medicinal chemistry and drug design 
Mannich bases are a structurally heterogeneous class of chemical compounds that are generated 
from various substrates through the introduction of an aminomethylene moiety by means of the 
Mannich reaction. The Mannich reaction is a three-component condensation between, more 
generally, a substrate (X-H) containing at least one active hydrogen atom, an aldehyde component 
(R-CHO) and an amine reagent (NH3, R-NH2 or R1R2NH).29 Variation in the structure of the substrate 
leads to structural diversity in the Mannich base formed (Figure 5.6). At least one Mannich base 
can be formed from a substrate depending on the number of active hydrogens present. Further, 
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the use of ammonia (in the form of an ammonium salt) or primary amine reagents can lead to bis- 
or tris-Mannich bases.29 Structural diversity in the Mannich base compound is therefore not 
exhaustive and this provides a wide range of applications in synthetic explorations. 
 
Figure 5.6: Examples of various types of Mannich bases29 
These compounds have displayed diverse biological activities including antitumor, cytotoxicity, 
antibacterial, antifungal, antimalarial, antiviral, anticonvulsant, anti-inflammatory, analgesic and 
antioxidant. Other biological activities such as ability to regulate blood pressure or inhibit platelet 
aggregation, antiparasitic, anti-ulcer effects, and as agents for the treatment of mental disorders 
have been reported. Moreover, Mannich bases have been explored as inhibitors of enzymes and 
as ligands of receptors.29–39 The biological usefulness of Mannich bases is evident in some current 
drugs on the market (Figure 5.7). Moreover, more biologically potent Mannich bases are 
continually being reported (at least 30 articles so far in 2018 according to PubMed database).40 
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Figure 5.7: Examples of drugs with Mannich bases 
Mannich bases have useful applications in medicinal chemistry. The Mannich side chain increases 
the hydrophilicity of a molecule attributable to the presence of the amino group. Moreover, 
quaternization of the amino group can enhance the solubility of a drug in water. This advantage 
of Mannich bases is exemplified in the tetracycline antibiotics rolitetracycline (reverin) and 
lymecycline (a congener which has further improved solubility due to the terminal polar groups) 
(Figure 5.7). The tetracyclines are a group of antibiotics first discovered from the soil sediment 
microbe Streptomyces. The first approved candidate was chlortetracycline (Aureomycin) in 1945.41 
According to a 1960 report, tetracycline administration was only possible by a permanent infusion 
of a large volume and therefore required a lot of time to administer the drug. The prodrug, 
pyrrolidino-methyl tetracycline (reverin), due to its enhanced solubility, arising from the Mannich 
side chain, offered the possibility of administration as a normal intravenous injection within 1 
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minute.42 Further, the enhanced solubility enabled administration of the drug in small doses (250 
mg/day) that did not affect enteric flora.43  
Topotecan offers another example of the importance of the Mannich base side chain to aqueous 
solubility of bioactive compounds. This approach rescued the potent antitumor natural product 
camptothecin. The downsides of camptothecin, which hampered further development included 
toxicity (severe hemorrhagic cystitis) and poor aqueous solubility.44,45 Topotecan hydrochloride is 
a semisynthetic derivative of camptothecin by incorporation of a dimethylamino methylene 
Mannich base side chain (Figure 5.7). It is this basic moiety of topotecan that confers water 
solubility at acid pH. The closed lactone ring of topotecan is important for its antitumor activity. 
The solubility of topotecan in acid medium is important because the lactone ring predominates at 
low pH. Topotecan acts by inhibiting the nuclear enzyme topoisomerase I, which is involved in DNA 
replication, by forming a covalent intermediate between topoisomerase I and DNA.46,47 
Another application of Mannich bases in medicinal chemistry and drug design is their use as 
prodrugs to deliver bioactive compounds which hitherto may not make it as clinical drugs. As 
prodrugs, they release the active drug under controlled hydrolytic conditions via 
deaminomethylation or deamination.48,49 This is exemplified in doxorubicin Mannich base 
prodrugs such as doxoform and doxaliform. Doxorubicin is a natural product obtained from a strain 
of Streptomyces which had been mutated using N-nitroso-N-methyl urethane.50 It is used to treat 
cancer, including breast cancer, bladder cancer, Kaposi's sarcoma, lymphoma, and acute 
lymphocytic leukemia. It inhibits DNA replication through inhibition of topoisomerase II by 
intercalation of DNA.51 Alkylation of DNA by doxorubicin via catalytic production of formaldehyde 
prompted the synthesis of doxoform, a bis-doxorubicin derivative, bearing formaldehyde moiety 
formed by an N-Mannich reaction.52 Fenick and coworkers explained that doxorubicin catalyzes 
“the production of superoxide and hydrogen peroxide through the redox machinery of the quinone 
functionality. These reactive oxygen species, through an iron-catalyzed Fenton reaction, oxidize 
cellular constituents to produce formaldehyde. The resulting formaldehyde reacts with the drug to 
produce doxoform or at least the respective mono-oxazolidines, 3′-N,4′-O-methylenedoxorubicin 
(the active metabolite). Doxoform (or the mono-oxazolidines) reacts with DNA to form virtual cross-
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links, which trigger apoptosis. Consequently, doxoform, which carry their own formaldehyde into 
the cells, are more effective against sensitive cells than their parent compounds”. Doxoform was 
found to be 150-fold more toxic to MCF-7 sensitive and 10000-fold more toxic to MCF-7/ADR 
resistant breast cancer cells, respectively.52 
Prolonged administration of doxorubicin leads to resistance by cancer cells. Further, doxoform has 
drawbacks of poor solubility, short lifetime and high toxicity.52 Conjugation of doxorubicin with 
salicylamide led to the N-Mannich base doxaliform. Doxaliform is a water soluble prodrug of 
doxorubicin with a half-life of approximately one hour and is 4-fold and 10-fold more cytotoxic 
than doxorubicin against MCF-7 and MCF-7/ADR breast cancer cells, respectively.53 Over 2000 
analogs of doxorubicin are currently known. 
Mannich bases derived from carbonyl substrates such as ketones and carboxylic acid derivatives 
or H-bond acceptors situated in close proximity to the Mannich side chain derived from ammonia 
or a primary amine can undergo reversible intramolecular hydrogen bonding. A similar 
phenomenon is true for substrates with H-bond donors located at a proximal distance to the 
Mannich base side chain to afford stable transient cyclic molecular conformations. Intramolecular 
hydrogen bonding (IMHB) introduces lipophilic character to a drug enabling a polar molecule to 
circumvent non-polar biological barriers, for example.54 When present, IMHB greatly impacts the 
molecular properties, function, and interaction of the molecule with biological systems.55–58  
Amodiaquine is the first Mannich base used to treat malaria. Although its mechanism of action is 
not well elucidated yet, it is believed to act via a similar mechanism as other 4-aminoquinolines 
through inhibition of hemozoin formation in the digestive vacuole of the Plasmodium parasite. 
Pyronaridine is a congener of amodiaquine successfully being used clinically as a drug.59 WR-
194,965 (Figure 5.8) is an aminomethylphenol discovered in the 1970s as part of a US Army 
Research Program in malaria. It exhibited high potency against both chloroquine-sensitive and 
chloroquine-resistant strains of P. falciparum with IC50 values in the sub-nanomolar range.60 It 
exhibited in vivo blood schizontocidal activity against P. berghei.61 The limited potency of WR-
194,965, however, led to its termination in clinical development by the US Army. A new Mannich 
base, MK-4815, developed from WR-194,965 exhibited improved antimalarial potency with good 
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pharmacokinetic profile in the P. berghei in vivo mouse model. It displayed in vitro efficacy against 
six drug-resistant P. falciparum strains with IC50 values in the 14 - 110 nM range. In vitro studies 
showed that the compound selectively accumulated in infected red blood cells and was most 
effective against the metabolically active late trophozoite/early schizont stages.62 JPC-2997 is 
related to WR-194,965 and MK-4815. It displayed high in vitro activity (IC50 = 7 - 34 nM) against 
the chloroquine-sensitive D6, the chloroquine-resistant W2, and the multidrug-resistant TM90-
C2B P. falciparum strains.60 JPC-2997 was twice as active as WR-194,965 in vitro against P. 
falciparum lines. With respect to the D6 strain of P. falciparum, JPC-2997 was found to be >2,500 
times less cytotoxic to the human HepG2 and HEK293 cancer cell lines and BHK rodent cell line. 
Moreover, it displayed high in vivo potency and a long elimination half-life of 49.8 hours.60 
 
Figure 5.8: Chemical structures of WR-194,965, MK-4815 and JPC-2997 
Amodiaquine is metabolized in the liver to its pharmacologically active metabolite, N-
desethylamodiaquine, by the cytochrome p450 enzyme CYP2C8.63 Like amodiaquine, the 
biological properties of some Mannich bases have been attributed to their active metabolites. For 
example, a high-throughput screening of 350000 compounds identified Mannich bases as a new 
class of thioredoxin reductase (TrxR) mechanism-based inhibitors. TrxR catalyzes the reduction of 
oxidized thioredoxin (Trx) by NADPH. It is involved in maintaining an adequate reducing 
environment and defense against oxidative stress in P. falciparum. Although TrxR is also present 
in humans, the protein sequences differ profoundly at the C-terminal redox center where human 
TrxR contains a cysteine-selenocysteine pair (Cys495′-Sec496′) while P. falciparum TrxR  (PfTrxR) 
has two cysteine residues (Cys535′ and Cys540′) separated by four amino acids.64 As a result, TrxR 
has been proposed as a possible target for antimalarial drug discovery. It was demonstrated that 
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α, β-unsaturated ketonic Mannich bases irreversibly inactivated TrxR by formation of an inactive 
macrocyclic species by bisalkylation, first of the C-terminal thiol of Cys540′ (the equivalent of SeCys 
in the human enzyme) and subsequently of Cys535′. It is essential that the ketonic Mannich base 
has two electrophilic sites (I, Figure 5.9) which includes the presence of an alpha proton to ensure 
bonding to both cysteine residues (Cys540’ and Cys535’). It was observed that the presence of 
only the alpha proton electrophilic site (II, Figure 5.9) allowed bonding to only one cysteine residue 
Cys540’. In both cases, the reactive metabolite (III, Figure 5.9) generated after deamination of the 
Mannich base was necessary for a Micheal addition to the dithiol 540’/535’ of PfTrxR.64 In another 
related example, ketonic Mannich bases derived from acetophenones and α, β-unsaturated 
ketones (or those arising from deamination reactions) have been shown to exert their cytotoxic 
action through the alkylation of cellular thiols such as glutathione or cysteine.65 Moreover, ortho 
phenolic Mannich bases (IV, Figure 5.9) readily undergo deamination reaction to form the quinone 
methine active metabolite (V, Figure 5.9) which is attributed to the potent cytotoxic activity of 
chalcones.66 
 
Figure 5.9: Chemical structures of compounds I-V 
5.1.5 Hemoglobin degradation pathway and inhibitors of beta-hematin formation 
The formation of hemozoin is a unique process adopted by Plasmodium spp. to detoxify free heme, 
which is a toxic by-product of the degradation of hemoglobin. Other hematophagous organisms 
such as Rhodnius and Schistosoma also make use of this process. Hemoglobin is ingested into the 
Plasmodium parasite’s food vacuole by pinocytosis in small tubular vesicles, which arise from the 
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cystostome (Figure 5.10). In the acidic medium of the food vacuole, oxidation is followed by 
hydrolysis by aspartic proteases (plasmepsins I and II) to form denatured globin and heme (Fe2+). 
Enzymatic hydrolysis by falcipain and falcilysin, followed by cytosolic exopeptidases, converts 
globin to peptides, and finally, amino acids, respectively (Figure 5.10).67  
Figure 5.10: Degradation of hemoglobin in Plasmodium parasite67,68 
Free heme (Fe2+-protoporphyrin IX) is toxic to the parasite. It is inactivated in the food vacuole by 
peroxidases and superoxide dismutases.69 In the presence of peroxide antimalarial drugs such as 
the artemisinins, free radical derivatives and other reactive derivatives of the drugs are 
generated.70,71 These reactive species cannot be quenched and, thus, cause the death of the 
parasite.68,72 Upon oxidation, however, heme (Fe2+) is converted to the equally toxic hematin Fe3+ 
congener. The lipophilicity of hematin (Fe3+) makes it easy to intercalate in the membrane of the 
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parasite, which may cause changes in membrane permeability and lipid organization and induce 
lipid peroxidation.67 Hematin (Fe3+) can induce oxidation of the components of the membrane, by 
forming reactive oxygen species (ROS), leading to cell lysis and eventually death of the parasite.73 
Heme detoxification is therefore an important process in the erythrocytic stage of the malaria 
parasite (Figure 5.11).  
Figure 5.11: Mechanisms of heme detoxification in Plasmodium parasite67 
Sequestration of heme into hemozoin is not an enzymatic process. It is a spontaneous process and 
occurs readily under appropriate physicochemical conditions.74 In fact, beta-hematin can be 
spontaneously synthesized, in vitro, if monomeric hematin (Fe3+) is allowed to incubate at 
physiological temperature (37 oC) at a pH of 4.8.75 Under these conditions, synthetic beta-hematin 
can only be formed in the presence of some biological factors including the malaria parasite lysate, 
organic solvent extracts of the parasite lysate, histidine rich protein II or III, preformed hemozoin 
or beta-hematin and some unsaturated lipids.75–78 Other methods of in vitro formation of beta-
hematin have also been reported.79–81 Structurally, a hemozoin crystal is composed of a series of 
hematin (Fe3+-protoporphyrin IX) molecules linked into dimers through reciprocal iron-carboxylate 
bonds to the propionic side chains of each porphyrin, and that the dimers form chains linked by 
hydrogen bonds between the remaining propionate groups in the crystal.82 
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The major drug families, which inhibit beta-hematin formation include the quinolines, azoles, 
isonitriles, xanthones, methylene blue and its derivatives, and metalloporphyrins (Figure 5.12). 
The quinoline class of beta-hematin formation inhibitors include the antimalarials amodiaquine, 
chloroquine, tebuquine, pyronaridine, halofantrine, quinine, quinidine and bisquinoline. These 
compounds form complexes with hematin through π-π stacking interactions.83–85 These 
interactions are believed to lead to oxidative stress, through the formation of reactive oxygen 
species (ROS), which may lead to peroxidation of parasite membrane lipids, damage of DNA, 
oxidation of protein and finally death of the parasite.67 Structure-activity relationship (SAR) studies 
of the quinoline drugs have revealed the importance of the 7-chloro group to beta-hematin 
inhibition activity. It has been demonstrated that the 4-aminoquinoline nucleus of chloroquine 
and related antimalarials is responsible for complexing free heme, while the beta-hematin 
inhibition activity is attributable to the C-7 substituent.86 Only few groups, such as the nitro and 
bromine substituents, are tolerated at the 7-position for beta-hematin activity. Optimum 
antimalarial activity is, however, achieved by the presence of the aminoalkyl side chain.80,87 The 
length of the chain only has an effect on the activity of the drug against the chloroquine-sensitive 
and chloroquine-resistant strains of P. falciparum. Although the stereochemistry of the C-8 and C-
9 is necessary for the antimalarial activities of the cinchona alkaloids, replacement of the 
quinuclidine group with a similarly basic piperidine has led to improvement in activity.88 
 
Figure 5.12: Examples of inhibitors of beta-hematin formation 
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Clotrimazole, a potent antimycotic drug, is an important member of the azole class of 
antimalarials. It inhibits in vitro parasite growth of different strains of chloroquine-sensitive and 
resistant of P. falciparum (IC50, 0.2 – 1.1 μM).89 Clotrimazole has a relative high affinity for heme, 
inhibits reduced glutathione-dependent heme catabolism, and enhances heme-induced 
hemolysis.90 Other antifungal agents, such as ketoconazole and miconazole, have demonstrated 
antimalarial properties, however, they are less active compared to clotrimazole.91 The azoles 
inhibit heme polymerization by displacing heme from histidine-rich peptide-heme complexes, 
which initiate heme polymerization.91 A similar phenomenon has been observed in the reduced 
glutathione-heme complexes which dissipate the concentration of heme in the food vacuole 
through catabolism.90 Two nitrogenous ligands derived from the imidazole moieties of two azole 
molecules are responsible for the stable azole-heme complexes. The importance of the imidazole 
scaffold to the activity of the azoles is supported by the reduction in activity (IC50 = 11 µM) of 
chlorophenyl-bis-phenyl methanol, one of in vivo metabolites of clotrimazole, which contains no 
imidazole group.92 
The isonitrile class of hemozoin inhibitors were discovered from a series of terpenoid isonitrile 
natural products of marine origin.93,94 The mechanisms responsible for their antimalarial 
properties include inhibiting the decomposition of H2O2, the peroxidative destruction of heme and 
the GSH-mediated breakdown of heme.94 Wright and coworkers have demonstrated that the 
isonitriles, diisocyanoadociane and axisonitrile-3, form coordination complexes with Fe3+ of 
heme.94 The phenothiazinium salt methylene blue [3, 7-bis (dimethylamino) phenothiazinium 
chloride] is the oldest known synthetic antimalarial drug. Methylene blue and its derivatives have 
exhibited antiplasmodium activity against various strains of P. falciparum (IC50, 0.2 - 100 nM), 
primarily due to their inhibition of hemozoin formation.95 While the antimalarial properties of 
these phenothiazines increased with an increase in the number of basic groups in the aminoalkyl 
side chain, as a result of increased drug accumulation in the parasite’s food vacuole, their ability 
to inhibit polymerization of heme has been attributed to π-π stacking interactions between the 
aromatic moieties of the phenothiazine core scaffold and the porphyrin.96 
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It has been shown that trophozoites treated with the 2,3,4,5,6-pentahydroxyxanthone were 
arrested in their development and became degenerate in appearance within 24 hours of drug 
exposure, an observation which supports their mode of action as inhibitors of hemozoin 
formation.97 The intermolecular interactions between xanthones and heme comprise of 
coordination between the Fe3+ and the carbonyl group of xanthone, hydrogen bonding between 
the xanthone hydroxyls and the propionate group of heme, and lastly, π-π stacking interactions 
between the aromatic moieties of both molecules.98,99 The complexation of heme with xanthones 
was found to not only depend on pH and solvent, but also it acts in a unique way by forming a 
soluble complex with a heme dimer in aqueous solution.98,99 Xanthones with high numbers of 
hydroxyl groups have exhibited better activity than those with lower numbers. More specifically, 
the most potent xanthone possesses hydroxyl groups at positions 3, 4, 5, and 6. The poor activity 
of the 1, 8 dihydroxy congener has been attributed to hydrogen bonding with the carbonyl oxygen, 
thereby leading to poor affinity for heme.97,100 Further, incorporation of R-groups bearing basic 
nitrogen atoms have led to increased heme binding affinity. Two 3,6-bis-ω-
diethylaminoalkoxyxanthone analogues, having side chains of 5 and 6 carbon atoms, exhibited IC50 
values of 8.26 and 9.02 µM, respectively. The increase in heme binding affinity was attributed to 
the strong ionic interactions with the propionate side chains of heme and increased drug 
accumulation in the low pH medium of the parasite’s food vacuole.101 
Metalloporphyrins have exhibited moderate antiplasmodium activity (IC50, 15.5 - 190 µM).102 Their 
mode of action involves intercalation of heme molecules through metal-enhanced 
heteroporphyrin π–π assemblies. The poor stability of these assemblies leads to a build up of free 
heme which is toxic to the parasite.102,103 The inhibitory activity of the metalloprotoporphyrins 
towards beta-hematin formation is highly dependent on the central metal ion, with the water 
exchange rate for the octahedral aqua complexes of the porphyrin's central metal ion playing a 
significant role.103 Mg (II) PPIX, Zn (II) PPIX, and Sn (IV) PPIX are as much as six times more 
efficacious than the free ligand protoporphyrin IX in preventing hemozoin formation and four 
times as efficacious as chloroquine.103 Other metals, such as Cr, Co, Mn, and Cu, have also been 
explored as metalloporphyrin antimalarial agents.  
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5.2 Research Program 
5.2.1 Hypothesis 
Benzimidazole analogues developed by incorporation of phenolic Mannich bases are potential 
novel antitubercular and antiplasmodium drug leads. 
5.2.2 Main objective 
To synthesize novel benzimidazole-phenolic Mannich base analogues for in vitro 
antimycobacterial and antiplasmodium activities evaluation. 
5.2.3 Specific aims 
 To synthesize benzimidazole-Mannich base analogues as potential antimycobacterial 
agents. 
 To synthesize benzimidazole-Mannich base analogues as potential antiplasmodium agents. 
 To evaluate the synthesized compounds for cytotoxic and beta-hematin inhibition 
activities. 
5.3 Design, Synthesis and characterization of benzimidazole analogues 
5.3.1 Design and Synthesis 
In the current study, the antiplasmodium activity of phenolic Mannich bases developed from 
aminophenols was explored. This is supported by the fact that a cursory search through the 
literature revealed that Mannich bases relevant to antiplasmodium activity have been obtained 
from aminophenols, exemplified by the 4-aminoquinoline antimalarial drug amodiaquine.29,30 
Hence, five phenolic Mannich bases from readily available aminophenols were synthesized and 
evaluated for their antiplasmodium activity as analogues of benzimidazole. Mannich bases of two 
of the aminophenols, 3-aminophenol and 4-aminophenol, have shown potent antiplasmodium 
activity having been employed in isoquine (and t-butyl isoquine) and amodiaquine, respectively. 
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Further, another literature search revealed no reports of the antiplasmodium activity of 2-
aminophenol, hence it was explored in the current work. The last two aminophenols investigated 
were the 3-methyl and 4-methyl substituted derivatives of 2-aminophenol. 
Compounds for structure activity-relationship (SAR) studies were synthesized from 2-chloro-1H-
benzimidazole and three 1-benzyl substituted 2-chlorobenzimidazole compounds. The choice of 
the benzyl moiety was inspired by previous SAR studies developed in our laboratory. In summary, 
four benzimidazole-based compounds were evaluated for their antiplasmodium activity by 
developing an SAR investigation which incorporated five phenolic Mannich bases. 
 
Scheme 5.1: Synthetic scheme to target compounds.  
Reagents and conditions: (i) (CH3CO)2O, THF, 60 oC, 1 h; (ii) HCHO, NHEt2, EtOH, 85 oC, 2 h; (iii) 6N 
HCl, 100 oC, 2 h; (iv) K2CO3, MeCN, 75 oC, 2 h; (v) KH2PO4, n-BuOH, 100 oC, 8 h 
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Figure 5.13: Summary of target compounds 
The Mannich bases (4a-4d) were obtained in three steps (Scheme 5.1 (i) – (iii)). In the first step, 
the amino group was protected as the acetamide to reduce the possibility of regioisomers in the 
Mannich base products. The three 2-aminophenol congeners (1a-1c) were acetylated using acetic 
anhydride in THF at 60 oC to obtain the N-acetylated products 2a-2c. The compounds (2a-2c) were 
then subjected to a Mannich reaction in the presence of formaldehyde and diethylamine in EtOH 
at 85 oC to afford 3a-3d. The 3-hydroxyphenyl acetamide, 2d, was obtained from a commercial 
source. Deacetylation of intermediates 3a-3d in the presence of dilute HCl afforded the Mannich 
bases 4a-4d as the HCl salts. The 4-aminophenol Mannich base 5.0 had already been synthesized 
and used in a previous reaction (Chapter four, Section 4.3.1) and so was used as such. All five 
Mannich bases were obtained as viscous oily matter in good yields (75 - 90%).  
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The two benzyl benzimidazole derivatives 7.0 and 8.0 were synthesized according to Scheme 5.1 
(iv). The 2-chloro-1H-benzimidazole compound (6.0) was heated together with the para-
substituted bromobenzyl reagent (4-CN and 4-CF3) in acetonitrile in a nucleophilic substitution 
reaction to afford the 1-benzylated 2-chlorobenzimidazole intermediates 7.0 (4-CN) and 8.0 (4-
CF3) as white solids in quantitative yields (>98%). The reaction was conducted in the presence of 
K2CO3 as base to mop up the by-product HBr. Compound 9.0, 1-(4-fluorobenzyl)-2-
chlorobenzimidazole, was acquired from a commercial source. 
The target compounds (6.1-9.5) were synthesized in another nucleophilic substitution reaction 
according to Scheme 5.1 (v). Each of the four benzimidazole compounds (6.0-9.0) was reacted 
separately with the Mannich bases 4a-4d and 5.0. The reaction conditions to obtain the target 
compounds, in a reproducible manner, involved KH2PO4 as base and n-BuOH as solvent, heated at 
the boiling point of n-BuOH (99 - 100oC). The compounds were obtained in moderate to good 
yields (35 - 95%). Attempts to synthesize the compounds by using other routine polar laboratory 
solvents (EtOH, MeOH, dioxane, THF-DMF and DMF) and bases (NEt3 and DIPEA) led to either no 
reaction at all or complex reaction mixtures, which made purification of the target compounds 
cumbersome. Twenty benzimidazole-phenolic Mannich base analogues (6.1-9.5) were synthesized 
in total. 
The progress of all reactions was followed by normal phase silica TLC, together with acquisition of 
the mass on reversed phase C18 LCMS to track formation of the intended compound. The 
synthesized compounds were fully characterized by their TLC Rf values in appropriate solvents, 
reversed phase C18 LC retention time, mass spectrometric and 1D NMR spectroscopic data. 
Where necessary, 2D NMR spectroscopic data was acquired to enable correct assignment of NMR 
signals. 
5.3.2 Characterization of target benzimidazole analogues 
All 1H-benzimidazole-Mannich base analogues (6.1–6.5) exhibited similar 1H NMR spectrum as 
shown for 6.3 in Figure 5.14. The aromatic signals of the benzimidazole scaffold were observed in 
the olefinic region of the 1H NMR spectrum resonating at δH 6.96 (dd, J = 3.2, 5.9 Hz, 2H) and 7.18 
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(dd, J = 3.1, 5.8 Hz, 2H) for H-5 and H-6, respectively. Meanwhile, the two olefinic protons of the 
Mannich base, H-10 and H-11, were observed at δH 6.71 (dd, J = 7.7 Hz, 1H) and 6.90 (d, J = 7.7 Hz, 
1H). The methylene protons H2-13 were assigned the chemical shift δH 3.84 (s, 2H) occurring 
downfield of the spectrum due to the deshielding effects of the phenyl ring and the diethylamino 
group. The signal at δH 2.24 (s, 3H) was assigned to the methyl group H3-16. The two methyl 
protons of the diethylamino group resonated at δH 1.11 (t, J = 7.2 Hz, 6H, 2×H3-15), being the most 
shielded of all the protons in 6.3. Moreover, the signal at δH 2.69 (q, J = 7.2 Hz, 4H) were assigned 
to the two methylene groups represented by H2-14. In a similar manner, based on the chemical 
environment, splitting pattern and the values of coupling constants, the 1H NMR spectra of the 
other 1H-benzimidazole analogues (6.1, 6.2, 6.4, and 6.5) were analyzed and characterized 
accordingly. 
 
Figure 5.14: 1H NMR (MeOH-d4, 600 MHz) spectrum of 6.3 
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The 1H NMR spectra acquired for the 1-(4-cyanobenzyl) benzimidazole (7.1-7.5) and 1-((4-
trifluoromethyl)benzyl) benzimidazole (8.1-8.5) target compounds are exemplified by the 1H NMR 
spectrum of compound 8.3 (Figure 5.15). Olefinic signals attributable to the protons, H-12 and H-
13, of the benzyl moiety were observed as doublets at δH 7.43 (d, J = 8.1 Hz, 2H) and 7.61 (d, J = 
8.2 Hz, 2H) integrating for two protons each due to the symmetry of the benzyl group. The H-13 
protons occurred downfield relative to H-12 as a result of the deshielding effect of the 
trifluoromethyl substituent at C-14. Meanwhile, the methylene protons (H2-10) of the benzyl 
group resonated as a singlet signal at δH 5.49 (s, 2H). 
 
Figure 5.15: 1H NMR (MeOH-d4, 600 MHz) spectrum of 8.3 
Each olefinic proton of the benzimidazole scaffold of the benzylated benzimidazole analogues (7.1-
9.5) exhibited a unique chemical shift. This is attributed to the fact that substitution of the benzyl 
group disrupted the tautomeric resonance of the imidazole substructure, which introduced 
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symmetry into the benzimidazole scaffold (Figure 5.15). The most deshielded of the protons, H-8, 
occurred at δH 7.25 (m, 1H) while H-5 resonated at δH 7.07 (m, 1H). Meanwhile, H-6 and H-7 each 
resonated at δH 6.97 (td, J = 7.5, 1.1 Hz, 1H) and 7.02 (td, J = 7.6, 1.2 Hz, 1H), respectively. Finally, 
the proton signals of the Mannich base were not significantly affected by substitution of the benzyl 
group on the benzimidazole scaffold, hence their chemical shifts are as they are in 6.3 (Figure 
5.14). 
 
Figure 5.16: 1H NMR (MeOH-d4, 600 MHz) spectrum of 9.3 
The 1H NMR spectra of the 1-(4-fluorobenzyl) benzimidazole analogues (9.1-9.5) were similar to 
the other benzylated derivatives (7.1-8.5). The chemical shifts and splitting pattern of the olefinic 
protons of the benzimidazole scaffold and the Mannich base protons were as previously observed. 
A key noticeable difference, however, was observed in the chemical shifts and splitting pattern of 
the olefinic protons of the benzyl group (Figure 5.16). Each of the protons H-12 and H-13 
resonated as double doublets as a result of the extra coupling due to the fluorine atom. Hence, 
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the signals were assigned to the protons on the basis of the coupling constant observed. The H-13 
methine protons were observed at δH 7.03 (t, J = 8.8 Hz, 2H) showing two strong ortho couplings 
to H-12 and the fluorine atom. The two methine protons H-12 occurred relatively downfield to H-
13 at δH 7.31 (dd, J = 5.4, 8.6 Hz, 2H).  
The 13C NMR spectrum (Figure 5.17) of 9.3 also exhibited signals corroborating the effect of the 
fluorine atom. Each of the four carbon atoms of the benzyl moiety was split into a doublet due to 
coupling to the fluorine atom. C-14 exhibited the largest coupling constant (J = 244.4 Hz) while C-
11, which is furthest away from the fluorine atom, exhibited the least coupling constant (J = 3.1 
Hz). 
 
Figure 5.17: 13C NMR (MeOH-d4, 151 MHz) spectrum of 9.3 
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5.4 Biological results and discussion 
5.4.1 Antimycobacterial activity 
Table 5.1: In vitro antimycobacterial (H37Rv strain) and cytotoxic (CHO cell line) activities of the 
benzimidazole analogues 
 
Compound R R' 
Mtb(H37Rv), MIC90 (µM) 
CHO 
IC50 (µM) 
7H9 GLU ADC 
TW 
7H9 GLU CAS 
TX 
6.1 
 
H >125 17.13 >50 
6.2 
 
H >125 8.97 >50 
6.3 
 
H >125 16.00 >50 
6.4 
 
H >125 >125 >50 
6.5 
 
H >125 >125 >50 
7.1 
  
>125 30.52 >50 
7.2 
  
>125 9.55 14.19 
7.3 
  
>125 15.67 >50 
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7.4 
  
>125 17.49 39.04 
7.5 
  
>125 34.84 >50 
8.1 
  
>125 3.80 >50 
8.2 
  
64.1 2.00 29.31 
8.3 
  
116 30.1 33.88 
8.4 
  
>125 6.49 41.50 
8.5 
  
>125 7.81 17.50 
9.1 
  
>125 6.46 >50 
9.2 
  
>125 7.09 18.70 
9.3 
  
>125 5.90 >50 
9.4 
  
>125 7.21 45.79 
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9.5 
  
>125 21.41 11.99 
Rifampicin   0.009 0.02  
Emetine     0.02 
For the purpose of SAR analysis, all compounds with MIC90 ≤10 μM were regarded as active; those 
with MIC90 ranging from 10 – 20 μM had moderate activity; MIC90 = 20 – 125 μM denoted as poorly 
active; whereas compounds exhibiting MIC90 >125 μM were considered inactive. In this regard, 
the synthesized benzimidazole analogues were inactive in the 7H9/ADC media, except 8.2 (MIC90 
= 64.10 µM) and 8.3 (MIC90 = 116 µM). However, they exhibited good to moderate activity in the 
7H9/CAS media, except compounds 6.4 and 6.5 which were inactive. Among the 1H-benzimidazole 
analogues, it was observed that the hydroxyl group ortho to the nitrogen atom in the Mannich 
base moiety was essential for activity. Moreover, about a two-fold increase in activity was 
observed for compound 6.2 (MIC90 = 8.97 µM) when the methyl substituent was para to the 
hydroxyl group compared to 6.3 (MIC90 = 16.00 µM), which had the methyl substituent in a meta 
position. 
Among the 1-(4-cyanobenzyl) benzimidazole analogues (7.1-7.5), compound 7.2 exhibited the best 
activity (MIC90 = 9.55 µM). Compounds 7.3 (MIC90 = 15.67 µM) and 7.4 (MIC90 = 17.49 µM) 
exhibited moderate activity while 7.1 and 7.5 were poorly active. Apart from 8.3, which showed 
poor activity (MIC90 = 30.1 µM), the other 1-((4-trifluoromethyl)benzyl) benzimidazole analogues 
showed good potency (MIC90 <10 µM). Similarly, all the 1-(4-fluorobenzyl) benzimidazole 
analogues exhibited good activity, except 9.5 which displayed moderate activity (MIC90 = 21.41 
µM). 
In summary, the N-benzyl benzimidazole analogues exhibited better activity than the 1H-
benzimidazole analogues. Generally, the analogues with Mannich base moieties bearing the 
hydroxyl group ortho to nitrogen atom exhibited better activity. Moreover, the activity was 
enhanced by substitution para to the hydroxyl group. With respect to substitution on the benzyl 
moiety, the fluoro and trifluoromethyl substituents led to an increase in activity compared to the 
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cyano group. Compound 8.2 exhibited the best activity (MIC90 = 2.00 µM) among the synthesized 
benzimidazole analogues. 
5.4.2 Antiplasmodium activity and cytotoxicity 
Table 5.2: In vitro activity against asexual (NF54 and K1 strains) and gametocyte (NF54 strain) P. falciparum 
parasites and cytotoxicity (CHO cell line) of the benzimidazole analogues 
 
Compound R R' 
Asexual 
parasites, 
IC50 (µM) 
Gametocyte 
parasites, 
% inhibition, 1 µM 
Cytotoxicity 
IC50 (µM) 
Pf(NF54) Pf(K1) 
Early 
stage 
Late 
stage 
CHO SI 
6.1 
 
H 0.56 0.77 - - >50 >89.28 
6.2 
 
H 0.23 0.42 - - >50 >217.39 
6.3 
 
H 0.86 1.62 - - >50 >58.13 
6.4 
 
H 1.88 >10 - - >50 >26.59 
6.5 
 
H 0.80 7.27 30 0 >50 >62.50 
7.1 
  
1.00 0.66 47 19 >50 >50 
7.2 
  
0.65 0.46 39 15 14.19 21.83 
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7.3 
 
 
0.87 0.83 19 0 >50 >57.47 
7.4 
 
 
0.37 0.76 38 4 39.04 105.51 
7.5 
 
 
0.47 1.97 20 9 >50 >106.38 
8.1 
  
0.44 0.13 71 35 >50 >113.63 
8.2 
  
0.19 0.06 91 41 29.31 154.26 
8.3 
  
2.88 0.94 18 1 33.88 11.76 
8.4 
  
0.47 0.87 36 2 41.50 88.29 
8.5 
  
0.39 1.69 34 31 17.50 44.87 
9.1 
  
0.36 0.18 65 11 >50 >136.88 
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9.2 
  
0.55 0.21 81 31 18.70 34.00 
9.3 
  
2.27 1.32 - - >50 >22.02 
9.4 
  
0.64 1.28 - - 45.79 71.54 
9.5 
  
0.68 1.95 33 22 11.99 17.63 
Chloroquine   0.01 0.42     
MMV390048     77 92   
Emetine       0.02  
The synthesized benzimidazole analogues were evaluated for their in vitro multi-stage 
antiplasmodium activity against asexual erythrocytic (NF54 and K1 strains) parasites and early and 
late stage gametocytes of P. falciparum (Table 5.2). The activity of the compounds against the 
asexual parasites was evaluated using the modified [3H]-hypoxanthine incorporation assay while 
their potential to inhibit gametocyte growth was evaluated using the luciferase reporter assay. 
In the synthesized 1H-benzimidazole series, compounds 6.1 and 6.2 displayed sub-micromolar 
potency against both chloroquine-sensitive NF54 and multidrug-resistant K1 strains of asexual 
parasites with IC50 PfNF54/K1 = 0.56/0.77 µM and IC50 PfNF54/K1 = 0.23/0.42 µM, respectively. 
Similarly, sub-miromolar activity was recorded by 6.3 and 6.5 against the NF54 parasites but the 
former displayed moderate activity (IC50 PfK1 = 1.62 µM) against the K1 parasites while 6.5 lost 
activity. Compound 6.4 was the least potent of the 1H-benzimidazole analogues (IC50 PfNF54/K1 = 
1.88/>10 µM).  
All analogues based on the N-benzyl benzimidazole scaffold displayed sub-micromolar activity 
against the chloroquine-sensitive strain of P. falciparum, except compounds 7.1 (IC50 PfNF54 = 
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1.00 µM), 8.3 (IC50 PfNF54 = 2.88 µM) and 9.3 (IC50 PfNF54 = 2.27 µM). Generally, the compounds 
were more potent towards the multi-drug resistant strain (K1) than the sensitive NF54 strain. 
Within the benzyl benzimidazole series, the 1-((4-trifluoromethyl)benzyl) and 1-(4-fluorobenzyl) 
benzimidazole analogues displayed better activity than the 1-(4-cyanobenzyl) benzimidazole 
analogues. In regard to the SAR based on the Mannich base used, synthesized compounds based 
on the 3-((N,N-diethylamino)methyl)-2-hydroxy aniline and its 5-methyl derivative were better 
tolerated for activity. All N-benzyl analogues of the 3-((N,N-diethylamino)methyl)-4-hydroxy 
aniline Mannich base were the least active in each series (Table 5.2). In summary, compound 8.2 
demonstrated the most potent activity against the asexual parasites (IC50 PfNF54/K1 = 0.19/0.06 
µM), with significant activity against the multidrug-resistant K1 strain. All the compounds were 
relatively non-cytotoxic (IC50 >10 µM) to the CHO cell line, recording acceptable selectivity indices, 
S1>10 (Table 5.2). 
The benzimidazole analogues based on the ortho-hydroxy Mannich bases and its derivatives 
displayed good activity against both early and late stage P. falciparum gametocytes, evident in the 
%inhibition of parasite growth at 1 µM and 5 µM (Table 5.2). Generally, the 1-(4-fluorobenzyl) and 
1-((4-trifluoromethyl)benzyl) benzimidazole analogues were more potent than their 1-(4-
cyanobenzyl) congeners, which displayed moderate activity. Compound 8.2 was the most potent 
analogue inhibiting 91% of parasite growth at 1 µM.  
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5.4.3 Beta-hematin inhibition activity and turbidimetric (kinetic) solubility 
Table 5.3: In vitro activity against asexual (NF54 strain), beta-hematin inhibition activity (BHIA) 
and solubility of the benzimidazole analogues 
 
Compound R R' 
Pf(NF54) 
IC50 (µM) 
BHIA 
IC50 (µM) 
Solubility, 
µM, pH 7.4 
6.1 
 
H 0.56 74.6 40 
6.2 
 
H 0.23 39.5 40 
6.3 
 
H 0.86 159.3 20 
6.4 
 
H 1.88 486.2 40 
6.5 
 
H 0.80 631.6 160 
7.1 
  
1.00 159.4 80 
7.2 
  
0.65 126.6 20 
7.3 
  
0.87 133.9 80 
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7.4 
  
0.37 131.8 80 
7.5 
  
0.47 1079 160 
8.1 
  
0.44 236.9 20 
8.2 
  
0.19 65.3 5 
8.3 
  
2.88 91.4 40 
8.4 
  
0.47 90.9 80 
8.5 
  
0.39 140.0 40 
9.1 
  
0.36 250.4 40 
9.2 
  
0.55 123.2 5 
9.3 
  
2.27 142.3 80 
9.4 
  
0.64 148.5 80 
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9.5 
  
0.68 399.2 10 
Chloroquine   0.01   
Amodiaquine    13.1  
The mechanistic potential of the synthesized analogues to inhibit hemozoin formation was 
evaluated in vitro by investigating their ability to inhibit beta-hematin formation. The Nonidet-P-
40 (NP-40) detergent-mediated assay was employed and the assay was conducted in acetate 
buffer (pH 4.8) at 37 oC. With an acceptable cut-off of IC50 <100 µM for good inhibition, it was 
observed that only four analogues acted as active inhibitors of beta-hematin formation (Table 5.3). 
The most potent inhibitor was 6.2 (IC50 = 39.5 µM) while its 1-((4-trifluoromethyl)benzyl) 
benzimidazole derivative, 8.2, was about two-fold less active with an IC50 value of 65.3 µM. 
Similarly, the 1-((4-trifluoromethyl)benzyl) benzimidazole derivatives, 8.3 and 8.4, exhibited 
comparable activity with IC50 values of 91.4 µM and 90.9 µM, respectively.  
 
Figure 5.18: Linear correlation between erythrocytic whole cell activity (PfNF54, IC50 values) and 
beta-hematin inhibition activity (BHIA) IC50 values 
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A linear correlation between whole cell activity (asexual blood stage NF54 parasites) and beta-
hematin inhibition activity (BHIA) of the synthesized compounds (Figure 5.18) reveals no apparent 
correlation (R2 = 0.0567). This data suggests that the compounds do not elicit their 
antiplasmodium potency via inhibition of hemozoin formation, and thus, they may act by a novel 
mode of action. This is supported by the observation that the compounds were generally more 
active against the multidrug-resistant K1 strain when compared to the sensitive NF54 strain. The 
good activities of the four compounds above could therefore be regarded as a surplus advantage 
specific to them. 
The approximate aqueous solubility of the synthesized compounds was evaluated as the 
concentration value above which the compounds precipitate from an aqueous buffer (phosphate 
buffered saline (PBS), pH 7.4), at ambient temperature, and causes turbidity. The occurrence of 
turbidity was detected by measuring the UV-VIS absorbance of the suspension at 620 nm, since 
most compounds, including the synthesized compounds, do not absorb in this region. With soluble 
solutions of the compounds in DMSO serving as internal control, their aqueous solubility was 
predicted as the definite deviation (point of inflection) from the baseline (DMSO plot) of a graph 
of corrected absorbance at 620 nm and concentration of test compound (Figure 5.19). 
The 1H-benzimidazole analogues showed moderate aqueous solubility (20 - 160 µM). Similarly, 
analogues of the benzyl benzimidazole series were moderately soluble, except compounds 8.2 (5 
µM), 9.2 (5 µM), and 9.5 (10 µM), which were poorly soluble (Table 5.3). Generally, the 1-(4-
cyanobenzyl) benzimidazole analogues were, as expected, more soluble than the lipophilic 1-(4-
fluorobenzyl) and 1-((4-trifluoromethyl)benzyl) benzimidazole congeners of the same Mannich 
base moiety. Further, the 3-((N,N-diethylamino)methyl)-2-hydroxy-5-methyl aniline Mannich base 
moiety was not tolerated for aqueous solubility (Table 5.3, Figure 5.19), although it yielded the 
most potent analogues in three of the four benzimidazole series (6.2: IC50 PfNF54/K1 = 0.23/0.42 
µM; 7.2: IC50 PfNF54/K1 = 0.65/0.46 µM; 8.2: IC50 PfNF54/K1 = 0.19/0.06 µM; 9.2: IC50 PfNF54/K1 
= 0.55/0.21 µM). 
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Figure 5.19: Representative graphical plots depicting the relative aqueous solubility of analogues 
based on the 3-((N,N-diethylamino)methyl)-2-hydroxy-5-methyl aniline Mannich base 
5.4.4 ‘Solubility’ structure-property relationship 
In view of the aforementioned, the physicochemical properties that influence the solubility of the 
synthesized benzimidazole analogues were investigated. A drug’s oral bioavailability is largely 
influenced by its aqueous solubility, permeability and metabolic stability. In drug discovery, 
solubility has a major impact on bioassays, formulation for in vivo dosing, and intestinal 
absorption.104 
The solubility of a compound depends on its structure and solution conditions. The contributions 
from the structure of the compound arise from its physicochemical properties namely, the 
lipophilicity, hydrogen bonding, molecular volume, crystal energy and ionizability. Solution 
conditions include pH, co-solvents, additives, ionic strength, time and temperature. The 
dependence of solubility on the physicochemical properties of the compound is expressed in the 
equations I-III below.104 
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a. Lipophilicity and crystal energy (Yalkowsky general solubility equation105): 
LogSo = 0.5 – LogP – 0.01 (MP – 25) … … … … (I) 
where, So is the intrinsic solubility (solubility when all molecules are neutral), Log P 
represents lipophilicity, and MP refers to the melting point of the compound (a measure 
of crystal energy) 
According to equation I, the solubility of a neutral/unionized compound generally decreases with 
increase in lipophilicity and crystal binding energy. 
b. Hydrogen bonding, molecular volume and crystal energy (Abraham aqueous solubility 
equation106): 
LogSw = 0.52 – R2 + 0.77π2H + 2.2αΣ2H + 4.2βΣ2H – 3.4αΣ2HβΣ2H – 4Vx … … … … (II) 
where the solubility of a compound is related to its polarity (π2H), hydrogen bond acidity 
(αΣ2H), hydrogen bond basicity (βΣ2H), hydrogen bonding in the crystal (αΣ2HβΣ2H), and 
molecular volume (Vx). 
According to equation II, solubility generally increases as polarity and hydrogen bonding increases, 
and decreases with increase in molecular volume and crystal hydrogen bonding. 
c. Ionizability (the ‘modified’ Henderson-Hasselbach equation107): 
          Sacid = So (1 + 10pH-pKa) 
 Sbase = So (1 + 10pKa-pH) … … … … (III) 
Equation III relates the solubility of an ionizable compound to its intrinsic solubility (So), pKa and 
pH of the aqueous solution and expresses the logarithmic effect of the difference between the pH 
of the solution and the pKa of the compound. According the equation, ionization increases the 
solubility of the compound than its neutral form.104 
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Based on the equations above, the solubility of the benzimidazole compounds was expressed as a 
function of their LogP (or cLogP), melting point, polarity, hydrogen bond donors and acceptors, 
molecular volume and pKa. 
Table 5.4: Physicochemical properties of the benzimidazole analogues 
Compound 
Calculated properties Experimental properties 
pKa (acid) 
pKa 
(base) 
Vx (mL) LogP HBD HBA tR (min) Rf 
LogS 
(µM) 
6.1 5.56 11.42 249.16 2.90 3 5 0.36 0.30 1.60 
6.2 5.51 11.43 265.53 3.32 3 5 0.60 0.30 1.60 
6.3 5.59 11.43 265.43 3.32 3 5 0.34 0.20 1.30 
6.4 6.76 11.53 249.16 2.86 3 5 0.33 0.20 1.60 
6.5 7.42 11.36 249.16 2.93 3 5 0.38 0.20 2.20 
7.1 5.37 11.41 360.06 4.44 2 6 2.46 0.70 1.90 
7.2 5.32 11.43 375.02 4.82 2 6 2.54 0.70 1.30 
7.3 5.41 11.43 375.02 4.82 2 6 2.45 0.50 1.60 
7.4 6.69 11.53 360.06 4.42 2 6 2.41 0.30 1.90 
7.5 7.36 11.36 360.06 4.49 2 6 2.38 0.40 2.20 
8.1 5.38 11.41 377.26 5.41 2 5 2.65 0.70 1.30 
8.2 5.33 11.43 392.43 5.76 2 5 2.68 0.70 0.69 
8.3 5.41 11.43 392.43 5.76 2 5 2.64 0.50 1.60 
8.4 6.69 11.53 377.26 5.35 2 5 2.61 0.30 1.90 
8.5 7.36 11.36 377.26 5.39 2 5 2.59 0.40 1.60 
9.1 5.39 11.41 350.14 4.75 2 5 2.55 0.70 1.60 
9.2 5.34 11.43 365.31 5.12 2 5 2.61 0.70 0.69 
9.3 5.42 11.43 365.31 5.12 2 5 2.51 0.50 1.90 
9.4 6.69 11.53 350.14 4.71 2 5 2.52 0.30 1.90 
9.5 7.36 11.36 350.14 4.77 2 5 2.41 0.40 1.00 
Table 5.4 lists the calculated and experimentally determined physicochemical properties of the 
synthesized compounds. The calculated LogP, numbers of hydrogen bond donors (HBD) and 
hydrogen bond acceptors (HBA) were predicted using OptibriumTM StarDropTM Version 6.4, while 
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the molecular volume (Vx) and pKa values were calculated using ACD/Labs Release 2017.2.1 and 
Chemdraw Professional 16, respectively. The polarity of the compounds was described by their 
HPLC retention time (tR) and TLC retardation factor (Rf) acquired under similar experimental 
conditions. However, the melting point parameter could not be described because the compounds 
were isolated as either viscous oils or semi-solids, which is congruent with some reported 
derivatives of benzimidazoles. For example, 1-methylbenzimidazole has a melting point of 59 - 62 
oC.12,108 The compounds are therefore predicted to have low crystal binding energy, and hence, 
according to equation I, must contribute to increased intrinsic solubility. 
A critical examination of Table 5.4 revealed that the four physicochemical properties pKa (of the 
Mannich base side chain), Vx, HBD and HBA did not either change from one benzimidazole series 
to another or from one analogue to another within the same series. For example, the pKa (base, 
that is, of the Mannich base) varied marginally within the range of 11.41 - 11.53 across all four 
benzimidazole series while pKa (acid, that is, of the phenolic hydroxyl group) varied within a wider 
range, 5.32 - 7.42. Further, it is observed that within the same benzimidazole series, analogues 
based on the three unsubstituted Mannich bases (that is, 6.1, 6.4 and 6.5; 7.1, 7.4 and 7.5; 8.1, 8.4 
and 8.5; 9.1, 9.4 and 9.5) shared a similar molecular volume, as was the case for the analogues 
derived from the methyl substituted Mannich base. A similar trend was observed for numbers of 
HBD and HBA present in the synthesized analogues. In contrast, however, the pKa (acid), cLogP, tR 
and Rf varied among analogues of the same series and from one series to another. It was therefore 
hypothesized that these physicochemical properties could significantly contribute to the observed 
solubility of the synthesized benzimidazole compounds. 
Linear correlation graphs (Figure 5.20 A-D) of the experimental aqueous solubility (LogS) of the 
benzimidazole compounds as a function of the aforementioned physicochemical parameters were 
therefore generated using Microsoft® Office Excel 2013. Generally, the plots revealed normal 
correlations between each of the four physicochemical properties and LogS of analogues within 
the same series. 
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A. pKa vs. LogS (µM)  
  
B. cLogP vs. LogS (µM)  
  
C. tR vs. LogS (µM)  
  
D. Rf vs. LogS (µM)  
  
Figure 5.20: Plot of pKa, cLogP, tR, and Rf against LogS of the benzimidazole analogues 
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The solubility of the 1H-benzimidazole series (6.1-6.5) seems to be influenced by the pKa (acid) 
and LogP, while almost zero correlation was observed between LogS and the polarity (tR and Rf) 
of the analogues. Meanwhile, the 1-(4-cyanobenzyl) and 1-((4-trifluoromethyl)benzyl) 
benzimidazole series, 7.1-7.5 and 8.1-8.5, respectively, exhibited good correlation between LogS 
and the four physicochemical parameters. In contrast, however, the 1-(4-fluorobenzyl) 
benzimidazole series (9.1-9.5) showed poor correlation. 
Analyses of the physicochemical property of analogues within each series revealed that analogues 
based on the 3-((N,N-diethylamino)methyl)-2-hydroxy-5-methyl aniline Mannich base (6.2, 7.2, 
8.2, and 9.2) exhibited the lowest pKa (acid) and polarity (tR and Rf). As expected, these analogues 
had slightly elevated cLogP values due to the presence of the lipophilic methyl group. The high 
acidity of these analogues could be attributed to the complimentary effect of electron-donation 
from the ortho-NH group and the electron-release from the para-methyl group. This hypothesis is 
corroborated by the comparatively higher pKa and polarity, irrespective of higher cLogP, of 
analogues based on the 3-(N,N-diethylaminomethyl)-2-hydroxy-6-methyl aniline Mannich base 
(6.3, 7.3, 8.3 and 9.3) than the unsubstituted 3-(N,N-diethylaminomethyl)-2-hydroxy aniline 
Mannich base analogues (6.1, 7.1, 8.1 and 9.1) (Table 5.4).  
Finally, Figure 5.21 is a heat map of LogSo, LogP and LogD of the most potent antiplasmodium and 
antimycobacterial benzimidazole analogue, 8.2. Briefly, the intrinsic solubility (So) could be 
increased by incorporating polar atoms or groups on the aromatic rings and increasing the polarity 
of the Mannich side chain by synthesizing the desalkyl or dealkylated analogues, while maintaining 
the 5-methyl group (Figure 5.21A). The lipophilicity (LogP) can be reduced largely by increasing 
the polarity of the hydroxyl group. This will require the replacement of the 5-methyl group with 
appropriate substituents that will increase the polarity and decrease the acidity of the hydroxyl 
group. The LogD, which is the partition coefficient of an ionizable molecule between a buffered 
aqueous solution and octanol, is largely affected by the hydroxyl group while it is unaffected by 
the basic Mannich base side chain. Polar or solubilizing groups on the aromatic rings will increase 
this parameter. These analyses and conclusions highlight some of the medicinal chemistry 
methodologies to improving the aqueous solubility of drug agents, namely introduction of polar 
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and ionizable groups, reduction of lipophilicity (LogP or LogD), addition of hydrogen-bonding 
moieties, and reduction of aromaticity. Other approaches, such as salt formation, disruption of 
molecular planarity and symmetry, lowering of molecular weight, design of chiral non-flat 
compounds, as well as construction of prodrugs are also well known.109–111 Although one or more 
of the aforementioned modifications could result in increased aqueous solubility, essentially, the 
activity of 8.2 must be enhanced and not compromised. 
 
Figure 5.21: Heat map of compound 8.2. (A). LogSo; (B). LogP; (C). LogD 
Colour code: red increases, blue decreases and green has no overall influence on the 
physicochemical property. Images were generated using OptibriumTM StardropTM Version 6.4. 
A B 
C 
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5.4.5 Antimalarial ‘drug-likeness’ of compound 8.2 
The Lipinski’s rule of five (RO5) has become an important guideline in modern day drug discovery 
campaigns, as it postulates acceptable cut-offs for the physicochemical properties necessary for 
good adsorption and permeability of an orally administered drug. According to this rule, the 
molecular weight must be ≤500 Da, cLogP ≤5, HBD ≤5, and HBA ≤10.112 Meanwhile, Veber’s rules 
on a drug’s oral bioavailability takes into consideration the compound’s molecular flexibility (<10 
rotatable bonds), total number of both HBD and HBA (HBD + HBA ≤12) and topological polar 
surface area (tPSA ≤140 Å2).113 Such rules/guidelines have become important as they predict a 
compound’s drug-likeness to ensure acceptable pharmacokinetic properties (adsorption, 
distribution, metabolism, excretion and toxicity: ADMET) prior to development. Table 5.5 lists the 
aforementioned physicochemical parameters of compound 8.2 in comparison to well established 
antimalarial drugs on the market or in advanced stages of drug development. 
In this regard, compound 8.2 conformed to both Lipinski and Veber rules for oral absorption and 
bioavailability. The antimalarial drugs were also in conformity to the rules, except four, riboflavin, 
azithromycin, doxycycline and thiostrepton, which is expected as natural products are exceptions 
to these rules (Table 5.5). To investigate the chemical space, in terms of polarity occupied by 8.2 
to ascertain its closeness to the different antimalarial drug chemotypes, a plot of tPSA against total 
number of HBD and HBA [HBD + HBA] was generated using Microsoft® Office Excel 2013 (Figure 
5.22). The compounds under study showed a strong linear correlation between tPSA and the total 
number of HBD and HBA (R2 >0.9) (Figure 5.22A). Moreover, with the exception of the four ‘outlier’ 
compounds, all the compounds including 8.2 clustered in a common chemical space, in good 
conformity to Veber’s rules for an orally bioavailable drug (tPSA <140 Å2, HBD + HBA <12) (Figure 
5.22B). Significantly, however, 8.2 shared a similar chemical space with the 4-aminoquinoline drug 
naphthoquine. A comparison of key physicochemical properties of the two compounds is 
presented in Figure 5.23. 
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Table 5.5: Compound 8.2/GAD025 and some antimalarial drugs and their Lipinski’s drug-likeness 
Drug class Compound 
Lipinski’s RO5 
tPSA,  
(Å2) 
MW 
≤500 
logP 
≤5 
HBD 
≤5 
HBA 
≤10 
Endoperoxides 
(EP) 
artemisinin 282.3 2.9 0 5 53.9 
Artermether 298.4 2.9 0 5 46.1 
Artemisone 401.5 1.4 0 7 74.3 
Dihydroartemisinin 284.3 2.1 1 5 57.1 
Artesunate 384.4 2.5 1 8 100.5 
OZ439 469.6 2.9 0 6 49.3 
OZ277 392.5 1.9 2 6 82.8 
4-
aminoquinolines 
(4-AQ) 
Amodiaquine 355.9 4.2 2 4 49.3 
AQ-13 291.8 3.7 1 3 82.8 
Chloroquine 319.9 4.6 1 3 49.3 
Hydroxychloroquine 335.9 3.6 2 4 82.8 
Naphthoquine 410.0 5.0 3 4 49.3 
Piperaquine 535.5 4.5 0 6 82.8 
Pyronaridine 518.1 3.9 2 7 49.3 
tert-butyl isoquine 355.9 4.1 3 4 82.8 
8-
aminoquinolines 
(8-AQ) 
Bulaquine 369.5 3.1 2 6 72.4 
NPC-1161B 434.4 4.5 2 5 69.4 
Primaquine 259.3 1.6 2 4 60.1 
Diethyl primaquine 315.5 3.8 1 4 37.3 
Tafenoquine 463.5 4.0 2 6 78.6 
Amino alcohols 
(AA) 
Mefloquine 378.3 3.5 2 3 45.1 
Halofantrine 500.4 7.6 1 2 23.4 
Lumefantrine 528.9 8.0 1 2 23.4 
Antifoliates  
(AF) 
Pyrimethamine 248.7 2.5 2 4 77.8 
Cycloquanil 251.7 0.7 2 5 80.0 
Proguanil 253.7 2.5 5 5 83.7 
Trimethoprim 290.3 1.5 2 7 105.5 
Amino biaryls 
(AB) 
MMV048 393.4 2.5 1 5 85.9 
UCT943 427.4 2.9 2 6 84.1 
Sulfonamides 
(SFN) 
Sulfadoxine 310.3 0.8 2 8 116.4 
Sulfamethoxazole 253.3 0.8 2 6 98.2 
Others  
(OTH) 
Atovaquone 366.8 5.3 1 3 54.3 
DHEA 288.4 3.2 1 2 37.3 
Cycloheximide 281.3 0.5 2 5 83.4 
Azithromycin 749.0 2.9 5 14 180.1 
Doxycyclin 444.4 -0.2 6 10 181.6 
Riboflavin 376.4 -0.7 5 10 161.6 
Thiostrepton 1665 0.7 17 37 562.7 
 8.2 482.5 5.7 2 5 53.3 
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A. tPSA vs. (HBD + HBA) 
 
B. An expanded plot of tPSA vs. (HBD + HBA) 
 
Figure 5.22: Plot of tPSA vs. [HBD + HBA]. Plots highlights the chemical space of 8.2 with respect to 
established antimalarial agents 
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Figure 5.23: Chemical structures of 8.2 and naphthoquine 
5.5 Conclusion and recommendations for future work 
Analogues based on the benzimidazole privileged scaffold with incorporated phenolic Mannich 
bases were successfully synthesized as potential and novel antimycobacterial and multi-stage 
(asexual blood and gametocyte stages) antiplasmodium agents. Evaluation of the aforementioned 
biological activities of the synthesized compounds revealed good in vitro potency towards Mtb in 
the 7H9/CAS media and sub-micromolar activity against the asexual blood stage P. falciparum 
parasites. Most of the compounds exhibited better potency against the multidrug-resistant K1 
strain than the chloroquine-sensitive NF54 strain of P. falciparum. One of the analogues, 
compound 8.2, emerged the most active compound in all the assays investigated albeit it displayed 
poor aqueous solubility. 
It is recommended that future work aimed at expanding the antimycobacterial and 
antiplasmodium SAR be explored. The SAR explorations must incorporate strategies to improve 
the aqueous solubility while improving antimycobacterial and antiplasmodium potency. 
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Acquisition of the IC50 values of the analogues towards the early and late stage gametocyte 
parasites of P.  falciparum is highly encouraged. The data could suggest the potential activity of 
the benzimidazole analogues as dual-inhibiting antimalarials. Finally metabolite identification 
studies on 8.2 should be performed in vitro in microsomal preparations as well as in vivo in mice 
so as to identify sites of metabolism and associated metabolites.  This will be critical for lead 
optimization studies towards an in vivo proof-of-concept in the relevant mouse model. 
5.6 Experimental 
5.6.1 General Experimental Procedures 
The general experimental procedures, with respect to solvents, instruments and materials for 
chromatographic and spectroscopic analyses of all reactions and the synthesized compounds, 
have been previously described in Chapter four, Section 4.6.1. The starting reagents, 2-chloro 
benzimidazole, 1-(4-fluorobenzyl)-2-chlorobenzimidazole and the aminophenols, were purchased 
from Sigma Aldrich. 
5.6.2 General Synthetic Procedure for compounds 2a – 2c 
A mixture of the corresponding hydroxyaniline (1.0 eq.) and acetic anhydride (1.5 eq.) in THF was 
heated at 60 οC for 1 h. After completion of reaction (TLC and LCMS), solvent was removed under 
reduced pressure and residue was triturated with diethyl ether to obtained N-(hydroxyphenyl) 
acetamides (2a – 2c). 
N-(2-hydroxyphenyl)acetamide (2a) 
White solid (1.3 g obtained from 1.0 g of 1a, 94%); Rf 0.5 (7% MeOH-DCM); 
Mp 198-200 οC; 1H NMR (600 MHz, MeOH-d4) δ 7.56 (dd, J = 1.6, 7.9 Hz, 1H, 
H-6), 6.98 (td, J = 7.5, 1.6 Hz, 1H, H-4), 6.85 (dd, J = 1.4, 8.0 Hz, 1H, H-3), 6.79 
(td, J = 7.6, 1.4 Hz, 1H, H-5), 2.16 (s, 3H, CH3-8); 13C NMR (151 MHz, MeOH-
d4) δ 172.2, 149.7, 127.1, 126.8, 124.0, 120.6, 117.3 and 23.4; LC-MS (ESI): 
m/z 152 [M+H]+; purity (LC-MS): 98% (tR = 0.23 min.) 
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N-(2-hydroxy-5-methylphenyl)acetamide (2b) 
White solid (1.2 g obtained from 1.0 g of 1b, 95%); Rf 0.5 (7% MeOH-DCM); 
Mp 197-199 οC; 1H NMR (600 MHz, MeOH-d4) δ 7.35 (d, J = 2.0 Hz, 1H, H-6), 
6.80 (dd, J = 2.2, 8.1 Hz, 1H, H-4), 6.73 (d, J = 8.1 Hz, 1H, H-3), 2.22 (s, 3H, 
CH3-9), 2.15 (s, 3H, CH3-8); 13C NMR (151 MHz, MeOH-d4) δ 172.2, 147.4, 
130.1, 127.3, 126.8, 124.3, 117.3, 23.4, and 20.7; LC-MS (ESI): m/z 166 
[M+H]+; purity (LC-MS): 98% (tR = 0.64 min.) 
N-(2-hydroxy-6-methylphenyl)acetamide (2c) 
Yellow solid (1.2 g obtained from 1.0 g of 1c, 95%); Rf 0.4 (7% MeOH-DCM); 
Mp 164-166 οC; 1H NMR (600 MHz, MeOH-d4) δ 7.00 (t, J = 7.8 Hz, 1H, H-4), 
6.71 (m, 2H, H-3 and H-5), 2.18 (s, 3H, CH3-9), 2.16 (s, 3H, CH3-8); 13C NMR 
(151 MHz, MeOH-d4) δ 172.9, 153.9, 137.6, 128.8, 124.4, 122.3, 115.0, 22.6 
and 18.2; LC-MS (ESI): m/z 166 [M+H]+; purity (LC-MS): 98% (tR = 0.26 min.) 
 
5.6.3 General Synthetic Procedure for compounds 3a – 3d 
The N-(hydroxyphenyl) acetamides (2a – 2d) (1 eq.) were dissolved in EtOH (10 mL) and heated 
(80 oC) with diethylamine (1.5 eq) and formaldehyde (1.5 eq.) until completion (TLC, 2 h). The 
solvent was removed in vacuo. The residue was dissolved in DCM (20 mL) and acidified with 1M 
HCl (15 mL). The aqueous layer was separated through a separating funnel and basified with a 
saturated solution of NaOH to a pH of 8-10. This was followed by extraction of the target 
compound with DCM (2×20 mL). The combined organic phase was dried over anhydrous Na2SO4. 
After filtration, the solvent was removed under reduced pressure to obtain compounds 3a – 3d. 
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N-(3-((N,N-diethylamino)methyl)-2-hydroxyphenyl)acetamide (3a) 
Yellow oil (0.616 g obtained from 0.500 g of 2a, 79%); Rf 0.3 (7% MeOH-
DCM); 1H NMR (400 MHz, MeOH-d4) δ 7.82 (dd, J = 1.7, 8.1 Hz, 1H, H-6), 
6.81 (d, J = 8.1 Hz, 1H, H-4), 6.71 (t, J = 7.9 Hz, 1H, H-5), 3.51 (s, 2H, 2×H-
9), 2.55 (q, J = 7.1 Hz, 4H, 4×H-10), 2.18 (s, 3H, CH3-8), 1.08 (t, J = 7.1 Hz, 
6H, 2×CH3-11); 13C NMR (101 MHz, MeOH-d4) δ 171.6, 150.7, 128.4, 
127.2, 126.9, 123.0, 122.7, 57.9, 47.3 (2C), 23.8 and 11.4 (2C); LC-MS 
(ESI): m/z 237 [M+H]+; purity (LC-MS): 98% (tR = 0.13 min.) 
N-(3-((N,N-diethylamino)methyl)-2-hydroxy-5-methylphenyl)acetamide (3b) 
Yellow oil (0.510 g obtained from 0.500 g of 2b, 67%); Rf 0.3 (7% MeOH-
DCM); 1H NMR (600 MHz, MeOH-d4) δ 7.61 (d, J = 2.0 Hz, 1H, H-6), 6.61 
(d, J = 2.0 Hz, 1H, H-4), 3.76 (s, 2H, 2×H-9), 2.64 (q, J = 7.2 Hz, 4H, 4×H-
10), 2.20 (s, 3H, CH3-12), 2.14 (s, 3H, CH3-8), 1.11 (t, J = 7.2 Hz, 6H, 2×CH3-
11); 13C NMR (151 MHz, MeOH-d4) δ 171.6, 148.0, 128.5, 126.7, 125.9, 
122.9, 122.8, 57.6, 47.4 (2C), 23.8, 20.9 and 11.5 (2C); LC-MS (ESI): m/z 
251 [M+H]+; purity (LC-MS): 98% (tR = 0.15 min.) 
N-(3-((N,N-diethylamino)methyl)-2-hydroxy-6-methylphenyl)acetamide (3c) 
Yellow oil (0.500 g obtained from 0.500 g of 2c, 66%); Rf 0.2 (7% MeOH-
DCM); 1H NMR (600 MHz, MeOH-d4) δ 6.84 (d, J = 7.6 Hz, 1H, H-4), 6.62 
(d, J = 7.6 Hz, 1H, H-5), 3.77 (s, 2H, 2×H-9), 2.63 (q, J = 7.1 Hz, 4H, 4×H-
10), 2.15 (s, 3H, CH3-12), 2.14 (s, 3H, CH3-8), 1.10 (t, J = 7.1 Hz, 6H, 2×CH3-
11); 13C NMR (151 MHz, MeOH-d4) δ 172.6, 155.2, 137.0, 128.1, 124.2, 
121.5, 120.9, 57.4, 47.4 (2C), 22.6, 18.2 and 11.5 (2C); LC-MS (ESI): m/z 
251 [M+H]+; purity (LC-MS): 98% (tR = 0.18 min.) 
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N-(4-((N,N-diethylamino)methyl)-3-hydroxyphenyl)acetamide (3d) 
Yellow oil (0.473 g obtained from 0.500 g of 2d, 61%); Rf 0.2 (7% MeOH-
DCM); 1H NMR (600 MHz, MeOH-d4) δ 6.98 (d, J = 1.5 Hz, 1H, H-2), 6.92-
6.90 (m, 2H, H-5 and H-6), 3.73 (s, 2H, 2×H-9), 2.61 (q, J = 7.1 Hz, 4H, 4×H-
10), 2.07 (s, 3H, CH3-8), 1.09 (t, J = 7.1 Hz, 6H, 2×CH3-11); 13C NMR (151 
MHz, MeOH-d4) δ 171.5, 159.7, 140.2, 129.7, 119.5, 111.9, 108.9, 57.1, 
47.4 (2C), 23.8 and 11.5 (2C); LC-MS (ESI): m/z 237 [M+H]+; purity (LC-
MS): 98% (tR = 0.13 min.) 
5.6.4 General Synthetic Procedure for compounds 4a – 4d 
Compounds 3a – 3d (2 mmol) were refluxed in 6N HCl (2 mL) at 100 οC for 2 h (TLC). Solvent was 
removed under reduced pressure. The residue was dissolved in EtOH (2×15 mL) and solvent was 
removed in vacuo to obtain the corresponding N-deactylated Mannich base products 4a – 4d (as 
HCl salt). 
6-Amino-2-((N,N-diethylamino)methyl)phenol (4a) 
Brown viscous oil (0.362 g obtained from 0.500 g of 3a, 88%); Rf 0.6 (20% 
MeOH-DCM); 1H NMR (600 MHz, MeOH-d4) δ 7.61 (dd, J = 1.6, 7.7 Hz, 
1H, H-5), 7.52 (dd, J = 1.6, 7.9 Hz, 1H, H-3), 7.17 (t, J = 7.8 Hz, 1H, H-4), 
4.49 (s, 2H, 2×H-7), 3.25 (m, 4H, 4×H-8), 1.38 (t, J = 7.3 Hz, 6H, 2×CH3-9); 
13C NMR (151 MHz, MeOH-d4) δ 151.2, 134.7, 127.3, 123.2, 123.0, 122.2, 
52.0, 48.5 (2C) and 9.1 (2C); LC-MS (ESI): m/z 195 [M+H]+; purity (LC-MS): 
98% (tR = 0.13 min.) 
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6-Amino-2-((N,N-diethylamino)methyl)-4-methylphenol (4b) 
Brown viscous oil (0.430 g obtained from 0.500 g of 3b, 86%); Rf 0.6 (20% 
MeOH-DCM); 1H NMR (600 MHz, MeOH-d4) δ 7.44 (d, J = 1.9 Hz, 1H, H-
5), 7.33 (d, J = 1.8 Hz, 1H, H-3), 4.43 (s, 2H, 2×H-7), 3.24 (m, 4H, 4×H-8), 
2.35 (s, 3H, CH3-10), 1.37 (t, J = 7.2 Hz, 6H, 2×CH3-9); 13C NMR (151 MHz, 
MeOH-d4) δ 148.6, 134.9, 133.6, 127.6, 122.7, 122.1, 52.1, 48.5 (2C), 
20.4 and 9.2 (2C); LC-MS (ESI): m/z 209 [M+H]+; purity (LC-MS): 98% (tR 
= 0.14 min.) 
6-Amino-2-((N,N-diethylamino)methyl)-5-methylphenol (4c) 
Brown viscous oil (0.400 g obtained from 0.500 g of 3c, 80%); Rf 0.6 (20% 
MeOH-DCM); 1H NMR (600 MHz, MeOH-d4) δ 7.56 (d, J = 7.9 Hz, 1H, H-
3), 7.07 (d, J = 7.9 Hz, 1H, H-4), 4.44 (s, 2H, 2×H-7), 3.24 (m, 4H, 4×H-8), 
2.44 (s, 3H, CH3-10), 1.37 (t, J = 7.3 Hz, 6H, 2×CH3-9); 13C NMR (151 MHz, 
MeOH-d4) δ 150.8, 137.0, 133.8, 125.4, 122.4, 119.6, 52.1, 48.3 (2C), 
17.6 and 9.1 (2C); LC-MS (ESI): m/z 209 [M+H]+; purity (LC-MS): 98% (tR 
= 0.15 min.) 
5-Amino-2-((N,N-diethylamino)methyl)phenol (4d) 
Brown viscous oil (0.330 g obtained from 0.450 g of 3d, 75%); Rf 0.2 (20% 
MeOH-DCM); 1H NMR (600 MHz, MeOH-d4) δ 7.61 (d, J = 8.1 Hz, 1H, H-
3), 7.10 (d, J = 2.1 Hz, 1H, H-6), 7.00 (dd, J = 2.1, 8.1 Hz, 1H, H-4), 4.36 (s, 
2H, 2×H-7), 3.23 (m, 4H, 4×H-8), 1.37 (t, J = 7.2 Hz, 6H, 2×CH3-9); 13C 
NMR (151 MHz, MeOH-d4) δ 159.1, 135.4, 134.6, 118.9, 115.5, 111.6, 
51.8, 48.8 (2C), 9.2 (2C); LC-MS (ESI): m/z 195 [M+H]+; purity (LC-MS): 
98% (tR = 0.12 min.) 
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5.6.5 General Synthetic Procedure for compounds 7.0 and 8.0 
A mixture of benzimidazole (6.0) (1 eq.) and the corresponding benzyl bromide (1.1 eq.) in 
acetonitrile were refluxed at 75 oC in the presence of K2CO3 (1.1 eq.) as base. Upon completion 
(TLC, 2 h), the reaction mixture was allowed to cool, diluted with DCM, filtered and the filtrate 
removed in vacuo to obtain a white amorphous solid residue. The residue was triturated with 
diethyl ether to remove unreacted benzyl bromide. The benzylated benzimidazole intermediates 
(7.0 and 8.0) were used for the next reaction without any further purification. 
2-Chloro-1-(4-cyanobenzyl)benzo[d]imidazole (7.0) 
White solid (0.174 g obtained from 0.100 g of 6.0, 99%); Rf 0.7 (5% MeOH-
DCM); Mp 149-151 oC; 1H NMR (600 MHz, MeOH-d4) δ 7.70 (d, J = 8.3 Hz, 
2H, 2×H-13), 7.65-7.61 (m, 1H, H-8), 7.45-7.42 (m, 1H, H-5), 7.34 (d, J = 
8.3 Hz, 2H, 2×H-12), 7.33-7.29 (m, 2H, H-6 and H-7), 5.62 (s, 2H, 2×H-10); 
13C NMR (151 MHz, MeOH-d4) δ 142.4, 142.3, 142.0, 136.3, 133.9 (2C), 
128.8 (2C), 125.1, 124.6, 119.7, 119.3, 113.1, 111.5 and 48.2; LC-MS (ESI): 
m/z 268 [M+H]+; purity (LC-MS): 98% (tR = 2.62 min.) 
2-Chloro-1-((4-trifluoromethyl)benzyl)benzo[d]imidazole (8.0) 
White solid (0.200 g obtained from 0.100 g of 6.0, 98%); Rf 0.7 (5% MeOH-
DCM); Mp 96-98 oC; 1H NMR (600 MHz, MeOH-d4) δ 7.64-7.59 (m, 3H, H-
8 and 2×H-13), 7.43-7.40 (m, 1H, H-5), 7.34 (d, J = 8.3 Hz, 2H, 2×H-12), 
7.31-7.29 (m, 2H, H-6 and H-7), 5.59 (s, 2H, 2×H-10); 13C NMR (151 MHz, 
MeOH-d4) δ 142.3, 142.0, 141.3, 136.3, 131.3 (q, J = 32.4 Hz, C-14), 128.5 
(2C), 126.9 (q, J = 3.8 Hz, 2×C-13), 125.4 (q, J = 270.0 Hz, C-15), 125.1, 
124.5, 119.7, 111.5 and 48.2; LC-MS (ESI): m/z 311 [M+H]+; purity (LC-
MS): 98% (tR = 2.85 min.) 
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5.6.6 General Synthetic Procedure for compounds 6.1 – 9.5 
A mixture of the corresponding benzimidazole (6.0 – 9.0) (1.0 eq.) in n-BuOH and the respective 
phenolic Mannich base (4a – 4d and 5.0) (1.1 eq.) in n-BuOH was heated at 100 oC in the presence 
of excess KH2PO4 as base. Upon completion (TLC, 8 h), the reaction mixture was allowed to cool, 
diluted with water and the solvent was removed under reduced pressure. The residue was 
dissolved in a mixture of DCM: MeOH 1:1 v/v and completely dried in the Genevac to remove all 
traces of n-BuOH. The target compounds (6.1 – 9.5) were obtained after column chromatography 
or preparative TLC on silica gel using mixtures of DCM and MeOH as mobile phase. 
2-(3-((N,N-diethylamino)methyl)-2-hydroxyanilino)-1H-benzo[d]imidazole (6.1) 
Brown semi-solid (0.081 g obtained from 0.100 g of 6.0, 40%); 
Rf 0.3 (10% MeOH-DCM); 1H NMR (600 MHz, MeOH-d4) δ 7.86 
(dd, J = 1.5, 7.9 Hz, 1H, H-12), 7.28 (dd, J = 3.3, 6.6 Hz, 2H, 2×H-
6), 7.03 (dd, J = 3.3, 6.6 Hz, 2H, 2×H-5), 6.77 (t, J = 7.7 Hz, 1H, 
H-11), 6.71 (dd, J = 1.5, 7.7 Hz, 1H, H-10), 3.84 (s, 2H, 2×H-13), 
2.68 (q, J = 7.1 Hz, 4H, 4×H-14), 1.13 (t, J = 7.1 Hz, 6H, 2×CH3-
15); 13C NMR (151 MHz, MeOH-d4) δ 153.0, 149.3, 129.2 (2C), 123.1 (2C), 122.8, 122.5 , 121.8 (2C), 
119.5 (2C), 118.7, 57.7, 47.5 (2C) and 11.5 (2C); LC-MS (ESI): m/z 311 [M+H]+; purity (LC-MS): 98% 
(tR = 0.36 min.) 
2-(3-((N,N-diethylamino)methyl)-2-hydroxy-5-methylanilino)-1H-benzo[d]imidazole (6.2) 
Yellow semi-solid (0.110 g obtained from 0.100 g of 6.0, 52%); 
Rf 0.3 (10% MeOH-DCM); 1H NMR (600 MHz, MeOH-d4) δ 7.69 
(d, J = 1.9 Hz, 1H, H-12), 7.29 (dd, J = 3.1, 5.8 Hz, 2H, 2×H-6), 
7.03 (dd, J = 3.1, 5.8 Hz, 2H, 2×H-5), 6.52 (d, J = 1.9 Hz, 1H, H-
10), 3.77 (s, 2H, 2×H-13), 2.65 (q, J = 7.1 Hz, 4H, 4×H-14), 2.27 
(s, 3H, CH3-16), 1.12 (t, J = 7.1 Hz, 6H, 2×CH3-15); 13C NMR (151 
MHz, MeOH-d4) δ 153.0, 146.6, 129.1 (2C), 128.8, 123.6 (2C), 122.6, 121.8 (3C), 119.2 (2C), 57.7, 
47.5 (2C), 21.0 and11.6 (2C); LC-MS (ESI): m/z 325 [M+H]+; purity (LC-MS): 98% (tR = 0.60 min.) 
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2-(3-((N,N-diethylamino)methyl)-2-hydroxy-6-methylanilino)-1H-benzo[d]imidazole (6.3) 
Brown viscous oil (0.106 g obtained from 0.100 g of 6.0, 50%); 
Rf 0.2 (15% MeOH-DCM); 1H NMR (600 MHz, MeOH-d4) δ 7.18 
(dd, J = 3.1, 5.8  Hz, 2H, 2×H-6), 6.96 (dd, J = 3.1, 5.8 Hz, 2H, 
2×H-5), 6.90 (d, J = 7.7 Hz, 1H, H-10), 6.71 (d, J = 7.7 Hz, 1H, H-
11), 3.84 (s, 2H, 2×H-13), 2.69 (q, J = 7.1 Hz, 4H, 4×H-14), 2.24 
(s, 3H, CH3-16), 1.11 (t, J = 7.1 Hz, 6H, 2×CH3-15); 13C NMR (151 
MHz, MeOH-d4) δ 155.7, 155.6, 138.5, 137.2, 127.8 (2C), 126.1, 121.6 (2C), 121.5, 121.4 (2C), 
113.0, 57.2, 47.4 (2C), 18.2 and 11.3 (2C); LC-MS (ESI): m/z 325 [M+H]+; purity (LC-MS): 98% (tR = 
0.34 min.) 
2-(4-((N,N-diethylamino)methyl)-3-hydroxyanilino)-1H-benzo[d]imidazole (6.4) 
Brown viscous oil (0.071 g obtained from 0.100 g of 6.0, 
35%); Rf 0.2 (15% MeOH-DCM); 1H NMR (600 MHz, MeOH-
d4) δ 7.59 (br s, 2H, 2×H-6), 7.46 (d, J = 8.1 Hz, 1H, H-11), 
7.16 (dd, J = 3.1, 5.9 Hz, 2H, 2×H-5), 6.91 (d, J = 2.1 Hz, 1H, 
H-8), 6.88 (dd, J = 2.2, 8.1 Hz, 1H, H-12), 4.31 (s, 2H, 2×H-
13), 3.26 (q, J = 7.2 Hz, 4H, 4×H-14), 1.40 (t, J = 7.2 Hz, 6H, 2×CH3-15); 13C NMR (151 MHz, MeOH-
d4) δ 159.2, 152.5, 142.2, 135.1 (2C), 123.4 (2C), 113.9 (2C), 112.3 (2C), 108.1 (2C), 52.5, 48.7 (2C) 
and 9.3 (2C); LC-MS (ESI): m/z 311 [M+H]+; purity (LC-MS): 98% (tR = 0.33 min.) 
2-(3-((N,N-diethylamino)methyl)-4-hydroxyanilino)-1H-benzo[d]imidazole (6.5) 
Brown viscous oil (0.082 g obtained from 0.100 g of 6.0, 41%); 
Rf 0.2 (15% MeOH-DCM); 1H NMR (400 MHz, DMSO-d6) δ 7.69 
(d, J = 2.7 Hz, 1H, H-8), 7.46 (dd, J = 3.2, 5.9 Hz, 2H, 2×H-6), 7.35 
(dd, J = 2.7, 8.7 Hz, 1H, H-12), 7.21 (dd, J = 3.2, 5.9 Hz, 2H, 2×H-
5), 7.13 (d, J = 8.6 Hz, 1H, H-11), 4.25 (s, 2H, 2×H-13), 3.14 (q, J 
= 7.1 Hz, 4H, 4×H-14), 1.31 (t, J = 7.1 Hz, 6H, 2×CH3-15); 13C 
NMR (101 MHz, DMSO-d6) δ 154.5, 148.3, 130.8 (2C), 127.9, 126.8, 125.6, 122.7 (2C), 117.1, 116.8, 
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111.8 (2C), 49.5, 46.0 (2C) and 8.3 (2C); LC-MS (ESI): m/z 311 [M+H]+; purity (LC-MS): 98% (tR = 
0.38 min.) 
1-(4-cyanobenzyl)-2-(3-((N,N-diethylamino)methyl)-2-hydroxyanilino)benzo[d]imidazole (7.1) 
Brown semi-solid (0.119 g obtained from 0.100 g of 7.0, 75%); 
Rf 0.7 (10% MeOH-DCM); 1H NMR (400 MHz, MeOH-d4) δ 7.74 
(dd, J = 2.9, 6.5 Hz, 1H, H-21), 7.65 (d, J = 8.3 Hz, 2H, 2×H-13), 
7.44-7.40 (m, 1H, H-8), 7.36 (d, J = 8.3 Hz, 2H, 2×H-12), 7.19-
7.15 (m, 1H, H-5), 7.11 (td, J = 7.7, 1.3 Hz, 1H, H-7), 7.05 (td, J 
= 7.7, 1.3 Hz, 1H, H-6), 6.76-6.69 (m, 2H, H-19 and H-20), 5.47 
(s, 2H, 2×H-10), 3.82 (s, 2H, 2×H-22), 2.67 (q, J = 7.2 Hz, 4H, 
4×H-23), 1.10 (t, J = 7.1 Hz, 6H, 2×CH3-24); 13C NMR (101 MHz, MeOH-d4) δ 152.4, 150.5, 143.3, 
142.6, 135.0, 133.8 (2C), 129.3, 128.9 (2C), 123.9, 123.0, 122.6, 122.0, 120.2, 119.4, 119.2, 117.5, 
112.7, 109.3, 57.6, 47.4 (2C), 46.4 and 11.3 (2C); LC-MS (ESI): m/z 426 [M+H]+; purity (LC-MS): 98% 
(tR = 2.46 min.) 
1-(4-cyanobenzyl)-2-(3-((N,N-diethylamino)methyl)-2-hydroxy-5-methylanilino)benzo[d]imidazole 
(7.2) 
Yellow semi-solid (0.145 g obtained from 0.100 g of 7.0, 88%); 
Rf 0.7 (10% MeOH-DCM); 1H NMR (400 MHz, MeOH-d4) δ 7.64 
(d, J = 8.0 Hz, 2H, 2×H-13), 7.55 (d, J = 1.9, Hz, 1H, H-21), 7.45-
7.40 (m, 1H, H-8), 7.35 (d, J = 7.8 Hz, 2H, 2×H-12), 7.19-7.14 (m, 
1H, H-5), 7.11 (td, J = 7.6, 1.3 Hz, 1H, H-7),7.05 (td, J = 8.1, 1.3 
Hz, 1H, H-6), 6.54 (d, J = 1.9, Hz, 1H, H-19), 5.46 (s, 2H, 2×H-
10), 3.76 (s, 2H, 2×H-22), 2.67 (q, J = 7.4 Hz, 4H, 4×H-23), 2.23 
(s, 3H, CH3-25), 1.09 (t, J = 7.1 Hz, 6H, 2×CH3-24); 13C NMR (101 MHz, MeOH-d4) δ 152.4, 147.7, 
143.3, 142.6, 135.0, 133.8 (2C), 128.9, 128.8 (2C), 128.7, 124.4, 123.0, 122.5, 122.0, 120.8, 119.4, 
117.4, 112.7, 109.3, 57.5, 47.5 (2C), 46.4, 21.0 and 11.4 (2C); LC-MS (ESI): m/z 440 [M+H]+; purity 
(LC-MS): 98% (tR = 2.54 min.) 
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1-(4-cyanobenzyl)-2-(3-((N,N-diethylamino)methyl)-2-hydroxy-6-methylanilino)benzo[d]imidazole 
(7.3) 
Brown semi-solid (0.098 g obtained from 0.100 g of 7.0, 60%); 
Rf 0.5 (10% MeOH-DCM); 1H NMR (600 MHz, MeOH-d4) δ 7.67 
(d, J = 8.1 Hz, 2H, 2×H-13), 7.42 (d, J = 8.1 Hz, 2H, 2×H-12), 7.26-
7.23 (m, 1H, H-8), 7.07-7.03 (m, 2H, H-5 and H-7), 6.97 (td, J = 
7.5, 1.1 Hz, 1H, H-6), 6.85 (d, J = 7.7 Hz, 1H, H-19), 6.67 (d, J = 
7.7 Hz, 1H, H-20), 5.49 (s, 2H, 2×H-10), 3.80 (s, 2H, 2×H-22), 
2.66 (q, J = 7.1 Hz, 4H, 4×H-23), 2.11 (s, 3H, CH3-25), 1.08 (t, J = 
7.1 Hz, 6H, 2×CH3-24); 13C NMR (151 MHz, MeOH-d4) δ 155.3, 154.6, 143.8, 142.5, 137.2, 135.4, 
133.6 (2C), 128.9 (2C), 127.5, 126.8, 122.7, 121.5, 121.3, 121.2, 119.5, 116.5, 112.4, 109.0, 57.3, 
47.3 (2C), 46.2, 18.3 and 11.4 (2C); LC-MS (ESI): m/z 440 [M+H]+; purity (LC-MS): 98% (tR = 2.45 
min.) 
1-(4-cyanobenzyl)-2-(4-((N,N-diethylamino)methyl)-3-hydroxyanilino)benzo[d]imidazole (7.4) 
Brown semi-solid (0.087 g obtained from 0.100 g of 7.0, 
55%); Rf 0.3 (10% MeOH-DCM); 1H NMR (600 MHz, MeOH-
d4) δ 7.63 (d, J = 8.2 Hz, 2H, 2×H-13), 7.43-7.39 (m, 1H, H-
8), 7.26 (d, J = 7.8 Hz, 2H, 2×H-12), 7.14-7.07 (m, 2H, H-5 
and H-7), 7.05-7.01 (m, 1H, H-6), 6.94-6.84 (m, 3H, H-17, 
H-20 and H-21), 5.49 (s, 2H, 2×H-10), 3.73 (s, 2H, 2×H-22), 
2.63 (q, J = 7.1 Hz, 4H, 4×H-23), 1.10 (t, J = 7.1 Hz, 6H, 2×CH3-24); 13C NMR (151 MHz, MeOH-d4) δ 
160.0, 152.4, 143.7, 142.3, 134.9, 133.7 (2C), 131.6, 130.1, 128.5 (2C), 123.1, 122.0, 119.4, 117.9, 
117.5, 112.4, 111.3, 109.6, 108.1, 57.1, 47.3 (2C), 46.3 and 11.6 (2C); LC-MS (ESI): m/z 426 [M+H]+; 
purity (LC-MS): 98% (tR = 2.41 min.) 
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1-(4-cyanobenzyl)-2-(3-((N,N-diethylamino)methyl)-4-hydroxyanilino)benzo[d]imidazole (7.5) 
Pink semi-solid (0.150 g obtained from 0.100 g of 7.0, 94%); Rf 
0.4 (10% MeOH-DCM); 1H NMR (600 MHz, MeOH-d4) δ 7.70 (d, 
J = 8.1 Hz, 2H, 2×H-13), 7.63 (d, J = 2.6 Hz, 1H, H-17), 7.42-7.39 
(m, 1H, H-8), 7.39-7.35 (m, 3H, 2×H-12 and H-21), 7.20-7.16 (m, 
2H, H-5 and H-7), 7.11 (td, J = 7.6, 1.0 Hz, 1H, H-6), 6.97 (d, J = 
8.6 Hz, 1H, H-20), 5.60 (s, 2H, 2×H-10), 4.32 (s, 2H, 2×H-22), 
2.66 (q, J = 7.2 Hz, 4H, 4×H-23), 1.39 (t, J = 7.2 Hz, 6H, 2×CH3-24); 13C NMR (151 MHz, MeOH-d4) δ 
155.0, 152.5, 142.8, 138.9, 134.2, 133.8 (2C), 132.2, 128.6 (2C), 127.6, 127.0, 123.9, 122.9, 119.4, 
118.2, 117.4, 115.9, 112.7, 110.1, 52.5, 48.5 (2C), 46.4 and 9.1 (2C); LC-MS (ESI): m/z 426 [M+H]+; 
purity (LC-MS): 98% (tR = 2.38 min.) 
1-((4-trifluoromethyl)benzyl)-2-(3-((N,N-diethylamino)methyl)-2-hydroxyanilino)benzo[d]imidazole 
(8.1) 
Brown semi-solid (0.105 g obtained from 0.100 g of 8.0, 70%); 
Rf 0.7 (10% MeOH-DCM); 1H NMR (400 MHz, MeOH-d4) δ 7.77 
(dd, J = 2.2, 7.2 Hz, 1H, H-21), 7.59 (d, J = 8.0 Hz, 2H, 2×H-13), 
7.44-7.40 (m, 1H, H-8), 7.38 (d, J = 8.0 Hz, 2H, 2×H-12), 7.19-
7.15 (m, 1H, H-5), 7.11 (td, J = 7.6, 1.3 Hz, 1H, H-7), 7.05 (td, J 
= 7.5, 1.1 Hz, 1H, H-6), 6.77-6.67 (m, 2H, H-19 and H-20), 5.46 
(s, 2H, 2×H-10), 3.81 (s, 2H, 2×H-22), 2.64 (q, J = 7.2 Hz, 4H, 
4×H-23), 1.09 (t, J = 7.1 Hz, 6H, 2×CH3-24); 13C NMR (101 MHz, MeOH-d4) δ 152.4, 150.4, 142.6, 
142.0, 135.1, 131.1 (q, J = 32.4 Hz, C-14), 129.3, 128.6 (2C), 126.8 (q, J = 3.7 Hz, 2×C-13), 125.5 (q, 
J = 270.0 Hz, C-15), 123.8, 122.9, 122.5, 121.9, 120.0, 119.3, 117.4, 109.4, 57.6, 47.4 (2C), 46.3 
and 11.3 (2C); LC-MS (ESI): m/z 469 [M+H]+; purity (LC-MS): 98% (tR = 2.65 min.) 
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1-((4-trifluoromethyl)benzyl)-2-(3-((N,N-diethylamino)methyl)-2-hydroxy-5-
methylanilino)benzo[d]imidazole (8.2) 
Yellow semi-solid (0.115 g obtained from 0.100 g of 8.0, 74%); 
Rf 0.7 (10% MeOH-DCM); 1H NMR (400 MHz, MeOH-d4) δ 7.61-
7.56 (m, 3H, 2×H-13 and H-21), 7.46-7.41 (m, 1H, H-8), 7.37 (d, 
J = 7.8 Hz, 2H, 2×H-12), 7.20-7.16 (m, 1H, H-5), 7.11 (td, J = 7.6, 
1.3 Hz, 1H, H-7), 7.05 (td, J = 7.6, 1.2 Hz, 1H, H-6), 6.53 (d, J = 
1.9, Hz, 1H, H-19), 5.44 (s, 2H, 2×H-10), 3.75 (s, 2H, 2×H-22), 
2.63 (q, J = 7.1 Hz, 4H, 4×H-23), 2.23 (s, 3H, CH3-25), 1.07 (t, J = 
7.1 Hz, 6H, 2×CH3-24); 13C NMR (101 MHz, MeOH-d4) δ 152.4, 147.5, 142.6, 142.0, 135.1, 131.1 
(q, J = 32.2 Hz, C-14), 128.9, 128.8, 128.6 (2C), 126.8 (q, J = 3.8 Hz, 2×C-13), 125.5 (q, J = 270.0 Hz, 
C-15), 124.3, 122.9, 122.5, 121.9, 120.6, 117.4, 109.3, 57.5, 47.5 (2C), 46.3, 21.0 and 11.4 (2C); LC-
MS (ESI): m/z 483 [M+H]+; purity (LC-MS): 98% (tR = 2.68 min.) 
1-((4-trifluoromethyl)benzyl)-2-(3-((N,N-diethylamino)methyl)-2-hydroxy-6-
methylanilino)benzo[d]imidazole (8.3) 
Brown semi-solid (0.096 g obtained from 0.100 g of 8.0, 62%); 
Rf 0.5 (10% MeOH-DCM); 1H NMR (600 MHz, MeOH-d4) δ 7.61 
(d, J = 8.2 Hz, 2H, 2×H-13), 7.43 (d, J = 8.1 Hz, 2H, 2×H-12), 7.26-
7.23 (m, 1H, H-8), 7.08-7.05 (m, 1H, H-5), 7.02 (td, J = 7.6, 1.2, 
Hz, 1H, H-7), 6.97 (td, J = 7.5, 1.1 Hz, 1H, H-6), 6.86 (d, J = 7.7 
Hz, 1H, H-19), 6.67 (d, J = 7.7 Hz, 1H, H-20), 5.49 (s, 2H, 2×H-
10), 3.82 (s, 2H, 2×H-22), 2.68 (q, J = 7.1 Hz, 4H, 4×H-23), 2.11 
(s, 3H, CH3-25), 1.09 (t, J = 7.1 Hz, 6H, 2×CH3-24); 13C NMR (151 MHz, MeOH-d4) δ 155.2, 154.5, 
142.5, 142.4, 137.3, 135.4, 130.7 (q, J = 32.2 Hz, C-14), 128.6 (2C), 127.6, 126.6 (q, J = 4.1 Hz, 2×C-
13), 125.5 (q, J = 270.0 Hz, C-15), 124.7, 122.6, 121.5, 121.2, 121.1, 116.4, 109.1, 57.1, 47.4 (2C), 
46.2, 18.3 and 11.2 (2C); LC-MS (ESI): m/z 483 [M+H]+; purity (LC-MS): 98% (tR = 2.64 min.) 
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1-((4-trifluoromethyl)benzyl)-2-(4-((N,N-diethylamino)methyl)-3-hydroxyanilino)benzo[d]imidazole 
(8.4) 
Brown semi-solid (0.075 g obtained from 0.100 g of 8.0, 
50%); Rf 0.3 (10% MeOH-DCM); 1H NMR (600 MHz, MeOH-
d4) δ 7.59 (d, J = 8.1 Hz, 2H, 2×H-13), 7.45-7.42 (m, 1H, H-
8), 7.29 (d, J = 8.3 Hz, 2H, 2×H-12), 7.17-7.09 (m, 4H, H-5, 
H-7, H-17 and H-20), 7.07 (td, J = 7.7, 1.1 Hz, 1H, H-6), 6.93 
(dd, J = 2.2, 8.2 Hz, 1H, H-21), 5.53 (s, 2H, 2×H-10), 4.04 (s, 
2H, 2×H-22), 2.97 (q, J = 7.2 Hz, 4H, 4×H-23), 1.25 (t, J = 7.2 Hz, 6H, 2×CH3-24); 13C NMR (151 MHz, 
MeOH-d4) δ 159.1, 151.9, 144.3, 142.4, 134.9, 132.3, 131.7, 130.9 (q, J = 32.7 Hz, C-14), 128.2, 
128.1 (2C), 126.7 (q, J = 3.8 Hz, 2×C-13), 125.5 (q, J = 270.0 Hz, C-15), 123.2, 122.3, 117.6, 111.4, 
109.9, 107.1, 54.5, 48.0 (2C), 46.3 and 10.1 (2C); LC-MS (ESI): m/z 469 [M+H]+; purity (LC-MS): 96% 
(tR = 2.61 min.) 
1-((4-trifluoromethyl)benzyl)-2-(3-((N,N-diethylamino)methyl)-4-hydroxyanilino)benzo[d]imidazole 
(8.5) 
Pink semi-solid (0.127 g obtained from 0.100 g of 8.0, 84%); Rf 
0.4 (10% MeOH-DCM); 1H NMR (600 MHz, MeOH-d4) δ 7.67 (d, 
J = 8.2 Hz, 2H, 2×H-13), 7.63 (d, J = 2.6 Hz, 1H, H-17), 7.46-7.42 
(m, 3H, H-8 and 2×H-12), 7.40 (dd, J = 2.7, 8.7 Hz, 1H, H-21), 
7.28-7.25 (m, 1H, H-5), 7.23 (td, J = 7.6, 1.2 Hz, 1H, H-7), 7.18 
(td, J = 7.6, 1.1 Hz, 1H, H-6), 7.02 (d, J = 8.6 Hz, 1H, H-20), 5.63 
(s, 2H, 2×H-10), 4.33 (s, 2H, 2×H-22), 3.26 (q, J = 7.3 Hz, 4H, 4×H-23), 1.39 (t, J = 7.3 Hz, 6H, 2×CH3-
24); 13C NMR (151 MHz, MeOH-d4) δ 155.9, 152.0, 141.1, 136.3, 133.6, 131.2 (q, J = 32.5 Hz, C-
14), 131.0, 128.4 (2C), 126.9 (q, J = 3.9 Hz, 2×C-13), 125.5 (q, J = 270.0 Hz, C-15), 126.4, 124.6, 
124.5, 123.7, 118.6, 117.6, 115.2, 110.6, 52.4, 48.6 (2C), 46.6 and 9.1 (2C); LC-MS (ESI): m/z 469 
[M+H]+; purity (LC-MS): 98% (tR = 2.59 min.) 
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1-(4-fluorobenzyl)-2-(3-((N,N-diethylamino)methyl)-2-hydroxyanilino)benzo[d]imidazole (9.1) 
Brown semi-solid (0.112 g obtained from 0.100 g of 9.0, 70%); 
Rf 0.7 (10% MeOH-DCM); 1H NMR (400 MHz, MeOH-d4) δ 7.77 
(dd, J = 2.2, 7.3 Hz, 1H, H-20), 7.44-7.40 (m, 1H, H-8), 7.27 (dd, 
J = 5.2, 8.6 Hz, 2H, 2×H-12), 7.25-7.21 (m, 1H, H-5), 7.13-7.06 
(m, 2H, H-6 and H-7), 7.03 (t, J = 8.7 Hz, 2H, 2×H-13), 6.77-6.69 
(m, 2H, H-18 and H-19), 5.36 (s, 2H, 2×H-10), 3.84 (s, 2H, 2×H-
21), 2.69 (q, J = 7.2 Hz, 4H, 4×H-22), 1.12 (t, J = 7.2 Hz, 6H, 
2×CH3-23); 13C NMR (101 MHz, MeOH-d4) δ 163.8 (d, J = 245.0 Hz, C-14), 152.2, 150.1, 142.6, 
135.1, 133.4 (d, J = 3.2 Hz, C-11), 130.0 (q, J = 8.2 Hz, 2×C-12), 129.4, 123.6, 122.8, 122.5, 121.9, 
119.5, 119.3, 117.4, 116.7 (d, J = 22.0 Hz, 2×C-13), 109.4, 57.6, 47.5 (2C), 46.1 and 11.3 (2C); LC-
MS (ESI): m/z 419 [M+H]+; purity (LC-MS): 98% (tR = 2.55 min.) 
1-(4-fluorobenzyl)-2-(3-((N,N-diethylamino)methyl)-2-hydroxy-5-methylanilino)benzo[d]imidazole 
(9.2) 
Yellow semi-solid (0.140 g obtained from 0.100 g of 9.0, 84%); 
Rf 0.7 (10% MeOH-DCM); 1H NMR (400 MHz, MeOH-d4) δ 7.61 
(d, J = 2.0 Hz, 1H, H-20), 7.45-7.41 (m, 1H, H-8), 7.24 (dd, J = 
5.3, 8.6 Hz, 2H, 2×H-12), 7.22-7.19 (m, 1H, H-5), 7.14-7.06 (m, 
2H, H-6 and H-7), 7.03 (t, J = 8.7 Hz, 2H, 2×H-13), 6.53 (d, J = 
2.0 Hz, 1H, H-18), 5.32 (s, 2H, 2×H-10), 3.77 (s, 2H, 2×H-21), 
2.65 (q, J = 7.2 Hz, 4H, 4×H-22), 2.24 (s, 3H, CH3-24), 1.09 (t, J = 
7.2 Hz, 6H, 2×CH3-23); 13C NMR (101 MHz, MeOH-d4) δ 163.8 (d, J = 245.1 Hz, C-14), 152.2, 147.2, 
142.5, 135.1, 133.4 (d, J = 3.2 Hz, C-11), 130.0 (q, J = 8.3 Hz, 2×C-12), 129.0, 128.9, 124.2, 122.8, 
122.4, 121.9, 120.2, 117.4, 116.7 (q, J = 21.9 Hz, 2×C-13), 109.4, 57.5, 47.5 (2C), 46.1, 21.0 and 
11.4 (2C); LC-MS (ESI): m/z 433 [M+H]+; purity (LC-MS): 98% (tR = 2.61 min.) 
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1-(4-fluorobenzyl)-2-(3-((N,N-diethylamino)methyl)-2-hydroxy-6-methylanilino)benzo[d]imidazole 
(9.3) 
Brown semi-solid (0.112 g obtained from 0.100 g of 9.0, 68%); 
Rf 0.5 (10% MeOH-DCM); 1H NMR (600 MHz, MeOH-d4) δ 7.31 
(dd, J = 5.3, 8.6 Hz, 2H, 2×H-12), 7.24-7.21 (m, 1H, H-8), 7.10-
7.07 (m, 1H, H-5), 7.03 (t, J = 8.7 Hz, 2H, 2×H-13), 7.00 (td, J = 
7.5, 1.3 Hz, 1H, H-7), 6.96 (td, J = 7.5, 1.1 Hz, 1H, H-6), 6.85 (d, 
J = 7.7 Hz, 1H, H-18), 6.67 (d, J = 7.7 Hz, 1H, H-19), 5.37 (s, 2H, 
2×H-10), 3.81 (s, 2H, 2×H-21), 2.66 (q, J = 7.2 Hz, 4H, 4×H-22), 
2.10 (s, 3H, CH3-24), 1.09 (t, J = 7.1 Hz, 6H, 2×CH3-23); 13C NMR (151 MHz, MeOH-d4) δ 163.7 (d, J 
= 244.4 Hz, C-14), 155.2, 154.5, 142.4, 137.1, 135.5, 133.9 (d, J = 3.1 Hz, C-11), 130.0 (d, J = 8.1 Hz, 
2×C-12), 127.4, 126.7, 122.4, 121.5, 121.3, 121.1, 116.5 (d, J = 21.6 Hz, 2×C-13), 116.4, 109.2, 57.3, 
47.3 (2C), 45.9, 18.3 and 11.4 (2C); LC-MS (ESI): m/z 433 [M+H]+; purity (LC-MS): 98% (tR = 2.51 
min.) 
1-(4-fluorobenzyl)-2-(4-((N,N-diethylamino)methyl)-3-hydroxyanilino)benzo[d]imidazole (9.4) 
Brown semi-solid (0.102 g obtained from 0.100 g of 9.0, 
63%); Rf 0.3 (10% MeOH-DCM); 1H NMR (600 MHz, MeOH-
d4) δ 7.41-7.38 (m, 1H, H-8), 7.16 (dd, J = 5.3, 8.5 Hz, 2H, 
2×H-12), 7.13-7.10 (m, 1H, H-5), 7.08 (td, J = 7.7, 1.1 Hz, 
1H, H-7), 7.03 (td, J = 7.7, 1.1 Hz, 1H, H-6), 7.00 (t, J = 8.7 
Hz, 2H, 2×H-13), 6.95-6.84 (m, 3H, H-16, H-19 and H-20), 
5.37 (s, 2H, 2×H-10), 3.74 (s, 2H, 2×H-21), 2.63 (q, J = 7.2 Hz, 4H, 4×H-22), 2.10 (s, 3H, CH3-24), 
1.10 (t, J = 7.1 Hz, 6H, 2×CH3-23); 13C NMR (151 MHz, MeOH-d4) δ 163.6 (d, J = 244.4 Hz, C-14), 
160.0, 152.3, 142.5, 134.9, 133.8 (d, J = 3.3 Hz, C-11), 131.6, 130.1, 129.7 (d, J = 8.2 Hz, 2×C-12), 
122.9, 121.9, 117.8, 117.3, 116.5 (d, J = 21.8 Hz, 2×C-13), 111.2, 109.8, 108.1, 57.1, 47.3 (2C), 46.0 
and 11.6 (2C); LC-MS (ESI): m/z 419 [M+H]+; purity (LC-MS): 98% (tR = 2.52 min.) 
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1-(4-fluorobenzyl)-2-(3-((N,N-diethylamino)methyl)-4-hydroxyanilino)benzo[d]imidazole (9.5) 
Pink semi-solid (0.146 g obtained from 0.100 g of 9.0, 91%); Rf 
0.4 (10% MeOH-DCM); 1H NMR (600 MHz, MeOH-d4) δ 7.64 (d, 
J = 2.6 Hz, 1H, H-16), 7.46-7.44 (m, 1H, H-8), 7.43 (dd, J = 2.6, 
8.6 Hz, 1H, H-20), 7.36 (dd, J = 5.2, 8.5 Hz, 2H, 2×H-12), 7.35-
7.32 (m, 1H, H-5), 7.26 (td, J = 7.7, 1.4 Hz, 1H, H-7), 7.23 (td, J 
= 7.6, 1.3 Hz, 1H, H-6), 7.11 (t, J = 8.7 Hz, 2H, 2×H-13), 7.07 (d, 
J = 8.6 Hz, 1H, H-19), 5.55 (s, 2H, 2×H-10), 4.34 (s, 2H, 2×H-21), 
3.27 (q, J = 7.2 Hz, 4H, 4×H-22), 1.40 (t, J = 7.2 Hz, 6H, 2×CH3-23); 13C NMR (151 MHz, MeOH-d4) δ 
163.9 (d, J = 245.5 Hz, C-14), 156.8, 151.2, 133.6, 132.9, 132.0 (d, J = 3.3 Hz, C-11), 130.1 (d, J = 
8.3 Hz, 2×C-12), 129.9, 129.8, 129.0, 124.9, 124.3, 118.9, 117.9, 116.9 (d, J = 22.0 Hz, 2×C-13), 
114.3, 111.3, 52.2, 48.6 (2C), 46.6 and 9.1 (2C); LC-MS (ESI): m/z 419 [M+H]+; purity (LC-MS): 98% 
(tR = 2.41 min.) 
5.6.7 Antimycobacterial evaluation protocol 
The in vitro antimycobacterial evaluation protocol has already been described in Section 4.6.8 
5.6.8 Antiplasmodium evaluation protocol 
The in vitro antiplasmodium evaluation protocol has already been described in Sections 4.6.9.1 
and 4.6.9.3. 
5.6.9 Cytotoxicity evaluation protocol 
The in vitro cytotoxic activity protocol has already been described in Section 4.6.10 
5.6.10 Beta-hematin inhibition assay 
The inhibition of beta-hematin formation assay was conducted to investigate the possible 
mechanism of antiplasmodium activity of the synthesized benzimidazole analogues as inhibitors 
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of heme polymerization. This non-cell assay evaluates the ability of the test compounds to prevent 
the synthetic dimerization of hematin (beta-hematin) in lipid medium. 
Hundred microliters of a solution containing water/305.5 µM NP-40/DMSO at a v/v ratio of 
70%/20%/10%, respectively, was added to every well in columns 2 - 12 of a 96-well plate. To 
column 1 was added 140 µL of water and 40 µL of 305.5 µM NP-40. Twenty microliters of the test 
compounds (20 mM), that is, the synthesized compounds and control, was added to column 1 in 
duplicate. One hundred microliters of the test solution was diluted to column 11, with column 12 
left as a blank (0 µM of compound). A 178.8 µL aliquot of hematin (hemin) stock was suspended 
in 20 mL of a 1 M acetate buffer, pH 4.8 and 100 µL of this hematin suspension added into each 
well. Plates were then incubated for ~5 hours at 37 oC after which 32 µL of pyridine solution (20% 
water, 20% acetone, 10% 2M HEPES buffer (pH 7.4), 50% pyridine) was added followed by addition 
of 60 µL of acetone to all wells. Plates were again read at 405 nm on a Thermo Scientific Multiscan 
Go Microplate Spectrophotometer. The IC50 values were determined using GraphPad Prism 6. 
5.6.11 Turbidimetric (kinetic) solubility assay 
The aqueous solubility of the synthesized compounds were assessed using the thermodynamic 
‘kinetic’ solubility assay in a 96-well microtiter plate. Stock solutions (10 mM) of the compounds 
were prepared in DMSO. The pre-dilution plate was prepared by making serial dilutions of the 
stock solution in DMSO, in triplicate, to obtain concentrations ranging from 0.25 to 8.0 mM. From 
the pre-dilution plate, the assay plate was prepared by pipetting 4 µL of solution and making 
secondary dilutions in DMSO and 0.01M pH 7.4 PBS, also in triplicate, to obtain the final volume 
in each assay plate well to be 200 μL. Thus, the concentrations of the wells in the assay plate range 
from 0 to 200 μM. The plates were then covered and left to incubate at ambient temperature (37 
oC) for 2 h. Absorbance measurements were taken at 620 nm on a Thermo Scientific Multiscan Go 
Microplate spectrophotometer. A plot of corrected absorbance against concentration was 
generated using Microsoft® Office Excel 2013 and used to identify the limit of solubility of each 
compound. 
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Chapter Six: Conclusion 
6.1 Summary 
Oberlies and Kroll (2004) wrote: “The events surrounding the discovery and development of these 
drugs (Camptothecin and Taxol) provide numerous examples of the power of natural products to 
uncover new therapeutic agents and define novel drug targets. Moreover, central to all of these 
lessons are the drive and persistence of two complementary researchers whose dedication to 
science transcended the obstacles encountered during the 30-plus year journey of these 
molecules from bench to bedside. Individually, both of these discoveries are seminal 
accomplishments, and taken together, this work represents a truly historic achievement in natural 
products research”.1 With few exceptions where a natural product (NP) ended up in the clinic in 
its original isolated form (for example, fusidic acid), most drugs inspired by natural products share 
a common testimony with camptothecin and taxol. The drug discovery journey is indeed a long, 
tedious, and cost-intensive venture. Many ‘potent’ NPs (extracts, fractions or pure compounds) 
have only ended up in the cupboards of academic research groups or safe repositories of 
pharmaceutical companies who once embarked on NP-led drug discovery but for reasons earlier 
highlighted in Chapter One of this thesis have abandoned such projects. 
In the current work reported in this thesis, eleven new NPs were isolated and fully characterized 
from three marine organisms, comprising a newly identified red seaweed (Laurencia alfredensis) 
and two sponges (Halichondria sp. and Hymeniacidon sp.). The new compound 7 (alfredensinol C) 
isolated from the seaweed exhibited selective anti-proliferative activity against the MDA-MB-231 
breast cancer cell line (IC50 = 8.8 µM) compared to the HeLa cervical carcinoma (IC50 = 133.8 µM). 
It would be useful to investigate the cytotoxicity of this compound against a normal human cell 
line to investigate its selectivity profile. However, the new compounds isolated from Halichondria 
sp. lacked antiplasmodium activity against the chloroquine-sensitive NF54 strain of Plasmodium 
falciparum. It will be worth investigating the biological activity of these compounds in other assays, 
for example, in those reported for congeners in the literature, such as antifouling, antibacterial 
and nematicidal activities to increase the scope of structure-activity relationships (SAR) of the 
naturally occuring betaine molecules.2–8 
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The fusidane triterpenoid fusidic acid has been used as an antibiotic drug since 1962. It is one of 
the successful stories of a NP in the clinic as a drug in its original isolated form. With a novel 
antibacterial mechanism of action, a drug-repositioning approach was embarked on towards 
identifying anti-tubercular and anti-malarial drug lead (s) based on fusidic acid. While our research 
group has previously explored and reported antimycobacterial and antiplasmodium derivatives 
through semi-synthesis of fusidic acid,9–11 the current work progressed on the available data to 
further expand the SAR in the two biological assays. The data generated and the results reported 
in this thesis will further inspire and direct future lead optimization efforts on fusidic acid. The (R)-
4-fluoro ethanamide analogue (1.4) was found to display comparable asexual erythrocytic blood 
stage antiplasmodium potency to the previous frontrunner compound with IC50 values of 0.57 and 
0.47 µM against the NF54 and K1 strains of P. falciparum, respectively. Meanwhile, the Mannich 
base 3-((N,N-diethylamino)methyl)-4-hydroxy Mannich base anilide congener (1.24) recorded the 
most potent antimycobacterial activity with MIC90 values of 0.40 µM and 10.35 µM in the 7H9/CAS 
and 7H9/ADC media, respectively, which is comparable to fusidic acid but far more potent than 
the frontrunner compounds in the current research. Future work aimed at further exploring the 
antiplasmodium and antimycobacterial SAR inspired by the two compounds, 1.4 and 1.24, is highly 
recommended. 
Further medicinal chemistry work, as reported in this thesis, led to the identification of a potent 
novel antiplasmodium and antimycobacterial agent based on the privileged benzimidazole 
scaffold, which is a structural isostere of the purine bases, adenine and guanine, and a potential 
bioisostere of indole, a very common scaffold in most natural products. Amongst the twenty 
synthesized analogues, comprising four benzimidazole scaffolds and five Mannich bases, 
compound 8.2 exhibited sub-micromolar antiplasmodium activity against the asexual blood stage 
drug sensitive NF54 strain (IC50 = 0.19 µM) and multidrug resistant K1 strain (IC50 = 0.06 µM) of P. 
falciparum, and early stage (II/III) gametocidal activity (inhibiting 91% of parasite growth at 1 µM). 
The compound occupies a similar chemical space to the antimalarial drug naphthoquine albeit it 
exhibited poor aqueous solubility at pH 7.4. Further, 8.2 was active against the H37Rv strain of 
Mycobacterium tuberculosis with a MIC90 = 2.31 µM in the 7H9/CAS media. It will be expedient to 
undertake follow up investigations, comprising of exploring additional benzimidazole-Mannich 
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base analogues as well as profiling for microsomal metabolic stability and in vivo efficacy of the 
benzimidazole frontrunner compound (8.2). 
According to Borris (1996), “Natural products research is a part, and in truth a small part, of the 
discovery process. The screening of natural products is one of the earliest steps in drug discovery, 
namely 'lead' identification. A lead compound, as the term is currently used, is a compound with 
many of the characteristics of a desired new drug which will be used as a model for chemical 
modification. It must be potent, but it does not need to possess the potency at the nanomolar or 
picomolar levels expected of a product candidate. It must be specific for the desired target, but it 
does not need to possess the exquisite biochemical specificity required for a new drug. Finally, it 
must be available in sufficient quantities to support the early stages of development, such as 
biological characterization and toxicity studies, while a total synthesis of the product candidate is 
being completed. It is much easier to find a lead compound than to find a product candidate. The 
transition from looking for drugs to looking for leads has been made possible by the tremendous 
advances that have occurred in organic and medicinal chemistry in the last few decades. We now 
expect that our chemists will be able to improve the potency and/or specificity of a good lead 
compound, perhaps by several orders of magnitude. It is thus the task of the medicinal chemist to 
take a lead compound and turn it into a drug”.12  
The work presented in this thesis well represents both the early discovery stages of natural 
products-based drug discovery and the lead identification stages from a medicinal chemistry 
perspective. As rightly indicated by Borris (1996),12 collaboration between the chemistry fields of 
natural products and medicinal chemistry is useful to move a lead NP compound to the bedside 
as a drug. In such a venture, the role of medicinal chemistry is inevitable. While the current work 
demonstrates the usefulness of such collaboration, drug discovery is an unending journey; for 
even when a drug finally makes it to patients, it is expedient to discover second, third, fourth, etc. 
generations so as to keep the disease in check, due in part to drug resistance. 
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